CN116783202A

CN116783202A - Thienopyrrole compounds

Info

Publication number: CN116783202A
Application number: CN202280013830.0A
Authority: CN
Inventors: S·E·阿曼; E·Y·卡纳雷斯; W·K·常; J·A·科德利; L·江; H·H·金夫; S·E·拉泽维斯; M·L·米切尔; S·D·施罗德; D·G·肖尔
Original assignee: Gilead Sciences Inc
Current assignee: Gilead Sciences Inc
Priority date: 2021-02-09
Filing date: 2022-02-08
Publication date: 2023-09-19

Abstract

The present disclosure relates generally to thieno [3,2- ] pyrrole derivatives, pharmaceutical compositions comprising the compounds, and methods of making and using the compounds and pharmaceutical compositions. The compounds and compositions provided herein are useful for treating or preventing autoimmune diseases and/or inflammatory disorders, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Description

Thienopyrrole compounds

Cross Reference to Related Applications

The present application claims priority from U.S. provisional application number 63/147,641 filed on day 2021, 2, 9 and U.S. provisional application number 63/210,832 filed on day 2021, 6, 15, each of which is incorporated herein in its entirety for all purposes.

Technical Field

The present disclosure relates generally to novel thienopyrrole compounds, pharmaceutical compositions comprising the compounds, and methods of making and using the compounds and pharmaceutical compositions. In some embodiments, the novel thienopyrrole compounds provided herein are useful for treating certain diseases and disorders, including but not limited to inflammatory conditions, systemic lupus erythematosus, cutaneous lupus erythematosus, or lupus nephritis.

Background

Toll-like receptors (TLRs) are a family of transmembrane immune receptors that sense pathogens, trigger innate immune responses, and elicit adaptive immunity. TLR7/8/9 is an endosomal localized TLR that responds to single stranded RNA (TLR 7/8) or unmethylated DNA (TLR 9) containing cytosine-phosphate-guanine (CpG) motifs. TLR7/8/9 activation leads to inflammatory responses including type I interferon and pro-inflammatory cytokine production, B cell activation and antibody production, and neutrophil arrest death (netois). Aberrant activation of TLR7/8/9 helps to raise type I interferon responses, increase pro-inflammatory cytokines, and sustain autoantibody production, which can promote chronic progression of a variety of autoimmune diseases and inflammatory conditions, leading to extensive inflammation and tissue damage. (Kawai et al, 2010,Nat Immunol 11,373;Joosten et al, 2016,Nat Rev Rheomatol 12,344;Crow et al, 2019,Lupus Sci Med 6,e000336;Garcia-Romo et al, 2011,Sci Transl Med 3,73ra20;Kono et al, 2009, PNA 106,12061; koh et al, 2013,J Immunol 190,4982). Thus, there is a need for compounds that are potent TLR7 and/or TLR8 and/or TLR9 antagonists that are stable and exhibit potent pharmacokinetic and/or pharmacodynamic profiles.

Disclosure of Invention

In one embodiment, provided herein are compounds of formula I,

or a pharmaceutically acceptable salt thereof,

wherein the method comprises the steps of

R ¹ Is a 4 to 7 membered monocyclic heterocyclyl, phenyl, naphthyl, 5 to 6 membered monocyclic heteroaryl, 8 to 10 membered fused bicyclic heterocyclyl or 8 to 10 membered fused bicyclic heteroaryl,

wherein 4 to 7 membered monocyclic heterocyclyl, phenyl, naphthyl, 5 to 6 membered monocyclic heteroaryl, 8 to 10 membered fused bicyclic heterocyclyl and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally

Is 1 to 4R ^a Group substitution;

R ² is H, -CN, C _1-6 Alkyl or C _3-7 Monocyclic cycloalkyl wherein C _1-6 Alkyl and C _3-7 Monocyclic cycloalkyl groups are each independently optionally substituted with 1 to 4 groups independently selected from halogen and C _1-6 Substitution of the alkoxy group;

x is N or CR ³ ；

R ³ Is H, halogen, -CN, C _1-6 Alkyl, C _3-6 Monocyclic cycloalkyl or-O (C) _1-4 Alkyl), wherein C _1-4 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ⁴ R ⁴ And C _1-4 Substitution of the alkoxy group;

z is C _1-10 Alkyl, C _2-6 Alkynyl, -NR ⁶ R ⁷ 、-C(O)R ¹³ 、-C(O)NR ⁶ R ⁷ 、-S(O) ₂ R ⁶ 、C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl or L ¹ ，

Wherein C is _1-10 Alkyl and C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 4R ^b Group substitution;

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally being substituted with 1-2R ⁸ Radical extraction

Substituted, and each independently is optionally substituted with 1 to 3R ^a Group substitution;

L ¹ is-OR ⁵ 、-C(O)R ⁵ 、-C(O)N(R ⁵ )(R ⁵ )、-NR ⁵ R ⁵ 、-N(R ⁵ ) ₂ (R ⁵ ) ⁺ 、-N(R ⁵ )C(O)R ⁵ 、-N(R ⁵ )C(O)OR ⁵ 、-N(R ⁵ )C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ )S(O) ₂ (R ^5a )、-NR ⁵ S(O) ₂ N(R ⁵ )(R ⁵ )、-NR ⁵ S(O) ₂ O(R ^5a )、-OC(O)N(R ⁵ )(R ⁵ )、-SR ⁵ 、-S(O)R ^5a 、-S(O)(NH)R ⁵ 、-S(O) ₂ R ^5a 、S(O) ₂ N(R ⁵ )(R ⁵ ) Or-n=s (R ^5a )(R ^5a )＝O；

R ⁶ Is C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclo ringAlkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _1-6 Alkyl is optionally substituted with 1 to 4R ^b The substitution of the groups is carried out,

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally substituted with 1-4R ^a Group substitution;

R ¹³ is C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

each R ⁴ Independently H or C _1-3 An alkyl group;

R ⁷ is H, C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl or 4-to 6-membered monocyclic heterocyclyl, wherein C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl and 4-to 6-membered monocyclic heterocyclyl are each independently optionally selected from the group consisting of-OH, halogen, -CN, and C, optionally by 1 to 4 _1-6 Substitution of the alkoxy group;

each R ⁸ Independently halogen, -C (O) R ⁹ 、-NR ¹⁰ R ¹⁰ 、C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ⁵ 、-C(O)OR ⁵ 、-C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ ) ₂ (R ⁵ ) ⁺ 、-N(R ⁵ )C(O)R ⁵ 、-N(R ⁵ )C(O)OR ⁵ 、-N(R ⁵ )C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ )S(O) ₂ (R ^5a )、-NR ⁵ S(O) ₂ N(R ⁵ )(R ⁵ )、-NR ⁵ S(O) ₂ O(R ^5a )、-OC(O)R ⁵ 、-OC(O)OR ⁵ 、-OC(O)N(R ⁵ )(R ⁵ )、-SR ⁵ 、-S(O)R ^5a 、-S(O)(NH)R ⁵ 、-S(O) ₂ R ^5a 、-S(O) ₂ N(R ⁵ )(R ⁵ ) Or-n=s (R ^5a )(R ^5a )＝O，

R ⁹ is C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _2-6 Alkenyl and C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 4R ^b The substitution of the groups is carried out,

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally substituted with 1-4R ^a Group substitution;

each R ⁵ And R is ¹⁰ H, C independently _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _1-6 Alkyl, C _2-6 Alkenyl and C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 4R ^b The substitution of the groups is carried out,

each R ^5a Independently C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

each R ^a Independently oxo, imino, halogen, -NO ₂ 、-N ₃ 、-CN、C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ¹¹ 、-C(O)R ¹¹ 、-C(O)OR ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ 、-N(R ¹¹ ) ₂ (R ¹¹ ) ⁺ 、-N(R ¹¹ )C(O)R ¹¹ 、-N(R ¹¹ )C(O)OR ¹¹ 、-N(R ¹¹ )C(O)N(R ¹¹ )(R ¹¹ )、-N(R ¹¹ )S(O) ₂ (R ^11a )、-NR ¹¹ S(O) ₂ N(R ¹¹ )(R ¹¹ )、-NR ¹¹ S(O) ₂ O(R ^11a )、-OC(O)R ¹¹ 、-OC(O)OR ¹¹ 、-OC(O)N(R ¹¹ )(R ¹¹ )、-SR ¹¹ 、-S(O)R ^11a 、-S(O)(NH)R ¹¹ 、-S(O) ₂ R ^11a 、-S(O) ₂ N(R ¹¹ )(R ¹¹ ) Or-n=s (R ^11a )(R ^11a )＝O，

Wherein C is _1-6 Alkyl, C _2-6 Alkenyl and C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 3R ^c Radical extractionInstead of the generation of the water,

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl each independently optionally being substituted with 1-3R ^d The substitution of the groups is carried out,

each R ^b Independently oxo, imino, halogen, -NO ₂ 、-N ₃ 、-CN、C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered bridged bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spirocyclic heterocyclyl, -OR ¹¹ 、-C(O)R ¹¹ 、-C(O)OR ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ 、-N(R ¹¹ ) ₂ (R ¹¹ ) ⁺ 、-N(R ¹¹ )C(O)R ¹¹ 、-N(R ¹¹ )C(O)OR ¹¹ 、-N(R ¹¹ )C(O)N(R ¹¹ )(R ¹¹ )、-N(R ¹¹ )S(O) ₂ (R ^11a )、-NR ¹¹ S(O) ₂ N(R ¹¹ )(R ¹¹ )、-NR ¹¹ S(O) ₂ O(R ^11a )、-OC(O)R ¹¹ 、-OC(O)OR ¹¹ 、-OC(O)N(R ¹¹ )(R ¹¹ )、-SR ¹¹ 、-S(O)R ^11a 、-S(O)(NH)R ¹¹ 、-S(O) ₂ R ^11a 、-S(O) ₂ N(R ¹¹ )(R ¹¹ ) Or-n=s (R ^11a )(R ^11a )＝O，

Wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl and 7-to 10-membered spirocyclic heterocyclylEach independently optionally substituted with 1 to 3R ^d Group substitution;

each R ^c Independently halogen, -CN, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ¹² 、-C(O)R ¹² 、-C(O)OR ¹² 、-C(O)N(R ¹² )(R ¹² )、-NR ¹² R ¹² 、-N(R ¹² ) ₂ (R ¹² ) ⁺ 、-N(R ¹² )C(O)R ¹² 、-N(R ¹² )C(O)OR ¹² 、-N(R ¹² )C(O)N(R ¹² )(R ¹² )、-N(R ¹² )S(O) ₂ (R ^12a )、-NR ¹² S(O) ₂ N(R ¹² )(R ¹² )、-NR ¹² S(O) ₂ O(R ^12a )、-OC(O)R ¹² 、-OC(O)OR ¹² 、-OC(O)N(R ¹² )(R ¹² )、-SR ¹² 、-S(O)R ^12a 、-S(O)(NH)R ¹² 、-S(O) ₂ R ^12a 、-S(O) ₂ N(R ¹² )(R ¹² ) Or-n=s (R ^12a )(R ^12a )＝O；

Each R ^d Independently oxo, halogen, -CN, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ¹² 、-C(O)R ¹² 、-C(O)OR ¹² 、-C(O)N(R ¹² )(R ¹² )、-NR ¹² R ¹² 、-N(R ¹² ) ₂ (R ¹² ) ⁺ 、-N(R ¹² )C(O)R ¹² 、-N(R ¹² )C(O)OR ¹² 、-N(R ¹² )C(O)N(R ¹² )(R ¹² )、-N(R ¹² )S(O) ₂ (R ^12a )、-NR ¹² S(O) ₂ N(R ¹² )(R ¹² )、-NR ¹² S(O) ₂ O(R ^12a )、-OC(O)R ¹² 、-OC(O)OR ¹² 、-OC(O)N(R ¹² )(R ¹² )、-SR ¹² 、-S(O)R ^12a 、-S(O)(NH)R ¹² 、-S(O) ₂ R ^12a 、-S(O) ₂ N(R ¹² )(R ¹² ) Or-n=s (R ^12a )(R ^12a )＝O；

Each R ¹¹ H, C independently _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl each independently optionally being substituted with 1-3R ^c Group substitution;

each R ^11a Independently C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heteroarylA cyclic group, a 6-to 10-membered bridged bicyclic heterocyclic group, a 8-to 10-membered fused bicyclic heteroaryl group, and a 7-to 10-membered spiro heterocyclic group, each independently, optionally substituted with 1 to 3R groups ^c Group substitution;

each R ¹² H, C independently _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, or 7-to 10-membered spiro heterocyclyl;

each R ^12a Independently C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, or 7-to 10-membered spiro heterocyclyl;

Wherein each 4-membered monocyclic heterocyclyl independently has 1 ring heteroatom selected from N, O and S;

wherein each 5-to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O and S;

wherein each 6-membered bridged bicyclic heterocyclyl independently has 1 ring heteroatom selected from N, O and S;

wherein each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O and S; and is also provided with

Wherein each of the 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O and S.

In one embodiment, provided herein are pharmaceutical compositions comprising a compound provided herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

In one embodiment, provided herein is a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating a disease or disorder associated with increased toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating a disease or disorder associated with increased toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating a disease or disorder associated with increased toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is the use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in therapy.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating a disease or disorder associated with increased toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating a disease or disorder associated with increased toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating a disease or disorder associated with increased toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

Detailed Description

I. Definition of the definition

It should be understood, upon making the following description, that the present disclosure is considered an exemplification of the claimed subject matter and is not intended to limit the appended claims to the specific embodiments illustrated. Headings used throughout this disclosure are provided for convenience and should not be construed as limiting the claims in any way. The embodiments illustrated under any heading may be combined with the embodiments illustrated under any other heading.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. It must be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a compound" includes a plurality of such compounds, and reference to "an assay" includes reference to one or more assays known to those skilled in the art and equivalents thereof, and so forth.

As used in this disclosure, the following words, phrases and symbols are generally intended to have the meanings described below, unless the context in which they are used indicates otherwise.

Breaking not between two letters or symbolsThe fold ("-") is used to indicate a point of attachment for a substituent. For example, -CONH ₂ Through a carbon atom. Dashes at the front or end of the chemical group are for convenience; chemical groups can be depicted without one or more dashes without losing their ordinary meaning. Wavy lines drawn through lines in the structure indicate attachment points of the groups. No directionality is indicated or implied by the order in which chemical groups are written or named unless chemical or structural requirements. Solid lines drawn from the center of a ring (including fused, bridged or spiro ring systems) indicate that the point of attachment of substituents on the ring can be at any ring atom. For example, R in the following structure ^aa Can be attached to any one of five carbon ring atoms, or R ^aa Hydrogen, which may be substituted for the nitrogen ring atom:

as another example, R in the following structure ^aa ：

R ^aa Can be connected to any of the numbered positions shown below:

solid lines drawn from the center of a ring (including fused, bridged or spiro ring systems) indicate that the point of attachment of the ring system to the remainder of the compound may be at any ring atom of the fused, bridged or spiro ring system. For example, in the following structure:

The monocyclic heterocyclyl may be attached to the remainder of the compound at any of the numbered positions shown below:

as another example, in the following fused bicyclic heterocyclic ring structure,

the fused bicyclic heterocyclic group may be at any of the eight numbered positions shown below

Attached to the remainder of the compound:

prefix "C _u-v "indicates that the following groups have u to v carbon atoms. For example, "C _1-6 Alkyl "indicates that the alkyl group has 1 to 6 carbon atoms. Likewise, the term "x-y membered" ring (where x and y are a range of values such as "3 to 12 membered heterocyclyl") refers to a ring containing x-y atoms (i.e., 3-12), up to 80% of which may be heteroatoms such as N, O, S, P, and the remaining atoms being carbon.

Moreover, some common alternative chemical names may or may not be used. For example, a divalent group (such as a divalent "alkyl" group, a divalent "aryl" group, etc.) may also be referred to as an "alkylene" group ("alkyl" group or "alkenyl group), an" arylene "group (" aryl "group or" alkenyl "group or" aryl group), respectively.

"Compounds disclosed herein" or "compounds of the present disclosure" or "compounds provided herein" or "compounds described herein" refer to compounds of formula I. Specific compounds of examples 1 to 68 are also included.

Reference herein to "about" a value or parameter includes (and describes) embodiments that relate to the value or parameter itself. In certain embodiments, the term "about" includes the indicated amount ± 10%. In other embodiments, the term "about" includes the indicated amount ± 5%. In certain other embodiments, the term "about" includes the indicated amount ± 1%. Furthermore, the term "about X" includes descriptions of "X".

"alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl groups have 1 to 20 carbon atoms (i.e., C _1-20 Alkyl), 1 to 12 carbon atoms (i.e., C _1-12 Alkyl), 1 to 8 carbon atoms (i.e., C _1-8 Alkyl), 1 to 6 carbon atoms (i.e., C _1-6 Alkyl), 1 to 4 carbon atoms (i.e., C _1-4 Alkyl), 1 to 3 carbon atoms (i.e., C _1-3 Alkyl) or 1 to 2 carbon atoms (i.e., C _1-2 Alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl. When an alkyl residue having a particular carbon number is named by chemical name or identified by molecular formula, all positional isomers having that carbon number are contemplated; thus, for example, a "butyl" includes n-butyl (i.e., - (CH) ₂ ) ₃ CH ₃ ) Sec-butyl (i.e. -CH (CH) ₃ )CH ₂ CH ₃ ) Isobutyl (i.e. -CH) ₂ CH(CH ₃ ) ₂ ) And tert-butyl (i.e. -C (CH) ₃ ) ₃ ) The method comprises the steps of carrying out a first treatment on the surface of the And "propyl" includes n-propyl (i.e. (CH) ₂ ) ₂ CH ₃ ) And isopropyl (i.e. -CH (CH) ₃ ) ₂ )。

"alkenyl" means a compound containing at least one carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C _2-20 Alkenyl), 2 to 8 carbon atoms (i.e., C _2-8 Alkenyl), 2 to 6 carbon atoms (i.e., C _2-6 Alkenyl) or 2 to 4 carbon atoms (i.e., C _2-4 Alkenyl) aliphatic groups. Examples of alkenyl groups include ethenyl, propenyl, butadienyl (including 1, 2-butadienyl and 1, 3-butadienyl).

"alkynyl" means a compound containing at least one carbon-carbon triple bond and having 2 to 20 carbon atoms (i.e., C _2-20 Alkynyl), 2 to 8 carbon atoms (i.e., C _2-8 Alkynyl), 2 to 6 carbon atoms (i.e., C _2-6 Alkynyl) or 2 to 4 carbon atoms (i.e., C _2-4 Alkynyl) aliphatic groups. The term "alkynyl" also includes those groups having one triple bond and one double bond.

"alkylene" refers to a divalent and unbranched saturated hydrocarbon chain. As used herein, alkylene groups have 1 to 20 carbon atoms (i.e., C _1-20 Alkylene), 1 to 12 carbon atoms (i.e., C _1-12 Alkylene), 1 to 8 carbon atoms (i.e., C _1-8 Alkylene), 1 to 6 carbon atoms (i.e., C _1-6 Alkylene), 1 to 4 carbon atoms (i.e., C _1-4 Alkylene), 1 to 3 carbon atoms (i.e., C _1-3 Alkylene) or 1 to 2 carbon atoms (i.e., C _1-2 An alkylene group). Examples of alkylene groups include methylene, ethylene, propylene, butylene, pentylene, and hexylene. In some embodiments, the alkylene is optionally substituted with an alkyl group. Examples of substituted alkylene groups include-CH (CH ₃ )CH ₂ -、-CH ₂ CH(CH ₃ )-、-CH ₂ CH(CH ₂ CH ₃ )-、-CH ₂ C(CH ₃ ) ₂ -、-C(CH ₃ ) ₂ CH ₂ -、-CH(CH ₃ )CH(CH ₃ )-、-CH ₂ C(CH ₂ CH ₃ )(CH ₃ ) -and-CH ₂ C(CH ₂ CH ₃ ) ₂ 。

"alkoxy" refers to the group "alkyl-O-". Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy and 1, 2-dimethylbutoxy. "haloalkoxy" refers to an alkoxy group, as defined above, wherein one or more hydrogen atoms are replaced with halogen.

"acyl" refers to the group-C (O) R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which can be optionally substituted as defined herein. Examples of acyl groups include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl and benzoyl.

"Acylamido" means a "C-acylamino" group (which meansgroup-C (═ O) NR ^y R ^z ) And an "N-amido" group (which refers to the group-NR) ^y C(═O)R ^z ) Wherein R is ^y And R is ^z Independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, heteroaryl, cycloalkyl, or heterocyclyl; each of which can be optionally substituted.

"amino" means a group-NR ^y R ^z Wherein R is ^y And R is ^z Independently selected from the group consisting of: hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; each of which can be optionally substituted.

"aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) containing fused systems. As used herein, aryl groups have 6 to 20 ring carbon atoms (i.e., C _6-20 Aryl), 6 to 12 carbon ring atoms (i.e., C _6-12 Aryl) or 6 to 10 carbon ring atoms (i.e., C _6-10 Aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthracyl. However, aryl does not encompass or overlap in any way with heteroaryl as defined below. If one or more aryl groups are fused to a heteroaryl ring, the resulting ring system is heteroaryl.

"cyano" or "carbonitrile" refers to the group-CN.

"cycloalkyl" refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term "cycloalkyl" includes cycloalkenyl groups (i.e., cyclic groups having at least one double bond). As used herein, cycloalkyl groups have 3 to 20 ring carbon atoms (i.e., C _3-20 Cycloalkyl), 3 to 12 ring carbon atoms (i.e., C _3-12 Cycloalkyl), 3 to 10 ring carbon atoms (i.e., C _3-10 Cycloalkyl), 3 to 8 ring carbon atoms (i.e., C _3-8 Cycloalkyl) or 3 to 6 ring carbon atoms (i.e., C _3-6 Cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

"bridging" refers to ring fusion in which the different atoms on the ring are connected by a divalent substituent (such as an alkylene group, an alkylene group containing one or two heteroatoms) or a single heteroatom. Quinuclidinyl and adamantyl are examples of bridging ring systems.

The term "fused" refers to a ring that binds to an adjacent ring.

"spiro" refers to a ring substituent attached at the same carbon atom through two bonds. Examples of spiro groups include 1, 1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, wherein cyclopentane and piperidine are each spiro substituents.

"halogen" or "halo" includes fluorine, chlorine, bromine and iodine.

"haloalkyl" refers to an unbranched or branched alkyl group as defined above wherein one or more hydrogen atoms are replaced by halogen. For example, in the case where the residue is substituted with more than one halogen, it may be mentioned by using a prefix corresponding to the number of attached halogen moieties. Dihaloalkyl and trihaloalkyl refer to alkyl groups substituted with two ("di") or three ("tri") halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl groups include difluoromethyl (-CHF) ₂ ) And trifluoromethyl (-CF) ₃ )。

"heteroalkylene" refers to a divalent and unbranched saturated hydrocarbon chain having one, two, or three heteroatoms selected from NH, O, or S. As used herein, a heteroalkylene has 1 to 20 carbon atoms and one, two, or three heteroatoms selected from NH, O, and S (i.e., C _1-20 A heteroalkylene group); 1 to 8 carbon atoms and one, two or three heteroatoms selected from NH, O and S (i.e., C _1-8 A heteroalkylene group); 1 to 6 carbon atoms and one, two or three heteroatoms selected from NH, O and S (i.e., C _1-6 A heteroalkylene group); 1 to 4 carbon atoms and one, two or three heteroatoms selected from NH, O and S (i.e., C _1-4 A heteroalkylene group); 1 to 3 carbon atoms and one, two or three heteroatoms selected from NH, O and S (i.e., C _1-3 A heteroalkylene group); or 1 to 2 carbon atoms and one, two or three heteroatoms selected from NH, O and S (i.e., C _1-3 Heteroalkylene groups). For example, CH ₂ O-is C ₁ Heteroalkylene and-CH ₂ SCH ₂ -is C ₂ A heteroalkylene group. Examples of heteroalkylene groups include-CH ₂ CH ₂ OCH ₂ -、-CH ₂ SCH ₂ OCH ₂ -、-CH ₂ O-and-CH ₂ NHCH ₂ -. In some embodiments, the heteroalkylene is optionally substituted with an alkyl group. Examples of substituted heteroalkylene groups include-CH (CH ₃ )N(CH ₃ )CH ₂ -、-CH ₂ OCH(CH ₃ )-、-CH ₂ CH(CH ₂ CH ₃ )S-、-CH ₂ NHC(CH ₃ ) ₂ -、-C(CH ₃ ) ₂ SCH ₂ -、-CH(CH ₃ )N(CH ₃ )CH(CH ₃ )O-、-CH ₂ SC(CH ₂ CH ₃ )(CH ₃ ) -and-CH ₂ C(CH ₂ CH ₃ ) ₂ NH-。

"heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, wherein one or more ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl includes 1 to 20 carbon ring atoms (i.e., C _1-20 Heteroaryl), 3 to 12 carbon ring atoms (i.e., C _3-12 Heteroaryl) or 3 to 8 carbon ring atoms (i.e., C _3-8 Heteroaryl group); and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridinyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass or overlap with aryl as defined above.

"heterocyclyl" or "heterocycle" refers to a non-aromatic cyclic alkyl group in which one or more ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. As used herein, unless otherwise indicated, "heterocyclyl" or "heterocycle" refers to a saturated or partially saturated ring, e.g., in some embodiments, "heterocyclyl" or "heterocycle" refers to a ring that is partially saturated under the specified circumstances. The term "heterocyclyl" or "heterocycle" includes heterocyclyl groups (i.e., heterocyclyl groups having at least one double bond). The heterocyclic group may beA single ring or multiple rings, wherein the multiple rings may be fused, bridged, or spiro. As used herein, heterocyclyl has 2 to 20 carbon ring atoms (i.e., C _2-20 Heterocyclyl), 2 to 12 carbon ring atoms (i.e., C _2-12 Heterocyclyl), 2 to 10 carbon ring atoms (i.e., C _2-10 Heterocyclyl), 2 to 8 carbon ring atoms (i.e., C _2-8 Heterocyclyl), 3 to 12 carbon ring atoms (i.e., C _3-12 Heterocyclyl), 3 to 8 carbon ring atoms (i.e., C _3-8 Heterocyclyl) or 3 to 6 carbon ring atoms (i.e., C _3-6 A heterocyclic group); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl. As used herein, the term "bridged-heterocyclyl" refers to a four to ten membered ring moiety having one or more (e.g., 1 or 2) four to ten membered ring moieties having at least one heteroatom attached to two non-adjacent atoms of the heterocyclyl, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur. As used herein, "bridged-heterocyclyl" includes both bicyclic and tricyclic ring systems. Also as used herein, the term "spiro-heterocyclyl" refers to a ring system in which a tri-to decanyl heterocyclyl has one or more additional rings, wherein the one or more additional rings are tri-to decanyl or tri-to decanyl, wherein a single atom of the one or more additional rings is also an atom of a tri-to decanyl. Examples of spiro-heterocyclyl groups include bicyclic and tricyclic ring systems such as 2-oxa-7-azaspiro [3.5 ] ]Nonyl, 2-oxa-6-azaspiro [3.4 ]]Octyl and 6-oxa-1-azaspiro [3.3 ]]A heptyl group. As used herein, the terms "heterocycle", "heterocyclyl" and "heterocycle" are used interchangeably. In some embodiments, the heterocyclyl is substituted with an oxo group.

"Hydroxy" or "hydroxyl" refers to the group-OH.

"oxo" refers to a group (=o) or (O).

"sulfonyl" refers to the group-S (O) ₂ R ^bb Wherein R is ^bb Is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl or aryl. Examples of sulfonyl groups are methylsulfonyl, ethylsulfonyl, phenylsulfonyl and tosyl.

Each time a graphic representation of a group terminates in a singly-bound nitrogen atom, the group represents an-NH group, unless otherwise indicated. Similarly, unless otherwise indicated, hydrogen atoms are implied and deemed to be present as necessary, based on knowledge of the skilled artisan to accomplish valences or to provide stability.

The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. Moreover, the term "optionally substituted" means that any one or more hydrogen atoms on a given atom or group may or may not be replaced by a moiety other than hydrogen.

The term "substituted" means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the normal valency of the designated atom is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof. Polymers or similar indefinite structures obtained by defining substituents with infinitely additional further substituents (e.g., substituted aryl groups with substituted alkyl groups themselves substituted with substituted aryl groups further substituted with substituted heteroalkyl groups, etc.) are not intended to be included herein. The maximum number of consecutive substitutions in the compounds described herein is three, unless otherwise indicated. For example, the sequential substitution of a substituted aryl group with two other substituted aryl groups is limited to ((substituted aryl) -substituted aryl. Similarly, the above definition is not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorine or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. The term "substituted" when used in reference to modifying a chemical group may describe other chemical groups as defined herein. For example, the term "substituted aryl" includes, but is not limited to "alkylaryl". Unless otherwise indicated, where groups are described as optionally substituted, any substituents of these groups are themselves unsubstituted.

In some embodiments, substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and/or substituted heteroaryl includes cycloalkyl, heterocyclyl, aryl, and/or heteroaryl groups having substituents on the ring atoms, which cycloalkyl, heterocyclyl, aryl, and/or heteroaryl groups are attached to the remainder of the compound. For example, in the following moieties, the cyclopropyl group is substituted with a methyl group:

the compounds of the embodiments disclosed herein or their pharmaceutically acceptable salts may include one or more asymmetric centers and thus may produce enantiomers, diastereomers and other stereoisomeric forms which may be defined as (R) -or (S) -or (D) -or (L) -for amino acids, depending on the absolute stereochemistry. The present disclosure is intended to include all such possible isomers and their racemic and optically pure forms. Optically active (+) and (-), (R) -and (S) -or (D) -and (L) -isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for preparing/separating the individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or of a salt or derivative) using, for example, chiral High Pressure Liquid Chromatography (HPLC). When a compound described herein contains an olefinic double bond or other geometric asymmetric center, and unless specified otherwise, it is intended that the compound include both E and Z geometric isomers. Also, all tautomeric forms are intended to be included. Where a compound is represented in its chiral form, it is to be understood that this embodiment encompasses, but is not limited to, a particular diastereomeric or enantiomerically enriched form. When chirality is not specified but is present, it is understood that this embodiment relates to a particular diastereomeric or enantiomerically enriched form; or a racemic or non-racemic mixture of such compounds. As used herein, a "non-racemic mixture" is a mixture of stereoisomers in a ratio other than 1:1.

"stereoisomers" refers to compounds that consist of the same atoms bonded by the same bonds but have different three-dimensional structures that are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refers to two stereoisomers whose molecules are non-superimposable mirror images of each other.

"enantiomers" are a pair of stereoisomers that are non-overlapping mirror images of each other. The 1:1 mixture of a pair of enantiomers is a "racemic" mixture. Mixtures of enantiomers other than 1:1 ratio are "non-racemic" mixtures.

"diastereomers" are stereoisomers that have at least two asymmetric atoms but which are not mirror images of each other.

"tautomer" refers to proton transfer from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any of the compounds provided herein.

Some of the compounds provided herein exist in tautomeric forms. Tautomers are balanced with each other. For example, amide-containing compounds may exist in equilibrium with imido tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium between the tautomers, one of ordinary skill in the art will understand that compounds include amide and imide tautomers. Thus, amide-containing compounds are understood to include the imido acid tautomers thereof. Also, the imide acid containing compounds are understood to include amide tautomers thereof.

"solvates" are formed by the interaction of a solvent and a compound. Solvates of salts of the compounds provided herein are also provided. Also provided are hydrates of the compounds provided herein.

Any formula or structure provided herein is also intended to represent an unlabeled form of a compound and an isotopically labeled form. Isotopically-labeled compounds have structures depicted by the formulae given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as, but not limited to ² H (deuterium, D), ³ H (tritium), ¹¹ C、 ¹³ C、 ¹⁴ C、 ¹⁵ N、 ¹⁸ F、 ³¹ P、 ³² P、 ³⁵ S、 ³⁶ Cl and Cl ¹²⁵ I. Also provided herein are various isotopically-labeled compounds of the present disclosure, for example, into which a radioisotope such as ² H、 ³ H、 ¹³ C and C ¹⁴ Those of C. Such isotopically-labeled compounds are useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as Positron Emission Tomography (PET) or single photon emission electron computed tomography (SPECT), tissue distribution assays including drugs or substrates, or in radiation therapy of patients.

The present disclosure also includes compounds of formula I or II wherein 1 to n hydrogens attached to a carbon atom are replaced with deuterium, where n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are therefore useful for extending the half-life of any compound of formula I or II when administered to a mammal, especially a human. See, for example, foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", trends pharmacol. Sci. Volume 5 (stage 12): pages 524-527 (1984). Such compounds are synthesized by methods well known in the art, for example, by employing starting materials in which one or more hydrogens have been replaced with deuterium.

Deuterium labeled or substituted therapeutic compounds of the present disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties involving absorption, distribution,Metabolism and Excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or improved therapeutic index. ¹⁸ F-labeled compounds can be used in PET or SPECT studies. Isotopically-labeled compounds of the present disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the examples and formulations described below by substituting a readily available isotopically-labeled reagent for a non-isotopically-labeled reagent. It is to be understood that deuterium in this context is considered a substituent in the compounds of formula I or II.

The concentration of such heavier isotopes, particularly deuterium, may be defined by an isotopic enrichment factor. In the compounds of the present disclosure, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise indicated, when a position is specifically designated as "H" or "hydrogen," that position is understood to be hydrogen having its natural abundance isotopic composition. Thus, in the compounds of the present disclosure, any atom specifically designated as deuterium (D) is meant to represent deuterium.

In many cases, the compounds of the present disclosure are capable of forming acid and/or base salts with the aid of amino groups and/or carboxyl groups or groups similar thereto.

The term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of the given compound and is not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. By way of example only, salts derived from inorganic bases include sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines such as alkylamines, dialkylamines, trialkylamines, substituted alkylamines, di (substituted alkyl) amines, tri (substituted alkyl) amines, alkenylamines, dienylamine, trialkenylamine, substituted alkenylamines, di (substituted alkenylamines, tri (substituted alkenylamines), monocycloalkylamines, dicycloalkylamines or tricycloalkylamines, monoarylamines, diarylamines or triarylamines or mixed amines, and the like. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri (isopropyl) amine, tri (N-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional medium or agent is incompatible with the active ingredient, its use in therapeutic compositions is contemplated. Supplementary active ingredients may also be incorporated into the composition.

"treatment" or "treatment" is a method for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results include one or more of the following: a) Inhibiting the disease or disorder (i.e., reducing one or more symptoms caused by the disease or disorder, and/or reducing the extent of the disease or disorder); b) Slowing or arresting the development of one or more clinical symptoms associated with the disease or disorder (i.e., stabilizing the disease or disorder, preventing or delaying the progression or worsening of the disease or disorder, and/or preventing or delaying the spread (i.e., metastasis of the disease or disorder); and/or c) alleviating the disease, i.e., causing regression of the clinical symptoms (i.e., improving the disease state, providing partial or total relief of the disease or condition, enhancing the effect of another drug, delaying the progression of the disease, increasing the quality of life, and/or extending survival).

"prevention" or "prevention" means any treatment of any disease or disorder that results in the absence of development of clinical symptoms of the disease or disorder. In some embodiments, the compounds may be administered to a subject (including a human) at risk or having a family history of the disease or disorder.

"subject" refers to an animal, such as a mammal (including a human), that has been or will be the subject of treatment, observation or experiment. The methods described herein may be used for human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.

The term "therapeutically effective amount" or "effective amount" of a compound, or pharmaceutically acceptable salt, isomer, or mixture thereof, as described herein, refers to an amount sufficient to effect treatment to provide a therapeutic benefit such as ameliorating symptoms or slowing the progression of a disease when administered to a subject. For example, a therapeutically effective amount may be an amount sufficient to ameliorate a symptom of a disease or disorder responsive to inhibition of toll-like receptor 7, 8, and/or 9. The therapeutically effective amount may vary depending on the subject, the disease or disorder being treated, the weight and age of the subject, the severity of the disease or disorder, and the mode of administration, as can be readily determined by one skilled in the art.

II compounds

In one embodiment, provided herein are compounds of formula I,

or a pharmaceutically acceptable salt thereof,

wherein the method comprises the steps of

wherein 4 to 7 membered monocyclic heterocyclyl, phenyl, naphthyl, 5 to 6 membered monocyclic heteroaryl, 8 to 10 membered fused bicyclic heterocyclyl and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 4R ^a Group substitution;

x is N or CR ³ ；

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally being substituted with 1-2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a Group substitution;

R ⁶ Is C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _3--7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally substituted with 1-4R ^a Group substitution;

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl and 7-to 10-membered spiro heterocycThe cyclic groups are each independently optionally substituted with 1 to 4R ^a Group substitution;

each R ⁴ Independently H or C _1-3 An alkyl group;

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 4R ^a Group substitution;

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered monocyclic heterocyclylThe fused bicyclic heteroaryl and 7-to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 4R ^a Group substitution;

Wherein C is _1-6 Alkyl, C _2-6 Alkenyl and C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 3R ^c The substitution of the groups is carried out,

Wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl each independently optionally being substituted with 1-3R ^d Group substitution;

Each R ^d Independently oxo, halogen, -CN, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ¹² 、-C(O)R ¹² 、-C(O)OR ¹² 、-C(O)N(R ¹² )(R ¹² )、-NR ¹² R ¹² 、-N(R ¹² ) ₂ (R ¹² ) ⁺ 、-N(R ¹² )C(O)R ¹² 、-N(R ¹² )C(O)OR ¹² 、-N(R ¹² )C(O)N(R ¹² )(R ¹² )、-N(R ¹² )S(O) ₂ (R ^12a )、-NR ¹² S(O) ₂ N(R ¹² )(R ¹² )、-NR ¹² S(O) ₂ O(R ^12a )、-OC(O)R ¹² 、-OC(O)OR ¹² 、-OC(O)N(R ¹² )(R ¹² )、-SR ¹² 、-S(O)R ^12a 、-S(O)(NH)R ¹² 、-S(O) ₂ R ^12a 、-S(O) ₂ N(R ¹² )(R ¹² ) Or-n=s (R ^12a )(R ^12a )＝O；

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof,

Is 1 to 4R ^a Group substitution;

x is N or CR ³ ；

z is C _1-10 Alkyl, C _2-6 Alkynyl, -NR ⁶ R ⁷ 、-C(O)R ¹³ 、-C(O)NR ⁶ R ⁷ 、-S(O) ₂ R ⁶ 、C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclicHeterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl or L ¹ ，

Wherein C is _1-10 Alkyl and C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 4R ^b The substitution of the groups is carried out,

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, are optionally substituted with 1-2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a The substitution of the groups is carried out,

wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a Group substitution;

wherein C is _1-6 Alkyl groups optionallyIs 1 to 4R ^b The substitution of the groups is carried out,

each R ⁴ Independently H or C _1-3 An alkyl group;

each R ⁸ Independently halogen, -C (O) R ⁹ 、-NR ¹⁰ R ¹⁰ 、C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spirocyclic heterocyclyl, -OR ⁵ 、-C(O)OR ⁵ 、-C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ ) ₂ (R ⁵ ) ⁺ 、-N(R ⁵ )C(O)R ⁵ 、-N(R ⁵ )C(O)OR ⁵ 、-N(R ⁵ )C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ )S(O) ₂ (R ^5a )、-NR ⁵ S(O) ₂ N(R ⁵ )(R ⁵ )、-NR ⁵ S(O) ₂ O(R ^5a )、-OC(O)R ⁵ 、-OC(O)OR ⁵ 、-OC(O)N(R ⁵ )(R ⁵ )、-SR ⁵ 、-S(O)R ^5a 、-S(O)(NH)R ⁵ 、-S(O) ₂ R ^5a 、-S(O) ₂ N(R ⁵ )(R ⁵ ) Or-n=s (R ^5a )(R ^5a )＝O，

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclylEach of a 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl independently of the other is optionally substituted with 1 to 4R ^a Group substitution;

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, are optionally substituted with 1 to 4R ^a Group substitution;

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroarylAryl and 7-to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3R ^d The substitution of the groups is carried out,

each R ^b Independently oxo, imino, halogen, -NO ₂ 、-N ₃ 、-CN、C _3--7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered bridged bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spirocyclic heterocyclyl, -OR ¹¹ 、-C(O)R ¹¹ 、-C(O)OR ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ 、-N(R ¹¹ ) ₂ (R ¹¹ ) ⁺ 、-N(R ¹¹ )C(O)R ¹¹ 、-N(R ¹¹ )C(O)OR ¹¹ 、-N(R ¹¹ )C(O)N(R ¹¹ )(R ¹¹ )、-N(R ¹¹ )S(O) ₂ (R ^11a )、-NR ¹¹ S(O) ₂ N(R ¹¹ )(R ¹¹ )、-NR ¹¹ S(O) ₂ O(R ^11a )、-OC(O)R ¹¹ 、-OC(O)OR ¹¹ 、-OC(O)N(R ¹¹ )(R ¹¹ )、-SR ¹¹ 、-S(O)R ^11a 、-S(O)(NH)R ¹¹ 、-S(O) ₂ R ^11a 、-S(O) ₂ N(R ¹¹ )(R ¹¹ ) Or-n=s (R ^11a )(R ^11a )＝O，

each R ^c Independently halogen, -CN, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiro heterocyclyl, -OR ¹² 、-C(O)R ¹² 、-C(O)OR ¹² 、-C(O)N(R ¹² )(R ¹² )、-NR ¹² R ¹² 、-N(R ¹² ) ₂ (R ¹² ) ⁺ 、-N(R ¹² )C(O)R ¹² 、-N(R ¹² )C(O)OR ¹² 、-N(R ¹² )C(O)N(R ¹² )(R ¹² )、-N(R ¹² )S(O) ₂ (R ^12a )、-NR ¹² S(O) ₂ N(R ¹² )(R ¹² )、-NR ¹² S(O) ₂ O(R ^12a )、-OC(O)R ¹² 、-OC(O)OR ¹² 、-OC(O)N(R ¹² )(R ¹² )、-SR ¹² 、-S(O)R ^12a 、-S(O)(NH)R ¹² 、-S(O) ₂ R ^12a 、-S(O) ₂ N(R ¹² )(R ¹² ) Or-n=s (R ^12a )(R ^12a )＝O；

R ¹ is a 4 to 7 membered monocyclic heterocyclyl, a 5 to 6 membered monocyclic heteroaryl or an 8 to 10 membered fused bicyclic heteroaryl,

wherein 4 to 7 membered monocyclic heterocyclyl, 5 to 6 membered monocyclic heteroaryl, and 8 to 10 membered fused

The bicyclic heteroaryl groups are each independently optionally substituted with 1 to 3R ^a Group substitution;

R ² is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-6 Substitution of the alkoxy group;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

z is C _1-10 Alkyl, -C (O) R ¹³ 、-C(O)NR ⁶ R ⁷ 、C _3-7 A monocyclic cycloalkyl group, a 4-to 7-membered monocyclic heterocyclic group, a phenyl group, a 5-to 6-membered monocyclic heteroaryl group, a 8-to 10-membered fused bicyclic heterocyclic group, a 6-to 10-membered bridged bicyclic heterocyclic group, a 8-to 10-membered fused bicyclic heteroaryl group or a 7-to 10-membered spiro heterocyclic group,

wherein C is _1-10 Alkyl is optionally substituted with 1 to 3R ^b The substitution of the groups is carried out,

wherein C is _3-7 Monocyclic cycloalkyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, are optionally substituted with 1-2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a The substitution of the groups is carried out,

R ⁶ is C _1-6 Alkyl, C _3-7 A monocyclic cycloalkyl group, a 4-to 7-membered monocyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group,

wherein C is _1-6 Alkyl is optionally substituted with 1 to 3R ^b The substitution of the groups is carried out,

wherein C is _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic

Heterocyclyl groups are each independently optionally substituted with 1 to 3R ^a Group substitution;

R ¹³ is a 4-to 7-membered monocyclic heterocyclic group, a 8-to 10-membered fused bicyclic heterocyclic group, a 6-to 10-membered bridged bicyclic heterocyclic group or a 7-to 10-membered spiro heterocyclic group,

wherein 4 to 7 membered monocyclic heterocyclyl, 8 to 10 membered fused bicyclic heterocyclyl, 6 to 10 membered bridged bisThe cyclic heterocyclyl and the 7-to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3R ^a Group substitution;

R ⁷ is H, C _1-3 Alkyl or C _3-7 A monocyclic cycloalkyl group,

wherein C is _1-3 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN and C _1-3 Substitution of the alkoxy group;

each R ⁸ independently-C (O) R ⁹ 、C _1-6 Alkyl, -NR ¹⁰ R ¹⁰ 、C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 7-to 10-membered spiroheterocyclyl or-S (O) ₂ R ^5a ，

wherein C is _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl, each independently, are optionally substituted with 1 to 3R ^a Group substitution;

R ⁹ is a 4-to 7-membered monocyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group,

wherein 4 to 7 membered monocyclic heterocyclyl and 6 to 10 membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3R ^a Group substitution;

each R ¹⁰ Independently is H, 4-to 7-membered monocyclic heterocyclyl or 6-to 10-membered bridged bicyclic heterocyclyl,

wherein 4 to 7 membered monocyclic heterocyclyl and 6 to 10 membered bridged bicyclic heterocyclyl are each independently

Optionally by 1 to 3R ^a Group substitution;

R ^5a is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a Group substitution;

wherein 4 to 7 membered monocyclic heterocyclyl, 5 to 6 membered monocyclic heteroaryl, and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen and CN

Group substitution;

R ² is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-3 Substitution of the alkoxy group;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

Wherein C is _1-10 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-4 The group of the alkoxy group is substituted,

wherein C is _3-7 Monocyclic cycloalkyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, are optionally substituted with 1-2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

wherein C is _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and R ^e Is substituted by a group of (a) or (b),

wherein C is _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -C (O) R ¹¹ 、-NR ¹¹ R ¹¹ 、C _1-4 Alkoxy, C _1-5 Alkyl and R ^f Is substituted by a group of (a) or (b),

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹² R ¹² and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (a) or (b),

wherein each R is ^e Independently 4 to 7 membered monocyclic heterocyclyl or 5 to 6 membered monocyclic heteroaryl,

wherein each R is ^f Independently C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl or 7-to 7-memberedA 10 membered spirocyclic heterocyclyl group wherein C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen;

wherein 4 to 7 membered monocyclic heterocyclyl, 8 to 10 membered fused bicyclic heterocyclyl, 6 to 10 membered bridged bicyclic heterocyclyl, and 7 to 10 membered spiro heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ Phenyl, C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹² R ¹² 、-C(O)N(R ¹² )(R ¹² ) And R is ^g Is substituted by a group of (a) or (b),

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl;

R ⁷ is H, C _1-3 Alkyl or C _3-7 A monocyclic cycloalkyl group,

wherein C is _1-3 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen and C _1-3 Substitution of the alkoxy group;

Wherein C is _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-S(O) ₂ R ^11a 、C _1-4 Alkoxy and R ^h Is substituted by a group of (a) or (b),

wherein C is _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-toThe 10-membered bridged bicyclic heterocyclyl and the 7-to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, oxo, and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (a) or (b),

wherein C is _1-4 Alkoxy groups optionally substituted with 1 to 3 halo groups,

wherein each R is ^h Independently C _3-7 A monocyclic cycloalkyl or 4-to 7-membered monocyclic heterocyclyl;

wherein 4 to 7 membered monocyclic heterocyclyl and 6 to 10 membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, and-CN;

each R ¹⁰ Independently is H, a 4-to 7-membered monocyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, wherein 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Alkyl substitution;

R ^5a is a 4 to 7 membered monocyclic heterocyclyl;

each R ¹¹ H, C independently _1-4 Alkyl or C _3-7 A monocyclic cycloalkyl group;

each R ^11a Independently H or C _1-4 An alkyl group;

each R ¹² Independently H or C _1-4 An alkyl group;

wherein 4 to 7 membered monocyclic heterocyclyl, 5 to 6 membered monocyclic heteroaryl, and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 3R ^a Group substitution;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

z is C _1-10 Alkyl, -C (O) R ¹³ 、-C(O)NR ⁶ R ⁷ 、C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _3-7 Monocyclic cycloalkyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, eachIndependently optionally substituted with 1 to 2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a The substitution of the groups is carried out,

wherein C is _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3R ^a Group substitution;

wherein 4 to 7 membered monocyclic heterocyclyl, 8 to 10 membered fused bicyclic heterocyclyl, 6 to 10 membered bridged bicyclic heterocyclyl and 7 to 10 membered spiro heterocyclyl are each independently optionally substituted with 1 to 3R ^a Group substitution;

R ⁷ is H, C _1-3 Alkyl or C _3-7 A monocyclic cycloalkyl group,

Optionally by 1 to 3R ^a Group substitution;

wherein 4 to 7 membered monocyclic heterocyclyl, 5 to 6 membered monocyclic heteroaryl, and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

wherein C is _3-7 Monocyclic cycloalkyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally substituted with 1-2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein each R is ^f Independently C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl or 7-to 10-membered spiro heterocyclyl, wherein C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen;

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl;

R ⁷ is H, C _1-3 Alkyl or C _3-7 A monocyclic cycloalkyl group,

Wherein C is _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、-S(O) ₂ R ^11a 、C _1-4 Alkoxy and R ^h Is substituted by a group of (a) or (b),

wherein C is _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl each independently are optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-4 Alkoxy groups optionally substituted with 1 to 3 halo groups,

wherein 4 to 7 membered monocyclic heterocyclyl and 6 to 10 membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

each R ¹⁰ Independently is H, 4-to 7-membered monocyclic heterocyclyl or 6-to 10-membered bridged bicyclic heterocyclyl, wherein 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with-OH, halogen, -CN, oxygenSubstituted, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Alkyl substitution;

R ^5a is a 4 to 7 membered monocyclic heterocyclyl;

each R ^11a Independently H or C _1-4 An alkyl group;

each R ¹² Independently H or C _1-4 An alkyl group;

R ² is C _1-6 An alkyl group, a hydroxyl group,

wherein C is _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-6 Substitution of the alkoxy group;

x is N or CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

z is-C (O) R ¹³ 、-C(O)NR ⁶ R ⁷ A 5-to 6-membered monocyclic heteroaryl group or a 7-to 10-membered spirocyclic heterocyclyl group,

wherein 5 to 6 membered monocyclic heteroaryl and 7 to 10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a Group substitution;

R ⁶ is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a Group substitution;

R ⁷ is H or C _1-3 An alkyl group;

each R ⁸ Independently 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a Group substitution;

In some embodiments of the compounds of formula I or II or pharmaceutically acceptable salts thereof,

R ² is C _1-6 An alkyl group, a hydroxyl group,

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

R ⁶ is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

R ⁷ is H or C _1-3 An alkyl group;

x is N or CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

wherein 5 to 6 membered monocyclic heteroaryl and 7 to 10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

R ⁶ is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

wherein C is _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-4 The group of the alkoxy group is substituted,

wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

wherein 4 to 7 membered monocyclic heterocyclyl, 8 to 10 membered fused bicyclic heterocyclyl, 6 to 10 membered bridged bicyclic heterocyclyl, and 7 to 10 membered spiro heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted by a group of (2);

R ⁷ is H or C _1-3 An alkyl group;

each R ⁸ Independently 4 to 7 membered monocyclic heterocyclyl wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

each R ¹¹ Independently H or C _1-4 An alkyl group;

each R ¹² Independently H or C _1-4 An alkyl group;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

wherein 5 to 6 membered monocyclic heteroaryl and 7 to 10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 2R ⁸ Radical extractionSubstituted, and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

R ⁶ is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

R ⁷ is H or C _1-3 An alkyl group;

each R ¹¹ Independently H or C _1-4 An alkyl group;

each R ¹² Independently H or C _1-4 An alkyl group;

As used herein, each 4-membered monocyclic heterocyclyl has 1 ring heteroatom selected from N, O and S, unless otherwise specified. As used herein, each 5-to 7-membered monocyclic heterocyclyl has 1 to 2 ring heteroatoms independently selected from N, O and S, unless otherwise specified. As used herein, each 6-membered bridged bicyclic heterocyclyl has 1 ring heteroatom selected from N, O and S, unless otherwise specified. As used herein, each 7-membered bridged bicyclic heterocyclyl has 1 to 2 ring heteroatoms independently selected from N, O and S, unless otherwise specified. As used herein, each of the 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O and S, unless otherwise specified.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4 to 7 membered monocyclic heterocyclyl, phenyl, naphthyl, 5 to 6 membered monocyclic heteroaryl, 8 to 10 membered fused bicyclic heterocyclyl or 8 to 10 membered fused bicyclic heteroaryl,

wherein 4 to 7 membered monocyclic heterocyclyl, phenyl, naphthyl, 5 to 6 membered monocyclic heteroaryl, 8 to 10 membered fused bicyclic heterocyclyl and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 4R ^a And (3) group substitution.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4 to 7 membered monocyclic heterocyclyl, a 5 to 6 membered monocyclic heteroaryl or an 8 to 10 membered fused bicyclic heteroaryl,

wherein 4 to 7 membered monocyclic heterocyclyl, 5 to 6 membered monocyclic heteroaryl, and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 3R ^a And (3) group substitution.

wherein 4 to 7 membered monocyclic heterocyclyl, 5 to 6 membered monocyclic heteroaryl, and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

wherein C is _1-5 The alkyl group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, and CN.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 6 membered monocyclic heterocyclyl, a 6 membered monocyclic heteroaryl, or an 8 to 10 membered fused bicyclic heteroaryl, wherein 6 membered monocyclic heterocyclyl, 6 membered monocyclic heteroaryl, and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5-to 7-membered monocyclic heterocyclyl, wherein 5-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5-to 7-membered monocyclic heterocyclic group, wherein the 5-to 7-membered monocyclic heterocyclic group is optionally substituted with 1 to 3R ^a And (3) group substitution. In the formulaIn some embodiments of the compounds of I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5-to 7-membered monocyclic heterocyclyl, wherein 5-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 6 membered monocyclic heterocyclyl wherein the 6 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5-to 7-membered monocyclic heterocyclic group, wherein the 5-to 7-membered monocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5-to 7-membered monocyclic heterocyclic group, wherein the 5-to 7-membered monocyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5-to 7-membered monocyclic heterocyclyl wherein the 5-to 7-membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 6 membered monocyclic heterocyclyl wherein the 6 membered monocyclic heterocyclyl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5-to 7-membered monocyclic heterocyclic group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 6-membered monocyclic heterocyclic group.

In some embodiments of the compounds of formula I or II or pharmaceutically acceptable salts thereof, R ¹ Is phenyl, wherein phenyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is phenyl, wherein phenyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is phenyl, wherein phenyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is phenyl, wherein phenyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is phenyl, wherein phenyl is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is phenyl, wherein phenyl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is phenyl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

A compound of formula I or II or a pharmaceutically acceptable salt thereofIn some embodiments, R ¹ Is naphthyl, wherein the naphthyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is naphthyl, wherein the naphthyl is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is naphthyl, wherein naphthyl is independently selected from-OH, halogen, -CN, oxo, -NR from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a naphthyl group.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5 to 6 membered monocyclic heteroaryl, wherein the 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II or pharmaceutically acceptable salts thereof,R ¹ is a 5 to 6 membered monocyclic heteroaryl, wherein the 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5 to 6 membered monocyclic heteroaryl, wherein the 5 to 6 membered monocyclic heteroaryl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 5 to 6 membered monocyclic heteroaryl. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a 6 membered monocyclic heteroaryl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In formula I orIn some embodiments of the compound of II or a pharmaceutically acceptable salt thereof, R ¹ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heterocyclic group.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 The alkyl group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, and CN.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is 8 to10-membered fused bicyclic heteroaryl wherein 8 to 10-membered fused bicyclic heteroaryl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heteroaryl group, wherein the 8-to 10-membered fused bicyclic heteroaryl group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heteroaryl group, wherein the 8-to 10-membered fused bicyclic heteroaryl group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heteroaryl group, wherein the 8-to 10-membered fused bicyclic heteroaryl group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 The alkyl group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, and CN.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is an 8-to 10-membered fused bicyclic heteroaryl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is that

Each of them is optionally substituted with 1 to 4R ^a And (3) group substitution.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is a pyridyl group,

Each of them is independently optionally selected from-OH, halogen, -CN, oxo, -NR, independently from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 The alkyl group is optionally substituted with 1 to 3 halogen groups.

Each of them is independently optionally selected from-OH, halogen, -CN, oxo, -NR, independently from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is independently selected from oxo, C1 to 3 _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Substituted with 1 to 3 groups independently selected from oxo, methoxy and methyl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹ Is pyridyl or

Each of which is independently optionally substituted with 1 to 3 groups independently selected from methoxy and methyl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is H, -CN, C _1-6 Alkyl or C _3-7 Monocyclic cycloalkyl wherein C _1-6 Alkyl and C _3-7 Monocyclic cycloalkyl groups are each independently optionally substituted with 1 to 4 groups independently selected from halogen and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is H, -CN, C _1-6 Alkyl or C _3-7 Monocyclic cycloalkyl wherein C _1-6 Alkyl and C _3-7 Monocyclic cycloalkyl groups are each independently optionally substituted with 1 to 3 groups independently selected from halogen and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is H, -CN, C _1-6 Alkyl or C _3-7 Monocyclic cycloalkyl wherein C _1-6 Alkyl and C _3-7 Monocyclic cycloalkyl groups are each independently optionally substituted with 1 to 3 groups independently selected from halogen and C _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is H. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² is-CN.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 4 groups independently selected from halogen and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-3 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-6 Alkyl, wherein C _1-6 Alkyl groups are independently selected from halogen and C by 1 to 4 _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-6 Alkyl, wherein C _1-6 Alkyl groups are independently selected from halogen and C by 1 to 3 _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-6 Alkyl, wherein C _1-6 Alkyl groups are independently selected from halogen and C by 1 to 3 _1-3 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-6 An alkyl group.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-4 Alkyl, wherein C _1-4 Alkyl is optionally substituted with 1 to 4 groups independently selected from halogen and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-4 Alkyl, wherein C _1-4 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-6 The groups of the alkoxy groups are substituted. In a compound of formula I or IIIn some embodiments of pharmaceutically acceptable salts thereof, R ² Is C _1-4 Alkyl, wherein C _1-4 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-4 Alkyl, wherein C _1-4 Alkyl groups are independently selected from halogen and C by 1 to 4 _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-4 Alkyl, wherein C _1-4 Alkyl groups are independently selected from halogen and C by 1 to 3 _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-4 Alkyl, wherein C _1-4 Alkyl groups are independently selected from halogen and C by 1 to 3 _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-4 An alkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-3 An alkyl group. In some embodiments of the compounds of formula I or II or pharmaceutically acceptable salts thereof, R ² Is ethyl or isopropyl. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is methyl. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is ethyl. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is propyl. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is isopropyl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4 groups independently selected from halogen and C _1-6 The groups of the alkoxy groups are substituted. In formula I or IIIn some embodiments of the compound or pharmaceutically acceptable salt thereof, R ² Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-3 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl groups are independently selected from halogen and C by 1 to 4 _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl groups are independently selected from halogen and C by 1 to 3 _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl groups are independently selected from halogen and C by 1 to 3 _1-3 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _3-7 A monocyclic cycloalkyl group.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is cyclopropyl, wherein cyclopropyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-3 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is cyclopropyl, wherein cyclopropyl is independently selected from halogen and C by 1 to 3 _1-3 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is cyclopropyl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is C _1-3 Alkyl and R ¹ Is that

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ² Is isopropyl and R ¹ Is that

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, X is N or CR ³ 。

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, X is N or CH. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, X is N. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, X is CR ³ . In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, X is CR ³ Wherein R is ³ Is H, halogen or C _1-4 An alkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, X is CR ³ Wherein R is ³ Is H, halogen or C _1-3 An alkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, X is CH.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ Is H, halogen, -CN, C _1-6 Alkyl, C _3-6 Monocyclic cycloalkyl or-O (C) _1-4 Alkyl), wherein C _1-4 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ⁴ R ⁴ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ Is H, halogen or C _1-4 An alkyl group. In some embodiments of the compounds of formula I or II or pharmaceutically acceptable salts thereofIn the scheme, R ³ Is H, halogen or C _1-3 An alkyl group.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ Is H. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ Is halogen. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ Is C _1-6 An alkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ Is C _1-4 An alkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ Is C _1-3 An alkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ Is C _3-6 A monocyclic cycloalkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ is-O (C) _1-4 Alkyl), wherein C _1-4 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ⁴ R ⁴ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ is-OCF ₃ . In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ³ is-OCHF ₂ 。

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, each R ⁴ Independently H or C _1-3 An alkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, one R ⁴ Is H. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, one R ⁴ Is C _1-3 An alkyl group.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 Alkyl, C _2-6 Alkynyl, -NR ⁶ R ⁷ 、-C(O)R ¹³ 、-C(O)NR ⁶ R ⁷ 、-S(O) ₂ R ⁶ 、C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl or L ¹ ，

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally being substituted with 1-2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a And (3) group substitution.

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, are optionally substituted with 1-2R ⁸ The substitution of the groups is carried out,and each independently is optionally substituted with 1 to 3R ^a Substituted with radicals, and

wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _7-10 Fused bicyclic cycloalkyl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl or 8-to 10-membered fused bicyclic heteroaryl,

wherein C is _7-10 Fused bicyclic cycloalkyl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 8-to 10-membered fused bicyclic heteroaryl, each independently, are optionally substituted with 1-2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a And (3) group substitution.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 Alkyl, -C (O) R ¹³ 、-C(O)NR ⁶ R ⁷ 、C _3-7 A monocyclic cycloalkyl group, a 4-to 7-membered monocyclic heterocyclic group, a phenyl group, a 5-to 6-membered monocyclic heteroaryl group, a 8-to 10-membered fused bicyclic heterocyclic group, a 6-to 10-membered bridged bicyclic heterocyclic group, a 8-to 10-membered fused bicyclic heteroaryl group or a 7-to 10-membered spiro heterocyclic group,

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 Alkyl, -C (O) R ¹³ 、-C(O)NR ⁶ R ⁷ 、C _3-7 Single ringCycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 Alkyl, -C (O) R ¹³ 、-C(O)NR ⁶ R ⁷ 、C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _3-7 Monocyclic cycloalkyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally substituted with 1-2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a Substituted with radicals, and

wherein 4 to 7 membered monocyclic heteroringThe cyclic radical being substituted by 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution.

wherein C is _3-7 Monocyclic cycloalkyl, phenyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally substituted with 1-2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is-C (O) R ¹³ 、-C(O)NR ⁶ R ⁷ A 5-to 6-membered monocyclic heteroaryl group or a 7-to 10-membered spirocyclic heterocyclyl group,

wherein 5 to 6 membered monocyclic heteroaryl and 7 to 10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is-C (O) R ¹³ 、-C(O)NR ⁶ R ⁷ 5-to 6-membered monocyclic heterologyAryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein 5 to 6 membered monocyclic heteroaryl and 7 to 10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 Alkyl, wherein C _1-10 Alkyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 Alkyl, wherein C _1-10 Alkyl is optionally substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 Alkyl, wherein C _1-10 Alkyl is substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 Alkyl, wherein C _1-10 Alkyl is substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-10 An alkyl group.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _1-6 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is substituted with one R ⁸ Group-substituted C _1-6 Alkyl, wherein R is ⁸ Is a 7-to 10-membered spiro heterocyclic group,

wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

wherein the 7-to 10-membered spiro heterocyclyl has only one ring heteroatom, and wherein the one ring heteroatom is N.

A compound of formula I or a pharmaceutically acceptable salt thereofIn some embodiments, Z is substituted with one R ⁸ Group-substituted C _1-3 Alkyl, wherein R is ⁸ Is that

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _2-6 Alkynyl groups.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is L ¹ 。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-OR ⁵ 、-C(O)R ⁵ 、-C(O)N(R ⁵ )(R ⁵ )、-NR ⁵ R ⁵ 、-N(R ⁵ ) ₂ (R ⁵ ) ⁺ 、-N(R ⁵ )C(O)R ⁵ 、-N(R ⁵ )C(O)OR ⁵ 、-N(R ⁵ )C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ )S(O) ₂ (R ^5a )、-NR ⁵ S(O) ₂ N(R ⁵ )(R ⁵ )、-NR ⁵ S(O) ₂ O(R ^5a )、-OC(O)N(R ⁵ )(R ⁵ )、-SR ⁵ 、-S(O)R ^5a 、-S(O)(NH)R ⁵ 、-S(O) ₂ R ^5a 、-S(O) ₂ N(R ⁵ )(R ⁵ ) Or-n=s (R ^5a )(R ^5a ) =o. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-OR ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-C (O) R ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-C (O) N (R) ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-NR ⁵ R ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-N (R) ⁵ ) ₂ (R ⁵ ) ⁺ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-N (R) ⁵ )C(O)R ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-N (R) ⁵ )C(O)OR ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-N (R) ⁵ )C(O)N(R ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-N (R) ⁵ )S(O) ₂ (R ^5a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-NR ⁵ S(O) ₂ N(R ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-NR ⁵ S(O) ₂ O(R ^5a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-OC (O) N (R) ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-SR ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-S (O) R ^5a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-S (O) (NH) R ⁵ . A compound of formula I or a pharmaceutically acceptable thereof In some embodiments of the salt, L ¹ is-S (O) ₂ R ^5a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ is-S (O) ₂ N(R ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, L ¹ Is-n=s (R ^5a )(R ^5a )＝O。

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is substituted with 1 to 2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _3-7 A monocyclic cycloalkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is substituted with one R ⁸ A cyclohexyl group substituted with a group such as a hydroxyl group,

wherein R is ⁸ is-NR ¹⁰ R ¹⁰ Or 5 to 7 membered monocyclic heterocyclyl wherein 5 to 7 membered monocyclic heterocyclyl is selected from-OH, halogen, -CN, -NR, by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-4 Alkoxy groups are optionally substituted with 1 to 3 halogen groups, and

one of R ¹⁰ Is a 4-to 7-membered monocyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 Fused bicyclic cycloalkyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 Fused bicyclic cycloalkyl is substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 Fused bicyclic cycloalkyl is substituted with 1 to 2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _7-10 Fused bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 2R ⁸ Substituted with radicals, and optionally1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl groups are substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl groups are substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl groups are substituted with 1 to 2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is C _5-10 Bridged bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 4 to7-membered monocyclic heterocyclyl, wherein 4 to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 7 membered monocyclic heterocyclyl, wherein 5 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 7 membered monocyclic heterocyclyl, wherein 5 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 7 membered monocyclic heterocyclyl, wherein 5 to 7 membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 7 membered monocyclic heterocyclyl, wherein 5 to 7 membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 7 membered monocyclic heterocyclyl, wherein 5 to 7 membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 5 to 7-membered monocyclic heterocyclic group, wherein 5-7-membered monocyclic heterocyclic group is substituted with 1-2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 7 membered monocyclic heterocyclyl, wherein 5 to 7 membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is a 5-to 7-membered monocyclic heterocyclyl, wherein 5-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5-to 7-membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is pyrrolidinyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ is-C (O) R ⁹ And R is ⁹ Is azetidinyl, pyrrolidinyl, or piperidinyl, wherein azetidinyl, pyrrolidinyl, and piperidinyl are each optionally substituted with one methyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ is-C (O) R ⁹ And R is ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is that

Optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is piperidinyl, wherein piperidinyl is substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl, wherein R ⁸ Is C _1-6 An alkyl group.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is piperidinyl substituted with one cyclobutyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、-S(O) ₂ R ^11a And C _1-4 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl:

i) Is substituted with one oxo group and is substituted with one oxo group,

ii) is covered with one R ^h Group substitution, wherein R ^h Is C _3-7 A monocyclic cycloalkyl group or a 4-to 7-membered monocyclic heterocyclic group, and

iii) Optionally one is independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ Is C _1-6 Alkyl, wherein C _1-6 The alkyl group is substituted with an oxetanyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ is-S (O) ₂ R ^5a 。

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is piperidinyl, wherein piperidinyl is substituted with 1 to 4 methyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is azepanyl, wherein azepanyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is azepanyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein phenyl is optionally substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein phenyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein phenyl is substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein phenyl is substituted with 1 to 2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein phenyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is phenyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein phenyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is naphthyl, wherein naphthyl is optionally substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is naphthyl, wherein naphthyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is naphthyl, wherein naphthyl is substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is naphthyl, wherein naphthyl is substituted with 1 to 2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is naphthyl, wherein naphthyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is naphthyl.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5-to 6-membered monocyclic heteroaryl.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is a 5-to 6-membered monocyclic heteroaryl,

wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

wherein the 5-to 6-membered monocyclic heteroaryl has one or two ring heteroatoms which are N.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, wherein 8-to 10-membered fused bicyclic heterocyclyl is optionally substituted with 1-2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, wherein 8-to 10-membered fused bicyclic heterocyclyl is optionally substituted with 1-2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, wherein 8-to 10-membered fused bicyclic heterocyclyl is substituted with 1-2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, wherein 8-to 10-membered fused bicyclic heterocyclyl is substituted with 1-2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, wherein 8-to 10-membered fused bicyclic heterocyclyl is substituted with 1-2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, wherein 8-to 10-membered fused bicyclic heterocyclyl is substituted with 1-2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, wherein 8-to 10-membered fused bicyclic heterocyclyl is substituted with 1-2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, wherein 8-to 10-membered fused bicyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereofIn this case, Z is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is a 6-to 10-membered bridged bicyclic heterocyclyl, wherein the 6-to 10-membered bridged bicyclic heterocyclyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is a 6-to 10-membered bridged bicyclic heterocyclyl, wherein the 6-to 10-membered bridged bicyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is a 6-to 10-membered bridged bicyclic heterocyclyl, wherein the 6-to 10-membered bridged bicyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is a 6-to 10-membered bridged bicyclic heterocyclyl, wherein the 6-to 10-membered bridged bicyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is a 6-to 10-membered bridged bicyclic heterocyclyl, wherein the 6-to 10-membered bridged bicyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is a 6-to 10-membered bridged bicyclic heterocyclyl, wherein the 6-to 10-membered bridged bicyclic heterocyclyl is substituted with 1 to 2R ⁸ And (3) group substitution. In formula IIn some embodiments of the compound or pharmaceutically acceptable salt thereof, Z is a 6-to 10-membered bridged bicyclic heterocyclyl, wherein the 6-to 10-membered bridged bicyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is a 6-to 10-membered bridged bicyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heteroaryl, wherein 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1-2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heteroaryl, wherein 8-to 10-membered fused bicyclic heteroaryl is substituted with 1-2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heteroaryl, wherein 8-to 10-membered fused bicyclic heteroaryl is substituted with 1-2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heteroaryl, wherein 8-to 10-membered fused bicyclic heteroaryl is substituted with 1-2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heteroaryl, wherein 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1-3R ^a And (3) group substitution. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heteroaryl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 7-to 10-membered spirocyclic heterocyclyl, wherein 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1-2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is a 7-to 10-membered spiro ringHeterocyclyl, wherein 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I, or pharmaceutically acceptable salts thereof, Z is a 7 to 10 membered spirocyclic heterocyclyl,

wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 7-to 10-membered spirocyclic heterocyclyl, wherein 7-to 10-membered spirocyclic heterocyclyl is substituted with 1-2R ⁸ Substituted with groups and optionally with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 7-to 10-membered spirocyclic heterocyclyl, wherein 7-to 10-membered spirocyclic heterocyclyl is substituted with 1-2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 7-to 10-membered spirocyclic heterocyclyl, wherein 7-to 10-membered spirocyclic heterocyclyl is substituted with 1-2R ⁸ Substituted by 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 7-to 10-membered spirocyclic heterocyclyl, wherein 7-to 10-membered spirocyclic heterocyclyl is substituted with 1-2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 7-to 10-membered spirocyclic heterocyclyl, wherein 7-to 10-membered spirocyclic heterocyclyl is substituted with 1-2R ⁸ And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 7-to 10-membered spirocyclic heterocyclyl, wherein 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is a 7-to 10-membered spirocyclic heterocyclyl.

Wherein C is _7-10 Fused bicyclic cycloalkyl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 8-to 10-membered fused bicyclic heteroaryl, each independently, are optionally substituted with 1-2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, or 8-to 10-membered fused bicyclic heteroaryl,

wherein 8 to 10 membered fused bicyclic heterocyclyl, 6 to 10 membered bridged bicyclic heterocyclyl, and 8 to 10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

wherein the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 8-to 10-membered fused bicyclic heteroaryl each independently have one or two ring heteroatoms that are N.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is a 5 to 6 membered monocyclic heteroaryl or a 7 to 10 membered spirocyclic heterocyclyl,

Wherein 5 to 6 membered monocyclic heteroaryl and 7 to 10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

wherein 5 to 6 membered monocyclic heteroaryl and 7 to 10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

wherein each of the 5-to 6-membered monocyclic heteroaryl and 7-to 10-membered spirocyclic heterocyclyl independently has one or two ring heteroatoms which are N.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is pyridinyl or

Each of them is independently optionally substituted with 1 to 2R ⁸ Substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is oxadiazolyl or thiadiazolyl, each of which is independently optionally substituted with one R ⁸ And (3) group substitution.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is

Each of them is independently optionally substituted with one R ⁸ And (3) group substitution.

Each of them is independently optionally substituted with one R ⁸ Substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

Each of them is independently optionally substituted with one R ⁸ Substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 Radicals of alkyl radicalsGroup substitution.

/>

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, is substituted with 1 to 2R ⁸ Z substituted by radicals is

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is cyclopropyl, wherein cyclopropyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is cyclopropyl, wherein cyclopropyl is substituted with one R ⁸ And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ⁸ Independently halogen, -C (O) R ⁹ 、-NR ¹⁰ R ¹⁰ 、C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ⁵ 、-C(O)OR ⁵ 、-C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ ) ₂ (R ⁵ ) ⁺ 、-N(R ⁵ )C(O)R ⁵ 、-N(R ⁵ )C(O)OR ⁵ 、-N(R ⁵ )C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ )S(O) ₂ (R ^5a )、-NR ⁵ S(O) ₂ N(R ⁵ )(R ⁵ )、-NR ⁵ S(O) ₂ O(R ^5a )、-OC(O)R ⁵ 、-OC(O)OR ⁵ 、-OC(O)N(R ⁵ )(R ⁵ )、-SR ⁵ 、-S(O)R ^5a 、-S(O)(NH)R ⁵ 、-S(O) ₂ R ^5a 、-S(O) ₂ N(R ⁵ )(R ⁵ ) Or-n=s (R ^5a )(R ^5a )＝O，

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally substituted with 1-4R ^a And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ⁸ independently-C (O) R ⁹ 、C _1-6 Alkyl, -NR ¹⁰ R ¹⁰ 、C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 7-to 10-membered spiroheterocyclyl or-S (O) ₂ R ^5a ，

Wherein C is _1-6 Alkyl is optionally substituted with 1 to 3R ^b Substituted with radicals, and

wherein C is _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl, each independently, are optionally substituted with 1 to 3R ^a And (3) group substitution.

Wherein C is _1-4 Alkoxy groups optionally substituted with 1 to 3 halo groups,

wherein each R is ^h Independently C _3-7 Monocyclic cycloalkyl or 4-to 7-membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is halogen. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-OR ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-C (O) OR ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-C (O) N (R) ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-N (R) ⁵ ) ₂ (R ⁵ ) ⁺ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-N (R) ⁵ )C(O)R ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-N (R) ⁵ )C(O)OR ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-N (R) ⁵ )C(O)N(R ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-N (R) ⁵ )S(O) ₂ (R ^5a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-NR ⁵ S(O) ₂ N(R ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-NR ⁵ S(O) ₂ O(R ^5a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-OC (O) R ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-OC (O) OR ⁵ . In the formulaIn some embodiments of the compound of I or a pharmaceutically acceptable salt thereof, one R ⁸ is-OC (O) N (R) ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-SR ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-S (O) R ^5a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-S (O) (NH) R ⁵ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-S (O) ₂ R ^5a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-S (O) ₂ N(R ⁵ )(R ⁵ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is-n=s (R ^5a )(R ^5a )＝O。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -C (O) N (R) ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-3 Alkyl, wherein C _1-3 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -C (O) N (R) ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In the form of a compound of formula I or a pharmaceutically acceptable salt thereofIn some embodiments of the accepted salts, one R ⁸ Is C _1-3 Alkyl, wherein C _1-3 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is independently selected from-OH, halogen, -CN, oxo, -C (O) N (R) by 1 to 3 ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-3 Alkyl, wherein C _1-3 Alkyl is independently selected from-OH, halogen, -CN, oxo, -C (O) N (R) by 1 to 3 ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-3 Alkyl, wherein C _1-3 Alkyl is independently selected from-OH, halogen, -CN, -NR by 1 to 2 ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-6 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. Compounds of formula IIn some embodiments of the substance or pharmaceutically acceptable salt thereof, one R ⁸ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _3-7 A monocyclic cycloalkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 Fused bicyclic cycloalkyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _7-10 Fused bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl groups are substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is C _5-10 Bridged bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution. A compound of formula I or a pharmaceutically acceptable thereofIn some embodiments of the salt of (2), one R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is phenyl, wherein phenyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is phenyl, wherein phenyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is phenyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is naphthyl, wherein the naphthyl is substituted with 1 to 4R ^a And (3) group substitution. A compound of formula I or a pharmaceutically acceptable salt thereofIn some embodiments, one R ⁸ Is a naphthyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 5 to 6 membered monocyclic heteroaryl, wherein the 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 5 to 6 membered monocyclic heteroaryl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is independently selected from 1 to 3-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is an 8-to 10-membered fused bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 groups ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 6-to 10-membered bridged bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 7-to 10-membered spirocyclic heterocyclic group in which the 7-to 10-membered spirocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ Is a 7-to 10-membered spirocyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In formula IIn some embodiments of the compound or pharmaceutically acceptable salt thereof, R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is a 6-membered monocyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is piperidinyl or piperazinyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is that

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 4-to 7-membered monocyclic heterocyclic group substituted with a group of an alkyl group,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, oxo, and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (C) and

wherein C is _1-4 The alkoxy groups are optionally substituted with 1 to 3 halogen groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is piperidinyl or piperazinyl, each of which is independently selected from-OH, halogen, C, independently from 1 to 3 _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 The alkyl group is optionally substituted with one member selected from the group consisting of-OH and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (C) and

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is piperidinyl or piperazinyl, each of which is independently substituted with 1 to 3 groupsIs selected from-OH, fluorine, -OCF ₃ 、-CH ₂ CH ₂ OH and-CH ₂ C(O)NH ₂ Is substituted with a group of (a).

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is pyrrolidinyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is independently selected from-OH, halogen, C by 1 to 3 _1-4 Alkoxy and C _1-5 Pyrrolidinyl substituted with a group of an alkyl group,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is independently selected from the group consisting of-OH, halogen and C by 1 to 3 _l-3 Pyrrolidinyl substituted with an alkoxy group, and wherein C _l-3 The alkoxy groups are optionally substituted with 1 to 3 fluoro groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is independently selected from-OH, fluorine, -OCF by 1 to 3 ₃ 、-CH ₂ CH ₂ OH and-CH ₂ C(O)NH ₂ Pyrrolidinyl substituted with a group of (a).

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 C substituted by groups of alkyl groups _3-7 A monocyclic cycloalkyl group,

In the form of a compound of formula I or a pharmaceutically acceptable salt thereof In some embodiments of the acceptable salts, R ⁸ Is quilt-NR ¹¹ R ¹¹ Substituted cyclohexyl wherein R ¹¹ Is H or C _1-4 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is optionally selected from-OH, halogen, -CN, oxo, -NR, optionally from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 6-to 10-membered bridged bicyclic heterocyclic group substituted with a group of an alkyl group,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is optionally C _1-5 Alkyl substituted 6-to 10-membered bridged bicyclic heterocyclyl wherein C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, oxo, and-C (O) N (R) ¹² )(R ¹² ) Wherein R is a group substituted with ¹² Is H or C _1-4 An alkyl group.

Which is optionally covered by-CH ₂ C(O)NH ₂ And (3) substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is optionally selected from-OH, halogen, -CN, oxo, -NR, optionally from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 7-to 10-membered spirocyclic heterocyclic group substituted with a group of an alkyl group,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, oxo, and-C (O) N(R ¹² )(R ¹² ) Is substituted by a group of (C) and

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is a 7-to 10-membered spirocyclic heterocyclyl optionally substituted with one or two oxo groups.

Each of them is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-S(O) ₂ R ^11a And C _1-4 C substituted by groups of alkoxy groups _1-6 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、-S(O) ₂ R ^11a And C _1-4 C substituted by groups of alkoxy groups _1-6 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl:

i) Is substituted with one oxo group and is substituted with one oxo group,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is C _1-6 Alkyl, wherein C _1-6 The alkyl group is substituted with an oxetanyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is substituted by-C (O) N (R) ¹¹ )(R ¹¹ ) And (3) substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ is-C (O) R ⁹ 。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-C (O) R ⁹ 。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl, each independently, optionally substituted with 1-4R ^a And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 4-to 7-membered monocyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group,

wherein 4 to 7 membered monocyclic heterocyclyl and 6 to 10 membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3R ^a And (3) group substitution.

wherein C is _1-5 The alkyl group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, and-CN.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 4 to 7 membered monocyclic heterocyclyl or a 6 to 10 membered bridged bicyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl and 6 to 10 membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _2-6 Alkenyl group, wherein C _2-6 Alkenyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 4R ^b And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _3-7 A monocyclic cycloalkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 Fused bicyclic cycloalkyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _7-10 Fused bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl groups are substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is C _5-10 Bridged bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is phenyl, wherein phenyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is phenyl, wherein phenyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is phenyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is naphthyl, wherein the naphthyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a naphthyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 5 to 6 membered monocyclic heteroaryl, wherein the 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 5 to 6 membered monocyclic heteroaryl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is an 8-to 10-membered fused bicyclic heterocyclic group.

In the form of a compound of formula I or a pharmaceutically acceptable salt thereofIn some embodiments of the acceptable salts, R ⁹ Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is an 8-to 10-membered fused bicyclic heteroaryl group, wherein the 8-to 10-membered fused bicyclic heteroaryl group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is an 8-to 10-membered fused bicyclic heteroaryl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 7-to 10-membered spirocyclic heterocyclic group in which the 7-to 10-membered spirocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 7-to 10-membered spirocyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 5-to 7-membered monocyclic heterocyclyl, wherein 5-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 5-to 7-membered monocyclic heterocyclyl, wherein 5-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 5-to 7-membered monocyclic heterocyclic group, wherein the 5-to 7-membered monocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 5-to 7-membered monocyclic heterocyclyl wherein the 5-to 7-membered monocyclic heterocyclyl is independently selected from-OH, halogen, -CN, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 5-to 7-membered monocyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group has one ring heteroatom which is N.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 4-to 7-membered monocyclic heterocyclic group substituted with a group of an alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is azetidinyl, pyrrolidinyl or piperidinyl, each of which is C _1-3 Alkyl substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is morpholinyl or piperazinyl, each of which is optionally substituted with one C _1-3 Alkyl substitution, wherein C _1-3 The alkyl group is optionally substituted with one group independently selected from-OH, halogen, and-CN.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 groups ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted. Compounds of formula I or a medicament thereofIn some embodiments of the pharmaceutically acceptable salts, R ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁹ Is optionally selected from-OH, halogen, -CN, oxo, -NR, optionally from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted with a 6-to 10-membered bridged bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ is-NR ¹⁰ R ¹⁰ 。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁸ is-NR ¹⁰ R ¹⁰ 。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁸ is-S (O) ₂ R ^5a 。

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is-NR ⁶ R ⁷ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is-NHR ⁶ or-N (CH) ₃ )R ⁶ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is-NHR ⁶ . In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is-N (CH ₃ )R ⁶ 。

In some embodiments of the compound of formula I, or a pharmaceutically acceptable salt thereof, Z is-S(O) ₂ R ⁶ 。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is-C (O) NR ⁶ R ⁷ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is-C (O) N (H) R ⁶ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is-C (O) N (CH 3) R ⁶ 。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, C _3-7 A monocyclic cycloalkyl group, a 4-to 7-membered monocyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group,

wherein C is _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3R ^a Group substitution

Wherein each R is ^f Independently C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl or 7-to 10-membered spiro heterocyclyl, wherein C _3-7 The monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution.

wherein the method comprises the steps ofC _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-4 The group of the alkoxy group is substituted,

wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ⁶ Is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

wherein C is _1-6 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -NR ¹¹ R ¹¹ And C _1-3 The group of the alkoxy group is substituted,

wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-3 The groups of the alkoxy groups are substituted.

In the form of a compound of formula I or a pharmaceutically acceptable salt thereofIn some embodiments of the accepted salts, R ⁶ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 2 ¹¹ R ¹¹ And C _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C substituted with 1 to 2 groups independently selected from 4 to 7 membered monocyclic heterocyclyl and 5 to 6 membered monocyclic heteroaryl _1-6 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C substituted with one group selected from pyrrolidinyl, piperidinyl, morpholinyl and pyridinyl _1-4 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-6 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 Alkyl, wherein C _1-4 Alkyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 Alkyl, wherein C _1-4 Alkyl is optionally substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 Alkyl group, itMiddle C _1-4 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 Alkyl, wherein C _1-4 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 Alkyl, wherein C _1-4 Alkyl is substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 Alkyl, wherein C _1-4 Alkyl is substituted with 1 to 3R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 Alkyl, wherein C _1-4 Alkyl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ And C _1-4 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 Alkyl, wherein C _1-4 Alkyl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 2 ¹¹ R ¹¹ And C _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is optionally covered with a-NR ¹¹ R ¹¹ Substituted C _1-4 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is independently selected from-NH ₂ 、NH(CH ₃ ) And N (CH) ₃ ) ₂ C substituted by a group of (C) _1-4 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _1-4 An alkyl group.

Compounds of formula IOr a pharmaceutically acceptable salt thereof, R ⁶ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _3-7 A monocyclic cycloalkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C optionally substituted with a 4-to 7-membered monocyclic heterocyclic group or a 7-to 10-membered spirocyclic heterocyclic group _3-7 A monocyclic cycloalkyl group wherein the 4-to 7-membered monocyclic heterocyclyl group and the 7-to 10-membered spiro heterocyclyl group are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C optionally substituted by a 6-to 10-membered bridged bicyclic heterocyclic group _3-7 Monocyclic cycloalkyl wherein the 6 to 10 membered bridged bicyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is cyclobutyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a cyclohexyl substituted with: azetidinyl, pyrrolidinyl, and,

Each of which is optionally substituted with 1 to 3 groups independently selected from oxo and fluoro.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is taken up by a 6-to 10-membered bridged bicyclic heterocyclic groupSubstituted cyclohexyl wherein the 6-to 10-membered bridged bicyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from oxo and halo.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a cyclohexyl substituted with:

in some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 Fused bicyclic cycloalkyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _7-10 Fused bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl groups are substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is C _5-10 Bridged bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4-to 7-membered monocyclic heterocyclic group, wherein 4-to 7-membered is7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4 to 7 membered monocyclic heterocyclyl wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 5-to 6-membered monocyclic heterocyclyl, wherein 5-to 6-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted. Some of the compounds of formula I or pharmaceutically acceptable salts thereofIn embodiments, R ⁶ Is a 5-to 6-membered monocyclic heterocyclic group, wherein the 5-to 6-membered monocyclic heterocyclic group is independently selected from-OH, halogen, -CN, -NR by 1 to 3 groups ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 4 to 7 membered monocyclic heterocyclyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 5-to 6-membered monocyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is azetidinyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -C (O) R ¹¹ 、-NR ¹¹ R ¹¹ 、C _1-4 Alkoxy, C _1-5 Alkyl and R ^f A 5-to 6-membered monocyclic heterocyclic group substituted with a group of (C),

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹² R ¹² and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (C) and

wherein R is ^f Is C _3-7 Monocyclic cycloalkyl or 4-to 7-membered monocyclic heterocyclyl

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is pyrrolidinyl or piperidinyl, each of which is 1 to 3 independently selected from fluoro, methyl, -CH ₂ OH、-CH ₂ CN、-CF ₃ Ethyl, -CH ₂ CH ₂ OH、-CH ₂ CH ₂ CN、-CH ₂ CF ₃ 、-CH ₂ CHF ₂ 、-CH ₂ CH ₂ CF ₃ Cyclobutyl, oxetanyl, -CH ₂ C(O)NH ₂ 、-CH ₂ C(O)N(CH ₃ ) ₂ 、-C(O)CH ₂ NH ₂ and-C (O) CH ₂ N(CH ₃ ) ₂ Is substituted with a group of (a).

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is pyrrolidinyl or piperidinyl, each of which is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Optionally from 1 to 3 independently selected from halogen and C _1-3 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Optionally substituted with 1 to 3 groups independently selected from fluoro and methyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is that

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is phenyl, wherein phenyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is phenyl, wherein phenyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is phenyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is naphthyl, wherein the naphthyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a naphthyl group.

In some embodiments of the compounds of formula I or pharmaceutically acceptable salts thereof，R ⁶ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 5 to 6 membered monocyclic heteroaryl, wherein the 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 5 to 6 membered monocyclic heteroaryl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

A compound of formula I or a pharmaceutically acceptable salt thereof In some embodiments of (2), R ⁶ Is an 8-to 10-membered fused bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 groups ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -C (O) R ¹¹ 、-NR ¹¹ R ¹¹ 、C _1-4 Alkoxy, C _1-5 Alkyl and R ^f Is substituted by a group of (a) or (b),

wherein each R is ^f Independently C _3-7 A monocyclic cycloalkyl group, a 4-to 7-membered monocyclic heterocyclic group, a 6-to 10-membered bridged bicyclic heterocyclic group or a 7-to 10-membered spiro heterocyclic group,

wherein C is _3-7 The monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group.

/>

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 7-to 10-membered spirocyclic heterocyclic group in which the 7-to 10-membered spirocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁶ Is a 7-to 10-membered spirocyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is H, C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl or 4-to 6-membered monocyclic heterocyclyl, wherein C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl and 4-to 6-membered monocyclic heterocyclyl are each independently optionally selected from the group consisting of-OH, halogen, -CN, and C, optionally by 1 to 4 _1-6 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is H, C _1-3 Alkyl or C _3-7 Monocyclic cycloalkyl wherein C _1-3 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN and C _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is H, C _1-3 Alkyl or C _3-7 Monocyclic cycloalkyl wherein C _1-3 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen and C _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is H or C _1-3 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is H or methyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is C _2-3 Alkyl or C _3-7 Monocyclic cycloalkyl wherein C _2-3 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen and C _1-3 The groups of the alkoxy groups are substituted.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is ethyl, -CH ₂ CH ₂ OCH ₃ Cyclopropyl, cyclobutyl, or cyclopentyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is H.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 4 groups independently selected from-OH, halogen, -CN and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is independently selected from-OH, halogen, -CN and C by 1 to 4 _1-6 The groups of the alkoxy groups are substituted.In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is C _1-6 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is C _1-3 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is methyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4 groups independently selected from-OH, halogen, -CN and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is independently selected from-OH, halogen, -CN and C by 1 to 4 _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is C _3-7 A monocyclic cycloalkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is a 4 to 6 membered monocyclic heterocyclyl wherein 4 to 6 membered monocyclic heterocyclyl is optionally substituted with 1 to 4 groups independently selected from-OH, halogen, -CN and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is a 4 to 6 membered monocyclic heterocyclyl wherein the 4 to 6 membered monocyclic heterocyclyl is substituted with 1 to 4 groups independently selected from-OH, halogen, -CN and C _1-6 The groups of the alkoxy groups are substituted. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is a 4-to 6-membered monocyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ⁷ Is oxetanyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, Z is-C (O) R ¹³ 。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _3-7 Monocyclic cycloalkyl、C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4-to 7-membered monocyclic heterocyclic group, a 8-to 10-membered fused bicyclic heterocyclic group, a 6-to 10-membered bridged bicyclic heterocyclic group or a 7-to 10-membered spiro heterocyclic group,

wherein 4 to 7 membered monocyclic heterocyclyl, 8 to 10 membered fused bicyclic heterocyclyl, 6 to 10 membered bridged bicyclic heterocyclyl and 7 to 10 membered spiro heterocyclyl are each independently optionally substituted with 1 to 3R ^a And (3) group substitution.

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, NR ¹² R ¹² 、-C(O)N(R ¹² )(R ¹² ) And R is ^g Is substituted by a group of (a) or (b),

wherein each R is ^g Independent and independentAnd is a 4-to 7-membered monocyclic heterocyclyl.

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a).

wherein C is _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN and-NR ¹² R ¹² Is substituted by a group of (C) and

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group,

wherein 8-to 10-membered fused bicyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ Phenyl, C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹² R ¹² 、-C(O)N(R ¹² )(R ¹² ) And R is ^g Is substituted by a group of (C) and

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and-C (O) N (R) ¹² )(R ¹² ) Is substituted with a group of (a).

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with one member selected from-NH ₂ 、-CF ₃ or-CH ₂ C(O)NH ₂ Is substituted with a group of (a).

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _3-7 A monocyclic cycloalkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _7-10 Condensed bicyclo ringAlkyl, wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 Fused bicyclic cycloalkyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _7-10 Fused bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl groups are substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is C _5-10 Bridged bicyclic cycloalkyl groups.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4-to 7-membered monocyclic ringHeterocyclyl wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4-to 7-membered monocyclic heterocyclic group,

wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 independent groupsIs selected from-OH, halogen, -NR ¹¹ R ¹¹ Phenyl and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, NR ¹² R ¹² 、-C(O)N(R ¹² )(R ¹² ) Phenyl and R ^g Is substituted by a group of (a) or (b),

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ^g Is pyrrolidinyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is phenyl, wherein phenyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is phenyl, wherein phenyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is phenyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is naphthyl, wherein the naphthyl is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a naphthyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 5 to 6 membered monocyclic heteroaryl, wherein the 5 to 6 membered monocyclic heteroaryl is substituted with 1 to 4R ^a Group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 5 to 6 membered monocyclic heteroaryl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group in which the 8-to 10-membered fused bicyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. Compounds of formula IIn some embodiments of the substance or pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 groups ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 groups ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

In formula IIn some embodiments of the compound or pharmaceutically acceptable salt thereof, R ¹³ Is a 6-to 10-membered bridged bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 7-to 10-membered spirocyclic heterocyclic group in which the 7-to 10-membered spirocyclic heterocyclic group is substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 7-to 10-membered spirocyclic heterocyclic group in which the 7-to 10-membered spirocyclic heterocyclic group is substituted with 1 to 3R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is 7A spiro-heterocyclic group having up to 10 members, wherein the spiro-heterocyclic group having 7 to 10 members is independently selected from the group consisting of-OH, halogen, -CN, oxo, -NR by 1 to 3 members ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 7-to 10-membered spirocyclic heterocyclyl wherein the 7-to 10-membered spirocyclic heterocyclyl is substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is optionally covered with a C _1-5 Alkyl-substituted 7-to 10-membered spirocyclic heterocyclyl, wherein C _1-5 Alkyl is optionally substituted by-C (O) N (R) ¹² )(R ¹² ) And (3) substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is a 7-to 10-membered spirocyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is pyrrolidinyl, piperidinyl, piperazinyl diazepan group,

Each of them is independently optionally selected from-OH, halogen, -CN, oxo, -NR, independently from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein C is _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen-CN and-NR ¹² R ¹² Is substituted by a group of (C) and

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is piperidinyl or piperazinyl, each of which is independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is that

Each of them is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl radicals, where C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and-C (O) N (R) ¹² )(R ¹² ) And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

Each of them is optionally substituted with one C _1-5 Alkyl substitution, wherein C _1-5 Alkyl is optionally substituted by-C (O) N (R) ¹² )(R ¹² ) Substituted, and itEach R of (2) ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ¹³ Is azetidinyl, pyrrolidinyl, piperidinyl or piperazinyl, each of which is independently selected from 1 to 3 methyl, -CH ₂ OH、-CHF ₂ 、-CF ₃ 、-CH ₂ NH ₂ 、-CH ₂ N(CH ₃ ) ₂ 、-CH ₂ (pyrrolidinyl) -CH ₂ CH ₂ OH、-NH ₂ 、-NHCH ₃ 、-N(Me) ₂ And phenyl groups.

In some embodiments of the compound of formula I, the compound is a compound of formula II:

or a pharmaceutically acceptable salt thereof,

wherein the method comprises the steps of

wherein C is _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -

CN, oxo, -NR ¹² R ¹² 、-C(O)N(R ¹² )(R ¹² ) And R is ^g Is substituted by a group of (a) or (b),

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹³ Is 8 to 10-membered fused bicyclic heterocyclyl or 6-to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

wherein C is _1-5 The alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and-

C(O)N(R ¹² )(R ¹² ) Is substituted with a group of (a).

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with one member selected from-NH ₂ 、-CF ₃ or-CH ₂ C(O)NH ₂ Is substituted with a group of (a).

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹³ Is optionally covered with a C _1-5 Alkyl-substituted 7-to 10-membered spirocyclic heterocyclyl, wherein C _1-5 Alkyl is optionally substituted by-C (O) N (R) ¹² )(R ¹² ) And (3) substitution.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹³ Is azetidinyl, pyrrolidinyl, piperidinyl or piperazinyl, each of which is independently selected from 1 to 3 methyl, -CH ₂ OH、-CHF ₂ 、-CF ₃ 、-CH ₂ NH ₂ 、-CH ₂ N(CH ₃ ) ₂ 、-CH ₂ (pyrrolidinyl) -CH ₂ CH ₂ OH、-NH ₂ 、-NHCH ₃ 、-N(Me) ₂ And phenyl groups.

or a pharmaceutically acceptable salt thereof,

wherein the method comprises the steps of

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula II or a pharmaceutically acceptable salt thereof,

is that

Is that

Each of them is optionally substituted with one C _1-5 Alkyl substitution, wherein C _1-5 Alkyl is optionally substituted by-C (O) N (R) ¹² )(R ¹² ) Substituted, and wherein each R ¹² Independently H or C _1-3 An alkyl group.

is that

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

is that

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, R ¹³ Optionally substituted with 1 to 3 groups independently selected from: halogen, -NH ₂ 、-OH、-OCH ₃ Oxo, -CN, -CF ₃ Methyl and

in some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ⁵ H, C independently _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is H. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is C _2-6 Alkenyl group, itMiddle C _2-6 Alkenyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is phenyl, wherein phenyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein 6-to 10-membered bridged bicyclic heterocyclic groupThe cyclic heterocyclic radical is optionally substituted by 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ⁵ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹⁰ H, C independently _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹⁰ Independently H or C _1-6 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹⁰ Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹⁰ Independently H, 4 to 7 memberedA monocyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, wherein 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3R ^a And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹⁰ Independently is H, a 4-to 7-membered monocyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, wherein 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Alkyl substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is optionally selected from-OH, halogen, -CN, oxo, -NR, optionally from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 4 to 7 membered monocyclic heterocyclyl or a 6 to 10 membered bridged bicyclic heterocyclyl substituted with a group of an alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is a 4-to 7-membered monocyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is oxetanyl or

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is H. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is C _1-3 Alkyl, wherein C _1-3 Alkyl is optionally substituted with 1 to 4R ^b And (3) group substitution. Compounds of formula I orIn some embodiments of the pharmaceutically acceptable salt, one R ¹⁰ Is C _1-3 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is C _2-6 Alkenyl group, wherein C _2-6 Alkenyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is phenyl, wherein phenyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is an 8-to 10-membered fused bicyclic heterocyclic group in whichThe 8-to 10-membered fused bicyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹⁰ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^5a Independently C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ^5a Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ^5a Is a 4 to 7 membered monocyclic heterocyclyl wherein the 4 to 7 membered monocyclic heterocyclyl has one or two ring heteroatoms which are N.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ^5a Is a 4 to 7 membered monocyclic heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R ^5a Is piperidinyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is C _2-6 Alkenyl group, wherein C _2-6 Alkenyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 4R ^b And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is phenyl, wherein phenyl is optionally substituted with 1 to 4R ^a And (3) group substitution. A compound of formula I or a pharmaceutically acceptable salt thereofIn some embodiments, one R ^5a Is naphthyl, wherein naphthyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 4R ^a And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^5a Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 4R ^a And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^a Independently oxo, imino, halogen, -NO ₂ 、-N ₃ 、-CN、C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ¹¹ 、-C(O)R ¹¹ 、-C(O)OR ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ 、-N(R ¹¹ ) ₂ (R ¹¹ ) ⁺ 、-N(R ¹¹ )C(O)R ¹¹ 、-N(R ¹¹ )C(O)OR ¹¹ 、-N(R ¹¹ )C(O)N(R ¹¹ )(R ¹¹ )、-N(R ¹¹ )S(O) ₂ (R ^11a )、-NR ¹¹ S(O) ₂ N(R ¹¹ )(R ¹¹ )、-NR ¹¹ S(O) ₂ O(R ^11a )、-OC(O)R ¹¹ 、-OC(O)OR ¹¹ 、-OC(O)N(R ¹¹ )(R ¹¹ )、-SR ¹¹ 、-S(O)R ^11a 、-S(O)(NH)R ¹¹ 、-S(O) ₂ R ^11a 、-S(O) ₂ N(R ¹¹ )(R ¹¹ ) Or-n=s (R ^11a )(R ^11a )＝O，

Wherein C is _1-6 Alkyl, C _2-6 Alkenyl and C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 3R ^c Substituted with radicals, and

wherein C is _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl each independently optionally being substituted with 1-3R ^d And (3) group substitution.

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, each R ^a independently-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy or C _1-5 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^a independently-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is oxo. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is an imino groupA base. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is halogen. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-NO ₂ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-N ₃ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-CN. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-OR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-C (O) R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-C (O) OR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-C (O) N (R) ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-NR ¹¹ R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-N (R) ¹¹ ) ₂ (R ¹¹ ) ⁺ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-N (R) ¹¹ )C(O)R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-N (R) ¹¹ )C(O)OR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-N (R) ¹¹ )C(O)N(R ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-N (R) ¹¹ )S(O) ₂ (R ^11a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-NR ¹¹ S(O) ₂ N(R ¹¹ )(R ¹¹ ). In some embodiments of the compounds of formula I or pharmaceutically acceptable salts thereofIn the scheme, one R ^a is-NR ¹¹ S(O) ₂ O(R ^11a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-OC (O) R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-OC (O) OR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-OC (O) N (R) ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-SR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-S (O) R ^11a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-S (O) (NH) R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-S (O) ₂ R ^11a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a is-S (O) ₂ N(R ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is-n=s (R ^11a )(R ^11a )＝O。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is C _2-6 Alkenyl group, wherein C _2-6 Alkenyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 3R ^c And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is C _3-7 Monocyclic cycloalkanesRadicals, wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is phenyl, wherein phenyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is naphthyl, wherein naphthyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^a Is a 7-to 10-membered spirocyclic heterocycleA group in which the 7-to 10-membered spirocyclic heterocyclic group is optionally substituted with 1 to 3R ^d And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^b Independently oxo, imino, halogen, -NO ₂ 、-N ₃ 、-CN、C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ¹¹ 、-C(O)R ¹¹ 、-C(O)OR ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ 、-N(R ¹¹ ) ₂ (R ¹¹ ) ⁺ 、-N(R ¹¹ )C(O)R ¹¹ 、-N(R ¹¹ )C(O)OR ¹¹ 、-N(R ¹¹ )C(O)N(R ¹¹ )(R ¹¹ )、-N(R ¹¹ )S(O) ₂ (R ^11a )、-NR ¹¹ S(O) ₂ N(R ¹¹ )(R ¹¹ )、-NR ¹¹ S(O) ₂ O(R ^11a )、-OC(O)R ¹¹ 、-OC(O)OR ¹¹ 、-OC(O)N(R ¹¹ )(R ¹¹ )、-SR ¹¹ 、-S(O)R ^11a 、-S(O)(NH)R ¹¹ 、-S(O) ₂ R ^11a 、-S(O) ₂ N(R ¹¹ )(R ¹¹ ) Or-n=s (R ^11a )(R ^11a )＝O，

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^b independently-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered bridged bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, or 7-to 10-membered spiro heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^b independently-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ Or C _1-4 An alkoxy group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^b independently-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ Or C _1-3 An alkoxy group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^b Independently halogen or C _1-3 An alkoxy group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^b Independently is a 4 to 7 membered monocyclic heterocyclyl, an 8 to 10 membered fused bicyclic heterocyclyl, or a 6 to 10 membered bridged bicyclic heterocyclyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is a 4 to 7 membered monocyclic heterocyclyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is a 5-to 7-membered monocyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is an 8-to 10-membered fused bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is a 6-to 10-membered bridged bicyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is oxo. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is an imino group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is halogen. In formula IIn some embodiments of the compound or pharmaceutically acceptable salt thereof, one R ^b is-NO ₂ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-N ₃ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-CN. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-OR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-C (O) R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-C (O) OR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-C (O) N (R) ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-NR ¹¹ R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-N (R) ¹¹ ) ₂ (R ¹¹ ) ⁺ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-N (R) ¹¹ )C(O)R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-N (R) ¹¹ )C(O)OR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-N (R) ¹¹ )C(O)N(R ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-N (R) ¹¹ )S(O) ₂ (R ^11a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-NR ¹¹ S(O) ₂ N(R ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-NR ¹¹ S(O) ₂ O(R ^11a ). In the form of a compound of formula I or a pharmaceutically acceptable salt thereofIn some embodiments of the accepted salts, one R ^b is-OC (O) R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-OC (O) OR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-OC (O) N (R) ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-SR ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-S (O) R ^11a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-S (O) (NH) R ¹¹ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-S (O) ₂ R ^11a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b is-S (O) ₂ N(R ¹¹ )(R ¹¹ ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is-n=s (R ^11a )(R ^11a )＝O。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is phenyl, wherein phenyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In the form of a compound of formula I or a pharmaceutically acceptable salt thereofIn some embodiments of the accepted salts, one R ^b Is naphthyl, wherein naphthyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 3R ^d And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^b Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 3R ^d And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^c Independently halogen, -CN, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ¹² 、-C(O)R ¹² 、-C(O)OR ¹² 、-C(O)N(R ¹² )(R ¹² )、-NR ¹² R ¹² 、-N(R ¹² ) ₂ (R ¹² ) ⁺ 、-N(R ¹² )C(O)R ¹² 、-N(R ¹² )C(O)OR ¹² 、-N(R ¹² )C(O)N(R ¹² )(R ¹² )、-N(R ¹² )S(O) ₂ (R ^12a )、-NR ¹² S(O) ₂ N(R ¹² )(R ¹² )、-NR ¹² S(O) ₂ O(R ^12a )、-OC(O)R ¹² 、-OC(O)OR ¹² 、-OC(O)N(R ¹² )(R ¹² )、-SR ¹² 、-S(O)R ^12a 、-S(O)(NH)R ¹² 、-S(O) ₂ R ^12a 、-S(O) ₂ N(R ¹² )(R ¹² ) Or-n=s (R ^12a )(R ^12a )＝O。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is halogen. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-CN. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is C _7-10 Fused bicyclic cycloalkyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is C _5-10 Bridged bicyclic cycloalkyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is phenyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is a naphthyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is a 4 to 7 membered monocyclic heterocyclyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is a 5 to 6 membered monocyclic heteroaryl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is an 8-to 10-membered fused bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is a 6-to 10-membered bridged bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is an 8-to 10-membered fused bicyclic heteroaryl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is 7 to 7A 10 membered spirocyclic heterocyclyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-OR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-C (O) R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-C (O) OR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-C (O) N (R) ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-NR ¹² R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-N (R) ¹² ) ₂ (R ¹² ) ⁺ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-N (R) ¹² )C(O)R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-N (R) ¹² )C(O)OR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-N (R) ¹² )C(O)N(R ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-N (R) ¹² )S(O) ₂ (R ^12a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-NR ¹² S(O) ₂ N(R ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-NR ¹² S(O) ₂ O(R ^12a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-OC (O) R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-OC (O) OR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-OC (O) N (R) ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-SR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-S (O) R ^12a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-S (O) (NH) R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-S (O) ₂ R ^12a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-S (O) ₂ N(R ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is-n=s (R ^12a )(R ^12a )＝O。

In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, each R ^c independently-OH, halogen, -CN, oxo or-NR ¹² R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c is-OH. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^c Is halogen.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^d Independently oxo, halogen, -CN, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ¹² 、-C(O)R ¹² 、-C(O)OR ¹² 、-C(O)N(R ¹² )(R ¹² )、-NR ¹² R ¹² 、-N(R ¹² ) ₂ (R ¹² ) ⁺ 、-N(R ¹² )C(O)R ¹² 、-N(R ¹² )C(O)OR ¹² 、-N(R ¹² )C(O)N(R ¹² )(R ¹² )、-N(R ¹² )S(O) ₂ (R ^12a )、-NR ¹² S(O) ₂ N(R ¹² )(R ¹² )、-NR ¹² S(O) ₂ O(R ^12a )、-OC(O)R ¹² 、-OC(O)OR ¹² 、-OC(O)N(R ¹² )(R ¹² )、-SR ¹² 、-S(O)R ^12a 、-S(O)(NH)R ¹² 、-S(O) ₂ R ^12a 、-S(O) ₂ N(R ¹² )(R ¹² ) Or-n=s (R ^12a )(R ^12a )＝O。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is oxo. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is halogen. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-CN. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is C _7-10 Fused bicyclic cycloalkyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is C _5-10 Bridged bicyclic cycloalkyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is phenyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is a naphthyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is a 4 to 7 membered monocyclic heterocyclyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is a 5 to 6 membered monocyclic heteroaryl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is an 8-to 10-membered fused bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is a 6-to 10-membered bridged bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is an 8-to 10-membered fused bicyclic heteroaryl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is a 7-to 10-membered spirocyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-OR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-C (O) R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-C (O) OR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-C (O) N (R) ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-NR ¹² R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-N (R) ¹² ) ₂ (R ¹² ) ⁺ . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-N (R) ¹² )C(O)R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-N (R) ¹² )C(O)OR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-N (R) ¹² )C(O)N(R ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-N (R) ¹² )S(O) ₂ (R ^12a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-NR ¹² S(O) ₂ N(R ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-NR ¹² S(O) ₂ O(R ^12a ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-OC (O) R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-OC (O) OR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-OC (O) N (R) ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-SR ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-S (O) R ^12a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-S (O) (NH) R ¹² . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-S (O) ₂ R ^12a . In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d is-S (O) ₂ N(R ¹² )(R ¹² ). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^d Is-n=s (R ^12a )(R ^12a )＝O。

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹¹ H, C independently _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

wherein C is _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, and 7-to 10-membered spiro heterocyclyl each independently optionally being substituted with 1-3R ^c And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹¹ Independently H or C _1-4 Alkyl, wherein C _1-4 Alkyl groupOptionally one selected from-OH and-NR ¹² R ¹² Is substituted with a group of (a). In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹¹ Independently H or C _1-4 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹¹ Independently H or methyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹¹ H, C independently _1-4 Alkyl or C _3-7 A monocyclic cycloalkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is C _1-4 Alkyl, wherein C _1-4 Alkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is methyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is H. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is C _2-6 Alkenyl group, wherein C _2-6 Alkenyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is phenyl, wherein phenyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is naphthyl, wherein naphthyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is a 7-to 10-membered spirocyclic heterocyclyl, wherein the 7-to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 3R ^c And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹¹ Is C _3-7 A monocyclic cycloalkyl group. A compound of formula I or a pharmaceutically acceptable thereofIn some embodiments of the salt, one R ¹¹ Is cyclopropyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^11a Independently C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^11a Independently H or C _1-4 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is C _1-6 Alkyl, wherein C _1-6 Alkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is C _2-6 Alkenyl group, wherein C _2-6 Alkenyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is C _2-6 Alkynyl group, wherein C _2-6 Alkynyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is C _3-7 Monocyclic cycloalkyl wherein C _3-7 Monocyclic cycloalkyl radicalOptionally by 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is C _7-10 Fused bicyclic cycloalkyl wherein C _7-10 The fused bicyclic cycloalkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is C _5-10 Bridged bicyclic cycloalkyl wherein C _5-10 Bridged bicyclic cycloalkyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is phenyl, wherein phenyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is naphthyl, wherein naphthyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is a 4 to 7 membered monocyclic heterocyclyl, wherein 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is a 5 to 6 membered monocyclic heteroaryl, wherein 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is an 8-to 10-membered fused bicyclic heterocyclic group, wherein the 8-to 10-membered fused bicyclic heterocyclic group is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is an 8-to 10-membered fused bicyclic heteroaryl, wherein the 8-to 10-membered fused bicyclic heteroaryl is optionally substituted with 1 to 3R ^c And (3) group substitution. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^11a Is a 7-to 10-membered spirocyclic heterocyclyl group, wherein 7-to 10-membered spirocyclic heterocyclyl groupHeterocyclyl is optionally substituted with 1 to 3R ^c And (3) group substitution.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹² H, C independently _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, or 7-to 10-membered spiro heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ¹² Independently H or C _1-4 An alkyl group. In some embodiments of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, each R ¹² Independently H or C _1-3 An alkyl group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is H. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is C _1-6 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is C _1-4 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is C _1-3 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is C _2-6 Alkenyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is C _2-6 Alkynyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is C _3-7 A monocyclic cycloalkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is C _7-10 Fused bicyclic cycloalkyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is C _5-10 Bridging doubleCycloalkyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is phenyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is a naphthyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is a 4 to 7 membered monocyclic heterocyclyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is a 5 to 6 membered monocyclic heteroaryl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is an 8-to 10-membered fused bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is a 6-to 10-membered bridged bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is an 8-to 10-membered fused bicyclic heteroaryl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ¹² Is a 7-to 10-membered spirocyclic heterocyclic group.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, each R ^12a Independently C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, or 7-to 10-membered spiro heterocyclyl.

In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is C _1-6 An alkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is C _2-6 Alkenyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is C _2-6 Alkynyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is C _3-7 A monocyclic cycloalkyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is C _7-10 Fused bicyclic cycloalkyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is C _5-10 Bridged bicyclic cycloalkyl groups. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is phenyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is a naphthyl group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is a 4 to 7 membered monocyclic heterocyclyl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is a 5 to 6 membered monocyclic heteroaryl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is an 8-to 10-membered fused bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is a 6-to 10-membered bridged bicyclic heterocyclic group. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is an 8-to 10-membered fused bicyclic heteroaryl. In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, one R ^12a Is a 7-to 10-membered spirocyclic heterocyclic group.

In one embodiment, provided herein is a compound selected from the group consisting of:

/>

or a pharmaceutically acceptable salt thereof.

/>

or a pharmaceutically acceptable salt thereof.

/>

or a pharmaceutically acceptable salt thereof.

/>

or a pharmaceutically acceptable salt thereof.

/>

or a pharmaceutically acceptable salt thereof.

/>

or a pharmaceutically acceptable salt thereof.

Or a pharmaceutically acceptable salt thereof.

III compositions and kits

The compounds provided herein, or pharmaceutically acceptable salts thereof, are generally administered in the form of a pharmaceutical composition. Accordingly, also provided herein are pharmaceutical compositions comprising one or more compounds provided herein, or a pharmaceutically acceptable salt, isomer, or mixture thereof, and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants, and excipients. The compounds provided herein, or pharmaceutically acceptable salts thereof, may be the only active ingredient or one of the active ingredients of the pharmaceutical composition. Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizers, and adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical arts. See, e.g., remington's Pharmaceutical Sciences, mace Publishing co., philiadelphia, pa., 17 th edition, (1985); and Modern Pharmaceutics, marcel Dekker, inc. 3 rd edition (edited by g.s. Banker and c.t. Rhodes).

In one embodiment, provided herein are pharmaceutical compositions comprising a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

In some embodiments, the pharmaceutical compositions provided herein further comprise one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical composition further comprises a therapeutically effective amount of one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents or pharmaceutically acceptable salts thereof.

In some embodiments, the one or more additional therapeutic agents comprise an antimalarial agent. In some embodiments, the antimalarial agent is selected from chloroquine and hydroxychloroquine or pharmaceutically acceptable salts thereof.

In some embodiments, the one or more additional therapeutic agents include an agent that treats an inflammatory disorder. In some embodiments, the one or more additional therapeutic agents are selected from the group consisting of: veltuzumab, PF-06835375, exkutuzumab, mi Latuo, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, sirolimus, damidi Li Shan, TAK-079, fezeitumumab, illicit mab, anilumab, iskuril mab, pegylated dapirubuzumab, ranavimumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obtulizumab, tatuzumab, wo Bali bead mab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, lobifuα (rozibafusp alfa), VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, asenaproxen, tiazepine, BMS-986256, M-5049, KZR-616, KPG-818, vandicable (verdinexor), ALPN-303, vallocipn, LA-1, cinnemmod, prednisone, corticotropium, deuterium cocoa-xitinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, juliemic acid, eos Bei Du amine, TAM-01, BML-258, bupropiotinib, SDC-1801, SDC-1802, ICP-330, NTR-441, dalazab peptide, 393K-2, I-O-703, kkeatinib, KK-5, KO-P-52, KK-P Lannaptinib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 subsequent biological preparation, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-X (SLE), AC-0058, non-nilotinib, XNW-1011, tiralutinib hydrochloride, brinbutinib, albuttinib, obutinib, DWP-213388, INV-103, R-salbutamol sulfate, dockerin, NIK-SMI1, X-6, INV-17, O Sha Di D (Oshadi D), barittinib, wu Pati, non-golitinib, tatinib, INCB-54707, dighatinib, DWP-212525, CKD-971, as mometasone, betamethasone, formoterol, arachidonylethanolamine, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (Qu Tai), allogenic human umbilical cord derived mesenchymal stem cell therapy (hUC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, TPX-6001, TPX-7001, dihydroartemisinin and AMG-592, or any of the foregoingPharmaceutically acceptable salts of the substances or any combination thereof.

The pharmaceutical composition may be administered in single or multiple doses. The pharmaceutical compositions may be administered by a variety of methods including, for example, rectal, buccal, intranasal, and transdermal routes. In some embodiments, the pharmaceutical composition may be administered by intra-arterial injection, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, oral, topical, or as an inhalant.

One mode of administration is parenteral, for example by injection. The pharmaceutical compositions described herein may be incorporated therein for administration by injection in forms such as aqueous or oil suspensions or emulsions, with sesame oil, corn oil, cottonseed oil or peanut oil, as well as elixirs, mannitol, dextrose or sterile aqueous solutions and similar pharmaceutical vehicles. In some embodiments, the compounds disclosed herein, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions are administered by subcutaneous injection.

The pharmaceutical compositions of the present disclosure may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. The suspensions may be formulated according to known techniques using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, such as a solution in 1, 3-butanediol, or as a lyophilized powder. Acceptable vehicles and solvents that may be employed are water, ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

In some embodiments, the sterile injectable formulations disclosed herein may also be sterile injectable solutions or suspensions (such as solutions in 1, 3-butanediol) prepared from reconstituted lyophilized powders in a non-toxic parenterally acceptable diluent or solvent. Acceptable vehicles and solvents that may be employed are water, ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may contain suspending agents and thickening agents. In certain embodiments, the suspension is a microsuspension. In certain embodiments, the suspension is a nanosuspension.

In some embodiments, formulations suitable for parenteral administration (e.g., intramuscular (IM) and Subcutaneous (SC) administration) will comprise one or more excipients. The excipient should be compatible with the other ingredients of the formulation and physiologically harmless to its recipient. Examples of suitable excipients are well known to those skilled in the art of parenteral formulations and can be found, for example, in Handbook of Pharmaceutical Excipients (Rowe, sheskey and Quinn editions), 6 th edition 2009. Examples of solubilizing excipients in parenteral formulations (e.g., SC or IM formulations) include, but are not limited to, polysorbates (e.g., polysorbate 20 or 80) and poloxamers (e.g., poloxamer 338, 188 or 207).

In some embodiments, the compounds disclosed herein, or pharmaceutically acceptable salts and pharmaceutical compositions thereof, are administered with an implant.

Oral administration may be another route for administering a compound provided herein or a pharmaceutically acceptable salt thereof. Administration may be via, for example, a capsule or an enteric coated tablet. In preparing pharmaceutical compositions comprising at least one compound provided herein, or a pharmaceutically acceptable salt, isomer, or mixture thereof, an active ingredient (such as a compound provided herein) is typically diluted and/or encapsulated with an excipient within such a carrier, which may be in the form of a capsule, pouch, paper, or other container. When the excipient serves as a diluent, it may be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier, or medium for the active ingredient. Thus, pharmaceutical compositions may be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions and sterile packaged powders.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose or any combination thereof. The pharmaceutical composition may additionally include lubricants such as talc, magnesium stearate and mineral oil; a wetting agent; emulsifying and suspending agents; preservatives such as methyl benzoate and propyl hydroxybenzoate; a sweetener; and a flavoring agent; or any combination thereof.

Pharmaceutical compositions comprising at least one compound described herein, or a pharmaceutically acceptable salt, isomer, or mixture thereof, may be formulated so as to provide rapid, sustained, or delayed release of the active ingredient (such as the compounds provided herein) upon administration to a subject by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolution systems that include polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. nos. 3,845,770, 4,326,525, 4,902,514 and 5,616,345. Another formulation for use in the methods of the present disclosure employs a transdermal delivery device ("patch"). Such transdermal patches may be used to provide continuous or discontinuous infusion of controlled amounts of the compounds provided herein. The construction and use of transdermal patches for delivering pharmaceutical agents is well known in the art. See, for example, U.S. Pat. nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be configured for continuous, pulsatile, or on-demand delivery of the medicament.

To prepare a solid composition (such as a tablet), the primary active ingredient may be admixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein, or a pharmaceutically acceptable salt, isomer or mixture thereof. When these preformulated compositions are referred to as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equivalent unit dosage forms such as tablets, pills and capsules.

Tablets or pills of the compounds provided herein or pharmaceutically acceptable salts thereof may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action or to protect against the acidic conditions of the stomach. For example, a tablet or pill may comprise an inner dosage component and an outer dosage component, the latter being in the form of an envelope over the former. The two components may be separated by an enteric layer that serves to resist disintegration in the stomach and allows the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials may be used for such enteric layers or coatings, including a variety of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol and cellulose acetate.

Pharmaceutical compositions for inhalation or insufflation may comprise solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, as well as powders. The liquid or solid composition may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the composition is administered by the oral or nasal respiratory route to achieve a local or systemic effect. In other embodiments, the composition in a pharmaceutically acceptable solvent may be nebulized by use of an inert gas. The aerosolized solution may be inhaled directly from the aerosolization device, or the aerosolization device may be attached to a mask tent or intermittent positive pressure ventilator. The solution, suspension or powder composition may be administered from a device that delivers the formulation in a suitable manner, preferably orally or nasally.

In one embodiment, provided herein is a kit comprising a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt, stereoisomer, prodrug, or solvate thereof, and a suitable package. In some embodiments, the kit further comprises instructions for use. In some embodiments, the kit includes a label and/or instructions for using a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt, stereoisomer, prodrug, or solvate thereof, to treat an indication (including a disease or disorder) described herein.

In some embodiments, the kit further comprises one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents or pharmaceutically acceptable salts thereof.

In one embodiment, provided herein are articles of manufacture comprising a compound described herein, or a pharmaceutically acceptable salt, isomer, or mixture thereof, in a suitable container. In some embodiments, the container may be a vial, a jar, an ampoule, a prefilled syringe, or an intravenous bag.

IV method

The methods provided herein can be applied to cell populations in vivo or ex vivo. By "in vivo" is meant within a living individual, such as within an animal or human. In this context, the methods provided herein may be used for the treatment of an individual. By "ex vivo" is meant outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples, including fluid or tissue samples obtained from an individual. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the present disclosure may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the present disclosure may be used ex vivo to determine an optimal schedule and/or dosage of administration of TLR 7, 8 and/or 9 inhibitors as disclosed herein for a given cell type, individual and other parameters. The information collected from such use may be used for experimental purposes or clinically in formulating an in vivo treatment regimen. Other ex vivo uses to which the present disclosure may be suitable are described below or will become apparent to those skilled in the art. The selected compounds may be further characterized as dosages that check the safety or tolerability of a human or non-human subject. Such properties can be checked using methods generally known to those skilled in the art.

In one embodiment, the present disclosure provides a method of inhibiting toll-like receptor 7, 8 and/or 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides methods of inhibiting toll-like receptor 7, 8, and 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of inhibiting toll-like receptor 7, 8, or 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides methods of inhibiting toll-like receptor 7 and 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of inhibiting toll-like receptor 7 or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 7, 8 and/or 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides methods of treating a disease or disorder associated with increased toll-like receptor 7, 8, and 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with increased toll-like receptor 7, 8 or 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating a disease or disorder associated with increased toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides methods of treating a disease or disorder associated with increased toll-like receptor 7 and 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with increased toll-like receptor 7 or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating a disease or disorder associated with increased toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with increased toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

Non-limiting examples of inflammatory conditions include, but are not limited to, acne, acid-induced lung injury, addison's disease, adrenal hyperplasia, adrenocortical insufficiency, adult-onset still disease, adult Respiratory Distress Syndrome (ARDS), age-related macular degeneration, aging, alcoholic hepatitis, alcoholic liver disease, allergen-induced asthma, allergic bronchopulmonary, allergic conjunctivitis, allergic contact dermatitis, allergy, allergic encephalomyelitis, allergic neuritis, allograft rejection, hair loss, alopecia areata, alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, angina, angioedema, vascular fibroma, antiperspirant ectodermal dysplasia, anti-glomerular basement membrane disease, antigen-antibody complex mediated disease, ankylosing spondylitis, antiphospholipid syndrome aphthous stomatitis, appendicitis, arthritis, ascites, aspergillosis, asthma, atherosclerosis, atherosclerotic plaques, atopic dermatitis, atrophic thyroiditis, autoimmune diseases, autoimmune hemolytic anemia (immune whole blood cytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune polycystic endocrine diseases, autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune mediated thrombocytopenia), autoimmune hepatitis, autoimmune thyroid disorders, autoimmune inflammatory diseases, back pain, bacillus anthracis infection, behcet's disease, inflammation caused by bee stings, behcet's syndrome, bell palsy, beryllium poisoning, blau syndrome, bone pain, bronchiolitis, bullous Pemphigoid (BP) asthma, burns, bursitis, cardiac hypertrophy, carpal tunnel syndrome, kalman's disease, catabolic disorders, cataracts, celiac disease, cerebral aneurysms, chemical stimulus-induced inflammation, chorioretinitis, chronic atypical neutrophil skin diseases with lipodystrophy and elevated body temperature (CANDLE) syndrome, chronic heart failure, chronic pulmonary disease in premature infants, chronic Obstructive Pulmonary Disease (COPD), chronic pancreatitis, chronic prostatitis, chronic recurrent multifocal osteomyelitis, cicatricial alopecia, colitis, complex regional pain syndrome, organ transplant complications, conjunctivitis, connective tissue disease, contact dermatitis, corneal graft neovascularization, corneal ulceration, crohn's disease, cryptothermal protein-related periodic syndrome, cutaneous Lupus Erythematosus (CLE), cryptococcosis, cystic fibrosis, interleukin-1 receptor antagonist Deficiency (DIRA) dermatitis, dermatitis endotoxemia, dermatomyositis, diabetic macular edema, diverticulitis, eczema, encephalitis, endometriosis, endotoxemia, eosinophilic pneumonia, epicondylitis, epidermolysis bullosa, erythema multiforme, juvenile erythropenia, esophagitis, familial amyloid polyneuropathy, familial cold urticaria, familial mediterranean fever, fetal growth retardation, fibromyalgia, fistula type Crohn's disease, food allergies, giant cell arteritis, glaucoma, glioblastoma, glomerular disease, glomerulonephritis (glomerular nephritis), glomerulonephritis (glomerulonephritis), gluten sensitive enteropathy, gout, gouty arthritis, graft Versus Host Disease (GVHD), granulomatosis hepatitis, graves disease, growth plate injury, guillain-Barre syndrome, intestinal tract disease, alopecia, hashimoto thyroiditis, head injury, headache, hearing loss, heart disease, hemangioma, hemolytic anemia, hemophilia joint, henno-Schonlein purpura, hepatitis, hereditary periodic fever syndrome, connective tissue hereditary disease, shingles and herpes simplex, suppurative sweat gland (HS), hip joint replacement, hodgkin's disease, huntington's disease, hyalopathy, hyperreactivity, hypercoammonemia, hypercalcemia, hypercholesteremia, hypereosinophilic syndrome (HES), hyperimmunoglobulin syndrome D with recurrent fever (HIDS), allergic pneumonia, hypertrophic bone formation, dysplasia and other anemias, dysplastic anemia, ichthyosis, idiopathic demyelinating polyneuropathy, idiopathic inflammatory myopathy (dermatomyositis, polymyositis), idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, immunoglobulin, immune complex hematophagic disease, immune deficiency, immunomic disease, idiopathic thrombocytopenic purpura (P-P), HIV infection, inflammatory disease, HIV infection, including viral diseases such as AIDS (HIV infection), hepatitis a, hepatitis b, hepatitis c, hepatitis D and hepatitis e, herpes; inflammation, CNS inflammation, inflammatory Bowel Disease (IBD), inflammatory diseases of the lower respiratory tract (including bronchitis or chronic obstructive pulmonary disease), inflammatory diseases of the upper respiratory tract (including nasal and nasal sinuses) such as rhinitis or sinusitis, inflammatory diseases of the respiratory tract, inflammatory ischemic events such as stroke or sudden cardiac arrest, inflammatory lung disease, inflammatory myopathies such as myocarditis, inflammatory liver disease, inflammatory neuropathy, inflammatory pain, inflammation caused by insect bites, interstitial cystitis, interstitial lung disease, iritis, inflammation caused by irritants, ischemia/reperfusion, joint replacement, juvenile arthritis, juvenile rheumatoid arthritis, keratitis, kidney injury caused by parasitic infection, renal transplant rejection, leptospirosis, leukocyte adhesion deficiency, lichen Sclerosus (LS), lambert-eaton myasthenia syndrome luffler's syndrome, lupus nephritis, lyme disease, ma Fanzeng Syndrome (MFS), mast cell activation syndrome, mastocytosis, meningitis, meningioma, mesothelioma, mixed connective tissue disease, mu Keer-wils syndrome (urticaria, deafness, amyloidosis), mucositis, multiple organ injury syndrome, multiple sclerosis, muscle atrophy, muscular dystrophy, and Myasthenia Gravis (MG), myelodysplastic syndrome, myocarditis, myositis, sinusitis, necrotizing enterocolitis, neonatal Onset Multisystem Inflammatory Disease (NOMID) neovascular glaucoma, nephrotic syndrome, neuritis, neuropathic disease, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant rejection, osler-Weber syndrome, osteoarthritis, osteogenesis imperfecta, osteonecrosis, osteoporosis, osteoarthritis, otitis, congenital panonycis, paget's disease, pancreatitis, parkinson's disease, pediatric rheumatism, pelvic inflammatory disease, pemphigus Vulgaris (PV), bullous Pemphigoid (BP), pericarditis, periodic fever, periodontitis, endometriosis, pernicious anemia (Addison's disease), pertussis, PFAPA (periodic fever aphtha pharyngitis and cervical adenosis), pharyngitis and adenosis (PFAPA syndrome), inflammation caused by plant irritants, infection by pneumosporosis, pneumonia, localized pneumonia, inflammation caused by Pugegen/urushiol oil, nodular polyarthritis, polychondritis, polycystic kidney disease, polymyalgia rheumatica, giant cell arteritis, polymyositis pouch inflammation, reperfusion injury and graft rejection, primary biliary cirrhosis, primary pulmonary hypertension, primary Sclerosing Cholangitis (PSC), proctitis, psoriasis vulgaris, psoriatic arthritis, psoriatic epidermis, psychosocial stress disease, pulmonary fibrosis, pulmonary hypertension, pyoderma gangrenosum, post-suppurative granulomatous fibrohyperplasia s, suppurative aseptic arthritis, raynaud's syndrome, leider's disease, reactive arthritis, kidney disease, renal transplant rejection, reperfusion injury, respiratory distress syndrome, retinal disease, post-lens fibrosis, raynaud's syndrome, rheumatic heart disease, rheumatic arthritis, rhinitis, psoriasis, rosacea, rhinitis, sarcoidosis, schnitzeler syndrome, scleritis, scleroderma, scoliosis, seborrhea, sepsis, septic shock, severe pain, szechuan syndrome, sickle cell anemia, silica-induced disease (silicosis), sjogren's syndrome, dermatological disorders, skin irritation, rash, skin allergies (contact dermatitis or allergic contact dermatitis), sleep apnea, spinal cord injury, spinal stenosis, spondyloarthropathies, sports injury, sprains and strains, stevens-johnson syndrome (SJS), stroke, subarachnoid hemorrhage, sunburn, synovial inflammation, systemic Inflammatory Response Syndrome (SIRS), systemic Lupus Erythematosus (SLE) Systemic Mastocytosis (SMCD) systemic vasculitis, idiopathic systemic vasculitis, temporal arteritis, tendinitis, tenosynovitis, thrombocytopenia, thyroiditis (thyroditis), thyroiditis (thyroiditis), tissue transplantation, toxoplasmosis, trachoma, transplant rejection, traumatic brain injury, tuberculosis, tubular interstitial nephritis, tumor Necrosis Factor (TNF) receptor-associated periodic syndrome (trap), type 1 diabetes, type 2 diabetes, type 1 or type 2 diabetic complications, ulcerative colitis, urticaria, uterine fibroids, uveitis, vascular restenosis, vasculitis (NHLBI), vitiligo, wegener granulomatosis, and whipple's disease.

In some embodiments, the inflammatory disorder is selected from the group consisting of inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, glomerulonephritis, mixed Connective Tissue Disease (MCTD), dermatomyositis, polymyositis, systemic sclerosis, anti-neutrophil cytoplasmic antibody-associated vasculitis, anti-phospholipid syndrome, autoimmune hemolytic anemia, macrophage activation syndrome-driven inflammatory anemia, igA nephropathy, type I diabetes, non-alcoholic steatohepatitis, and sjogren syndrome. In some embodiments, the inflammatory disorder is inflammatory bowel disease. In some embodiments, the inflammatory disorder is psoriasis. In some embodiments, the inflammatory disorder is psoriatic arthritis. In some embodiments, the inflammatory disorder is rheumatoid arthritis. In some embodiments, the inflammatory disorder is glomerulonephritis. In some embodiments, the inflammatory disorder is Mixed Connective Tissue Disease (MCTD). In some embodiments, the inflammatory disorder is dermatomyositis. In some embodiments, the inflammatory disorder is polymyositis. In some embodiments, the inflammatory disorder is systemic sclerosis. In some embodiments, the inflammatory disorder is anti-neutrophil cytoplasmic antibody associated vasculitis. In some embodiments, the inflammatory disorder is antiphospholipid syndrome. In some embodiments, the inflammatory disorder is autoimmune hemolytic anemia. In some embodiments, the inflammatory disorder is macrophage activation syndrome-driven inflammatory anemia. In some embodiments, the inflammatory disorder is IgA nephropathy. In some embodiments, the inflammatory disorder is type I diabetes. In some embodiments, the inflammatory condition is non-alcoholic steatohepatitis. In some embodiments, the inflammatory disorder is sjogren's syndrome.

The compounds provided herein, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions provided herein, can treat or ameliorate Systemic Lupus Erythematosus (SLE), cutaneous Lupus Erythematosus (CLE), lupus nephritis, lupus-associated SLE symptoms, CLE symptoms, or other autoimmune disorders. Symptoms of systemic lupus erythematosus include joint pain, joint swelling, arthritis, fatigue, hair loss, canker sores, lymphadenectasis, sun sensitivity, rash, headache, tingling, stinging, epilepsy, vision problems, personality changes, abdominal pain, nausea, vomiting, heart rhythm abnormalities, hemoptysis and dyspnea, patchy skin color, and Raynaud's phenomenon.

In one embodiment, the present disclosure provides a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In some embodiments, the methods provided herein further comprise administering a therapeutically effective amount of one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

In some embodiments, the one or more additional therapeutic agents are selected from the group consisting of: vitozumab, PF-06835375, exkulizumab, mi Latuo bead mab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, cilarizumab, dasardiod Li Shan, TAK-079, fevertuzumab, illimumab, anilauzumab, iskarituxab, PEGylated dapirobenzolimumab, ranafuzumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obtuzumab, tatuzumab Wo Bali bead mab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine sulfate, COV-08-4; GNKS-356, AVO-101, lobifuα, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, asenapine, tiazepine, BMS-986256, M-5049, KZR-616, KPG-818, vandicable, ALPN-303, valoxepin, LA-1, cinnimod, prednisone, corticotropin, deuterostaximide, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, juliemic acid, eos Bei Du amine, TAM-01, BML-258, bupacitinib, SDC-1801, SDC-ICP 1802, 1802-330, NTR-441, dala Zalexin, GSK-2646264, SKI-O-703, lannapini (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 subsequent biological agent, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002 Pegylated HLA-X (SLE), AC-0058, non-nilotinib, XNW-1011, tiramitinib hydrochloride, brinbutinib Albutinib, obutinib, DWP-213388, INV-103, R-salbutamol sulfate, ankyrin NIK-SMI1, X-6, INV-17, O Sha Di D, barittinib, wu Pati, non-golitinib, italtinib, INCB-54707, di-Gatinib, DWP-212525, CKD-971, as mometasone, betamethasone, furitmod, arachidonylethanolamine, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (per Qu Tai), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370,TPX-6001, TPX-7001, dihydroartemisinin and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

In some embodiments, the one or more additional therapeutic agents are selected from chloroquine and hydroxychloroquine or pharmaceutically acceptable salts thereof. In some embodiments, the one or more additional therapeutic agents is chloroquine. In some embodiments, the one or more additional therapeutic agents is hydroxychloroquine. In some embodiments, the one or more additional therapeutic agents is a pharmaceutically acceptable salt of hydroxychloroquine. In some embodiments, the one or more additional therapeutic agents is hydroxychloroquine sulfate.

In some embodiments of the methods provided herein, the subject is a human.

In some embodiments, the methods provided herein comprise administering a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II) or a pharmaceutically acceptable salt thereof. In some embodiments, the methods provided herein comprise administering a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein in therapy.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of inhibiting toll-like receptor 7, 8 and/or 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of inhibiting the activity of toll-like receptors 7, 8, and 9 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of inhibiting toll-like receptor 7, 8, or 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of inhibiting toll-like receptor 7 and 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II) or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of inhibiting toll-like receptor 7 or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II) or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II) or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating a disease or disorder associated with increased toll-like receptor 7, 8 and/or 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of treating a disease or disorder associated with increased toll-like receptor 7, 8, and 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of treating a disease or disorder associated with increased toll-like receptor 7, 8, or 9 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating a disease or disorder associated with increased toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of treating a disease or disorder associated with increased toll-like receptor 7 and 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of treating a disease or disorder associated with increased toll-like receptor 7 or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating a disease or disorder associated with increased toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, is used in a method of treating a disease or disorder associated with increased toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides the use of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, in a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In some embodiments, the uses provided herein further comprise administering a therapeutically effective amount of one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

In some embodiments, the one or more additional therapeutic agents are selected from the group consisting of: vitozumab, PF-06835375, exkulizumab, mi Latuo bead mab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, cilarizumab, dasardiod Li Shan, TAK-079, fevertuzumab, illimumab, anilauzumab, iskarituxab, PEGylated dapirobenzolimumab, ranafuzumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obtuzumab, tatuzumab Wo Bali bead mab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine sulfate, COV-08-4; GNKS-356, AVO-101, lobifuα, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, asenapine, tiazepine, BMS-986256, M-5049, KZR-616, KPG-818, vandicable, ALPN-303, valoxepin, LA-1, cinnimod, prednisone, corticotropin, deuterostaximide, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, juliemic acid, I Bei Du amine, TAM-01, BML-258, bupacitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, darazamide, GSK-2646264, SKI-O-703, lannaptinib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 subsequent biological agent, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, pegylated HLA-X (SLE), AC-0058, non-Nib, XNW-1011, tirapatinib hydrochloride, brinbutinib, ailbutinib, obutinib, DWP-213388, INV-103, R-salbutamol sulfate Anchor protein, NIK-SMI1, X-6, INV-17, O Sha Di D, barittinib, wu Pati, fagolitinib, italtinib, INCB-54707, di-Gatinib, DWP-212525, CKD-971, as mometasone, betamethasone, furitmod, arachidonylethanolamine, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (per Qu Tai), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370,TPX-6001, TPX-7001, dihydroartemisinin and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

In some embodiments of the uses provided herein, the subject is a human.

In some embodiments, the uses provided herein include administering a therapeutically effective amount of a compound provided herein (i.e., a compound of formula I or II) or a pharmaceutically acceptable salt thereof. In some embodiments, the methods provided herein comprise administering a therapeutically effective amount of a pharmaceutical composition provided herein.

V. application of

The compounds of the present disclosure, or pharmaceutically acceptable salts thereof (also referred to herein as active ingredients), may be administered by any route suitable for the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary depending on, for example, the recipient's conditions. An advantage of certain compounds disclosed herein, or pharmaceutically acceptable salts thereof, is that they are orally bioavailable and can be administered orally.

The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, may be administered to an individual for a desired period or duration of time, such as at least about 1 month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or more, according to an effective dosing regimen. In some embodiments, the compound or pharmaceutically acceptable salt thereof is administered on a daily or intermittent schedule during the life of the individual.

The specific dosage level of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for any particular subject will depend on a variety of factors including the activity of the particular compound employed, the age, weight, general health, sex, diet, time of administration, route of administration and rate of excretion, drug combination and the severity of the particular disease of the subject undergoing therapy. For example, the dosage may be expressed as milligrams of a compound provided herein or a pharmaceutically acceptable salt thereof per kilogram of subject body weight (mg/kg). Dosages between about 0.1mg/kg and 150mg/kg may be appropriate. In some embodiments, a dosage of between about 0.1mg/kg and 100mg/kg may be appropriate. In other embodiments, a dosage of between 0.5mg/kg and 60mg/kg may be appropriate. Normalization to the weight of a subject is particularly useful in adjusting the dose between subjects of widely varying sizes, such as when using drugs in children and adults, or when converting an effective dose in a non-human subject such as a dog to a dose suitable for a human subject.

Daily doses may also be described as the total amount of a compound described herein or a pharmaceutically acceptable salt thereof per dose or administered daily. The daily dose of a compound of formula I or II, or a pharmaceutically acceptable salt or pharmaceutically acceptable tautomer thereof, may be between about 1mg and 4,000mg, between about 2,000 mg/day and 4,000 mg/day, between about 1 mg/day and 2,000 mg/day, between about 1 mg/day and 1,000 mg/day, between about 10 mg/day and 500 mg/day, between about 20 mg/day and 500 mg/day, between about 50 mg/day and 300 mg/day, between about 75 mg/day and 200 mg/day, or between about 15 mg/day and 150 mg/day.

The dosage or frequency of administration of a compound of the present disclosure or a pharmaceutically acceptable salt thereof can be adjusted during treatment based on the judgment of the administering physician.

The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, can be administered to a subject (e.g., a human) in a therapeutically effective amount. In some embodiments, the compound or pharmaceutically acceptable salt thereof is administered once daily.

The compounds provided herein, or pharmaceutically acceptable salts thereof, may be administered by any useful route and means, such as by oral or parenteral (e.g., intravenous) administration. A therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof may include from about 0.00001mg/kg body weight/day to about 10mg/kg body weight/day, such as from about 0.0001mg/kg body weight/day to about 10mg/kg body weight/day, or such as from about 0.001mg/kg body weight/day to about 1mg/kg body weight/day, or such as from about 0.01mg/kg body weight/day to about 1mg/kg body weight/day, or such as from about 0.05mg/kg body weight/day to about 0.5mg/kg body weight/day. In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, comprises from about 0.3 mg/day to about 30 mg/day, or from about 30 mg/day to about 300 mg/day, or from about 0.3 μg/day to about 30 mg/day, or from about 30 μg/day to about 300 μg/day.

The compounds of the present disclosure or pharmaceutically acceptable salts thereof may be combined with one or more additional therapeutic agents at any dose (e.g., 1mg to 1000mg of the compound) of the compounds of the present disclosure or pharmaceutically acceptable salts thereof. A therapeutically effective amount may comprise from about 0.1 mg/dose to about 1000 mg/dose, such as from about 50 mg/dose to about 500 mg/dose, or such as from about 100 mg/dose to about 400 mg/dose, or such as from about 150 mg/dose to about 350 mg/dose, or such as from about 200 mg/dose to about 300 mg/dose, or such as from about 0.01 mg/dose to about 1000 mg/dose, or such as from about 0.01 mg/dose to about 100 mg/dose, or such as from about 0.1 mg/dose to about 100 mg/dose, or such as from about 1 mg/dose to about 10 mg/dose, or such as from about 1 mg/dose to about 1000 mg/dose. Other therapeutically effective amounts of the compounds of formula I or II, or pharmaceutically acceptable salts thereof, are about 1 mg/dose, or about 2 mg/dose, 3 mg/dose, 4 mg/dose, 5 mg/dose, 6 mg/dose, 7 mg/dose, 8 mg/dose, 9 mg/dose, 10 mg/dose, 15 mg/dose, 20 mg/dose, 25 mg/dose, 30 mg/dose, 35 mg/dose, 40 mg/dose, 45 mg/dose, 50 mg/dose, 55 mg/dose, 60 mg/dose, 65 mg/dose, 70 mg/dose, 75 mg/dose, 80 mg/dose, 85 mg/dose, 90 mg/dose, 95 mg/dose, or about 100 mg/dose. Other therapeutically effective amounts of the compounds of the present disclosure or pharmaceutically acceptable salts thereof are about 100 mg/dose, 125 mg/dose, 150 mg/dose, 175 mg/dose, 200 mg/dose, 225 mg/dose, 250 mg/dose, 275 mg/dose, 300 mg/dose, 325 mg/dose, 350 mg/dose, 375 mg/dose, 400 mg/dose, 425 mg/dose, 450 mg/dose, 475 mg/dose, 500 mg/dose, 525 mg/dose, 550 mg/dose, 575 mg/dose, 600 mg/dose, 625 mg/dose, 650 mg/dose, 675 mg/dose, 700 mg/dose, 725 mg/dose, 750 mg/dose, 775 mg/dose, 800 mg/dose, 825 mg/dose, 850 mg/dose, 875 mg/dose, 900 mg/dose, 925 mg/dose, 950 mg/dose, 975 mg/dose, or about 1000 mg/dose.

In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 600mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 500mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 400mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 300mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 200mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 100mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 75mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 50mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 25mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 20mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 15mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 10mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is from about 1mg to about 5mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 1mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 7mg, about 8mg, about 9mg, about 10mg, about 11mg, about 12mg, about 13mg, about 14mg, about 15mg, about 16mg, about 17mg, about 18mg, about 19mg, about 20mg, about 21mg, about 22mg, about 23mg, about 24mg, or about 25mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 5mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 10mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 15mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 20mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 25mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 30mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 35mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 40mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 45mg. In some embodiments, the therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, is about 50mg.

In some embodiments, the methods described herein comprise administering to a subject an initial daily dose of about 1mg to 500mg of a compound provided herein, or a pharmaceutically acceptable salt thereof, and gradually increasing the dose until clinical efficacy is achieved. Increments of about 5mg, 10mg, 25mg, 50mg or 100mg may be used to increase the dose. The dosage may be increased daily, every other day, twice weekly, biweekly, tricyclically or monthly.

When administered orally, the total daily dose of a human subject may be between about 1mg and 1,000mg, between about 10 mg/day and 500 mg/day, between about 50 mg/day and 300 mg/day, between about 75 mg/day and 200 mg/day, or between about 100 mg/day and 150 mg/day. In some embodiments, the total daily dose of a human subject may be about 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day, 600 mg/day, 700 mg/day, 800 mg/day, 900 mg/day, or 1000 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day, 600 mg/day, 700 mg/day, or 800 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day administered in a single dose.

In some embodiments, the total daily dose of a human subject may be about 100 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 150 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 200 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 250 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 300 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 350 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 400 mg/day administered in a single dose. In some embodiments, the total daily dose of the human subject may be about 450 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 500 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 550 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 600 mg/day administered in a single dose. In some embodiments, the total daily dose of the human subject may be about 650 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 700 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 750 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 800 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 850 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 900 mg/day administered in a single dose. In some embodiments, the total daily dose of the human subject may be about 950 mg/day administered in a single dose. In some embodiments, the total daily dose of a human subject may be about 1000 mg/day administered in a single dose.

A single dose may be administered hourly, daily, weekly or monthly. For example, a single dose may be administered every 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, or every 24 hours. A single dose may also be administered once every 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or once every 7 days. A single dose may also be administered once every 1 week, 2 weeks, 3 weeks, or once every 4 weeks. In certain embodiments, a single dose may be administered once a week. A single dose may also be administered once a month. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once daily in a method disclosed herein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered twice daily in a method disclosed herein.

The frequency of the dosage of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, will be determined by the needs of the individual patient and may be, for example, once a day or two or more times a day. Administration of the compound or pharmaceutically acceptable salt thereof continues for a period of time necessary to treat the inflammatory disorder or any other indication described herein. For example, the compound or pharmaceutically acceptable salt thereof may be administered to a human afflicted with an inflammatory disorder for a period of 20 to 180 days, or for a period of, for example, 20 to 90 days, or for a period of, for example, 30 to 60 days.

Administration may be intermittent, with the patient receiving a daily dose of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, over a period of days or more, followed by a period of days or more, with the patient not receiving a daily dose of the compound, or a pharmaceutically acceptable salt thereof. For example, the patient may receive a dose of the compound or a pharmaceutically acceptable salt thereof every other day or three times a week. Again by way of example, a patient may receive a dose of a compound or a pharmaceutically acceptable salt thereof daily for a period of 1 day to 14 days, then the patient does not receive a dose of the compound or a pharmaceutically acceptable salt thereof for a period of 7 days to 21 days, then the patient receives a dose of the compound or a pharmaceutically acceptable salt thereof again for a subsequent period of time (e.g., 1 day to 14 days). The alternating periods of administration of the compound or pharmaceutically acceptable salt thereof followed by the absence of administration of the compound or pharmaceutically acceptable salt thereof may be repeated depending on the clinical needs of the patient being treated.

The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the present disclosure, may be administered once, twice, three times, or four times a day using any suitable pattern described above. Moreover, administration or treatment with the compound or pharmaceutically acceptable salt thereof may continue for a number of days; for example, for one treatment cycle, typically treatment will continue for at least 7 days, 14 days, or 28 days. The therapeutic cycle is well known for inflammatory conditions and other indications described herein. In some embodiments, the treatment cycle typically alternates with a rest period of about 1 to 28 days, typically about 7 days or about 14 days between cycles. In other embodiments, the treatment cycle may also be continuous.

VI combination therapy

Patients treated by administration of the compounds provided herein, or pharmaceutically acceptable salts thereof, generally exhibit diseases or disorders that benefit from treatment with other therapeutic agents. These diseases or conditions may be of an inflammatory nature, or may be associated with cancer, metabolic disorders, gastrointestinal disorders, and the like. Thus, one embodiment of the present disclosure is a method of treating an inflammatory-related disease or condition or metabolic disorder, gastrointestinal disorder, or cancer, or the like, comprising administering a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, to a subject, particularly a human subject, in need thereof in combination with one or more compounds useful in treating such diseases.

In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four, or more additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents. The one, two, three, four or more additional therapeutic agents may be different therapeutic agents selected from the same class of therapeutic agents and/or they may be selected from different classes of therapeutic agents.

In some embodiments, when a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one or more additional therapeutic agents as described herein, the components of the composition are administered in a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.

In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one or more additional therapeutic agents in a single dosage form for simultaneous administration to a patient, e.g., as a solid dosage form for oral administration.

In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more additional therapeutic agents.

Co-administration includes administering a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, before or after administering a unit dose of one or more additional therapeutic agents. The compounds provided herein, or pharmaceutically acceptable salts thereof, can be administered within seconds, minutes, or hours of administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered first, followed by administration of the unit dose of one or more additional therapeutic agents within seconds or minutes. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, within seconds or minutes. In some embodiments, a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered first, followed by administration of the unit dose of one or more additional therapeutic agents after a period of several hours (i.e., 1 to 12 hours). In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of the unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, after a period of several hours (i.e., 1 to 12 hours).

In some embodiments, the compound of formula I or II, or a pharmaceutically acceptable salt thereof, is formulated as a tablet, which may optionally contain one or more other compounds useful in the treatment of the disease being treated. In certain embodiments, the tablet may contain another active ingredient for use in treating an inflammatory disorder or other indications described herein. In some embodiments, such tablets are suitable for once daily administration.

Also provided herein are methods of treatment, wherein a compound of formula I or II, or a tautomer or pharmaceutically acceptable salt thereof, is administered to a patient in combination with one or more additional therapeutic agents or therapies. In some embodiments, the total daily dose of a compound of formula I or II, or a tautomer or pharmaceutically acceptable salt thereof, may be from about 1 mg/day to about 500 mg/day, administered to a human subject in a single dose.

Combination therapy for inflammatory disorders or diseases

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, may be combined with one or more additional therapeutic agents to treat or ameliorate an inflammatory disorder. Non-limiting examples of inflammatory conditions include, but are not limited to, acne, acid-induced lung injury, addison's disease, adrenal hyperplasia, adrenocortical insufficiency, adult-onset still disease, adult Respiratory Distress Syndrome (ARDS), age-related macular degeneration, aging, alcoholic hepatitis, alcoholic liver disease, allergen-induced asthma, allergic bronchopulmonary, allergic conjunctivitis, allergic contact dermatitis, allergy, allergic encephalomyelitis, allergic neuritis, allograft rejection, hair loss, alopecia areata, alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, angina, angioedema, vascular fibroma, antiperspirant ectodermal dysplasia, anti-glomerular basement membrane disease, antigen-antibody complex mediated disease, ankylosing spondylitis, antiphospholipid syndrome aphthous stomatitis, appendicitis, arthritis, ascites, aspergillosis, asthma, atherosclerosis, atherosclerotic plaques, atopic dermatitis, atrophic thyroiditis, autoimmune diseases, autoimmune hemolytic anemia (immune whole blood cytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune polycystic endocrine diseases, autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune mediated thrombocytopenia), autoimmune hepatitis, autoimmune thyroid disorders, autoimmune inflammatory diseases, back pain, bacillus anthracis infection, behcet's disease, inflammation caused by bee stings, behcet's syndrome, bell palsy, beryllium poisoning, blau syndrome, bone pain, bronchiolitis, bullous Pemphigoid (BP) asthma, burns, bursitis, cardiac hypertrophy, carpal tunnel syndrome, kalman's disease, catabolic disorders, cataracts, celiac disease, cerebral aneurysms, chemical stimulus-induced inflammation, chorioretinitis, chronic atypical neutrophil skin diseases with lipodystrophy and elevated body temperature (CANDLE) syndrome, chronic heart failure, chronic pulmonary disease in premature infants, chronic Obstructive Pulmonary Disease (COPD), chronic pancreatitis, chronic prostatitis, chronic recurrent multifocal osteomyelitis, cicatricial alopecia, colitis, complex regional pain syndrome, organ transplant complications, conjunctivitis, connective tissue disease, contact dermatitis, corneal graft neovascularization, corneal ulceration, crohn's disease, cryptothermal protein-related periodic syndrome, cutaneous Lupus Erythematosus (CLE), cryptococcosis, cystic fibrosis, interleukin-1 receptor antagonist Deficiency (DIRA) dermatitis, dermatitis endotoxemia, dermatomyositis, diabetic macular edema, diverticulitis, eczema, encephalitis, endometriosis, endotoxemia, eosinophilic pneumonia, epicondylitis, epidermolysis bullosa, erythema multiforme, juvenile erythropenia, esophagitis, familial amyloid polyneuropathy, familial cold urticaria, familial mediterranean fever, fetal growth retardation, fibromyalgia, fistula type Crohn's disease, food allergies, giant cell arteritis, glaucoma, glioblastoma, glomerular disease, glomerulonephritis (glomerular nephritis), glomerulonephritis (glomerulonephritis), gluten sensitive enteropathy, gout, gouty arthritis, graft Versus Host Disease (GVHD), granulomatosis hepatitis, graves disease, growth plate injury, guillain-Barre syndrome, intestinal tract disease, alopecia, hashimoto thyroiditis, head injury, headache, hearing loss, heart disease, hemangioma, hemolytic anemia, hemophilia joint, henno-Schonlein purpura, hepatitis, hereditary periodic fever syndrome, connective tissue hereditary disease, shingles and herpes simplex, suppurative sweat gland (HS), hip joint replacement, hodgkin's disease, huntington's disease, hyalopathy, hyperreactivity, hypercoammonemia, hypercalcemia, hypercholesteremia, hypereosinophilic syndrome (HES), hyperimmunoglobulin syndrome D with recurrent fever (HIDS), allergic pneumonia, hypertrophic bone formation, dysplasia and other anemias, dysplastic anemia, ichthyosis, idiopathic demyelinating polyneuropathy, idiopathic inflammatory myopathy (dermatomyositis, polymyositis), idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, immunoglobulin, immune complex hematophagic disease, immune deficiency, immunomic disease, idiopathic thrombocytopenic purpura (P-P), HIV infection, inflammatory disease, HIV infection, including viral diseases such as AIDS (HIV infection), hepatitis a, hepatitis b, hepatitis c, hepatitis D and hepatitis e, herpes; inflammation, CNS inflammation, inflammatory Bowel Disease (IBD), inflammatory diseases of the lower respiratory tract (including bronchitis or chronic obstructive pulmonary disease), inflammatory diseases of the upper respiratory tract (including nasal and nasal sinuses) such as rhinitis or sinusitis, inflammatory diseases of the respiratory tract, inflammatory ischemic events such as stroke or sudden cardiac arrest, inflammatory lung disease, inflammatory myopathies such as myocarditis, inflammatory liver disease, inflammatory neuropathy, inflammatory pain, inflammation caused by insect bites, interstitial cystitis, interstitial lung disease, iritis, inflammation caused by irritants, ischemia/reperfusion, joint replacement, juvenile arthritis, juvenile rheumatoid arthritis, keratitis, kidney injury caused by parasitic infection, renal transplant rejection, leptospirosis, leukocyte adhesion deficiency, lichen Sclerosus (LS), lambert-eaton myasthenia syndrome luffler's syndrome, lupus nephritis, lyme disease, ma Fanzeng Syndrome (MFS), mast cell activation syndrome, mastocytosis, meningitis, meningioma, mesothelioma, mixed connective tissue disease, mu Keer-wils syndrome (urticaria, deafness, amyloidosis), mucositis, multiple organ injury syndrome, multiple sclerosis, muscle atrophy, muscular dystrophy, and Myasthenia Gravis (MG), myelodysplastic syndrome, myocarditis, myositis, sinusitis, necrotizing enterocolitis, neonatal Onset Multisystem Inflammatory Disease (NOMID) neovascular glaucoma, nephrotic syndrome, neuritis, neuropathic disease, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant rejection, osler-Weber syndrome, osteoarthritis, osteogenesis imperfecta, osteonecrosis, osteoporosis, osteoarthritis, otitis, congenital panonycis, paget's disease, pancreatitis, parkinson's disease, pediatric rheumatism, pelvic inflammatory disease, pemphigus Vulgaris (PV), bullous Pemphigoid (BP), pericarditis, periodic fever, periodontitis, endometriosis, pernicious anemia (Addison's disease), pertussis, PFAPA (periodic fever aphtha pharyngitis and cervical adenosis), pharyngitis and adenosis (PFAPA syndrome), inflammation caused by plant irritants, infection by pneumosporosis, pneumonia, localized pneumonia, inflammation caused by Pugegen/urushiol oil, nodular polyarthritis, polychondritis, polycystic kidney disease, polymyalgia rheumatica, giant cell arteritis, polymyositis pouch inflammation, reperfusion injury and graft rejection, primary biliary cirrhosis, primary pulmonary hypertension, primary Sclerosing Cholangitis (PSC), proctitis, psoriasis vulgaris, psoriatic arthritis, psoriatic epidermis, psychosocial stress disease, pulmonary fibrosis, pulmonary hypertension, pyoderma gangrenosum, post-suppurative granulomatous fibrohyperplasia s, suppurative aseptic arthritis, raynaud's syndrome, leider's disease, reactive arthritis, kidney disease, renal transplant rejection, reperfusion injury, respiratory distress syndrome, retinal disease, post-lens fibrosis, raynaud's syndrome, rheumatic heart disease, rheumatic arthritis, rhinitis, psoriasis, rosacea, rhinitis, sarcoidosis, schnitzeler syndrome, scleritis, scleroderma, scoliosis, seborrhea, sepsis, septic shock, severe pain, szechuan syndrome, sickle cell anemia, silica-induced disease (silicosis), sjogren's syndrome, dermatological disorders, skin irritation, rash, skin allergies (contact dermatitis or allergic contact dermatitis), sleep apnea, spinal cord injury, spinal stenosis, spondyloarthropathies, sports injury, sprains and strains, stevens-johnson syndrome (SJS), stroke, subarachnoid hemorrhage, sunburn, synovial inflammation, systemic Inflammatory Response Syndrome (SIRS), systemic Lupus Erythematosus (SLE) Systemic Mastocytosis (SMCD) systemic vasculitis, idiopathic systemic vasculitis, temporal arteritis, tendinitis, tenosynovitis, thrombocytopenia, thyroiditis (thyroditis), thyroiditis (thyroiditis), tissue transplantation, toxoplasmosis, trachoma, transplant rejection, traumatic brain injury, tuberculosis, tubular interstitial nephritis, tumor Necrosis Factor (TNF) receptor-associated periodic syndrome (trap), type 1 diabetes, type 2 diabetes, type 1 or type 2 diabetic complications, ulcerative colitis, urticaria, uterine fibroids, uveitis, vascular restenosis, vasculitis (NHLBI), vitiligo, wegener granulomatosis, and whipple's disease.

Non-limiting examples of therapeutic agents that may be used in combination with the compounds provided herein or pharmaceutically acceptable salts thereof for the treatment of inflammatory diseases or conditions include alpha fetoprotein modulators; adenosine A3 receptor antagonists; adrenomedullin ligand; AKT1 gene inhibitors; an antibiotic; an antifungal agent; ASK1 inhibitors; atpase inhibitors; beta adrenergic receptor antagonists; BTK inhibitors; calcineurin inhibitors; a carbohydrate metabolism modulator; cathepsin S inhibitors; CCR9 chemokine antagonists; CD233 modulators; CD29 modulators; CD3 antagonists; a CD40 ligand inhibitor; CD40 ligand receptor antagonists; chemokine CXC ligand inhibitors; CHST15 gene inhibitors; collagen modulators; COT protein kinase inhibitors; CSF-1 agonists; CSF-1 antagonists; CX3CR1 chemokine modulator DYRK-1 alpha protein kinase inhibitor, eosinophil chemokine ligand inhibitor; EP4 prostaglandin receptor agonists; f1f0 ATP synthase modulators; a farnesyl ester X receptor (FXR, NR1H 4) agonist or modulator; fecal Microorganism Transplantation (FMT), actin ligand inhibitor; free fatty acid receptor 2 antagonists; GATA 3 transcription factor inhibitors; glucagon-like peptide 2 agonists; glucocorticoid agonists; glucocorticoid receptor modulators; guanylate cyclase receptor agonists; HIF prolyl hydroxylase inhibitors; histone deacetylase inhibitors; HLA class II antigen modulators; hypoxia inducible factor-1 stimulators; ICAM1 gene inhibitors; IL-1 beta ligand modulators; an IL-12 antagonist; IL-13 antagonists; IL-18 antagonists; IL-18 receptor accessory protein antagonists and IL-22 agonists; an IL-23 antagonist; inhibitors of IL-23A; IL-6 antagonists; IL-7 receptor antagonists; IL-8 receptor antagonists; IL-36 inhibitors, integrin alpha-4/beta-1 antagonists; integrin alpha-4/beta-7 antagonists; integrin antagonists; an interleukin ligand inhibitor; an interleukin receptor 17A antagonist; an interleukin-1 beta ligand; an interleukin 1-like receptor 2 inhibitor; IL-6 receptor modulators; JAK tyrosine kinase inhibitors; jak1 tyrosine kinase inhibitors; jak3 tyrosine kinase inhibitors; lactoferrin stimulators; lanC-like protein 2 modulators; leukocyte elastase inhibitors; an inhibitor of leukocyte protease-3; MAdCAM inhibitors; melanin-concentrating hormone (MCH-1) antagonists; melanocortin agonists; metalloproteinase-9 inhibitors; therapies targeting microbiome; a natriuretic peptide receptor C agonist; a neuregulin-4 ligand; NLRP3 inhibitors; NKG 2D activates NK receptor antagonists; NR1H4 receptor (FXR) agonists or modulators (deleted); nuclear factor κb inhibitors; opioid receptor antagonists; an OX40 ligand inhibitor; an oxidoreductase inhibitor; P2X7 purinergic receptor modulators; PDE 4 inhibitors; pellino homolog 1 inhibitors; PPAR alpha/beta agonists; pparγ agonists; protein arginine deiminase IV inhibitors, protein fimH inhibitors; p-selectin glycoprotein ligand-1 inhibitors; ret tyrosine kinase receptor inhibitors; inhibitors of RIP-1 kinase; inhibitors of RIP-2 kinase; an RNA polymerase inhibitor; sphingosine 1 phosphatase 1 stimulators; sphingosine-1 phosphate receptor-1 agonists; sphingosine-1 phosphate receptor-5 agonists; sphingosine-1 phosphate receptor-1 antagonists; sphingosine-1 phosphate receptor-1 modulators; stem cell antigen-1 inhibitors; superoxide dismutase modulators; SYK inhibitors; tissue transglutaminase inhibitors; TLR-3 antagonists; TLR-4 antagonists; toll-like receptor 8 (TLR 8) inhibitors; a tnfα ligand inhibitor; TNF ligand inhibitors; tnfα ligand modulators; TNF antagonists; TPL-2 inhibitors; tumor necrosis factor 14 ligand modulators; tumor necrosis factor 15 ligand inhibitors; tyk2 tyrosine kinase inhibitors; type I IL-1 receptor antagonists; capsaicin VR1 agonist; and a desmin inhibitor; or any combination thereof.

Adenosine A3 receptor antagonists include, but are not limited to, PBF-677.

Adrenomedullin ligands include, but are not limited to, adrenomedullin.

Antibiotics include, but are not limited to, ciprofloxacin, clarithromycin, metronidazole, vancomycin, rifamycin, rifaximin, and tosufloxacin.

ASK1 inhibitors include, but are not limited to GS-4997.

Alpha fetoprotein modulators include, but are not limited to ACT-101.

anti-CD 28 inhibitors include, but are not limited to JNJ-3133 and abacavir.

Beta adrenergic receptor antagonists include, but are not limited to NM-001.

BTK inhibitors include, but are not limited to GS-4059.

Calcineurin inhibitors include, but are not limited to, tacrolimus and cyclosporine.

Modulators of carbohydrate metabolism include, but are not limited to ASD-003.

Cathepsin S inhibitors include, but are not limited to VBY-129.

CCR9 chemokine antagonists include, but are not limited to CCX-507.

CD233 modulators include, but are not limited to GSK-2831781.

CD29 modulators include, but are not limited to, PF-06687234.

CD3 antagonists include, but are not limited to, NI-0401, moromiab-CD 3, and ti Li Zhushan.

CD4 antagonists include, but are not limited to IT-1208.

CD40 ligand inhibitors include, but are not limited to SAR-441344 and Leuconostoc.

CD40 gene inhibitors include, but are not limited to, NJA-730.

CD40 ligand receptor antagonists include, but are not limited to, FFP-104, BI-655064, ABBV-323, and VIB-4920.

Chaperonin-binding immunoglobulins include, but are not limited to IRL-201805.

Chemokine CXC ligand inhibitors include, but are not limited to LY-3041658.

CHST15 gene inhibitors include, but are not limited to STNM-01.

Collagen modulators include, but are not limited to ECCS-50 (DCCT-10).

COT protein kinase inhibitors include, but are not limited to GS-4875.

CSF-1 antagonists include, but are not limited to, JNJ-40346527 (PRV-6527) and SNDX-6352.

CX3CR1 chemokine modulators include, but are not limited to E-6130.

DYRK-1 alpha protein kinase inhibitors include, but are not limited to VRN-02

Therapies targeting microbiome include, but are not limited to, SER-287, SER-301 and SER-155.

Eosinophil chemokine ligand inhibitors include, but are not limited to, bai Ti xylanase.

EP4 prostaglandin receptor agonists include, but are not limited to KAG-308.

Modulators of F1F0 ATP synthase include, but are not limited to LYC-30937 EC.

Inhibitors of the actin ligand include, but are not limited to, quinine Mo Lishan anti (E-6011).

Free fatty acid receptor 2 antagonists include, but are not limited to, GLPG-0974.

GATA 3 transcription factor inhibitors include, but are not limited to SB-012.

Glucagon-like peptide 2 agonists include, but are not limited to, tiltutin and apltutin.

Glucocorticoid receptor agonists include, but are not limited to, budesonide, beclomethasone dipropionate, and dexamethasone sodium phosphate.

Glucocorticoid receptor modulators/TNF ligand inhibitors include, but are not limited to ABBV-3373.

Guanylate cyclase receptor agonists include, but are not limited to, dulcamide (dolcanatide).

HIF prolyl hydroxylase inhibitors include, but are not limited to, DS-1093 and AKB-4924.

HIF prolyl hydroxylase-2 inhibitors/hypoxia inducible factor-1 stimulators include, but are not limited to, GB-004.

Histone deacetylase inhibitors include, but are not limited to, ji Weisi he and NIPEP-CARE.

Inhibitors of histone deacetylase-6 include, but are not limited to, CKD-506.

HLA class II antigen modulators include, but are not limited to, HLA class II protein modulators.

ICAM1 gene inhibitors include, but are not limited to, A Li Kafu sen (Alicaforsen).

IL-12 antagonists include, but are not limited to, utility model antibody (IL 12/IL 23).

IL-13 antagonists include, but are not limited to, qu Luolu monoclonal antibodies.

IL-18 antagonists include, but are not limited to GSK-1070806.

IL-18 receptor accessory protein antagonists include, but are not limited to, anti-IL-1R 7 canonical antibodies.

IL-22 agonists include, but are not limited to, AMT-126 and RG-7880.

IL-23 antagonists include, but are not limited to, teridazumab, rasagilawood monoclonal antibody (BI-655066), mi Jizhu monoclonal antibody (LY-3074828), cloth Lei Kushan antibody (AMG-139), IBI-112, and PTG-200.

IL-23A inhibitors include, but are not limited to, antilinukab.

IL-6 antagonists include, but are not limited to, olorimab.

IL-7 receptor antagonists include, but are not limited to OSE-127.

IL-8 receptor antagonists include, but are not limited to, clotrimazole.

Integrin alpha-4/beta-1 antagonists include, but are not limited to natalizumab.

Integrin alpha-4/beta-7 antagonists include, but are not limited to, itraconazole (a 4b7/aEb 7), vedolizumab, methylcalicheat (carotegrast methyl), TRK-170 (a 4b7/a4b 1), PTG-100 and PN-10943.

Integrin antagonists include, but are not limited to, E-6007.

Interleukin ligand inhibitors include, but are not limited to, bicizumab (IL-17A/IL-17F).

Interleukin receptor 17A antagonists include, but are not limited to, bai Dalu monoclonal antibodies.

Interleukin-1 beta ligands include, but are not limited to, K (D) PT.

Interleukin 1-like receptor 2 inhibitors include, but are not limited to, BI-655130.

IL-6 receptor modulators include, but are not limited to, amilo-5MER and Oxizepine.

JAK tyrosine kinase inhibitors include, but are not limited to, tofacitinib (1/3), pefacitinib (1/3), TD-3504, and TD-1473.

Jak1 tyrosine kinase inhibitors include, but are not limited to, the compounds disclosed in U.S. patent No. 9238628.

Jak3 tyrosine kinase inhibitors include, but are not limited to OST-122 and PF-06651600.

Jak3 tyrosine kinase inhibitors/TrkA receptor antagonists include, but are not limited to SNA-125.

Examples of other JAK inhibitors include, but are not limited to, AT9283, AZD1480, baratinib, BMS-911543, phenanthrene Zhuo Tini, non-golitinib (GLPG 0634), gan Duo tinib (LY 278444), INCB039110, letatinib, molotinib (CYT 0387), NS-018, panatinib (SB 1518), pefitinib (ASP 015K), lu Suoti, tofacitinib (previously known as tasatinib), XL019, wu Pati ni (ABT-494), LPG-0555, SHR-0302, and bupatinib (PF-06700841) (JAK 1/Tyk 2).

Lactoferrin stimulators include, but are not limited to, recombinant human lactoferrin (VEN-100).

LanC-like protein 2 modulators include, but are not limited to, BT-11 and BT-104.

Leukocyte elastase inhibitors/leukocyte protease-3 inhibitors include, but are not limited to, tiprenostat (tiprelestat).

MAdCAM inhibitors include, but are not limited to, SHP-647 (PF-547659).

Melanin concentrating hormone (MCH-1) antagonists include, but are not limited to, CSTI-100.

Melanocortin MC1 receptor agonists include, but are not limited to, ASP-3291 and PL-8177.

Metalloproteinase-9 inhibitors include, but are not limited to GS-5745.

Microbiome modulators include, but are not limited to, ABI-M201.

Natriuretic peptide receptor C agonists include, but are not limited to, procalcitonin.

Neuregulin-4 ligands include, but are not limited to, NRG-4.

NKG 2D-activating NK receptor antagonists include, but are not limited to JNJ-4500.

NLRP3 inhibitors include, but are not limited to, dapam Shu Jing, BMS-986299, SB-414, MCC-950, IFM-514, JT-194, PELA-167 and NBC-6.

The farnesyl ester X receptor (FXR, NR1H 4) agonists or modulators include, but are not limited to, AGN-242266, cilofaxadiol (cilofexor tromethamine) (GS-9674), EDP-305, EYP-001, GNF-5120, MET-409, MET-642, nidufexol (nidofor) (LMB-763), obeticholic acid, TERN-101, and topifexol (tropifexor).

Nuclear factor kappa B inhibitors include, but are not limited to, setannix (Thetanix).

Opioid receptor antagonists include, but are not limited to, naltrexone and IRT-103.

OX40 ligand inhibitors include, but are not limited to, KHK-4083.

Oxidoreductase inhibitors include, but are not limited to, olsalazine.

Pellino homolog 1 inhibitors include, but are not limited to, BBT-401.

P2X7 purinergic receptor modulators include, but are not limited to SGM-1019.

PDE 4 inhibitors include, but are not limited to, apremilast.

PPARα/δ agonists include, but are not limited to, eiafeno (elafiltrano) (GFT-1007).

PPARgamma agonists include, but are not limited to, GED-0507-34-Levo.

Protein fimH inhibitors include, but are not limited to, sibofimoc (EB-8018).

P-selectin glycoprotein ligand-1 inhibitors include, but are not limited to, SEL-K2, abGn-168H, and Ne Hu Zhushan antibodies.

Ret tyrosine kinase receptor inhibitors include, but are not limited to, GSK-3179106.

RIP-1 kinase inhibitors include, but are not limited to, GSK-2982772 and VRN-04.

RIP-2 kinase inhibitors include, but are not limited to GSK-2983559.

Sphingosine 1 phosphate phosphatase 1 stimulators include, but are not limited to, itramod.

Sphingosine-1-phosphate receptor-1 agonists include, but are not limited to, mo Kewei molds (mocravidmod) (KRP-203) and BMS-986166.

Sphingosine-1-phosphate receptor-1 agonists/sphingosine-1-phosphate receptor-5 agonists include, but are not limited to, ozanimod (ozanimod).

Sphingosine-1-phosphate receptor-1 antagonists include, but are not limited to, amixomod (MT-1303).

Sphingosine-1-phosphate receptor-1 modulators include, but are not limited to OPL-002, SK1-I.

Stem cell antigen-1 inhibitors include, but are not limited to, amountin (Ampion) (DMI-9523).

Superoxide dismutase modulators include, but are not limited to, medium dismutase (missmase).

Syk inhibitors include, but are not limited to GS-9876.

Tissue transglutaminase inhibitors include, but are not limited to, zanpipimumab

TLR-3 antagonists include, but are not limited to PRV-300.

TLR-4 antagonists include, but are not limited to JKB-122.

Toll-like receptor 8 (TLR 8) inhibitors include, but are not limited to, E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, mo Tuo molde (motolimod), raschimod (resiquimod), VTX-1463, and VTX-763.

TNFα ligand inhibitors include, but are not limited to, adalimumab, pegylated cetuximab, infliximab, golimumab, DLX-105, debio-0512, HMPL-004, CYT-020-TNFQb, hemay-007, and V-565.

TNFα ligand modulators/IL-1β ligand modulators include, but are not limited to, PUR-0110.

TNF antagonists include, but are not limited to, AVX-470, tolengept (tulingercept), and etanercept.

Tumor necrosis factor 14 ligand modulators include, but are not limited to AEVI-002.

Tumor necrosis factor 15 ligand inhibitors include, but are not limited to PF-06480605.

Tyk2 tyrosine kinase inhibitors include, but are not limited to PF-06826647 and BMS-986165.

Type I IL-1 receptor antagonists include, but are not limited to, anakinra.

The catenin inhibitors include, but are not limited to, lanreozole acetate.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be combined with one or more anti-inflammatory agents. Anti-inflammatory agents include, but are not limited to, non-steroidal anti-inflammatory drugs (NSAIDs), non-specific and COX-2 specific cyclooxygenase inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptor antagonists, and immunosuppressants.

Examples of NSAIDs include, but are not limited to, ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, a combination of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac (etodolac), fenoprofen calcium, ketoprofen, nabumetone sodium, sulfasalazine, tolmetin sodium, and hydroxychloroquine. Additional examples of NSAIDs also include, but are not limited to, COX-2 specific inhibitors (i.e., IC in a specific ratio to COX-1 ₅₀ At least 50 times lower IC ₅₀ COX-2 inhibiting compounds) such as celecoxib, valdecoxib, lumiracoxib, etoricoxib and/or rofecoxib.

In some embodiments, the anti-inflammatory agent is salicylate. Salicylates include, but are not limited to, acetylsalicylic acid or aspirin, sodium salicylate, choline, and magnesium salicylate.

In some embodiments, the anti-inflammatory agent is a corticosteroid. Non-limiting examples of corticosteroids include cortisone, dexamethasone, methylprednisolone, prednisolone sodium phosphate, and prednisone.

In some embodiments, the anti-inflammatory agent is a gold compound, such as gold sodium thiomalate or gold nofin.

In some embodiments, the anti-inflammatory agent is a metabolic inhibitor. Non-limiting examples of metabolic inhibitors include dihydrofolate reductase inhibitors such as methotrexate, or dihydroorotate dehydrogenase (DHODH) inhibitors such as leflunomide.

In some embodiments, the anti-inflammatory agent is an anti-C5 monoclonal antibody (such as eculizumab or pegzhuzumab), a TNF antagonist (such as etanercept), or infliximab, which is an anti-tnfα monoclonal antibody.

In some embodiments, the anti-inflammatory agent is an immunosuppressant. Non-limiting examples of immunosuppressants include methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, sodium mycophenolate, mercaptopurine, and mycophenolate mofetil.

Combination therapy for lupus

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is combined with one or more additional therapeutic agents, the one or more additional therapeutic agents target adenosine homocysteine, ADP ribosyl cyclase-1 (CD 38), corticotropin ligand, AIMP multisynthetase complex protein 1, annexin A1 modulator, B and T lymphocyte attenuation factor (BTLA), BDCA2, beta 2 adrenergic receptor, B lymphocyte antigen CD19, B lymphocyte antigen CD20, B lymphocyte adhesion molecule (CD 22), B lymphocyte stimulatory factor ligand (BAFF), btk tyrosine kinase, cannabinoid CB2 receptor, CD11B agonist, CD38 activation-inducible TNF receptor, CD40 (CD 154) ligand, CD74, CD79B modulator, CDw123, collagen VII (ColVII), complement C5 factor type C lectin domain protein 4C, CXCR5 chemokine modulators, deoxyribonuclease modulators, DNA binding proteins Ikaros, DYRK-1 alpha protein kinase, dndoplasmin, exporter 1, FK506 binding proteins, glucocorticoid receptor, HLA antigen, IL-10, IL-23 mIL-12 receptor, IL-2 receptor alpha subunit, IL-21 modulator, IL-6R, immunoglobulin gamma Fc receptor II modulator, immunoglobulin gamma Fc receptor IIB, inducible T cell costimulatory molecules, interferon alpha ligand (INF-alpha), interferon omega ligand (INFomega), interferon type I receptor, interleukin-2 ligand, itk tyrosine kinase, JAK tyrosine kinase, jak1 tyrosine kinase, jak2 tyrosine kinase, jak3 tyrosine kinase, KCNA voltage-gated potassium channel-3, leukocyte Ig-like receptor A4 modulator, mitochondrial 10kDa heat shock protein, mTOR, non-receptor tyrosine kinase TYK2, nuclear export, nuclear factor κb-induced kinase, nuclease stimulator, OX-40 receptor, PARP modulator, proteasome modulator, protein arginine deiminase IV (PAD 4), cerebellar protein modulator, protein MB21D1, retinoid Z receptor gamma reversal, rho-associated protein kinase 1, rho-associated protein kinase 2, serine threonine protein kinase TBK1 (TBK 1), sphingosine kinase 1, sphingosine-1-phosphate receptor-1 modulator, interferon gene stimulator protein, syk tyrosine kinase, T cell surface glycoprotein CD28, T cell differentiation antigen CD6, tyrosine-7 modulator, TLR-8 modulator, TLR-9 modulator, transcription factor modulator, tumor necrosis factor ligand 13 (apl), TYK2 kinase, ubiquitin ligase modulator and/or zinc finger binding protein.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be combined with one, two, three, or four additional therapeutic agents selected from the group consisting of:

activation-induced TNF receptor agonists including, but not limited to BMS-986256;

adenosine homocysteine inhibitors including, but not limited to, DZ-2002;

corticotropin ligands including, but not limited to, corticotropin;

AIMP multiple synthase complex protein 1 stimulators/Endoplasmin inhibitors, including but not limited to, dockerin;

anti-CDw 123 antibodies, including but not limited to tuzumab-b;

annexin A1 modulators, including but not limited to annexuzlimab;

anti-IL-12/IL 23 antibodies, including but not limited to AK-101;

anti-BAFF-R antibodies, including but not limited to ranagliptin;

anti-BDCA 2 antibodies, including but not limited to BIIB-059;

anti-BLys antibodies, including but not limited to belgium and UBP-1213;

anti-BTLA modulator antibodies, including but not limited to LY-3361237;

anti-C5 antibodies, including but not limited to eculizumab;

anti-CD 154 antibodies, including but not limited to TNX-1500;

anti-CD 19/CD32b antibodies, including but not limited to obeticlopidine;

anti-CD 20 antibodies, including but not limited to veltuzumab;

anti-CD 22 antibodies, including but not limited to SM-06, SM-03;

anti-CD 28 antibodies, including but not limited to sirolimus;

anti-CD 38 antibodies, including but not limited to TAK-079 and fezetuzumab;

anti-CD 40 antibodies, including but not limited to, iscalicheamicin and pegylated dapiromant;

anti-CD 6 antibodies, including but not limited to illicit mab;

anti-CD 74 antibodies, including but not limited to Mi Latuo bead mab;

anti-CXCR 5 antibodies including but not limited to PF-06835375;

anti-IFN- α antibodies, including but not limited to QX-006-N;

anti-IFN-alpha/omega antibodies, including but not limited to JNJ-55920839;

anti-IL-10 antibodies, including but not limited to BT-063;

anti-IL-21 antibodies, including but not limited to BOS-161721;

anti-IL-6R nanobodies, including but not limited to Wo Bali bead mab;

anti-ILT 7 antibodies, including but not limited to dasdipy Li Shan antibodies;

an anti-interferon alpha vaccine, including but not limited to CKD-971;

anti-interferon receptor type I antibodies, including but not limited to anilurumab;

anti-PAD 4 antibodies, including but not limited to PFI-102;

anti-TLR-7 antibodies, including but not limited to DS-7011;

BAFF/APRIL inhibitors, including but not limited to ALPN-303;

β2 adrenergic receptor agonists including, but not limited to, salbutamol R-sulfate;

bispecific antibodies targeting BAFF/ICOSL, including but not limited to lobifuα;

bispecific antibodies targeting CD32B/CD79B, including but not limited to PRV-3279;

bispecific antibodies targeting Col VII/BAFF, including but not limited to TE-2324;

b lymphocyte stimulating factor ligand inhibitors including, but not limited to, asenapine and taitaziprap;

btk tyrosine kinase inhibitors including, but not limited to, AC-0058, non-nilotinib, XNW-1011, tiramitinib hydrochloride, brinbutinib, albuttinib, and obutinib;

btk/itk tyrosine kinase inhibitors, including but not limited to DWP-213388;

Btk/Jak3 tyrosine kinase inhibitors including, but not limited to DWP-212525;

cannabinoid CB2 receptor agonists, including but not limited to juliemic acid;

CD11b agonists, including but not limited to LA-1;

deoxyribonuclease gamma stimulators, including but not limited to NTR-441;

deoxyribonuclease modulators, including but not limited to ao Sha Di D;

DYRK-1 alpha protein kinase inhibitors, including but not limited to VRN-02;

Output protein 1 inhibitors, including but not limited to SINE compounds;

glucocorticoid receptor agonists including, but not limited to, prednisone;

HLA antigen modulators, including but not limited to pegylated HLA-x (SLE);

IL-2 receptor alpha subunit stimulators including, but not limited to, NKTR-35;

immunoglobulin gamma Fc receptor IIB modulators, including but not limited to valoxepin;

inducible T cell costimulatory molecule Inhibitors (ICOS)/T cell surface glycoprotein CD28 inhibitors including, but not limited to ALPN-101;

interferon alpha ligand modulators/TLR-7/TLR-9 modulators, including but not limited to DV-1079;

interleukin-2 ligands including, but not limited to, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101 and CUG-252;

interleukin-2 ligand/IL-2 receptor agonist including but not limited to interleukin-2 subsequent biologic;

JAK 1/2/3 and ROCK 1/2 inhibitors, including but not limited to CPL-409116;

JAK tyrosine kinase inhibitors including, but not limited to, diltiatinib;

jak1/Jak2 tyrosine kinase inhibitors, including but not limited to baratinib;

jak1 tyrosine kinase inhibitors including, but not limited to Wu Pati Ni, fingolitinib, itatinib and INCB-54707;

Jak1/Tyk2 tyrosine kinase inhibitors including, but not limited to, bupacitinib, SDC-1801, and SDC-1802;

JAK3/1 and TBK1 kinase inhibitors including, but not limited to CS-12192;

JAK3/JAK1 tyrosine kinase inhibitors including, but not limited to, tofacitinib citrate;

KCNA voltage-gated potassium channel-3 inhibitors, including but not limited to dalapatin;

mitochondrial 10kDa heat shock protein stimulators including, but not limited to, INV-103;

mTOR inhibitors, including but not limited to TAM-01;

non-receptor tyrosine kinase TYK2 antagonists including, but not limited to ICP-330;

nuclear output inhibitors, including but not limited to, vandinisole;

nuclear factor κb-induced kinase inhibitors including, but not limited to NIK-SMI1;

nuclease-stimulating agents, including but not limited to RSLV-132;

OX-40 receptor antagonists including, but not limited to ISB-830;

PARP modulators, including but not limited to bendamustine hydrochloride;

NK-92 cell therapy expressing PD-L1 CAR;

proteasome inhibitors, including but not limited to KZR-616;

cerebellar protein modulators, including but not limited to, ifenprodil Bei Du;

protein MB21D1 inhibitors, including but not limited to X-6;

retinoid Z receptor gamma inverse agonists, including but not limited to INV-17;

Sphingosine kinase 1 inhibitors, including but not limited to BML-258;

sphingosine-1-phosphate receptor-1 modulators, including but not limited to, cinnemod;

syk tyrosine kinase inhibitors, including but not limited to GSK-2646264, SKI-O-703, lanrapini (GS-9876), GNS-1653, and HMPL-523;

TLR-9 antagonists including, but not limited to, chloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356 and AVO-101;

TLR7/8 antagonists including, but not limited to, M-5049, E-6887, and BMS-986256;

TLR-8 antagonists including, but not limited to ZG-170607;

TLR7/8/9 antagonists including, but not limited to IMO-8400 and IMO-9200;

tyk2 tyrosine kinase inhibitors including, but not limited to, deuterated celecoxib;

ubiquitin ligase modulators including, but not limited to, KPG-818; and

other agents for treating lupus, including but not limited to, mometasone, betamethasone, formoterol, arachidonylethanolamine, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (Qu Tai), allogenic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370,TPX-6001, TPX-7001, dihydroartemisinin, AMG-592, phosphatidylserine-liposome based immunotherapy and CD4+CD317lo/-CD25+ polyclonal regulatory T cells.

In some embodiments, provided hereinThe compound or pharmaceutically acceptable salt thereof may be combined with one, two, three or four additional therapeutic agents selected from the group consisting of: vitozumab, PF-06835375, exkulizumab, mi Latuo bead mab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, cilarizumab, dasardiod Li Shan, TAK-079, fevertuzumab, illimumab, anilauzumab, iskarituxab, PEGylated dapirobenzolimumab, ranafuzumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obtuzumab, tatuzumab Wo Bali bead mab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine sulfate, COV-08-4; GNKS-356, AVO-101, lobifuα, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, asenapine, tiazepine, BMS-986256, M-5049, KZR-616, KPG-818, vandicable, ALPN-303, valoxepin, LA-1, cinamomod, prednisone, corticotropin, deuterostatinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, juliemic acid, I Bei Du amine, TAM-01, BML-258, bupacitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, datazapeptide, GSK-2646264, SKI-O-703, lanprinib (GS-9876), GNS-1653, HMPL-523; RSLV-132, interleukin-2 subsequent biological preparation, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-X (SLE), AC-0058, non-Nibutinib, XNW-1011, tiralutinib hydrochloride, brinbutinib, albutinib, obutinib, DWP-213388, INV-103, R-salbutamol sulfate, ankyrin, NIK-SMI1, X-6, INV-17, O Sha Di D, barittinib, wu Pati, non-golitinib, itatinib, INCB-54707, dighatinib, DWP-212525, CKD-971, as mometasone, betamethasone, furitol, arachidonylethanolamine, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (Qu Tai), allogenic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, TPX-6001, TPX-7001, dihydroartemisinin and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

Combination therapy for psoriasis

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, may be combined with one, two, three, or four additional therapeutic agents useful in treating or ameliorating psoriasis. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be combined with one, two, three, or four additional therapeutic agents selected from the group consisting of: acetaldehyde dehydrogenase inhibitors, adenosine A1 receptor antagonists, adenosine A3 receptor agonists, ADPribosyl cyclase-1 inhibitors, alpha 2 adrenergic receptor modulators, apolipoprotein A antagonists, arene receptor agonists, bcl-xL Bcl-2 related death promoter modulators, beta amyloid antagonists, beta-catenin inhibitors, bromodomain-containing protein inhibitors, ca2+ release-activating Ca2+ channel 1 inhibitors, calcineurin inhibitors, calcium channel inhibitors, cannabinoid CB1 receptor antagonists, cathepsin S inhibitors, CCR3 chemokine antagonists, CXCR2 chemokine antagonists, CXCR1/2 chemokines, CCR6 chemokine antagonists, CD223 modulators, CD40 ligand receptor antagonists, cell adhesion molecule inhibitors, cell surface glycoprotein MUC18 inhibitors, CREB binding protein inhibitors, CXCR4 chemokine modulators, cytokine receptor antagonists, cytoplasmic phospholipase A2 inhibitors, DHFR inhibitors, DYRK-1 alpha protein kinase inhibitors, EGFR family tyrosine kinase receptor inhibitors, enolase 1 inhibitors, eosinophil chemokine ligand inhibitors, F1F0ATP synthase modulators, free fatty acid receptor 2 agonists, free fatty acid receptor 3 agonists, galectin-3 inhibitors, glucocorticoid agonists, GM-CSF ligand inhibitors, GNRH receptor modulators, 5-HT 1a receptor antagonists, FGF receptor antagonists, groEL protein 2 inhibitors, histamine H1 receptor antagonists, histamine H4 receptor antagonists, histone deacetylase-1 inhibitors, histone deacetylase-2 inhibitors, histone deacetylase-3 inhibitors, histone deacetylase-6 inhibitors, hsp 90 inhibitors, IL-1 receptor antagonists, interleukin 1-like receptor 2 inhibitors, IL-2 receptor alpha subunit stimulators, IL-2 modulators, IL-10 antagonists, IL-12 antagonists, IL-17 agonists, IL17RA gene inhibitors, IL-17 antagonists, IL-23 antagonists, IL-8 antagonists, immunoglobulin-like domain receptor 2 antagonists, insulin receptor substrate-1 inhibitors, interferon gamma receptor antagonists, interleukin 17 ligand inhibitors, interleukin 17A ligand modulators, interleukin 17F ligand inhibitors, interleukin 23A inhibitors, interleukin receptor 17A antagonists, interleukin receptor 17A modulators, interleukin-1 alpha ligand inhibitors, interleukin-1 beta ligand modulators, IRAK-4 protein kinase inhibitors, itk tyrosine kinase inhibitors, JAK tyrosine kinase inhibitors, jak1 tyrosine kinase inhibitors, jak2 tyrosine kinase inhibitors, jak3 tyrosine kinase inhibitors, KCNA voltage-gated potassium channel-3 inhibitors, lck tyrosine kinase inhibitors, lysophosphatidic acid-1 receptor antagonists, MALT protein 1 inhibitors, MAP kinase inhibitors, membrane copper amine oxidase inhibitors, metalloprotease-1 inhibitors, mitochondrial 10kDa heat shock protein stimulators, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, non-receptor tyrosine kinase TYK2 antagonists, nuclear factor erythroid 2-related factor 2 stimulators, nuclear factor kappa B inhibitors, nucleotide reverse transcriptase inhibitors, oncostatin M receptor subunit beta inhibitors, opioid receptor delta antagonists, OX40 ligand inhibitors, parathyroid hormone ligand inhibitors, PDE 4b inhibitors, P2Y6 purinergic receptor modulators; p-glycoprotein inhibitors, phosphoinositide-3 kinase delta inhibitors, phosphoinositide-3 kinase gamma inhibitors, phospholipase A2 inhibitors, apoptosis ligand 1 modulators, apoptosis protein 1 stimulators, P-selectin glycoprotein ligand-1 stimulators, retinoic acid receptor agonists, retinoic acid receptor gamma antagonists, retinoic acid receptor gamma inverse agonists, retinoid receptor agonists, retinoid X receptor modulators, retinoid Z receptor gamma agonists, retinoid Z receptor gamma inverse agonists, retinoid Z receptor gamma antagonists, rho-related protein kinase 2 inhibitors, ribonuclease P inhibitors, RIP-1 kinase inhibitors, sphingosine-1-phosphate receptor-1 antagonists sphingosine-1-phosphate receptor-1 modulators, src tyrosine kinase inhibitors, STAT-3 inhibitors, syk tyrosine kinase inhibitors, T-box transcription factor TBX21 modulators, T cell differentiation antigen CD6 inhibitors, T cell surface glycoprotein CD8 inhibitors, T cell surface glycoprotein CD28 stimulators, TGF beta agonists, TLR-7 antagonists, TLR-8 antagonists, TLR-9 antagonists, TNF alpha ligand inhibitors, TNF alpha ligand modulators, TNF antagonists, TNF binding agents, TNF gene inhibitors, topoisomerase II inhibitors, trkA receptor antagonists, tubulin binding agents, tyk2 tyrosine kinase inhibitors, type II TNF receptor modulators, unspecified cytokine receptor antagonists, vitamin D3 receptor agonists, vitamin D3 receptor modulators, wnt ligand inhibitors and Wnt 5A ligand inhibitors.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be combined with one, two, three, or four additional therapeutic agents selected from the group consisting of: AP-005, 18C3 (anti-IL-1α fully human antibody), ABX-464, averment, adalimumab, adipocell, AFB-035, alganison (aganirsen), AKP-11, alfasin, aliskiren acid, amilo-5mer, aminopterin, amiximod, apremilast, ASKP-1240, AST-005, ATI-2138, AVX-001, balatinib, beraprost (belapectin) (GR-MD-02), bai Ti Mumab, betamethasone, BI-655066, BI-730357, BI-730460, BI-730460, bimeigzhuzumab, BMS-986165, BMX-010, bruuzumab, bai Dalu mab, BTT-1023, C-82, calciposide, triol, calcitriol, CC-90005, CCL-20LD, CD-10367' Pegylated cetuximab, CF-101, cyclosporin, CJM-112, CKBA, clobetasol propionate+retinoic acid, CM-2489, CPL-409116, clenbuterol, CS-12192, CT-327, CTX-101, darapatide, DFD-06, dimethyl fumarate, dithranol, DLX-105, DSXS-1411, DSXS-1535, DUR-928, EDP-1815, etanercept, fluocinolone acetonide, FPP-003, GK-664-S, GLG-801, GLPG-3121, GLPG-3667, GLPG-3970, GLY-2028, GMDP, GSK-2800528, GSK-2831781, GSK-2981278A, guzekuzumab, halometasone, HAT-1, IMO-3100, IMO-8400, inecalcitol, infliximab, INV-103 IR-444, IR-502, illicimumab, EQizumab, JN-2528, KBL-697, KD-025, LAS-41004, LEO-124249, LEO-29102, LEO-32731, LEO-35299, lithium succinate, LNP-1955, LP-0200, M-1095, maxacalcitol, MDX-018, methotrexate, MOL-4249, mometasone, MP-1032, MSB-03, myristyl nicotinate, nalmeflozumab, ne Hu Zhushan antibody, niclosamide, NLP-91, NP-000888, NVN-1000, olopatadine, oreotid (orilmod), P-3072, P-3073, PAT-7, 4, pentafluorostol (pefcall), PF-06700841 Prurisol, PRX-003, PRX-167700, PUR-0110, recombinant human LFA-3/antibody fusion protein, RON-2315, RTU-1096, S-414114, stuzumab, SHP-141, SMET-D1, SNK-01, SP-14019, SSS-07, tacalcitol, tazarotene, teridakamab, ter Ban Bulin (KX-01), tofacitinib, tolireline, trorimab, TU-2100, UCB-5857, UHE-105, ubetasol, ubeclomab, VBY-891, fuciclosporin, VTP-43742, WBI-1001 and ZPL-389 or a pharmaceutically acceptable salt of any of the foregoing or any combination thereof.

acetaldehyde dehydrogenase inhibitors including, but not limited to ADX-629;

adenosine A3 receptor agonists including, but not limited to, piridenoson (CF-101);

adenosine A3 receptor antagonists including, but not limited to PBF-1650;

ADP ribosyl cyclase-1 inhibitors, including but not limited to IMO-3100;

5-HT 1a receptor antagonists, including, but not limited to AX-1602;

apolipoprotein a antagonists including, but not limited to, octreotide Su Shan antibodies;

cytokine receptor antagonists, including but not limited to, ben-rimod (tapinaof);

aromatic hydrocarbon receptor modulators including, but not limited to, NTI-528 and RLV-102;

Bcl-xL Bcl-2 related death promoting factor modulators, including but not limited to Pc4;

beta-catenin inhibitors, including but not limited to C-82;

bromodomain-containing protein inhibitors including, but not limited to BOS-475;

ca2+ release activates ca2+ channel 1 inhibitors, including but not limited to CM-2489 and PRCL-02;

calcineurin inhibitors including, but not limited to, fu Huan sporon, pimecrolimus, tacrolimus, cyclosporine, HS-378, oxycyclosporin, OLO-400, ADV-P3, and CTX-006;

Calcium channel inhibitors, including but not limited to RP-3128;

cathepsin S inhibitors including, but not limited to VBY-129, VBY-891, RWJ-445380 and CRA-028129;

CCR3 chemokine antagonists including, but not limited to Bai Ti mab;

CXCR2 chemokine antagonists including, but not limited to CCX-624;

CD223 modulators, including but not limited to GSK-2831781;

CD40 ligand receptor antagonists including, but not limited to ASKP-1240, lu Kamu monoclonal antibodies and tolaguemab;

cell adhesion molecule inhibitors including, but not limited to BIRT-2584, PC-114, A Li Kafu Sen, IC-747, ICM-3 and ISIS-2302;

cell surface glycoprotein MUC18 inhibitors including, but not limited to, PRX-003 and ipu Li Shan antibodies;

CREB binding protein inhibitors including, but not limited to, C-82;

CXCR1/2 chemokines including, but not limited to LY-3041658;

CXCR4 chemokine modulators, including but not limited to CD184-FK506 ADC;

cytosolic phospholipase A2 inhibitors including, but not limited to AVX-001;

DHFR inhibitors, including but not limited to methotrexate, CH-4051, cePep, CH-1504, MQX-5902, and MPI-2505;

DYRK-1 alpha protein kinase inhibitors, including but not limited to VRN-02;

EGFR family tyrosine kinase receptor inhibitors including, but not limited to erlotinib, icotinib hydrochloride and SGT-210;

enolase 1 inhibitors, including but not limited to HuL-001;

eosinophil chemokine ligand inhibitors, including but not limited to Bai Ti xylanase;

F1F0 ATP synthase modulators, including but not limited to LYC-30937;

FGF receptor antagonists including, but not limited to, potassium oxybenzene sulfonate;

free fatty acid receptor 2, 3 agonists, including but not limited to SFA-002;

galectin-3 inhibitors including, but not limited to, beraprost (GR-MD-02);

glucocorticoid agonists including, but not limited to, betamethasone, clobetasol, auranofin, NM-135, DSXS-1538b and SEGRA;

GM-CSF ligand inhibitors including, but not limited to, nalmefene;

GNRH receptor modulators, including but not limited to NL-001;

GroEL protein 2 inhibitors, including but not limited to prozumab;

histamine H1 receptor antagonists including, but not limited to olopatadine and loratadine + nortriptyline;

histamine H4 receptor antagonists including, but not limited to, tolterodine and ZPL-389;

inhibitors of histone deacetylase-2, including but not limited to KAR-1880;

Inhibitors of histone deacetylases 1, 6, 2, 3, including but not limited to remimetinostat (SHP-141);

hsp 90 inhibitors, including but not limited to CTXT-102;

IL-2 receptor alpha subunit stimulators including, but not limited to, NKTR-358;

IL-2 modulators; including but not limited to CC-92252;

IL-10 antagonists, including but not limited to pimecrolimus;

IL-12 antagonists, including but not limited to BOW-090, bryumab, FM-202, and apilimod;

IL-17 antagonists, including but not limited to, evodiumab, stuzumab, AFB-035, KD-025, DLX-3003, EBI-028, M-1095, IMO-3100, GR-1501, 608, funadir monoclonal antibody, solodizumab, AK-111, HB-0017 and SIM-335;

IL-17 agonists, including but not limited to ZL-1102;

IL17RA gene inhibitors, including but not limited to XCUR-17;

IL-23 antagonists, including but not limited to, teridazumab, BI-655066, AMG-139, brauzumab, mi Jizhu mab (LY-3074828), FM-202, apilimod, LY-2525623, ruixabebian, and IBI-112;

IL-23 antagonists, including but not limited to Utility mab and AK-101;

IL-8 antagonists, including but not limited to BMS-986253 (MDX-018), AS-101, ABX-IL8, LI-312, SB-332235, and LF-216;

Immunoglobulin-like domain receptor 2 antagonists, including but not limited to CGEN-15001;

insulin receptor substrate-1 inhibitors including, but not limited to, alganison;

interferon gamma receptor antagonists including, but not limited to, pimecrolimus, AMG-811, OA-1, AGT-1, mometasone + nortriptyline and rituximab;

interleukin 17 ligand inhibitors including, but not limited to, CJM-112, nitazomycin and AFB-035;

interleukin 17A ligand inhibitors including, but not limited to, COVA-322, JS-005, and ABY-035/AFO2;

interleukin 17A ligand modulators, including but not limited to QX-002-N;

interleukin 17A/17F ligand inhibitors including, but not limited to, bimagrumab;

interleukin 23A inhibitors including, but not limited to, antique pessary mab and QX-004-N;

interleukin receptor 17A antagonists including, but not limited to, bai Dalu mab and LZM-012;

interleukin 1-like receptor 2 inhibitors including, but not limited to, ste Bai Suoli mab (spisolimab) and ismidolimab (imsidolimab);

interleukin-1 alpha ligand inhibitors including, but not limited to, bei Maiji mab (bermekimab) (CA-18C 3);

interleukin-1 beta ligand modulators, including but not limited to PUR-0110 and AR-100;

IRAK-4 protein kinase inhibitors including, but not limited to BAY-1834845;

itk tyrosine kinase inhibitors, including but not limited to JTE-051;

JAK tyrosine kinase inhibitors including, but not limited to CS-17380;

jak1 tyrosine kinase inhibitors including, but not limited to, itatinib, abxitinib (PF-04965842), soritinib, SHR-0302 and non-gotinib;

JAK1,2,3 tyrosine kinase inhibitors including, but not limited to, jacktinib;

JAk1,2 tyrosine kinase inhibitors including, but not limited to, barytinib and ruxotinib;

TYk2 tyrosine kinase inhibitors including, but not limited to, bupacitinib;

jak1 tyrosine kinase inhibitors, including but not limited to PF-06263276;

JAk1, 3 tyrosine kinase inhibitors including, but not limited to, CS-944X, tofacitinib, and pefacitinib;

KCNA voltage-gated potassium channel-3 inhibitors including, but not limited to KPI-150, dalazalide, BNC-164, and SPS-4251;

lck tyrosine kinase inhibitors, including but not limited to BMS-350751 and NTRC-0625-0;

lysophosphatidic acid-1 receptor antagonists including, but not limited to BMS-986202;

MAP kinase inhibitors, including but not limited to AIK-33 and KIN-3032;

Membrane copper amine oxidase inhibitors including, but not limited to, vipamomab, BTT-1023, RTU-1096, and PRX-167700;

inhibitors of metalloprotease-1, including but not limited to KIN-3032 and HMR-1571;

non-receptor tyrosine kinase TYK2 antagonists including, but not limited to SAR-20347, ICP-332 and SDC-1801;

nuclear factor Red 2-associated factor 2 stimulators, including but not limited to dimethyl fumarate and XP-23829;

nuclear factor κb inhibitors including but not limited to S-414114, VGX-1027, AKBA, SP-100030 and YP-008;

nucleotide reverse transcriptase inhibitors, including but not limited to Prurisol;

inhibitors of oncostatin M receptor subunit β including, but not limited to, vitamin Sha Ruili mab (vixarelimab);

opioid receptor delta antagonists including, but not limited to, HS-378;

OX40 ligand inhibitors, including but not limited to KY-1005;

p38 MAP kinase inhibitors, including but not limited to AMG-101, AIK-3, VGX-1027, AIK-a1, BMS-582949, da Ma Mode, plug Ma Mode, TA-5493, HEP-689, and RWJ-68354;

parathyroid hormone ligand inhibitors including, but not limited to, inecalcitol;

PDE 4 inhibitors including, but not limited to, apremilast, roflumilast, orelset, MK-0873, ro-20-1724, HMR-1571, RPR-122818, HPP-737, clenbuterol and DC-591042;

PDE 4b inhibitors, including but not limited to GRT-6015;

tnfα ligand inhibitors, including but not limited to Hemay-005;

p-glycoprotein inhibitors including, but not limited to, boningmycin;

beta amyloid antagonists including, but not limited to GC-021109;

phosphoinositide-3 kinase delta inhibitors including, but not limited to, celecoxib Li Xibu (UCB-5857);

mTOR complex 2 inhibitors, including but not limited to, sibutra (bimiralisib) at ratio Mi Lali;

phosphoinositide-3 kinase gamma inhibitors including, but not limited to TAT-N25 peptide;

phospholipase A2 inhibitors including, but not limited to ZPL-521, items P-0229, BMS-181162 and BMS-188184;

apoptosis ligand 1 modulators, including but not limited to GX-P2;

apoptosis protein 1 stimulators, including but not limited to LY-3462817 and CC-90006;

p-selectin glycoprotein ligand-1 stimulators, including but not limited to, ne Hu Zhushan antibodies;

p-selectin glycoprotein ligand-1, including but not limited to AbGn-168H;

Retinoic acid receptor agonists including, but not limited to, abamectin, tazarotene, tretinoin, tazarotene Luo Tingfang tretinoin tromethamine, CD-1599, AM-580, BMS-181163 and CPR-2005;

retinoic acid receptor gamma antagonists, including but not limited to VTP-43742 and BBI-6000;

retinoic acid receptor gamma inverse agonists including, but not limited to, GSK-2981278A and JNJ-3534;

retinoid receptor agonists, including but not limited to RASP;

retinoid X receptor agonists, including but not limited to LGD-1550;

retinoid X receptor modulators including, but not limited to, bexarotene, alisretinate, ALRT-1069, LGD-1069 and Net-4IB;

retinoid Z receptor gamma agonists, including but not limited to NCE-407;

retinoid Z receptor gamma inverse agonists, including but not limited to ARN-6039, IMU-935, BOS-172767, SAR-441169 and INV-17;

retinoid Z receptor gamma antagonists including, but not limited to, AUR-101, JTE-451, ESR-114, ABBV-157 and AZD-0284;

rho-associated protein kinase 2 inhibitors, including but not limited to KD-025;

RIP-1 kinase inhibitors, including but not limited to GSK-2982772, DNL-758, and VRN-04;

ribonuclease P inhibitors, including but not limited to RASP;

Sphingosine-1-phosphate receptor-1 modulators, including but not limited to amixomod, AKP-11, FP-253, and CS-0777;

sphingosine-1-phosphate receptor-1 agonists, including but not limited to AK-119, SCD-044 and SYL-927;

sphingosine-1-phosphate receptor-5 modulators, including but not limited to CBP-307;

src tyrosine kinase inhibitors including, but not limited to, japanese patent Ban Bulin (KX-01);

STAT-3 inhibitors, including but not limited to TAK-114, GLG-801, and MOL-4249;

syk tyrosine kinase inhibitors, including but not limited to HMPL-523;

t-box transcription factor TBX21 modulators, including but not limited to SB-020;

t cell differentiation antigen CD6 inhibitors including, but not limited to, illicit mab;

t cell surface glycoprotein CD8 inhibitors including, but not limited to, trestuzumab;

t cell surface glycoprotein CD28 stimulators including, but not limited to, sirolimus;

tgfβ agonists, including but not limited to trestuzumab;

TLR-7 antagonists, including but not limited to IMO-3100;

TLR-9 antagonists including, but not limited to IMO-3100 and GNKS-356;

TLR 7,8,9 antagonists, including but not limited to IMO-8400;

TNFα ligand inhibitors including, but not limited to, adalimumab, CHS-1420, BAX-2923, MSB-11022, ABP-501, MYL-1401A, infliximab, pegylated cetuximab, AST-005, etanercept, openkempt, ISIS-104838, DLX-105, SSS-07, DLX-2751, DLX-105, debio-0512, TAQ-588, adalimumab, praguemab, PMI-001, CYT-020-TNFQb, AN-0128, CYT-007-TNFQb, SYI-2074, YP-008, SCT-640A, SBT-104, and T-1649;

TNFα ligand modulators, including but not limited to PUR-0110, CDP-571, and ACU-D2;

TNF antagonists, including but not limited to, PEGylated cetuximab, SCB-808, BAX-2200, CT-P05, SCB-131, GSK-2800528, onacemide, and ALS-00T2-0501;

TNF binding agents including, but not limited to, adalimumab, pegylated cetuximab SCB-131, onacemide, CT-P17, SBC-808, ABP-501, MYL-1401A, MSB-11022, BAX-2923, CHS-1420, and BCD-057;

TNF gene inhibitors, including but not limited to AST-005;

topoisomerase II inhibitors including, but not limited to GPX-150;

TrkA receptor antagonists including, but not limited to, VM-902A, CT-327, K-252a, and letatinib;

tubulin binding agents including, but not limited to, KX-01 and paclitaxel;

tyk2 tyrosine kinase inhibitors including, but not limited to, deuterated celecoxib, PF-06826647, ABBV-712, and CS-43001;

type II TNF receptor modulators, including but not limited to TNR-001, BAX-2200, and SCB-131;

unspecified cytokine receptor antagonists including, but not limited to, tetrathiomolybdate, JD-4000, X-083-NAB, SPHD-400, pimecrolimus, and HMPL-010;

vitamin D3 receptor agonists including, but not limited to, inecalcitol, maxacalcitol, calcipotriol, fluoxetol, maxacalcitol, calcitriol NS-78, tacalcitol, calcithiozol, ecalcitrane, linacalcitol, atocalcitol, and Ro-65-2299;

Vitamin D, D3 receptor modulators, including but not limited to VS-320 and VS-105;

wnt ligand inhibitors including, but not limited to SM-04755; and

wnt 5A ligand inhibitors including, but not limited to Box-5.

Combination therapy for rheumatoid arthritis

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, may be combined with one, two, three, or four additional therapeutic agents useful in treating or ameliorating rheumatoid arthritis. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be combined with one, two, three, or four additional therapeutic agents selected from the group consisting of: 14-3-3 protein eta inhibitors, 5-lipoxygenase inhibitors, abl tyrosine kinase inhibitors, ACTH receptor agonists, adenosine A3 receptor agonists, adenosine deaminase inhibitors, ADP-ribosyl cyclase-1 modulators, ADP-ribosylating factor 6 inhibitors, corticotropin ligands, polyproteinase-2 inhibitors, albumin modulators, anti-TNF steroid conjugates, adenosine A1 receptor antagonists, annexin A1 modulators, AP1 transcription factor inhibitors, apolipoprotein B modulators, arene receptor agonists plus autoantigens, basic immunoglobulin inhibitors, bcr protein inhibitors, B lymphocyte antigen CD19 inhibitors, B lymphocyte antigen CD20 modulators, B lymphocyte adhesion molecule inhibitors, B lymphocyte stimulating factor ligand inhibitors bradykinin receptor modulators, BRAF gene inhibitors, branched amino acid transaminase 1 inhibitors, bromodomain-containing protein inhibitors, btk tyrosine kinase inhibitors, cadherin-11 antagonists, calcineurin inhibitors, calcium channel inhibitors, calreticulin inhibitors, carbonic anhydrase inhibitors, cathepsin K inhibitors, cathepsin S inhibitors, CCR1 chemokine antagonists, CCR2 chemokine antagonists, CCR3 gene modulators, CCR5 chemokine antagonists, CD126 antagonists, CD29 modulators, CD3 modulators, CD39 agonists, CD4 antagonists, CD40 ligand inhibitors, CD40 ligand receptor antagonists, CD40 ligand receptor modulators, CD52 antagonists, CD73 agonists, CD79B modulators, CD80 antagonists, CD86 antagonists, CD95 antagonists, cell adhesion molecule inhibitor, chaperonin modulator, choline kinase inhibitor, aggregative stimulator, complement C5 factor inhibitor, complement factor stimulator, C-reactive protein inhibitor, CSF-1 antagonist, CXC10 chemokine ligand inhibitor, CXCR4 chemokine antagonist, cyclin-dependent kinase inhibitor 1 inhibitor, cyclin-dependent kinase-2 inhibitor, cyclin-dependent kinase-4 inhibitor, cyclin-dependent kinase-5 inhibitor, cyclin-dependent kinase-6 inhibitor, cyclin-dependent kinase-7 inhibitor, cyclin-dependent kinase-9 inhibitor, cyclooxygenase 2 modulator, cyclooxygenase inhibitor, cytoplasmic phospholipase A2 inhibitor, cytotoxic T lymphocyte protein-4 modulator, cytotoxic T lymphocyte protein-4 stimulator deoxyribonuclease gamma stimulator, DHFR inhibitor, diamine acetyltransferase inhibitor, dihydroorotate dehydrogenase inhibitor, DYRK-1 alpha protein kinase inhibitor, elongation factor 2 inhibitor, enolase 1 inhibitor, eosinophil chemokine 2 ligand inhibitor, EP4 prostaglandin receptor antagonist, erythropoietin receptor agonist, factor XIIa antagonist, fas ligand, FGF-2 ligand inhibitor, FK506 binding protein-12 modulator, folic acid antagonist, folic acid receptor agonist, folic acid receptor beta antagonist, folic acid receptor modulator, actin ligand inhibitor, fyn tyrosine kinase inhibitor, G protein coupled receptor 15 antagonist, GABA A receptor modulator, glucocorticoid agonist, glucocorticoid antagonist, glucocorticoid-induced leucine zipper protein stimulator, GM-CSF ligand inhibitors, GM-CSF receptor antagonists, GM-CSF receptor modulators, growth regulator alpha ligand inhibitors, H+K+ ATPase inhibitors, histamine H4 receptor antagonists, histone deacetylase inhibitors, histone deacetylase-6 inhibitors, HIV-1gp120 protein inhibitors, HLA class II antigen DQ-2 alpha modulators, HLA class II antigen inhibitors, HLA class II antigen modulators, hsp 70 family inhibitors, hypoxia inducible factor-1 inhibitors, IFNB gene stimulators, I-kappa B kinase beta inhibitors, I-kappa B kinase inhibitors, IL-1 antagonists, IL-10 agonists, IL-11 agonists, IL-12 antagonists, IL-15 antagonists, IL-17 receptor modulators, IL-18 receptor accessory protein antagonists IL-8 ligand inhibitors, IL-2 agonists, IL-2 antagonists, IL-21 antagonists, IL-23 antagonists, IL-3 antagonists, IL-4 agonists, IL-6 antagonists, IL-6 receptor modulators, IL-6 neutralizing human antibodies, anti-IL 6 antibodies, immunoglobulin antagonists, immunoglobulin G1 agonists, immunoglobulin G1 antagonists, immunoglobulin G1 modulators, immunoglobulin G2 antagonists, immunoglobulin G2 modulators, immunoglobulin gamma Fc receptor II modulators, immunoglobulin gamma Fc receptor IIB antagonists, immunoglobulin kappa modulators, immunoglobulin M antagonists, inducible nitric oxide synthase inhibitors (iNOS inhibitors), inosine monophosphate dehydrogenase inhibitors, insulin sensitizers, integrin alpha-1/beta-1 antagonists, integrin alpha-4/beta-1 antagonists, integrin alpha-9 antagonists, integrin antagonists, interferon beta ligands, interferon gamma ligands, interleukin 17A ligand inhibitors, interleukin 17F ligand inhibitors, interleukin 23A inhibitors, interleukin ligand, interleukin receptor 17A antagonists, interleukin-1 beta ligand inhibitors, interleukin-10 ligand, interleukin-2 ligand, interleukin-4 ligand, interleukin-6 ligand inhibitors, itk tyrosine kinase inhibitors, JAK tyrosine kinase inhibitors, jak1 tyrosine kinase inhibitors, jak2 tyrosine kinase inhibitors, JAK3 gene inhibitors, jak3 tyrosine kinase inhibitors Jun N-terminal kinase inhibitor, KCNA voltage-gated potassium channel-3 modulator, kelch-like ECH-related protein 1 modulator, kit tyrosine kinase inhibitor, lanC-like protein 2 modulator, leukotriene BLT receptor antagonist, LITAF gene inhibitor, lymphocyte function antigen-3 receptor antagonist, lyn tyrosine kinase inhibitor, macrophage-drug conjugate (MDC), macrophage mannose receptor 1 modulator, MAdCAM inhibitor, MAP kinase modulator, MAP3K2 gene inhibitor, MAPKAPK5 inhibitor, matrix metalloproteinase inhibitor, MCL1 gene inhibitor, MEK protein kinase inhibitor, MEK-1 protein kinase inhibitor, MEK-2 protein kinase inhibitor, membrane copper amine oxidase inhibitor, metalloproteinase-2 inhibitor, metalloproteinase-9 inhibitor, methylprednisolone, midkine ligand inhibitor, mitochondrial 10kDa heat shock protein stimulator, mTOR complex 1 inhibitor, mTOR inhibitor, NAD ADP ribosyl transferase stimulator, NAMPT gene inhibitor, NF kappa B inhibitor stimulator, NFAT gene inhibitor, NFE2L2 gene stimulator, nicotinic acetylcholine receptor antagonist, NK cell receptor modulator, NKG 2A B-activated NK receptor antagonist, NKG 2D-activated NK receptor antagonist, nuclear factor erythroid 2-associated factor 2 stimulator, nuclear factor kappa B inhibitor, nuclear factor kappa B modulator, nuclear factor kappa B P105 inhibitor, opioid growth factor receptor agonist, opioid receptor delta antagonist, osteoclast differentiation factor ligand inhibitor, oxidoreductase inhibitor, P2X7 purine receptor agonist, P38 MAP kinase alpha inhibitor P38 MAP kinase inhibitors, PDE 4 inhibitors, PDE 5 inhibitors, PDGF receptor agonists, PDGF receptor antagonists, PDGF-B ligand inhibitors, PERK gene inhibitors, phosphoinositide-3 kinase delta inhibitors, phosphoinositide-3 kinase gamma inhibitors, phospholipase A2 inhibitors, platelet activating factor receptor antagonists, PPARgamma agonists, modulators of apoptosis protein 1, prostaglandin D synthase stimulators, protein arginine deiminase inhibitors, protein tyrosine kinase inhibitors, protease activating receptor-2 antagonists, purH purine biosynthesis protein inhibitors, rho-associated protein kinase 2 inhibitors, separation enzyme (seprase) inhibitors, signal transduction protein CD24 modulators, signal transduction inhibitors, sodium glucose transporter-2 inhibitors, sphingosine 1 phosphophosphatase modulators, STAT3 gene inhibitors, serum amyloid A modulators, superoxide dismutase stimulators, SYK family tyrosine kinase inhibitors, syk tyrosine kinase inhibitors, multi-ligand proteoglycan-1 inhibitors, T cell receptor antagonists, T cell receptor modulators, T cell surface glycoprotein CD28 inhibitors, T cell surface glycoprotein CD28 stimulators, TAK1 binding protein modulators, ankyrin modulators, T cell differentiation antigen CD6 inhibitors, T cell surface glycoprotein CD8 inhibitors, tenascin modulators, TGF beta agonists, thymosin agonists, TLR-2 antagonists, TLR-4 antagonists, TLR-9 antagonists, TNF alpha ligand inhibitors, TNF alpha ligand modulators, TNF antagonists TNF gene inhibitors, TNF receptor modulators, TNFSF11 gene inhibitors, transcription factor p65 inhibitors, transcription factor RelB inhibitors, transferrin modulators, transthyretin modulators, tumor necrosis factor 13C receptor antagonists, tumor necrosis factor 15 ligand inhibitors, tumor necrosis factor ligand 13 inhibitors, tumor necrosis factor ligand inhibitors, IL-1 receptor antagonists type I, TNF receptor modulators type II, unspecified GPCR agonists, VEGF receptor antagonists, VEGF-2 receptor modulators, VEGF-B ligand inhibitors, X-linked apoptosis inhibitor proteins and zap70 tyrosine kinase inhibitors.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be combined with one, two, three, or four additional therapeutic agents selected from the group consisting of: 99mTc labeled annexin V-128, abapyrip, abapyric biological analog, ABBV-257, ABT-122, ABT-494, acartinib, aceclofenac, axolitide, adMSCs, MS-392, adalimumab biological analog, adalimumab subsequent biological preparation, AK-106, ALX-0061, amilo-5MER, aminopterin, AMT-101, anakinout biological preparation, annexuzlimab, ARG-301, ARQ-250, ASLAN-003, ASP-5094, AT-132, AZD-9567, barittinib, BI-655064, biMegambirab, biP (rheumatoid arthritis), BLHP-006, BS-986104, BMS-986142, ABBV-105, BTT-1023, cardamascen Cortili (Cartistem), CCX-354, CD24-IgFc, celecoxib, ceritinib, PEGylated cetuximab, CF-101, CFZ-533, CHR-5154, silbivalide, cyclosporine, cladazazumab, CNTO-6785, corticotropin, CR-6086, creaVax-RA, CWG-92, CWG-940, cx-611, DE-098, DEN-181, defucort, rheumavax, denomab, diacerein, diclofenac, DWJ-1421, E-6011, eicosapentaenoic acid glycerol monoester, etanercept subsequent biologicals, etodolac, etoricoxib, non-gotinib, fodacobate (fosdagrosat), GLPG-3970, gilimab (glimezumab), ginsenoside C-K, ji Weisi He, GLPG-4399, goat polyclonal antibody, golimumab, GS-5745, GS-9876, GSK-3196165, HHT-109, HM-71224, HMPL-523, HST-003, sodium hyaluronate, (S) -hydroxychloroquine, IB-RA (injectable, rheumatoid arthritis), IB-RA (oral, rheumatoid arthritis), icanoMAB, ICP-022, iguratimod, IMD-2560, imidazole salicylate, infliximab antibiotic bioaugmente, infliximab antibiotic analogue, CT-P13, INSIX RA, interferon gamma subsequent biologic, interleukin-2 (injectable), interleukin-2 subsequent biologic, INV-103, IR-501, illimumab, JNJ-40346527, casutinin, KB-312, KD-025, ketoprofen + omeprazole, KINE-101, LB-600, leflunomide, renz lumab LLDT-8, LNK-01001, LNP-1955, lumiracoxib, LY-3090106, marfolimumab, MBS-2320, MEDI-5117, meloxicam, methotrexate, MGD-010, misoprostol+diclofenac, MM-A01-01, mo Nali bead mab, MORAB-022, MPC-300-IV, MRC-375, nabumetone, nalmeflozumab, naproxen+esomeprazole strontium, NIP-046, oxcarbatozumab, ofatumumab, OHR-118, oxford monoclonal antibody, OM-89, naproxen (oral controlled release, pain), ONO-4059, oralgam, olanimumab, PAR-2 inhibitor, pefetinib, pebiprofen, PF-06687234, piperidone hydrochloride, piroxicam, prednisolone, prednisone, procell, prosorba, PRT-2607, PRTX-100, PRX-167700, QBSAU, rabeximod (rabeximod), RCT-18, recombinant human CD22 monoclonal antibody (intravenous infusion), lonn Ryonn Pharma/SinoMab Bioscience (deep zhen), RA-curcumin liposome, recombinant human interleukin-1 receptor antagonist (rheumatoid arthritis), recombinant human interleukin-2 recombinant TNF receptor 2-Fc fusion protein mutant, RG-6125, rhuDex, rifabutin+clarithromycin+clofazimine, rituximab rituximab anti-biological analogues, torriz, rituximab follow-up biological preparation, RPI-78, SAN-300, sha Lilu mab, SBI-087, ce Li Xili, SHR-0302, ce Lu Kushan mab, capetinib, SR-047, SSS-07, KDF-201110-06, syn-1002, T-5224, TAB-08, tacrolimus, TAK-020, TAK-079, tarenflurbiprate (transdermal insufflation gel, dermatological/rheumatoid arthritis), technetium Tc 99 m-Ma Nuosai, technetium [99Tc ] methylenediphosphate, tenoxicam, debio-0512, tozumab, tofacitinib citrate, TQG-2813, pig flagellin, umbilical cord-derived mesenchymal stem cells (veins, RA/liver disease), utekey monoclonal antibody, VAY-736, VB-201, WF-10, xmAb-5871, YH-1713, YHB-1411-2, YRA-1909 and ZM-008 or pharmaceutically acceptable salts of any of the foregoing or any combination thereof.

14-3-3 protein eta inhibitors including, but not limited to, anti-AGX-020 mab (rheumatoid arthritis) and Augurex;

5-lipoxygenase inhibitors including, but not limited to, debuflounder, japanese Ding Feilong, ZD-2138, etalloside (etalloccib), PGV-20229, L-708780, T-0757, T-0799, ZM-216800, L-699333, BU-4601A, and SKF-104351;

5-lipoxygenase/cyclooxygenase inhibitors including, but not limited to, tenoxicam, li Kefei Dragon, tenidap, teposaline, fluo Luo Bufen, SKF-86002, WY-28342, and CI-986;

5-lipoxygenase/PPARgamma agonists, including but not limited to etaloxy;

abl tyrosine kinase inhibitor/Bcr protein inhibitor/Kit tyrosine kinase inhibitor/PDGF receptor antagonist/signal transduction inhibitor, including but not limited to imatinib;

ACTH receptor agonists/corticotropin ligands/opioid growth factor receptor agonists including, but not limited to FAR-404 and methionine enkephalin acetate + Qu Kake peptide acetate;

adenosine A1 receptor antagonists, including but not limited to CP-25;

Adenosine A3 receptor agonists including, but not limited to CF-101 (piridesone);

adenosine deaminase inhibitors, cladribine, pravastatin and FR-221647;

ADP ribosyl cyclase-1 inhibitors including, but not limited to, darimumab;

ADP ribosyl cyclase-1 modulators/multi-ligand proteoglycan-1 inhibitors, including but not limited to infliximab;

ADP ribosylating factor 6 inhibitors including, but not limited to NAV-2729;

corticotropin ligands including, but not limited to, corticotropin and Mallinckrodt;

inhibitors of the polyproteinase-2/TNF gene including, but not limited to, GIBH-R-001-2;

albumin modulators, including but not limited to ONS-1210;

albumin modulators/IL-6 antagonists including, but not limited to ALX-0061 (Wo Bali bead mab);

albumin modulators/tnfα ligand inhibitors, including but not limited to HOT-3010;

AP1 transcription factor/nuclear factor kb inhibitors including, but not limited to, talent fluroxypyr and SP-100030;

anti-TNF steroid antibody-drug conjugates (anti-TNF-GRM), including but not limited to ABBV-3373 and ABBV-154;

basic immunoglobulin inhibitors/branched chain amino acid transaminase 1/metalloprotease 9 inhibitors/metalloprotease 2 inhibitors, including but not limited to ERG-240;

BET inhibitors including, but not limited to GSK-3358699;

bispecific anti-CD 86/IL-10, including but not limited to APVO-210;

bispecific humanized monoclonal antibodies targeting BAFF and IL-17A, including but not limited to tibrizumab;

bispecific antibody-peptide conjugates (BAFF/ICOSL), including but not limited to AMG-570;

b lymphocyte antigen CD19 inhibitors including, but not limited to MDX-1342;

b lymphocyte antigen CD19 inhibitors/immunoglobulin gamma Fc receptor IIB antagonists, including but not limited to XmAb-5871;

b lymphocyte antigen CD20 inhibitors, including but not limited to, oregano mab, ofatuzumab, rituximab, ABP-798, maball, mabtas, reditux, zytux, veltuzumab, oxcarbatuzumab, BLX-301, IDEC-102, ABP-798, GP-2013, MK-8808, HLX-01, CT-P10, TL-011, PF-05280586, IBPM-001RX, IBI-301, AME-133v, BCD-020, BT-D004, SAIT-101, and JHL-1101;

b lymphocyte antigen CD20 modulators, including but not limited to SBI-087, TRU-015, DXL-625 and MabionCD20;

b lymphocyte cell adhesion molecule inhibitors including, but not limited to SM-06;

b lymphocyte stimulating factor ligand inhibitors including, but not limited to, belimumab, RCT-18, cloth Li Mode, he Bei Lushan antibody, and bupropion;

B lymphocyte stimulating factor ligand/tumor necrosis factor ligand 13 inhibitors including, but not limited to, asenapine;

bradykinin receptor modulators/histone deacetylase inhibitors/P2X 7 purinergic agonists including but not limited to Ji Weisi he;

BRAF gene/MEK protein kinase/PERK gene inhibitors, including but not limited to bemetinib;

bromodomain-containing protein inhibitors including, but not limited to RVX-297, ZEN-003694

Btk tyrosine kinase inhibitors including, but not limited to, AC-0058, acartinib, HM-71224, capetinib, BMS-986142, TAK-020, tiramitinib (ONO-4059), TAS-5315, ABBV-105, GDC-0834, EBI-1459, BMS-986195, ibrutinib, febutinib, SIMM-016 and YZJ-3058;

btk tyrosine kinase inhibitor/Syk tyrosine kinase inhibitor/VEGF-2 receptor antagonists, including but not limited to CG-026806;

btk tyrosine kinase inhibitors/IL-6 antagonists including, but not limited to RN-486;

btk tyrosine kinase/Jak 1 tyrosine kinase inhibitors, including but not limited to Wu Pati Ni+ABBV-105;

btk tyrosine kinase/Jak 3 tyrosine kinase inhibitors, including but not limited to AC-0025;

cadherin-11 antagonists, including but not limited to RG-6125;

Calcineurin inhibitors including, but not limited to, cyclosporine;

calcineurin inhibitors/opioid receptor delta antagonists including, but not limited to HS-378;

calcium channel inhibitors, including but not limited to RP-3128;

calreticulin inhibitors including, but not limited to ALB-001 and ZYBK-2;

carbonic anhydrase/cyclooxygenase 2 inhibitors including, but not limited to, pam Ma Kao shake;

cathepsin K inhibitors including, but not limited to CRA-013783 and VEL-0230;

cathepsin K/cathepsin S inhibitors including, but not limited to AM-3876 and NPI-2019;

cathepsin S inhibitors including, but not limited to MIV-247 and RWJ-445380;

CCR1 chemokine antagonists including, but not limited to, BX-471, BMS-817399, BI-638683, CCX-354, MLN-3701, MLN-3897, CP-481715 and PS-375179;

CCR2 chemokine antagonists including, but not limited to MK-0812 and AZD-6942;

CCR3 gene modulators/eosinophil chemokine 2 ligand inhibitors, including but not limited to CM-102;

CCR5 chemokine antagonists including, but not limited to, OHR-118, NIBR-6465, AZD-5672 and AZD-8566;

CD29 modulators/interleukin-10 ligands, including but not limited to PF-06687234;

CD3 modulators, including but not limited to oxybutynin;

CD39/CD73 agonists, including but not limited to AAV5-CD39/CD73 (rheumatoid arthritis) and Arthrogen;

CCR5 chemokine antagonists/CD 4 agonists/HIV-1 gp120 protein inhibitors, including but not limited to maraviroc;

CD4 antagonists including, but not limited to, zazalomab, MTRX-1011A, BW-4162W94, EP-1645, cleiximab and DerG-PG275Cit;

CD40 ligand inhibitors including, but not limited to, pegylated dapiromab and TNX-1500;

CD40 ligand receptor antagonists including, but not limited to, BI-655064, anti-CD 40-XTEN, tenectimab, VIB-4920 and Iskarituximab;

CD40 ligand receptor modulators/immunoglobulin G1 modulators, including but not limited to CFZ-533;

CD52 antagonists/collectin stimulators, including but not limited to alemtuzumab;

bispecific CD32B/CD79B antibodies, including but not limited to PRV-3279 (MGD-010);

CD80 antagonists, including but not limited to abamectin improvers;

CD80 antagonists/T cell surface glycoprotein CD28 inhibitors including, but not limited to RhuDex;

CD80 antagonists/CD 86 antagonists including, but not limited to XENP-9523 and ASP-2408;

CD86 antagonists including, but not limited to, abamectin biological winners (biosuperior);

CD86 antagonists/cytotoxic T lymphocyte protein-4 modulators, including but not limited to ES-210;

CD95 antagonists, including but not limited to DE-098 and CS-9507;

cell adhesion molecule inhibitors including, but not limited to, aj Li Kafu sen, NPC-17923, TK-280 and PD-144795;

chemokine receptor antagonists including, but not limited to, PF-06835375;

complement C5 factor inhibitors including, but not limited to, eculizumab,

complement C5 factor inhibitors/IL-1 antagonists including, but not limited to, antisense oligonucleotides (rheumatoid arthritis), and the university of leyton medical center (Leiden University Medical Center) complement factor stimulators including, but not limited to CM-101;

inhibitors of C-reactive protein including, but not limited to ISIS-353512;

c-reactive protein inhibitor/cyclooxygenase 2 inhibitor/nuclear factor κb inhibitor/immunoglobulin M antagonist/IL-2 receptor antagonist/PGE 2 antagonist: IB-RACCF-1 antagonists including, but not limited to, marseitinib, FPA-008, JNJ-27301937, JNJ-40346527, PLX-5622, CT-1578, PD-360324, and JNJ-28312141;

CSF-1 antagonists/Fyn tyrosine kinase inhibitors/Kit tyrosine kinase inhibitors/Lyn tyrosine kinase inhibitors/NK cell receptor modulators/PDGF receptor antagonists, including but not limited to masitinib;

CXC10 chemokine ligand inhibitors including, but not limited to 946414-98-8 and BMS-936557;

CXCR4 chemokine antagonists, including but not limited to plexafu;

CDK-2/7/9 inhibitor/MCL 1 gene inhibitor, including but not limited to plug Li Xili;

inhibitors of CDK-1/2/5/7/9, including but not limited to BP-14;

chaperonin modulators, including but not limited to IRL-201805;

cyclooxygenase 2 inhibitors including, but not limited to, celecoxib, etoricoxib, meloxicam and lumiracoxib;

cyclooxygenase 2/oxidoreductase inhibitors including, but not limited to, etodolac;

cyclooxygenase 2 modulators, including but not limited to DRGT-46;

cyclooxygenase inhibitors including, but not limited to, aceclofenac, diclofenac, naproxen etemesil, nabumetone, naproxen, pebiprofen, LY-210073, NS-398, bromfenac, L-746483, LY-255283, ibuprofen, flurbiprofen, SC-57666, and bermoprofen;

cyclooxygenase inhibitors/H+K+ATPase inhibitors including, but not limited to, naproxen+esomeprazole strontium;

cyclooxygenase inhibitors/PGE 1 agonists including, but not limited to misoprostol + diclofenac;

cyclooxygenase inhibitors/oxidoreductase inhibitors including, but not limited to, imidazole salicylate;

Cytosolic phospholipase A2 inhibitors/phospholipase A2 inhibitors, including but not limited to AVX-002;

cytotoxic T lymphocyte protein-4 stimulators/T cell surface glycoprotein CD28 inhibitors including, but not limited to, abamectin, BMS-188667 and beracetirizine;

deoxyribonuclease gamma stimulators, including but not limited to NTR-441;

DHFR inhibitors including, but not limited to MPI-2505, jylamvo and ZeNEO-methotrexate;

DHFR inhibitors/folic acid antagonists/transferrin modulators, including but not limited to methotrexate;

diamine acetyltransferase inhibitors, including but not limited to diacetyl amide;

dihydroorotate dehydrogenase inhibitors including, but not limited to, ASLAN-003, HWA-486, and ABR-224050;

dihydroorotate dehydrogenase/protein tyrosine kinase inhibitors including, but not limited to, leflunomide;

DYRK-1 alpha protein kinase inhibitors, including but not limited to VRN-02;

elongation factor 2 inhibitors/interleukin-2 ligand/NAD ADP ribosyl transferase stimulators, including but not limited to dini interleukin-toxin linker (denileukin diftitox);

enolase 1 inhibitors, including but not limited to HuL-001;

EP4 prostaglandin receptor antagonists including, but not limited to CR-6086;

Erythropoietin receptor agonists including, but not limited to, sibiricin;

fas ligands, including but not limited to AP-300;

FGF-2 ligand inhibitors, including but not limited to RBM-007;

FK506 binding protein-12 modulator/mTOR inhibitors, including but not limited to temsirolimus;

folic acid antagonists/transferrin modulators/DHFR inhibitors, including but not limited to MBP-Y003;

folate receptor modulators, including but not limited to technetium (99 mTc) etaforatide (etarfatide);

inhibitors of the actin ligand, including but not limited to E-6011;

fyn tyrosine kinase inhibitors/GABA a receptor modulators/cyclooxygenase 2 inhibitors/dihydroorotate dehydrogenase inhibitors, including but not limited to raffinolimus;

glucocorticoid agonists including, but not limited to, prednisone Long Hefu s-dakola;

glucocorticoid antagonists, including but not limited to REC-200;

glucocorticoid-induced leucine zipper protein stimulators including, but not limited to ART-G01;

GM-CSF ligand inhibitors including, but not limited to, nalmefene, gemmizumab (MORAB-022), and TJM-2;

GM-CSF receptor antagonists including, but not limited to, mafrerimab;

Modulators of GM-CSF receptors including, but not limited to GSK-3196165 and octreotide Li Shan antibodies;

growth regulator protein alpha ligand inhibitor/AP 1 transcription factor inhibitor/IL-6 antagonist/interleukin-1 beta ligand inhibitor/cathepsin K inhibitor/NFAT gene inhibitor, including but not limited to T-5224;

h+k+atpase inhibitors including, but not limited to, naproxen+esomeprazole, ketoprofen+omeprazole, KEO-25001, HC-1004 and PN-40020;

histamine H4 receptor antagonists including, but not limited to, tolterodine and GD-48;

histone deacetylase inhibitors, including but not limited to CHR-5154 (GSK-3117391) and NIPEP-CARE;

histone deacetylase-6 inhibitors, including but not limited to CKD-506;

HLA class II antigens DQ-2 alpha modulators, including but not limited to NexVax2;

HLA class II antigen inhibitors, including but not limited to HLA-DR1/DR4 inhibitors (rheumatoid arthritis) and Provid;

HLA class II antigen modulators, including but not limited to recombinant T-cell receptor ligands (rheumatoid arthritis) and artielles;

hsp 70 family inhibitors including, but not limited to, guanrolimus dihydrochloride;

hypoxia inducible factor-1 inhibitors/VEGF receptor antagonists including, but not limited to, 2-methoxyestradiol;

IFNB gene stimulators including but not limited to ART-102;

i- κB kinase β inhibitors including, but not limited to, IMD-2560;

i- κB kinase β inhibitors/nuclear factor κB inhibitors including, but not limited to, IMD-0560;

i- κB kinase inhibitor/NFE 2L2 gene stimulator/nuclear factor κB inhibitor/STAT 3 gene inhibitor, including but not limited to methyl bardoxolone;

IL-1 antagonists, including but not limited to recombinant human interleukin-1 receptor antagonists (rheumatoid arthritis), shanghai's Kangdan Zhang biological medicine Co., ltd;

IL-1 antagonists/interleukin-1 beta ligand inhibitors, including but not limited to, cilomimetic;

IL-10 agonists, including but not limited to polyethylene glycol-ilointerleukin;

IL-11 agonists/PDGF receptor agonists, including but not limited to, epleril;

IL-12 antagonists/IL-23 antagonists, including but not limited to, utility mab and branchizumab;

IL-15 antagonists, including but not limited to AMG-714;

IL-17 antagonists, including but not limited to, evizumab and Stuzumab;

IL-17 receptor modulators, including but not limited to CNTO-6785;

IL-2 receptor agonists, including but not limited to interleukin-2 subsequent biological agents (IL-2), anteluke, and interning;

IL-2/IL-21/IL-15 antagonists, including but not limited to BNZ-132-2;

IL-21 antagonists, including but not limited to NN-8828;

IL-4 agonists, including but not limited to SER-130-AMI;

IL-6 antagonists, including but not limited to BCD-089, olomoumab, cladagumab, cetuximab Lu Kushan, SA-237, FB-704A, OP-R003, peptide IL-6 antagonists, MEDI-5117, AMG-220, FM-101, BLX-1025, ai Na molars, TA-383, and Sha Lilu monoclonal antibodies;

IL-6 antagonists/interleukin-1 beta ligand inhibitors/TNFα ligand inhibitors, including but not limited to K-832;

IL-6 antagonists/insulin sensitizers/interleukin-1 beta ligand inhibitors, including but not limited to BLX-1002;

IL-6 receptor antagonists/modulators, including but not limited to Touzumab, HS-628 and LusiNEX;

IL-6 receptor modulators, including but not limited to BAT-1806 and RO-4877533;

immunoglobulin antagonists including, but not limited to, iguratimod;

immunoglobulin G1 agonists, including but not limited to BX-2922 and HF-1020;

immunoglobulin G1 agonists/interleukin-1 beta ligand inhibitors, including but not limited to cinacalcet;

immunoglobulin G1 agonists/tnfα ligand inhibitors, including but not limited to STI-002;

Immunoglobulin G1 antagonists/TNFα ligand inhibitors, including but not limited to YHB-1411-2;

immunoglobulin G1 modulators/GM-CSF ligand inhibitors/immunoglobulin kappa modulators, including but not limited to, lorentzumab;

immunoglobulin G2 antagonists/nfkb inhibitor stimulators/osteoclast differentiation factor antagonists/osteoclast differentiation factor ligand inhibitors/TNFSF 11 gene inhibitors, including but not limited to denomab;

immunoglobulin gamma Fc receptor II modulators, including but not limited to MGD-010;

inducible nitric oxide synthase inhibitors/cyclooxygenase 2 inhibitors/MAP kinase modulators/nuclear factor κB inhibitors, including but not limited to SKLB-023;

inosine monophosphate dehydrogenase inhibitors including, but not limited to, mizoribine;

insulin sensitizers/nuclear factor κb inhibitors/interleukin ligand inhibitors, including but not limited to HE-3286;

integrin alpha-1/beta-1 antagonists including, but not limited to SAN-300;

integrin alpha-4/beta-1 antagonists/cell adhesion molecule inhibitors including, but not limited to natalizumab;

integrin alpha-9 antagonists including, but not limited to, ASP-5094;

integrin antagonists including, but not limited to, PEG-HM-3 and CY-9652;

Interferon beta ligands, including but not limited to recombinant interferon beta-1 a;

interferon beta ligand/IL-6 antagonists including, but not limited to, TA-383;

interferon gamma ligands including, but not limited to, li Zhu Yin De Fu and cloned gamma;

interleukin 17A ligand inhibitor/tumor necrosis factor ligand inhibitor including, but not limited to ABT-122 and ABBV-257;

interleukin 17F ligand inhibitors including, but not limited to, bimagrumab;

interleukin 18 ligand inhibitors including, but not limited to, tad interleukin alpha (tadekinig alfa);

interleukin 23A inhibitors including, but not limited to, antique pessary;

interleukin ligand/IL-1 antagonists including, but not limited to IBPB-007-IL;

interleukin receptor 17A antagonists, including but not limited to Bai Dalu mab;

interleukin-1 beta ligand inhibitors including, but not limited to, gemini mab, LY-2189102, CDP-484, and AR-100;

interleukin-1 beta ligand inhibitor/tnfα ligand inhibitor, including but not limited to PMI-001;

interleukin-1 beta ligand/tnfα ligand modulators, including but not limited to PUR-0110;

interleukin-2 ligands including, but not limited to, recombinant interleukin-2 and CUG-252;

IL-2 modulators, including but not limited to AMG-592;

interleukin-4 ligand/tenascin-modulating agents including, but not limited to, tetravil;

interleukin-6 ligand inhibitors including, but not limited to, gemtuzumab (gerilimzumab) and PF-4236921;

IRAK-4 protein kinase inhibitors including, but not limited to, BAY-1830839, BAY-1834845, PF-06650833 and KT-474;

itk tyrosine kinase inhibitors, including but not limited to JTE-051;

itk tyrosine kinase inhibitors/Jak 3 tyrosine kinase inhibitors, including but not limited to ARN-4079;

JAK tyrosine kinase inhibitors including, but not limited to, deuterated tofacitinib analogs, SD-900, and WXSH-0150;

JAK tyrosine kinase inhibitors/Syk tyrosine kinase inhibitors including, but not limited to, ceritinib and CVXL-0074;

jak1 tyrosine kinase inhibitors including, but not limited to, ABT-494 (Wu Pati Ni), lu Suoti Ni, fingolitinib, itatinib, NIP-585, YJC-50018, GLPG-0555, MRK-12 and SHR-0302;

jak1/3 tyrosine kinase inhibitors including, but not limited to, tofacitinib citrate, pefacitinib, CKD-374 and CS-944X;

JAK1/3 inhibitor/ROCK 1/2 inhibitor: CPL-409116

Jak1/2 tyrosine kinase inhibitors including, but not limited to, baritinib, lu Suoti ni, LW-104 and TLL-018;

jak2 tyrosine kinase inhibitors/CSF-1 antagonists, including but not limited to CT-1578;

JAK3 gene inhibitors, including but not limited to PF-06651600;

jak3 tyrosine kinase inhibitors including, but not limited to, dixitinib, DNX-04042, MTF-003, and PS-020613;

jun N-terminal kinase inhibitors, including but not limited to IQ-1S;

KCNA voltage-gated potassium channel-3 modulators, including but not limited to MRAD-P1;

kelch-like ECH-related protein 1 modulators/nuclear factor erythroid 2-related factor 2 stimulators, including but not limited to dimethyl fumarate;

LanC-like protein 2 modulators, including but not limited to BT-11 and BT-104;

LDL receptor-associated protein-1 stimulators including but not limited to SP-16;

leukotriene BLT receptor antagonists/complement C5 factor inhibitors, including but not limited to nor Ma Kepan;

LITAF gene inhibitor/JAK 3 gene inhibitor/MAP 3K2 gene inhibitor/TNF antagonist, including but not limited to GBL-5b;

lymphocyte function antigen-3 receptor antagonists, including but not limited to alfasin;

macrophage mannose receptor 1 modulators, including but not limited to technetium Tc 99m instead Ma Nuosai;

MAdCAM inhibitors/immunoglobulin G2 modulators, including but not limited to PF-547659;

MAPKAPK5 inhibitors/matrix metalloproteinase inhibitors, including, but not limited to GLPG-0259;

MEK protein kinase inhibitors, including but not limited to AD-GL0001;

membrane copper amine oxidase inhibitors including, but not limited to, BTT-1023, PRX-167700, and vipamomab;

metalloproteinase-9 inhibitors, including but not limited to GS-5745;

microbiome modulators, including but not limited to EDP-1815;

midkine ligand inhibitors, including but not limited to CAB-102;

mTOR inhibitors including, but not limited to, everolimus;

NAMPT gene inhibitors, including but not limited to ART-D01;

nicotinic acetylcholine receptor antagonists, including but not limited to RPI-78 and RPI-MN;

NKG 2A B activates NK receptor antagonists including, but not limited to Mo Nali bead mab;

NKG 2D-activated NK receptor antagonists including, but not limited to NNC-0142-002;

nuclear factor kappa B inhibitors including, but not limited to, dehydroepoxymethylquinone mycin, MP-42, VGX-1027, SP-650003, MG-132, SIM-916, VGX-350, VGX-300, GIT-027, MLN-1145, and NVP-IKK-005;

Nuclear factor κb modulator/nuclear factor κ B p105 inhibitor/transcription factor RelB inhibitor/transcription factor p65 inhibitor, including but not limited to REM-1086;

osteoclast differentiation factor antagonists, including but not limited to cyclic peptide mimics (rheumatoid arthritis/osteoporosis), michigan university;

p38 MAP kinase alpha inhibitors, including but not limited to VX-745, BMS-582949 and BMS-751324;

p38 MAP kinase inhibitors, including but not limited to BCT-197, lomod and ARRY-797;

PDE 4 inhibitors including, but not limited to, apremilast;

PDE5 inhibitors, including but not limited to PDE5 inhibitors (rheumatoid arthritis), university of rochester;

PDGF-B ligand inhibitors/VEGF receptor antagonists including, but not limited to SL-1026;

phosphoinositide-3 kinase delta inhibitors including but not limited to CT-732, INK-007 and GNE-293;

phosphoinositide-3 kinase delta/gamma inhibitors including, but not limited to, dimelli and RP-6503;

phospholipase A2 inhibitors including, but not limited to AK-106, methyl varesplady, ro-31-4493, BM-162353, ro-23-9358 and YM-26734;

platelet activating factor receptor antagonists including, but not limited to, piperidone hydrochloride;

Pparγ agonists, including but not limited to rosiglitazone XR;

pparγ agonists/insulin sensitizers, including but not limited to rosiglitazone;

apoptosis protein 1 modulators, including but not limited to INSIX RA;

prostaglandin D synthase stimulators including, but not limited to HF-0220;

protein tyrosine kinase inhibitors including, but not limited to, tairuimide;

PurH purine biosynthesis protein inhibitors/inosine monophosphate dehydrogenase inhibitors including, but not limited to mycophenolate mofetil;

rev protein modulators, including but not limited to ABX-464;

RIP-1 kinase inhibitors, including but not limited to GSK-2982772 and VRN-04;

IL-17 antagonists/rho-associated protein kinase 2 inhibitors, including but not limited to KD-025;

signal transduction protein CD24 modulators, including but not limited to CD24-IgFc;

sodium glucose transporter-2 inhibitors/ppary agonists/insulin sensitizers, including but not limited to THR-0921;

STAT3 gene inhibitors, including but not limited to vidoflradium (vidofludimus);

STAT-3 inhibitors, including but not limited to HL-237;

superoxide dismutase stimulators including, but not limited to, i Mi Pameng;

SYK family tyrosine kinase inhibitors/Zap 70 tyrosine kinase inhibitors, including but not limited to MK-8457;

Syk tyrosine kinase inhibitors including, but not limited to, futaminib, entoltinib, KDF-201110-06, HMPL-523, AB-8779, GS-9876, PRT-2607, CG-103065 and SKI-O-703;

t cell receptor antagonists, including but not limited to TCR-inhibitory SCHOOL peptides (systemic/local, rheumatoid arthritis/dermatitis/scleroderma), singibook and CII-modified peptides (rheumatoid arthritis);

t cell receptor modulators/HLA class II antigen modulators, including but not limited to ARG-301;

t cell surface glycoprotein CD28 stimulators including, but not limited to, TAB-08 and sirolimus;

TAK1 binding protein modulators, including but not limited to epigallocatechin 3-gallate;

tamarin modulators, including but not limited to short-form Tamarin modulators (rheumatoid arthritis), kayteeBio;

t cell surface glycoprotein CD8 inhibitors/tgfβ agonists/CD 4 antagonists, including but not limited to treglimumab;

thymosin agonists, including but not limited to Syn-1002;

TLR-2/TLR-4 antagonists, including but not limited to VB-201;

TLR-4 antagonists, including but not limited to NI-0101;

TLR-2/4/9 antagonists, including but not limited to P-13;

TNF agonists/TNF antagonists/type II TNF receptor modulators, including but not limited to lifmix;

a tnfα ligand inhibitor and a therapeutic agent, including but not limited to Adfrar, FKB-327, ximale, cinnora, mabura, adalimumab, infliximab, flixabi, PF-06438179, hadlima, recombinant humanized anti-TNF-alpha monoclonal antibodies, CMAB-008, CT-P13, GB-242, golimumab (CNTO-148), olimumab, AT-132, ISIS-104838, ISU-202, CT-P17, MB-612, debio-0512, anti-TNF-alpha human monoclonal antibodies, UB-721, KN-002, DA-3113, BX-2922, R-TPR-015, BOW-050, PF-06410293, CKD-760, CHS-1420, GS-071, ABP-710 BOW-015, HLX-03, BI-695501, MYL-1401A, ABP-501, BAX-2923, SCH-215596, ABT-D2E7, BAT-1406, XPro-1595, atsttrin, SSS-07, golimu single antibiotic analog, TA-101, BLX-1002, ABX-0401, TAQ-588, teHL-1, praguemab, CYT-007-TNFQb, SSR-150106, passTNF, verigen, DOM-0200, DOM-0215, AME-527, anti-TNF-alpha mab, GENZ-38167, BLX-1028, CYT-020-TNFQb, CC-1080, CC-1069, LBAL, GP-2017, idacio, IBI-303, HS-016, TNF-2 and IA-14069;

Tnfα ligand inhibitors/TNF antagonists/type II TNF receptor modulators, including but not limited to BAX-2200;

tnfα ligand inhibitors/type II TNF receptor modulators, including but not limited to Eucept, tnfα ligand modulators: MM-A01-01, CDP-571, card Mo Bu, and JNJ-63823539;

TNF antagonists, including but not limited to DNX-114, TNF antagonists+IL-12 antagonists (rheumatoid arthritis), oxford university, BN-006, perindopril, ACE-772, onazepine, DE-096, PN-0615, lenacil, ITF-1779, MDL-201112, HD-203, jiang Ke (Qiangke) and TNF a Fc;

TNF antagonists/type II TNF receptor modulators, including but not limited to Altebrel, intacept, QL-0902, etanercept, erelzi, etanercept, ecosystem, annuo, benepali, YLB-113, SCB-808, DA-3853, and SCB-131;

TNF antagonists/tnfα ligand inhibitors including, but not limited to, pegylated cetuximab;

TNF receptor modulators, including but not limited to recombinant TNF receptor 2-Fc fusion protein mutants, T-0001;

TNF receptor modulators/TNF alpha ligand inhibitors, including but not limited to tgAAV-TNFR;

tumor necrosis factor 13C receptor antagonists, including but not limited to VAY-736;

Tumor necrosis factor 15 ligand inhibitors including, but not limited to, anti-TL 1A antibodies (rheumatoid arthritis/inflammatory bowel disease), NIAMS;

tumor necrosis factor ligand inhibitors including, but not limited to, etanercept biosimilar;

type I IL-1 receptor antagonists, including but not limited to anakinra, IL-1Ra, anakinra-subsequent biologicals, and AXXO;

type I TNF receptor antagonists, including but not limited to NM-940 and EN-2001;

type II TNF receptor modulators, including but not limited to LBEC-0101, DMB-3853, DWP-422, and BT-D001;

unspecified GPCR agonists, including but not limited to NCP-70X;

VEGF receptor antagonists, including but not limited to NSC-650853;

VEGF-2 receptor modulators, including but not limited to VEGFR2 neutralizing antibodies (rheumatoid arthritis), university of Rochester;

VEGF-B ligand inhibitors, including but not limited to CSL-346;

x-linked apoptosis inhibitor proteins including, but not limited to IAP inhibitors (oral), pharmascience; and

zap70 tyrosine kinase inhibitors including, but not limited to CT-5332.

Combination therapy for inflammatory bowel disease

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, may be combined with one or more additional therapeutic agents to treat or ameliorate Inflammatory Bowel Disease (IBD).

As used herein, the term "inflammatory bowel disease" or "IBD" is a collective term describing inflammatory lesions of the gastrointestinal tract, the most common forms of which are ulcerative colitis and crohn's disease. Other forms of IBD that may be treated with the compounds provided herein or pharmaceutically acceptable salts thereof or the pharmaceutical compositions provided herein include, but are not limited to, diversion colitis, ischemic colitis, infectious colitis, chemical colitis, microscopic colitis (including collagenous colitis and lymphocytic colitis), atypical colitis, pseudomembranous colitis, fulminant colitis, autism enterocolitis, non-established colitis, behcet's disease, gastroduodenal CD, jejunum ileitis, ileal colitis, crohn's (granulomatous) colitis, irritable bowel syndrome, mucositis, radiation enteritis, short bowel syndrome, celiac disease, gastric ulcers, diverticulitis, chu Daiyan, proctitis, and chronic diarrhea.

Treating or preventing IBD also includes ameliorating or reducing one or more symptoms of IBD. As used herein, the term "symptoms of IBD" refers to detected symptoms such as abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite, and other more serious complications such as dehydration, anemia, and malnutrition. Many such symptoms require quantitative analysis (e.g., weight loss, fever, anemia, etc.). Some symptoms are readily determined from blood tests (e.g., anemia) or tests that detect the presence of blood (e.g., rectal bleeding). The term "wherein the symptom is reduced" refers to a qualitative or quantitative reduction in a detectable symptom, including but not limited to a detectable effect on recovery from a disease (e.g., weight gain rate). Diagnosis is typically determined by endoscopic observation of the mucosa and pathological examination of endoscopic biopsy specimens.

The course of IBD varies and is often associated with intermittent periods of disease remission and disease progression. Various methods for characterizing the disease activity and severity of IBD and the response to treatment of a subject with IBD have been described. The treatment according to the methods and uses of the invention is generally applicable to subjects suffering from any level or extent of disease activity in IBD.

The methods and uses provided herein are also applicable to any point in the disease process. In some embodiments, these methods and uses are applied to a subject suffering from IBD during periods of remission (i.e., inactive disease). In some embodiments, the methods and uses of the invention provided herein provide benefits by extending the period of remission (e.g., extending the period of inactivity disease) or by preventing, reducing, or delaying the onset of activity disease. In some embodiments, the methods and uses provided herein may be applied to a subject suffering from IBD during active disease. In some embodiments, the methods and uses provided herein provide benefits by reducing the duration of active disease, reducing or ameliorating one or more symptoms of IBD, or treating IBD.

Measures for determining the efficacy of treatment of IBD in clinical practice have been described and include, for example, the following: symptom control; fistula closure; the extent of corticosteroid therapy required; and improvement of quality of life. Quality of Life (HRQL) associated with health can be assessed using an Inflammatory Bowel Disease Questionnaire (IBDQ), which is widely used in clinical practice to assess quality of life in IBD subjects. (see Guyatt et al (1989) Gastroenterology 96:804-810.)

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, may be combined with one or more additional therapeutic agents to treat or ameliorate IBD. Non-limiting examples of therapeutic agents for treating or ameliorating IBC include allogeneic bone marrow derived MSC therapy, AMP-activated protein kinase stimulators, aromatic hydrocarbon receptor agonists and T-cell receptor modulators, ASK1 inhibitors, beta adrenergic receptor antagonists, BTK inhibitors, beta-catenin stimulators, beta-glucuronidase inhibitors, bradykinin receptor modulators, calcineurin inhibitors, calcium channel inhibitors, cathepsin S inhibitors, CCR3 chemokine antagonists, CD40 ligand receptor antagonists, chemokine CXC ligand inhibitors, CHST15 gene inhibitors, collagen modulators, CXCR3 chemokine antagonists, CSF-1 antagonists, cyclooxygenase inhibitors, cytochrome P450 A4 inhibitors, DYRK-1 alpha protein kinase inhibitors, endothelial dysfunction and vascular leakage blockers enolase 1 inhibitors, eosinophil ligand inhibitors, EP4 prostaglandin receptor agonists, erythropoietin receptor agonists, exporter 1 inhibitors, actin ligand inhibitors, free fatty acid receptor 2 antagonists, GATA 3 transcription factor inhibitors, glucagon-like peptide 2 agonists, glucocorticoid agonists, guanylate cyclase receptor agonists, histone deacetylase inhibitors, HLA class II antigen modulators, IL-12 antagonists, IL-13 antagonists, interleukin-2 ligands, IL-23 antagonists, IL-6 receptor modulators, interleukin-7 receptor modulators, IL-7 antagonists, IL-8 antagonists, integrin alpha-4/beta-1 antagonists, integrin alpha-4/beta-7 antagonists, integrin alpha-E antagonists, integrin beta-7 antagonists, interleukin ligand inhibitors, interleukin-10 ligands, interleukin receptor 17A antagonists, interleukin 23A inhibitors, interleukin-1 beta ligands, interleukin-1 beta ligand modulators, IRAK4 inhibitors, JAK tyrosine kinase inhibitors, jak1 tyrosine kinase inhibitors, jak3 tyrosine kinase inhibitors, lanC-like protein 2 modulators, lipoxygenase modulators, macrophage mannose receptor 1 modulators, MAdCAM inhibitors, matrix metalloproteinase inhibitors, melanocortin agonists, metalloproteinase-9 inhibitors, NADPH oxidase inhibitors, natriuretic peptide receptor C agonists, NC-301, next generation intestinal flora therapy, and methods of treating or preventing a disease neuregulin-4 ligand, NKG 2D-activating NK receptor antagonist, non-receptor tyrosine kinase TYK2 antagonist, opioid receptor delta antagonist, oxidoreductase inhibitor, P2X7 purinergic agonist, PDE 4 inhibitor, phagocytosis stimulating peptide modulator, potassium channel inhibitor, PPARα agonist, PPARδ agonist, PPARγ agonist, protein fimH inhibitor, P-selectin glycoprotein ligand-1 inhibitor, RNA polymerase inhibitor, sphingosine 1 phosphophosphatase 1 stimulator, sphingosine 1 phosphophosphatase modulator, sphingosine 1-phosphate receptor-1 agonist, sphingosine 1-phosphate receptor-1 antagonist, sphingosine 1-phosphate receptor-1 modulator, sphingosine 1-phosphate receptor-5 modulator, STAT3 gene inhibitor, stem cell antigen-1 inhibitors, superoxide dismutase modulators, superoxide dismutase stimulators, SYK inhibitors, TGF beta 1 ligand inhibitors, thymosin agonists, TLR antagonists, TNF alpha ligand inhibitors, TNF antagonists, tumor necrosis factor 14 ligand modulators, type II TNF receptor modulators, tpl 2 inhibitors, X-box binding protein 1 stimulators, and even inhibitors.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, may be combined with one or more additional therapeutic agents selected from the group consisting of: ABX-464, adalimumab; ALLO-ASC-CD, AMG-966, AMT-101, anakinra, apremilast; alequesl; ALV-304, AMG-139; amicetmod, anti-CXCR 3 mab, ASD-003, ASP-3291, AX-1505, balsalazide; beclomethasone dipropionate; BI-655130, BMC-321, BMC-322, BMS-986184; BT-051, budesonide; CBX-111, CEQ-508; cetuximab; xibonnide, clostridium butyricum; chAdOx2-HAV, CU-06, CUG-252 dexamethasone sodium phosphate, DNVX-078, EB-7020, EM-101, etanercept; ENERGI-F704, ETX-201, golimumab; GS-4997, GS-5718, GS-9876, GS-4875, GS-4059, infliximab; IMS-001, mesalamine, HLD-400, IBI-112, IMM-H013, KB-295, LFS-829, LYC-30937 EC; IONIS-JBI1-2.5Rx, JNJ-64304500, JNJ-66525433, JNJ-4447, aspargonic acid, MET-642, MVA-HAV, naltrexone; natalizumab; inner Hu Lizhu mab, oxalazine; ext> NOSext> -ext> 1244ext>,ext> NTGext> -ext> Aext> -ext> 009ext>,ext> PHext> -ext> 46ext> -ext> Aext>,ext> propionylext> -ext> Lext> -ext> carnitineext>;ext> PTG-100; remstemcel-L; tacrolimus; tidollutide; tofacitinib; ASP-1002; utekey monoclonal antibody; vedolizumab; AVX-470; INN-108; SGM-1019; PF-06480605; PF-06651600; PR-600; RBX-8225, R-2187, RG-6287, SER-287; TOP-1288; VBY-129;99 mTc-annexin V-128; bai Ti wood monoclonal antibody; DLX-105; a dulcina peptide; quinuclidine Mo Lishan antibody (E-6011); FFP-104; non-gotinib; resistance to Fu Lei Lushan; GED-0507-34-Levo; ji Weisi he; GLPG-0974; i Bei Jiate (iberogast); ICP-330, JNJ-40346527; k (D) PT; KAG-308; KHK-4083; KRP-203; larezodone acetate; LY-3074828, missmase; oloside monoclonal antibody; ovaSave; P-28-GST; PF-547659; prednisolone; qbcco; RG-7835; RBX-2660, RO7049665, JKB-122; SYGN-313, SB-012; STNM-01; SZN-1326, TJC-0434, debio-0512; TRK-170; ABT-494; an ame; BI-655066; methyl calicheat; comparable tolmod; elaflibanor; itrarinab; GS-5745; HMPL-004; LP-02, ozanimod; pefeitinib; QX-004-N, RHB-104; SEFA-1024, teridamab; TOP-1890, qu Luolu monoclonal antibodies; bromobudadizumab; laquinimod; and procalcitonin; or a pharmaceutically acceptable salt of any of the foregoing; or any combination thereof.

VII preparation of the Compounds

Some embodiments of the present disclosure relate to methods and intermediates useful for preparing compounds provided herein or pharmaceutically acceptable salts thereof.

The compounds described herein may be purified by any method known in the art, including chromatographic methods, such as High Performance Liquid Chromatography (HPLC), preparative thin layer chromatography, flash column chromatography, and ion exchange chromatography. Any suitable stationary phase may be used, including normal and reverse phases, as well as ion resins. Most typically, the disclosed compounds are purified by silica gel and/or alumina chromatography.

During any of the methods for preparing the compounds provided herein, it may be necessary and/or desirable to protect sensitive or reactive groups on any molecule of interest. This can be achieved by conventional protecting groups as described in standard works such as T.W.Greene and P.G.M.Wuts, "Protective Groups in Organic Synthesis", 4 th edition, wiley, new York 2006. The protecting groups may be removed at a convenient subsequent stage using methods known in the art.

Exemplary chemical entities useful in the methods of embodiments will now be described by reference to the general preparations herein and the specific examples of illustrative synthetic schemes below. The skilled artisan will recognize that in order to obtain the various compounds herein, the starting materials may be appropriately selected such that the final desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to replace the final desired substituent with a suitable group that can be subjected to the reaction scheme and optionally substituted with the desired substituent. Furthermore, one of skill in the art will recognize that the transformations shown in the schemes below may be performed in any order compatible with the functionality of the particular pendant group. Each reaction depicted in the general scheme is preferably run at a temperature of about 0 ℃ to the reflux temperature of the organic solvent used.

The methods of the present disclosure generally provide a particular enantiomer or diastereomer as a desired product, although stereochemistry of the enantiomer or diastereomer is not established in all cases. When the stereochemistry of a particular stereocenter in an enantiomer or diastereomer is not determined, the compound is depicted without the particular stereocenter exhibiting any stereochemistry, even though the compound may be substantially enantiomerically or diastereomerically pure.

Representative syntheses of the compounds of the present disclosure are described in the following schemes and in the specific examples that follow.

Certain abbreviations and acronyms are used to describe experimental details. While most abbreviations and abbreviations will be readily recognized and understood by those of ordinary skill in the art, the following list provides many meanings of the abbreviations and abbreviations.

Abbreviations and abbreviation list

/>

General synthetic procedure

General reaction schemes 1-15 are provided as additional embodiments of the present disclosure and illustrate general methods for preparing certain compounds of the present disclosure and additional compounds useful for preparing the present disclosure. Each variable (e.g., R) of the compounds disclosed in general schemes 1-15 ¹ 、R ² 、R ³ 、R ⁴ ) As defined herein.

The compounds of the present disclosure may be prepared using the methods disclosed herein and conventional modifications thereof, as will be apparent to those skilled in the art in view of the disclosure herein and methods well known in the art. Conventional and well known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein can be accomplished as described in the examples below. Reagents, if available, are commercially available, for example from Sigma Aldrich or other chemical suppliers. In general, the compounds described herein are generally stable and separable at moderate temperatures and pressures.

Typical embodiments of the compounds disclosed herein can be synthesized using the general reaction schemes described below. It will be apparent to those skilled in the art in view of the description herein that the general scheme may be altered by substituting starting materials with other materials having similar structures to produce correspondingly different products. A description of the synthesis then provides many examples of how the starting materials may be varied to provide the corresponding products. In view of the desired product defining the substituent groups, the necessary starting materials can generally be determined by examination. The starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing the compounds of the embodiments disclosed in this disclosure, an examination of the structure of the compound to be synthesized will provide an identification of each of the substituent groups. In view of the examples herein, the identification of the end product will typically render the identification of the starting material apparent through a simple inspection process.

The term "solvent", "inert organic solvent" or "inert solvent" refers to a solvent that is inert under the reaction conditions described in connection therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, and the like). Unless specified to the contrary, the solvents used in the reactions of the present disclosure are all inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen or argon.

General reaction scheme 1：

Intermediate 1.1 can be reacted in the presence of a suitable halogenating reagent (e.g., NBS, NIS, NCS) to yield intermediate 1.2, where x= I, br or Cl. Intermediate 1.3 may be reacted with a suitable nitrogen protecting reagent (e.g., boc anhydride) to provide intermediate 1.3. Intermediate 1.3 can be reacted with a suitable alkenyl metallized coupling partner (where M is-B, -Sn, -Zn, -Si, or-Mg) using a suitable palladium catalyst and base (e.g., cesium carbonate, tripotassium phosphate, sodium carbonate) to produce intermediate 1.4. Can then (e.g., using a metal catalyst and H ₂ Gas) reduces the olefin portion of intermediate 1.4 to produce intermediate 1.5. Intermediate 1.5 can be reacted in the presence of an acid (e.g., TFA, HCl) to yield intermediate 1.6.Intermediate 1.6 can be reacted in the presence of a suitable halogenating reagent (e.g., NBS, NIS, NCS) to yield intermediate 1.7, where x= I, br or Cl.

General reaction scheme 2：

Intermediate 1.7 can be coupled with a suitable metallized coupling partner R by using a suitable palladium catalyst and a base (e.g., cesium carbonate, tripotassium phosphate, sodium carbonate) ¹ -M (wherein M is-B, -Sn, -Zn, -Si or-Mg) to assemble the compound of formula 2.1. Intermediate 2.1 can then be reacted in the presence of an aqueous base (e.g., liOH) to produce intermediate 2.2.

General reaction scheme 3：

The compound of formula 3.1 can be produced by reacting intermediate 1.7 in the presence of an aqueous base (e.g., liOH). Intermediate 3.1 can then be reacted with a suitable acyclic primary or secondary amine 3.2 in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N-diisopropylethylamine, triethylamine) to produce intermediate 3.3. Alternatively, intermediate 3.1 can be reacted with a suitable cyclic secondary amine 3.4 in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N-diisopropylethylamine, triethylamine) to produce intermediate 3.5.

General reaction scheme 4：

Can be prepared by reacting intermediate 1.7 with a suitable primary or secondary amine 3.2 in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.gE.g., N-diisopropylethylamine, triethylamine) to assemble the compound of formula (i.a). If the compound of formula (i.a) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g. trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (i.a) containing a primary or secondary amine. If the compound of formula (I.a) contains a benzylamine function, this can then be removed (e.g. using a metal catalyst and H) ₂ Gas) to show a compound of formula (i.a) containing a primary or secondary amine.

General reaction scheme 5：

Intermediate 3.3 can be coupled with a suitable metallized coupling partner R by using a suitable palladium catalyst and a base (e.g., cesium carbonate, tripotassium phosphate, sodium carbonate) ¹ -M (wherein R ¹ Is aryl or heteroaryl, and M is-B, -Sn, -Zn, -Si or-Mg) to assemble the compound of formula (I.a). If the compound of formula (i.a) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g. trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (i.a) containing a primary or secondary amine. If the compound of formula (I.a) contains a benzylamine function, this can then be removed (e.g. using a metal catalyst and H) ₂ Gas) to show a compound of formula (i.a) containing a primary or secondary amine.

General reaction scheme 6：

The compound of formula (I.b) can be assembled by combining intermediate 1.7 with a suitable cyclic secondary amine 3.4 in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N-diisopropylethylamine, triethylamine). If the compound of formula (I.b) contains a tert-butyl carbamate functional group, this can be followed by treatment with an acid (e.g., trifluoroacetic acid orHydrochloric acid) to reveal a compound of formula (I.b) containing a primary or secondary amine. If the compound of formula (I.b) contains a benzylamine functionality, this can then be removed (e.g., using a metal catalyst and H ₂ Gas) to show a compound of formula (I.b) containing a primary or secondary amine.

General reaction scheme 7：

Intermediate 3.5 can be coupled with a suitable metallized coupling partner R by using a suitable palladium catalyst and a base (e.g., cesium carbonate, tripotassium phosphate, sodium carbonate) ¹ -M (wherein R ¹ Is aryl or heteroaryl, and M is-B, -Sn, -Zn, -Si or-Mg) to assemble the compound of formula (I.b). If the compound of formula (I.b) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.b) containing a primary or secondary amine. If the compound of formula (I.b) contains a benzylamine functionality, this can then be removed (e.g., using a metal catalyst and H ₂ Gas) to show a compound of formula (I.b) containing a primary or secondary amine.

General reaction scheme 8：

Compounds of formula (I.c) containing a (1, 3, 4) -oxadiazole moiety can be assembled by first reacting intermediate 1.7 with intermediate 8.1 in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC, CDI) and a suitable base (e.g., N-diisopropylethylamine, triethylamine), followed by subsequent reaction in the presence of an oxidizing agent (e.g., a berges reagent). Alternatively, intermediate 1.7 and intermediate 8.1 may be prepared by first reacting the intermediate with an appropriate peptide coupling reagent (e.g., HATU, TCFH, EDC, CDI) and an appropriate base (e.g., N, N-diisopropylethylamine, triethylamine) in the presence of a suitable peptide coupling reagent, followed by the subsequent reaction of the intermediate with the appropriate peptide coupling reagentSulfur reagents (e.g. Lawson reagent, P ₂ S ₅ ) Is reacted to assemble a compound of formula (i.d) containing a (1, 3, 4) -thiadiazole moiety. If the compound of formula (I.c) or (i.d) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.c) or (i.d) containing a primary or secondary amine. If the compound of formula (I.c) or (I.d) contains a benzylamine functionality, this can then be removed (e.g., using a metal catalyst and H) ₂ Gas) to show a compound of formula (I.c) or (i.d) containing a primary or secondary amine.

General reaction scheme 9：

Compounds of formula (I.e) containing a (1, 2, 4) -oxadiazole moiety can be assembled by first reacting intermediate 1.7 with intermediate 9.1 in the presence of a coupling reagent (e.g., CDI). If the compound of formula (I.e) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.e) containing a primary or secondary amine. If the compound of formula (I.e) contains a benzylamine functionality, this can then be removed (e.g., using a metal catalyst and H ₂ Gas) to show a compound of formula (I.e) containing a primary or secondary amine.

General reaction scheme 10：

The oxazoline moiety-containing compound of formula (I.f) may be assembled by first reacting intermediate 1.7 with intermediate 10.1 in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC, CDI) and a suitable base (e.g., N-diisopropylethylamine, triethylamine), followed by the presence of an oxidizing agent (e.g., a bergius reagent). Alternatively, intermediate 1.7 and intermediate 1 may be prepared by reacting0.1 first in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC, CDI) and a suitable base (e.g., N, N-diisopropylethylamine, triethylamine), followed by the presence of a sulfur reagent (e.g., lawson reagent, P) ₂ S ₅ ) Is reacted to assemble a compound of formula (I.g) containing a thiazoline moiety. If the compound of formula (I.f) or (I.g) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.f) or (I.g) containing a primary or secondary amine. If the compound of formula (I.f) or (I.g) contains a benzylamine functionality, this can then be removed (e.g., using a metal catalyst and H) ₂ Gas) to show a compound of formula (I.f) or (I.g) containing a primary or secondary amine.

General reaction scheme 11：

Intermediate 1.7 can be reacted in the presence of a base (e.g., DBU) and heat to produce intermediate 11.1. Intermediate 8.1 can be reacted in the presence of a suitable halogenating reagent (e.g., NBS, NIS, NCS) to yield intermediate 11.2, where x= I, br or Cl.

General reaction scheme 12：

The compound of formula (I.h) can be assembled by combining intermediate 11.2 with a suitable metallized coupling partner M-Z (where Z is aryl, heteroaryl, alkenyl, and M is-B, -Sn, -Zn, -Si, or-Mg) using a suitable palladium catalyst and a base (e.g., cesium carbonate, tripotassium phosphate, sodium carbonate) to produce the compound of formula (I.h). If the compound of formula (I.h) contains an olefin, this can then be removed (e.g., using a metal catalyst and H ₂ Gas). If the compound of formula (I.h) contains tert-butyl carbamate functionality, this can be followed by treatment with an acid (exampleSuch as trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.h) containing a primary or secondary amine. If the compound of formula (I.h) contains a benzylamine functionality, this can then be removed (e.g., using a metal catalyst and H ₂ Gas) to show a compound of formula (I.h) containing a primary or secondary amine.

General reaction scheme 13：

The compound of formula (I.j) can be assembled by combining a compound of formula (I.i) (produced via one of the methods set forth above, such as scheme 6) with a suitable carboxylic acid 13.1 in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N-diisopropylethylamine, triethylamine). Alternatively, a compound of formula (I.i) can be combined with a suitable aldehyde 13.2 in the presence of a suitable reducing agent (e.g., naBH ₄ 、Na(OAc) ₃ BH、Na(CN) ₃ BH) are combined to assemble the compounds of formula (I.k). Alternatively, a base (e.g., N, N-diisopropylethylamine, triethylamine, K) may be present through a compound of formula (I.i) and intermediate 13.3 ₂ CO ₃ 、CsCO ₃ ) In which X is a leaving group (e.g., -Cl, 0Br, -I, OTs, -OMs). If a compound of formula (i.j.), (I.k) or (I.l) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (i.j.), (I.k) or (I.l) containing a primary or secondary amine. If a compound of formula (i.j.), (I.k) or (I.l) contains a benzylamine functionality, this can be subsequently removed (e.g., using a metal catalyst and H) ₂ Gas) to show compounds of formula (i.j.), or (I.k), or (I.l) containing a primary or secondary amine.

General reaction scheme 14：

Intermediate 11.2 can be coupled with intermediate 14.1 (where-M is-B, -Sn, or-Zn, and Pg is Boc or Bn) in the presence of a palladium catalyst and a base (e.g., cesium carbonate, tripotassium phosphate, sodium carbonate) to produce intermediate 14.2. Intermediate 14.2 may be formed in the presence of a metal catalyst (e.g., palladium) and H ₂ The reaction under gas conditions to produce intermediate 14.3. If pg=boc, intermediate 14.3 can be reacted in the presence of an acid (e.g., TFA, HCl) to produce a compound of formula (I.m). Alternatively, if pg=bn, intermediate 14.3 may be made in the presence of a metal catalyst (e.g., palladium) and H ₂ Reacted under gas conditions to produce the compound of formula (I.m).

General reaction scheme 15：

The compound of formula (I.n) can be assembled by combining a compound of formula (I.n) (produced via one of the methods set forth above, such as scheme 14) with a suitable carboxylic acid 15.1 in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N-diisopropylethylamine, triethylamine). Alternatively, a compound of formula (I.m) can be combined with a suitable aldehyde 15.2 in the presence of a suitable reducing agent (e.g., naBH ₄ 、Na(OAc) ₃ BH、Na(CN) ₃ BH) are combined to assemble the compounds of formula (I.o). Alternatively, a base (e.g., N, N-diisopropylethylamine, triethylamine, K) may be present through a compound of formula (I.m) and intermediate 15.3 ₂ CO ₃ 、CsCO ₃ ) In which X is a leaving group (e.g., -Cl, 0Br, -I, OTs, -OMs). If the compound of formula (I.n), (I.o) or (I.p) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.n), (I.o) or (I.p) containing a primary or secondary amine. If the compound of formula (I.n), (I.o) or (I.p) contains a benzylamine functionality, this can be subsequently removed (e.g., usingMetal catalyst and H ₂ Gas) to show a compound of formula (I.n), (I.o) or (I.p) containing a primary or secondary amine.

General reaction scheme 16：

Can make R ¹ M (where M is-B, -Sn, -Zn, -Si or-Mg) reacts with intermediate 16.2 in the presence of a suitable palladium catalyst to yield intermediate 16.2. Intermediate 16.3 may be reacted in the presence of a metallization reagent (e.g., iPrMgBr, n-BuLi) and di-tert-butyl azodicarboxylate (16.4) to afford intermediate 16.5. Intermediate 16.2 and intermediate 16.5 may be reacted at elevated temperatures in the presence of an acid (e.g., PTSA) to afford intermediate 2.1.

General reaction scheme 17：

Intermediate 11.2 can be coupled with intermediate 17.1 (where-M is-B or-Zn and Pg is Boc or Bn) in the presence of a palladium or nickel catalyst to yield intermediate 14.3. Alternatively, intermediate 11.2 can be coupled with intermediate 17.2 (where-X is-Cl, -Br, -I, OMs, -OTs, -OTf, and Pg is Boc or Bn) in the presence of a palladium or nickel catalyst to yield intermediate 14.3. If pg=boc, intermediate 14.3 can be reacted in the presence of an acid (e.g., TFA, HCl) to produce a compound of formula (I.m). Alternatively, if pg=bn, intermediate 10.3 may be made in the presence of a metal catalyst (e.g., palladium) and H ₂ Reacted under gas conditions to produce the compound of formula (I.m).

General reaction scheme 18：

Intermediate 11.2 can be coupled with intermediate 18.1 (where-M is-B, -Sn, or-Zn, and the ketal moiety may or may not cyclize to form a ring) in the presence of a palladium catalyst and a base (e.g., cesium carbonate, tripotassium phosphate, sodium carbonate) to yield intermediate 18.2. Intermediate 18.2 may be formed in the presence of a metal catalyst (e.g., palladium) and H ₂ The reaction under gas conditions to produce intermediate 18.3. Alternatively, intermediate 11.2 may be coupled with intermediate 18.4 (where-M is-B or-Zn, and the ketal moiety may or may not be cyclized to form a ring) in the presence of a palladium or nickel catalyst to yield intermediate 18.3. Alternatively, intermediate 11.2 can be coupled with intermediate 18.5 (where-X is-Cl, -Br, -I, OMs, -OTs, -OTf, and the ketal moiety may or may not be cyclized to form a ring) in the presence of a palladium or nickel catalyst to yield intermediate 18.3. Intermediate 10.3 can be reacted in the presence of an acid (e.g., TFA, HCl) to produce a compound of formula (I.q).

General reaction scheme 19：

Can be prepared by reacting a compound of formula (I.q) with a suitable primary or secondary amine 3.4 in the presence of a suitable reducing agent (e.g., naBH ₄ 、Na(OAc) ₃ BH、Na(CN) ₃ BH) are combined to assemble the compounds of formula (I.r). Can be prepared by reacting a compound of formula (I.q) with a suitable cyclic amine 3.4 in the presence of a suitable reducing agent (e.g., naBH ₄ 、Na(OAc) ₃ BH、Na(CN) ₃ BH) are combined to assemble the compounds of formula (I.s). If the compound of formula (I.r) or (I.s) contains a tert-butyl carbamate functionality, this can then be removed by treatment with an acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.r) or (I.s) containing a primary or secondary amine. If the compound of formula (I.r) or (I.s) contains a benzylamine functionality, this can then be removed (e.g., using a metal catalyst and H) ₂ Gas) to show a compound of formula (I.r) or (I.s) containing a primary or secondary amine.

VIII.Examples

Exemplary chemical entities of the present disclosure are provided in the following specific examples. Those skilled in the art will recognize that in order to obtain the various compounds herein, the starting materials may be appropriately selected such that the final desired substituents will be reacted, optionally with or without protection, to yield the desired product. Alternatively, it may be necessary or desirable to replace the final desired substituent with a suitable group that can be subjected to the reaction scheme and optionally substituted with the desired substituent. Furthermore, one of skill in the art will recognize that the transformations shown in the schemes below may be performed in any order compatible with the functionality of the particular pendant group.

The examples provided herein describe the synthesis of the compounds disclosed herein and intermediates useful in the preparation of these compounds. It should be understood that the various steps described herein may be combined. It will also be appreciated that individual batches of the compounds may be combined and then continued in the next synthesis step.

In the following example description, specific embodiments are described. These embodiments are described in sufficient detail to enable those skilled in the art to practice certain embodiments of the disclosure. Other embodiments may be utilized, and logical and other changes may be made without departing from the scope of the present disclosure. Accordingly, the following description is not intended to limit the scope of the present disclosure.

Intermediate products

Preparation of intermediate I-1：

6-iodo-4H-thieno [3,2-b ]]Pyrrole-2-carboxylic acid ethyl ester: to 4H-thieno [3,2-b ]]To a solution of pyrrole-2-carboxylic acid ethyl ester (21.0 g,107.7 mmol) in THF (300 mL) was added NIS (24.3 g,107.7 mmol) and the mixture was stirred at 25℃for 1 hour. The reaction was diluted with EtOAc and water. The organic layer was separated, washed with brine, and dried over Na ₂ SO ₄ Drying and concentrating.The residue was washed with hexane and dried to give 6-iodo-4H-thieno [3,2-b ]]Pyrrole-2-carboxylic acid ethyl ester, which was used in the next step. ES/MS:321.9 (M+H) ⁺ )。

6-iodo-4H-thieno [3,2-b ]]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester: to 6-iodo-4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid ethyl ester (37.0 g,115.6 mmol) in DCM (300 mL) was added DMAP (1.4 g,11.6 mmol) and Boc ₂ O (50.4 g,231.2 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction was diluted with EtOAc and water. The organic layer was separated, washed with brine (50 mL), and dried over Na ₂ SO ₄ Drying and concentrating. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 200/1) to give the product 6-iodo-4H-thieno [3,2-b]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester.

6- (prop-1-en-2-yl) -4H-thieno [3,2-b]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester: to 6-iodo-4H-thieno [3,2-b]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester (21.0 g,49.9 mmol) and 4, 5-tetramethyl-2- (prop-1-en-2-yl) -1,3, 2-dioxaborolan (25.3 g,149.6 mmol) in dioxane (300 mL) and H ₂ Pd (dppf) Cl was added to a solution in O (80 mL) ₂ (3.7 g,5.0 mmol) and K ₃ PO ₄ (21.2 g,99.8 mmol) and the mixture was stirred at 85℃for 18 hours. The reaction was diluted with EtOAc (250 mL) and water (100 mL). The organic layer was separated, washed with brine (250 mL), and dried over Na ₂ SO ₄ Dried, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 100/1) to give the product 6- (prop-1-en-2-yl) -4H-thieno [3, 2-b)]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester. ES/MS:336.0 (M+H) ⁺ )。

6-isopropyl-4H-thieno [3,2-b ]]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester: 6- (prop-1-en-2-yl) -4H-thieno [3,2-b]A solution of pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester (7.2 g,21.5 mmol) and Pd/C (10 wt%, 800 mg) in THF (200 mL) at room temperature and H ₂ Stirring is carried out for 18 hours under an atmosphere. The mixture was then degassed with argon, filtered through celite, and the filtrate concentrated under reduced pressure. By column chromatography on silica gel (elution)And (3) liquid: petroleum ether/EtOAc: 100/1) purification of the crude residue to give the product 6-isopropyl-4H-thieno [3,2-b ]]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester. ES/MS:338.1 (M+H) ⁺ )。

6-isopropyl-4H-thieno [3,2-b ]]Pyrrole-2-carboxylic acid ethyl ester: to 6-isopropyl-4H-thieno [3,2-b ]]To a solution of 4-tert-butyl 2-ethyl pyrrole-2, 4-dicarboxylic acid (4.5 g,13.3 mmol) in DCM (20 mL) was added TFA (5 mL), and the resulting mixture was stirred at room temperature for 3 hours. The reaction was concentrated, and the residue was diluted with EtOAc and saturated NaHCO ₃ Washing with aqueous solution. The organic layer was purified by Na ₂ SO ₄ Dried, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 20/1) to give the product.

5-bromo-6-isopropyl-4H-thieno [3,2-b]Pyrrole-2-carboxylic acid ethyl ester (I-1): 6-isopropyl-4H-thieno [3,2-b]Pyrrole-2-carboxylic acid ethyl ester (2.5 g,10.5 mmol) in CH ₂ Cl ₂ The solution in (30 mL) was cooled to 0deg.C and treated with NBS (1.8 g,10.5 mmol). The reaction mixture was stirred at 0 ℃ for 1 hour and LCMS showed conversion to the desired product. The reaction system was treated with H ₂ O was quenched and extracted with EtOAc. The combined organic phases were washed with brine and dried over Na ₂ SO ₄ Dried, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 20/1) to give the productI-1。ES/MS：315.9(M+H ⁺ )。 ¹ H NMR (400 MHz, chloroform-d) delta 8.27 (brs, 1H), 7.61 (s, 1H), 4.33-4.38 (m, 1H), 3.01-3.08 (m, 1H), 1.46-1.49 (t, J=5.6 Hz, 3H), 1.31 (d, J=7.2 Hz, 6H).

Preparation of intermediate I-2：

5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole-2-carboxylic acid ethyl ester: to a vial were added (I-1) (750 mg,2.37 mmol), 2, 6-dimethyl-4- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (750 mg 2.85 mmol), XPhos Pd G2 (178 mg,0.237 mmol), cesium carbonate (1932 mg,5.93 mmol) and a 10:1 mixture of 1, 4-dioxane and water (20.5 mL). The solution was degassed by bubbling argon for 30 seconds and then heated in a sealed tube at 110 ℃ for 3 hours. The reaction mixture was cooled, filtered through celite (eluent: etOAc), and concentrated. The resulting residue was purified by column chromatography on silica gel (eluent: etOAc/Hex) to give the desired product. ES/MS:342.5 (M+H) ⁺ )。

5- (2, 6-dimethylpyridin-4-yl) -6-isopropyl-4H-thieno [3,2-b ]]Pyrrole-2-carboxylic acid (I-2): to methylethyl 5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b ]]To a solution of pyrrole-2-carboxylate (700 mg,2.04 mmol) in 1:1:1THF, etOH and water (50 mL) was added lithium hydroxide monohydrate (147 mg,6.13 mmol) and the reaction mixture was stirred at 80℃for 2 hours. The reaction system was acidified to pH 4 by addition of 1M aqueous citric acid and the resulting precipitate was filtered to give product I-2.ES/MS:315.3 (M+H) ⁺ )。

Preparation of intermediate I-3：

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid ethyl ester: to 200mL RBF were added (I-1) (1.05 g,3.32 mmol), 8-methyl-6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) - [1,2,4 ]Triazolo [1,5-a ]]Pyridine (0.946G, 3.65 mmol), XPhos Pd G2 (125 mg,0.166 mmol), cesium carbonate (2.7G, 8.3 mmol) and a 10:1 mixture of 1, 4-dioxane and water (50 mL). The solution was degassed by bubbling argon for 30 seconds and then heated in a sealed tube at 110 ℃ for 3 hours. The reaction mixture was cooled, filtered through celite (eluent: etOAc), and concentrated. The resulting residue was purified by column chromatography on silica gel (eluent: etOAc/Hex) to give the desired product. ES/MS:369.2 (M+H) ⁺ )。

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl)-4H-thieno [3,2-b ]]Pyrrole-2-carboxylic acid (I-3): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid ethyl ester (1.73 g,4.70 mmol) in 1:1 THF:water (50 mL) was added lithium hydroxide monohydrate (0.390 mg,9.39 mmol) and the reaction mixture was stirred at 70℃overnight. The reaction was cooled to 0deg.C and acidified by addition of 1N HCl (11.7 mL,11.7 mmol). The precipitate was filtered and washed with water and hexane to give product I-3.ES/MS:341.0 (M+H) ⁺ )。

Preparation of intermediate I-4：

5-bromo-6-isopropyl-4H-thieno [3,2-b ]Pyrrole-2-carboxylic acid: to 5-bromo-6-isopropyl-4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid ethyl ester (I-1) (1.35 g,4.27 mmol) in 1:1:1THF, etOH and water (100 mL) was added lithium hydroxide monohydrate (1.534 g,64.0 mmol) and the reaction mixture was stirred at 80℃for 2 h. The reaction system was acidified to pH 4 by addition of 1M aqueous citric acid and the resulting precipitate was filtered to give the product, which was continued directly for the next step. ¹ H NMR(400MHz,DMSO-d6)δ12.78(s,1H),12.08(s,1H),7.53(s,1H),3.04–2.86(m,1H),1.25(d,J＝6.9Hz,6H)。

4- (5-bromo-6-isopropyl-4H-thieno [3, 2-b)]Pyrrole-2-carbonyl) piperazine-1-carboxylic acid tert-butyl ester (I-4): to 5-bromo-6-isopropyl-4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (150 mg,0.52 mmol) in DCM (5.0 mL) was added piperazine-1-carboxylic acid tert-butyl ester (116 mg,0.63 mmol) and 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea hexafluorophosphate (238 mg,0.63 mmol), then N, N-diisopropylethylamine (0.46 mL,2.60 mmol) and the reaction mixture was stirred at room temperature for 30 min. The reaction was quenched by the addition of water and the mixture was extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and the filtrate concentrated in vacuo. The crude residue was purified by column chromatography (0-100% EtOAc/hexanes), The product I-4 is obtained. ES/MS:480.1 (M+Na) ⁺ )。 ¹ H NMR (400 MHz, chloroform-d) delta 8.42 (s, 1H), 7.28 (s, 1H), 3.56-3.47 (m, 8H), 2.50-2.33 (m, 1H), 1.50-1.46 (m, 15H).

Preparation of intermediate I-5：

6-bromo-2-iodo-3-ethyl-1H-indole (I-5): prepared in a similar manner to I-4, but replacing 1-Boc-piperazine with tert-butyl (3S) -3- (methylamino) pyrrolidine-1-carboxylate. ES/MS:494.1 (M+Na) ⁺ )。

Preparation of intermediate I-6：

5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole: i-2 (390 mg,1.24 mmol) and 1, 8-diazabicyclo [5.4.0]A mixture of undec-7-ene (0.761 mL,5.09 mmol) in dimethylacetamide (2 mL) was heated in a sealed vessel in a microwave reactor (600W) for 1 hour. After cooling to room temperature, the mixture was poured into 1N HCl and the product was extracted into ethyl acetate. The organic phase was separated over MgSO ₄ Drying, filtration and concentration under reduced pressure gave the product which was used directly in the next step. ES/MS:271.2 (M+H) ⁺ )。

5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole (I-6): 5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b]A mixture of pyrrole (200 mg,0.740 mmol) and NBS (132 mg,0.74 mmol) in THF (2 mL) was stirred at room temperature for 1 hour. After this time, the mixture was poured into water and the product was extracted into ethyl acetate. The organic phase was separated over MgSO ₄ Dried, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography on silica gel (eluent: etOAc/Hex) to give product I-6.ES/MS:350.1 (M+H) ⁺ )。

Preparation of intermediate I-7：

6-bromo-4H-thieno [3,2-b ]]Pyrrole-2-carboxylic acid ethyl ester: to 4H-thieno [3,2-b ]]To a solution of pyrrole-2-carboxylic acid ethyl ester (73.0 g,373.90 mmol) in THF (500 mL) was added NBS (66.6 g,373.90 mmol) and the reaction mixture was stirred at 25 ℃ for 1 hour. After complete consumption of the starting material, the reaction mixture was diluted with EtOAc and water. The organic layer was separated, washed with brine and over Na ₂ SO ₄ And (5) drying. The organic phase was filtered and the filtrate was concentrated to give the product.

6-bromo-4H-thieno [3,2-b ]]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester: to 6-bromo-4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid ethyl ester (92.0 g,335.59 mmol) in DCM (500 mL) was added DMAP (4.1 g,33.56 mmol) and Boc ₂ O (109.9 g,503.39 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, the reaction mixture was diluted with EtOAc and water. The organic layer was separated, washed with brine (500 mL) and dried over Na ₂ SO ₄ And (5) drying. The organic phase was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 200/1) to give the product. ES/MS:374.0 (M+H+). ¹ H NMR(400MHz,CDCl3-d)δ:8.01(s,1H),7.54(s,1H),4.34-4.39(m,2H),1.63(s,9H),1.37-1.41(t,J＝7.2Hz,3H)。

6-vinyl-4H-thieno [3,2-b ]]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester: to 6-bromo-4H-thieno [3,2-b ] under nitrogen atmosphere]Pd (dppf) Cl was added to a solution of pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester (10.0 g,26.71 mmol) and potassium vinyltrifluoroborate (7.2 g,53.44 mmol) in 1, 4-dioxane (150 mL) and water (30 mL) ₂ (1.96 g,2.7 mmol) and K ₃ PO ₄ (11.4 g,53.44 mmol). The reaction mixture was degassed under vacuum and purified with N ₂ Purging was performed several times, followed by stirring at 80℃for 2 hours. After the reaction was complete (monitored by LCMS), the reaction was diluted with EtOAc and water. The organic layer was separated and the organic layer was separated,washed with brine and dried over Na ₂ SO ₄ And (5) drying. The organic phase was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 100/1) to give the product.

6-ethyl-4H-thieno [3,2-b ]]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester: to 6-vinyl-4H-thieno [3,2-b ]]To a solution of pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester (7.1 g,22.09 mmol) and Pd/C (10 wt%, 750 mg) was added THF (300 mL), and the mixture was cooled at room temperature and H ₂ Stirring is carried out for 18 hours under an atmosphere. The reaction was then degassed with argon, filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 100/1) to give the product.

5-bromo-6-ethyl-4H-thieno [3,2-b]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester (I-7): 6-ethyl-4H-thieno [3,2-b]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester (7.1 g,21.95 mmol) in CH ₂ Cl ₂ The solution in (200 mL) was cooled at 0deg.C, and NBS (3.91 g,21.95 mmol) was added in portions. The reaction mixture was stirred at 0 ℃ for 1 hour and LCMS showed the reaction was complete. The reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine and dried over Na ₂ SO ₄ Dried, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 100/1) to give product I-7.ES/MS:403.9 (M+H+). ¹ H NMR(400MHz,CDCl3-d)δ:7.97(s,1H),4.33-4.39(m,2H),2.62-2.67(m,2H),1.66(s,9H),1.37-1.40(m,3H),1.25-1.29(t,J＝7.6Hz,3H)。

Preparation of intermediate I-8：

6-ethyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl 2-ethyl ester: to the vial was added I-7 (1.05 g,2.61 mmol), 5-bromo-6-ethyl-4H-thieno [3,2-b]Pyrrole-2, 4-dicarboxylic acid 4-tert-butyl esterEster 2-ethyl ester (0.744G, 2.87 mmol), XPhos Pd G2 (98.2 mg,0.130 mmol), cesium carbonate (2.13G, 6.52 mmol) and a 10:1 mixture of 1, 4-dioxane in water (50 mL). The solution was degassed by bubbling argon for 30 seconds and then heated in a sealed tube at 110 ℃ for 3 hours. The reaction mixture was cooled, filtered through celite (rinsing with EtOAc), and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (eluent: etOAc/Hex) to give the desired product. ES/MS:455.2 (M+H) ⁺ )。

6-ethyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid (I-8): to 6-ethyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of 4-tert-butyl 2-ethyl pyrrole-2, 4-dicarboxylic acid (1.10 g,2.42 mmol) in 1:1:1 THF:EtOH:water (50 mL) was added lithium hydroxide monohydrate (174 mg,7.26 mmol) and the reaction mixture was stirred at 80℃for 2 hours. The reaction system was acidified to pH 4 by addition of 1M citric acid and the resulting precipitate was filtered to give product I-8.ES/MS:327.1 (M+H) ⁺ )。

Preparation of intermediate I-9：

5-bromo-2-hydrazino-3-methyl-1, 2-dihydropyridine: to a stirred solution of 2, 5-dibromo-3-methylpyridine (10 g,40 mmol) in ethanol (100 mL) was added hydrazine hydrate (20 mL,400 mmol) at room temperature. After the addition was complete, the reaction mixture was heated to 110 ℃ and stirred for 48 hours. The progress of the reaction was monitored by TLC. After 48 hours, the reaction mixture was cooled to room temperature and the suspension was filtered. The precipitate was washed with ethanol (20 mL) and dried under reduced pressure to give the product.

6-bromo-8-methyltetrazolo [1,5-a ]]Pyridine (I-9): to 5-bromo-2-hydrazino-3-methyl-1, 2-dihydropyridine (4 g,19.8 mmol) in AcOH: H at 0deg.C over a period of 30 minutes ₂ NaNO was added dropwise to the stirred solution of O (3:1) (100 mL) ₂ Aqueous solution (4.0 g in 10mL water). The reaction mixture was stirred at 0 ℃2 hours. The progress of the reaction was monitored by TLC. After the reaction was complete, etOAc and water were added to the reaction mixture and stirred for an additional 20 minutes. The layers were separated and the aqueous layer was extracted with EtOAc (3X 100 mL). The combined organic layers were first treated with saturated Na ₂ CO ₃ Aqueous (500 mL) and brine (300 mL). The organic layer was treated with anhydrous Na ₂ SO ₄ Dried, filtered and concentrated under reduced pressure. The crude residue obtained was triturated with diethyl ether followed by n-pentane to give I-9.ES/MS:213.1 (M+).

Preparation of intermediate I-10：

8-methyl-6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) tetrazolo [1,5-a ]]Pyridine (I-10): 6-bromo-8-methyl-tetrazolo [1,5-a ] was added to the flask]Pyridine (I-9) (2 g,9.39 mmol), bis (pinacolato) diboron (3.1 g,12.2 mmol), [1,1' -bis (diphenylphosphine) ferrocene]Palladium (II) dichloride (0.557 g,0.751 mmol) and potassium propionate (3.16 g,28.2 mmol). The mixture was dissolved in 1, 4-dioxane (40 mL) and nitrogen was bubbled into the reaction mixture for 4 minutes. The mixture was heated at 100 ℃ under nitrogen for 1 hour. The mixture was cooled to room temperature, filtered through celite, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (eluent: etOAc/hexane) to give product I-10.ES/MS:179.2 (M+H) ⁺ ) (mass of the corresponding boric acid).

Preparation of intermediate I-11：

5- (7, 8-dimethyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole-2-carboxylic acid (I-11): prepared in a similar manner to I-10, but with 6-bromo-8-methyl-tetrazolo [1,5-a ]]Substitution of pyridine for 6-bromo-7, 8-dimethyl- [1,2,4]Triazolo [1,5-a ]]Pyridine. ES/MS:274.2 (M+H) ⁺ )。

Preparation of intermediate I-12：

8-methoxy-6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) - [1,2,4 ]]Triazolo [1,5-a ]]Pyridine (I-12): prepared in a similar manner to I-10, but with 6-bromo-8-methyl-tetrazolo [1,5-a ]]Substitution of pyridine with 6-bromo-8-methoxy- [1,2,4]Triazolo [1,5-a ]]Pyridine. ES/MS:276.2 (M+H) ⁺ )。

Preparation of intermediate I-13：

(3R, 4S) -3- (((benzyloxy) carbonyl) amino) -4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester: to 100mL of RBF are added (3R, 4S) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (0.47 g,2.3 mmol) and methylene chloride (10 mL). The mixture was cooled to 0 ℃ under a nitrogen atmosphere, and N, N-diisopropylethylamine (0.8 ml,4.6 mmol) was added followed by benzyl chloroformate (0.34 ml,2.42 mmol) dropwise. The mixture was stirred at 0 ℃ for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure, and the crude residue was purified by silica gel chromatography (eluent: etOAc/hexane) to give the product. ES/MS:361.174 (M+Na) ⁺ )。 ¹ H NMR (400 MHz, chloroform-d) delta 7.39 (d, j=5.1 hz, 5H), 5.15 (s, 2H), 5.06 (d, j=55.7 hz, 1H), 4.39 (dd, j=28.7, 9.6hz, 1H), 3.91 (q, j=9.0 hz, 1H), 3.86-3.40 (m, 2H), 3.11 (t, j=9.5 hz, 1H), 1.48 (s, 9H).

(3R, 4S) -3- (((benzyloxy) carbonyl) (methyl) amino) -4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester: to 100mL of RBF under nitrogen was added tert-butyl (3R, 4S) -3- (((benzyloxy) carbonyl) amino) -4-fluoropyrrolidine-1-carboxylate (0.366 g,1.08 mmol) and dry THF (10 mL). The mixture was cooled to 0 ℃ and sodium hydride (60 wt% dispersion in mineral oil, 0.062g,1.62 mmol) was added. The mixture was stirred at 0deg.C for 30 min, followed by the addition of iodothyronAlkane (0.2 mL,3.24 mmol). The mixture was stirred overnight and warmed to room temperature. The mixture was then concentrated under reduced pressure and the crude residue was purified by silica gel chromatography (eluent: etOAc/hexane) to give the product. ES/MS:275.2 (M+Na) ⁺ )。 ¹ H NMR (400 MHz, chloroform-d) delta 7.46-7.30 (m, 5H), 5.19 (s, 2H), 5.17-4.91 (m, 1H), 4.89-4.42 (m, 1H), 3.93-3.36 (m, 4H), 3.03 (s, 3H), 1.49 (s, 9H).

(3S, 4R) -3-fluoro-4- (methylamino) pyrrolidine-1-carboxylic acid tert-butyl ester (I-13): to 100mL of RBF are added (3R, 4S) -3- (((benzyloxy) carbonyl) (methyl) amino) -4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester (0.28 g,0.79 mmol) and ethanol (20 mL). The mixture was degassed with argon for 2 minutes. Palladium on carbon (10 wt%, 0.85g,0.79 mmol) was added, and hydrogen was bubbled through the mixture for 2 minutes. The reaction was stirred under a hydrogen balloon overnight. Subsequently, the mixture was degassed with argon for 5 min and the solids were removed by filtration through celite, rinsing with EtOAc. The solution was concentrated under reduced pressure to give product I-13.ES/MS:219.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, chloroform-d) delta 5.13 (dp, j=54.0, 3.3hz, 1H), 3.93-3.43 (m, 3H), 3.23 (dddd, j=26.9, 10.8,7.9,3.1hz, 1H), 3.05 (q, j=10.8 hz, 1H), 2.52 (s, 3H), 1.48 (s, 9H).

Preparation of intermediate I-14：

(3R, 4R) -3-fluoro-4- (methylamino) pyrrolidine-1-carboxylic acid tert-butyl ester (I-14): prepared in a similar manner to I-13, but replacing (3 r,4 s) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester with (3 r,4 r) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester. ES/MS:163.2 (M+H) ⁺ ) (mass minus t-butyl). ¹ H NMR (400 MHz, chloroform-d) delta 4.92 (dd, j=51.1, 3.0hz, 1H), 3.85-3.20 (m, 5H), 2.49 (s, 3H), 1.48 (s, 9H).

Preparation of intermediate I-15：

(3R, 4S) -3-fluoro-4- (methylamino) pyrrolidine-1-carboxylic acid tert-butyl ester (I-15): prepared in a similar manner to I-13 except that (3 r,4 s) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester is replaced with (3 s,4 r) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester. ES/MS:219.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, chloroform-d) delta 5.13 (ddt, j=54.0, 5.8,3.3hz, 1H), 3.93-3.41 (m, 3H), 3.32-3.14 (m, 1H), 3.05 (q, j=10.7 hz, 1H), 2.53 (s, 3H), 1.48 (s, 9H).

Preparation of intermediate I-16：

(3S, 4S) -3-fluoro-4- (methylamino) pyrrolidine-1-carboxylic acid tert-butyl ester (I-16): prepared in a similar manner to I-13, but replacing (3 r,4 s) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester with (3 s,4 s) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester. ES/MS:163.2 (M+H) ⁺ ) (mass minus t-butyl). ¹ H NMR (400 MHz, chloroform-d) δ4.92 (dd, J=51.5, 2.9Hz, 1H), 3.81-3.49 (m, 3H), 3.46-3.20 (m, 3H), 2.49 (s, 3H), 1.48 (s, 9H).

Preparation of intermediate I-17：

5- (7, 8-dimethyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole-2-carboxylic acid (I-17): prepared in a similar manner to I-2, but with the substitution of 2, 6-dimethyl-4- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine for I-11.ES/MS:355.1 (M+H) ⁺ )。

Preparation of intermediate I-18：

5- (1, 5-dimethyl-6-oxo-1, 6-dihydropyridin-3-yl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole-2-carboxylic acid (I-18): prepared in a similar manner to I-2, but replacing 2, 6-dimethyl-4- (4, 5-tetramethyl-1, 3, 2-dioxapentalan-2-yl) pyridine with 1, 3-dimethyl-5- (4, 5-tetramethyl-1, 3, 2-dioxapentalan-2-yl) pyridin-2 (1H) -one. ES/MS:331.1 (M+H) ⁺ )。

Preparation of intermediate I-19：

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole: to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (I-3) (6.00 g,17.6 mmol) in DMA (50 mL) was added 1, 8-diazabicyclo [5.4.0 ]Undec-7-ene (7.89 mL,52.9 mmol) and the solution was stirred at 150℃for 24 h. The reaction was quenched by addition of saturated aqueous ammonium chloride and the mixture was extracted with EA (3×). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-50% EtOAc/hexanes) to give the title compound. ES/MS:297.2 (M+H) ⁺ )。

Preparation of intermediate I-20：

2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (I-20): to 6-isopropyl-5- (8-methyl- [1,2, 4) cooled to 0 DEG C]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]A solution of pyrrole (I-19) (0.5 g,1.69 mmol) in acetonitrile (60 mL) and methanol (40 mL) was added dropwise N-bromosuccinimide (284 mg,1.6 mmol) (dissolved in 10mL acetonitrile) and the reaction mixture was allowed to warm to room temperature. Dry-loading the reaction system into the dioxideOn silicon, and purified by column chromatography (eluent: etOAc/hexane) to give the title compound. ES/MS:375.1 (M) ⁺ )。 ¹ H NMR (400 MHz, methanol-d) ₄ )δ8.69–8.61(m,1H),8.44(s,1H),7.64(d,J＝1.5Hz,1H),7.08(d,J＝0.8Hz,1H),3.29–3.18(m,1H),2.70(d,J＝0.8Hz,5H),2.69(s,3H),1.36(d,J＝6.8Hz,6H)。

Preparation of intermediate I-21：

3-methyl-1- (8-methyl- [1,2, 4)]Triazolo [1,5-a ] ]Pyridin-6-yl) butan-1-one (I-21): addition of 8-methyl-6- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) - [1,2,4 to the vial]Triazolo [1,5-a ]]Pyridine (7.77 g,30.0 mmol), palladium acetate (0.337 g,1.50 mmol) and tris (4-methoxyphenyl) phosphine (0.611 g,1.75 mmol) were then added THF (100 mL), water (1.13 mL,62.5 mmol) and isovaleryl anhydride (5.00 mL,25.0 mmol). Argon was bubbled through the mixture for 4 minutes and the reaction mixture was heated to 60 ℃ for 16 hours. The reaction mixture was filtered through celite, eluted with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-50% EtOAc/hexanes) to give the title compound. ES/MS:218.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d) ₄ )δ9.39(s,1H),8.52(s,1H),7.98(s,1H),2.97(d,J＝6.8Hz,2H),2.66(s,3H),2.37–2.23(m,1H),1.04(dd,J＝6.7,0.8Hz,6H)。

Preparation of intermediate I-22：

4- (2-tert-Butoxycarbonylhydrazino) -3-methyl-thiophene-2-carboxylic acid methyl ester (I-22): to 4-bromo-3-methyl-thiophene-2-carboxylic acid methyl ester (500 mg,2.13 mmol) in tBuOH (12 mL) were added tert-butyl N-amino-carbamate (428 mg,3.19 mmol), tripotassium phosphate (1.34 g,6.38 mmol) and tBuBrettPhos Pd G3 (193 mg,0.213 mmol). The reaction mixture is reactedAt N ₂ Heat to 120 ℃ for 1 hour. The reaction was filtered through celite, eluted with DCM and the filtrate concentrated under reduced pressure. The crude residue was purified by column chromatography (eluent: etOAc/hexane) to give the title compound. ¹ H NMR(400MHz,MeOD)δ7.72(s,1H),4.60(s,1H),3.88(s,3H),2.55(s,3H),1.63(s,1H),1.54–1.45(m,19H),1.12(dd,J＝18.0,6.1Hz,4H)。

Preparation of intermediate I-23：

6-isopropyl-3-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid methyl ester (I-23): to a solution of 4- (2-tert-butoxycarbonylhydrazino) -3-methyl-thiophene-2-carboxylic acid methyl ester (I-22) (422 g,1.47 mmol) and p-toluenesulfonic acid monohydrate (761 mg,4.42 mmol) in ethanol (33 mL) in a 500mL round bottom flask was added 3-methyl-1- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) butan-1-one (I-21) (352 mg,1.62 mmol) and the reaction mixture was heated to 120℃in a microwave oven for 1 hour. The reaction mixture was concentrated under reduced pressure, dissolved in EtOAc and washed with saturated aqueous sodium bicarbonate. The layers were separated, the aqueous layer was extracted with EtOAc (2×), and the combined organic layers were washed with brine, dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The crude residue was purified by column chromatography (0% -100% etoac/hexanes) to give the title compound. ES/MS:369.2 (M+H) ⁺ )。 ¹ H NMR(400MHz,DMSO)δ12.38(s,1H),11.69(s,1H),8.87(d,J＝1.7Hz,1H),8.54(s,1H),7.65(t,J＝1.5Hz,1H),3.23–3.17(m,1H),2.64(s,3H),2.61(s,3H),1.30(d,J＝6.8Hz,6H)。

Preparation of intermediate I-24：

6-isopropyl-3-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thiophenesAnd [3,2-b ]]Pyrrole-2-carboxylic acid (I-24): to 6-isopropyl-3-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ] ]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid methyl ester (I-23) in THF (1.00 mL) and water (1 mL) was added lithium hydroxide monohydrate (0.0152 g,0.362 mmol) and the reaction mixture was stirred at 80deg.C for 4 hours. The reaction mixture was concentrated in vacuo, then diluted with hydrochloric acid (1.00 mol/L,1.18ml,1.18 mmol) and water, and the precipitate was collected by filtration to give the title compound. ES/MS:355.2 (M+H) ⁺ )。 ¹ H NMR(400MHz,DMSO)δ12.38(s,1H),11.69(s,1H),8.87(d,J＝1.7Hz,1H),8.54(s,1H),7.65(t,J＝1.5Hz,1H),3.23–3.17(m,1H),2.64(s,3H),2.61(s,3H),1.30(d,J＝6.8Hz,6H)。

Preparation of intermediate I-25：

4- (6-amino-5-nitro-2-pyridinyl) piperazine-1-carboxylic acid tert-butyl ester (I-25): to a 100mL round bottom flask was added 6-chloro-3-nitro-pyridin-2-amine (1.00 g,5.76 mmol) and piperazine-1-carboxylic acid tert-butyl ester (1.61 g,1.61 mmol), followed by dioxane (50 mL) and 99.5% (1.81 mL,10.4 mmol) of N, N-diisopropylethylamine purified by redistillation. The reaction mixture was heated to 100 ℃ for 16 hours. Then, the solvent was removed under reduced pressure, and the residue was separated by flash column chromatography (Hex: ea= 1:l) to give the title compound. ES/MS:324.2 (M+H) ⁺ )。

Preparation of intermediate I-26：

4- (5, 6-diamino-2-pyridinyl) piperazine-1-carboxylic acid tert-butyl ester (I-26): to a solution of tert-butyl 4- (6-amino-5-nitro-2-pyridinyl) piperazine-1-carboxylate (I-25) (1.00 g,3.09 mmol) in ethanol (10 mL) and ethyl acetate (2 mL) was bubbled nitrogen for 4 min, then palladium on carbon (10 wt%; 160.2mg,0.152 mmol) was added and the reaction was mixed The mixture was stirred for 5 hours. The reaction mixture was degassed with argon, diluted with EtOAc, and filtered through celite, eluting with EtOAc and the filtrate concentrated under reduced pressure to give the crude product, which was used directly in the next step. ES/MS:480.3 (M+H) ⁺ )。

Preparation of intermediate I-27：

6-isopropyl-N-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -N- (4-oxycyclohexyl) -4H-thieno [3,2-b]Pyrrole-2-carboxamide (I-27): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (I-3) (150 mg,0.44 mmol) in DCM (4 mL) was added 4- (methylamino) cyclohexanone; hydrochloride (86 mg,0.53 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethyluronium Hexafluorophosphate (HATU) (207 mg,0.88 mmol) and triethylamine (0.12 ml,0.88 mmol) and the reaction mixture was stirred overnight. After the reaction was complete (monitored by LCMS), the reaction was diluted with EtOAc and water. The organic layer was separated, washed with brine and over Na ₂ SO ₄ And (5) drying. The organic phase was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc: 100/1) to give the product. ES/MS:450.2 (M+H).

Preparation of intermediate I-28：

(3 r,5 s) -3- ((tert-butoxycarbonyl) amino) -5- (trifluoromethyl) piperidine-1-carboxylic acid benzyl ester: n- [ (3R, 5S) -5- (trifluoromethyl) -3-piperidinyl was added to 100mL RBF]Tert-butyl carbamate (1 g,3.73 mmol) and dichloromethane (15 mL). The mixture was cooled to 0 ℃ under nitrogen, and N, N-diisopropylethylamine (1.3 ml,7.46 mmol) was added followed by benzyl chloroformate (0.56 ml,3.9 mmol) dropwise. The mixture was stirred at 0deg.C for 1 hrWhen (1). After the reaction was completed, the mixture was concentrated under reduced pressure, and the crude residue was purified by silica gel chromatography (eluent: etOAc/hexane) to give the product. ES/MS:425.2 (M+Na) ⁺ )。

(3R, 5S) -3- [ tert-Butoxycarbonyl (methyl) amino group]-benzyl 5- (trifluoromethyl) piperidine-1-carboxylate: to 100mL of RBF under nitrogen was added benzyl (3R, 5S) -3- ((tert-butoxycarbonyl) amino) -5- (trifluoromethyl) piperidine-1-carboxylate (1.25 g,3.11 mmol) and dry THF (10 mL). The mixture was cooled to 0 ℃ and sodium hydride (60 wt% dispersion in mineral oil, 0.143g,3.73 mmol) was added. The mixture was stirred at 0deg.C for 30 min, then methyl iodide (0.39 mL,6.21 mmol) was added. The mixture was stirred overnight and warmed to room temperature. The mixture was then concentrated under reduced pressure and the crude residue was purified by silica gel chromatography (eluent: etOAc/hexane) to give the product. ES/MS:439.2 (M+Na) ⁺ )。

(3R, 5S) -3- (methylamino) -5- (trifluoromethyl) piperidine-1-carboxylic acid benzyl ester (I-28): to 100mL RBF was added (3R, 5S) -3- [ tert-butoxycarbonyl (methyl) amino group]-benzyl 5- (trifluoromethyl) piperidine-1-carboxylate (1.15 g,2.76 mmol) and dioxane (7.5 mL) and methanol (5 mL). HCl (4M in dioxane; 2.76mL,11 mmol) was added and the mixture was stirred at room temperature overnight. The solution was concentrated under reduced pressure to give I-28.ES/MS:317.2 (M+H) ⁺ )。

Preparation of intermediate I-29：

(3S, 5R) -3- (methylamino) -5- (trifluoromethyl) piperidine-1-carboxylic acid benzyl ester (I-29): prepared in a similar manner to I-28, but with N- [ (3R, 5S) -5- (trifluoromethyl) -3-piperidinyl]Replacement of tert-butyl carbamate with N- [ (3S, 5R) -5- (trifluoromethyl) -3-piperidinyl]Tert-butyl carbamate. ES/MS:317.2 (M+H) ⁺ )。

Preparation of intermediate I-30：

2- (hydroxymethyl) -6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester: to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid ethyl ester (produced by the method described in the I-3 synthesis) (1.0 g,2.71 mmol) in THF (30 mL) was added N, N-dimethylpyridine-4-amine (DMAP) (0.5 g,4.07 mmol), triethylamine (0.45 mL,3.26 mmol) and tert-butylbutoxycarbonyl carbonate (711 mg,3.26 mmol). The mixture was stirred at RT for 30 min. The mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography using a mixture of ethyl acetate and hexane as eluent to give the title product. ES/MS:469.2 (M+H) ⁺ )。

2- (hydroxymethyl) -6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester: to 2- (hydroxymethyl) -6-isopropyl-5- (8-methyl- [1,2, 4) at 0deg.C]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]To a solution of tert-butyl pyrrole-4-carboxylate (1.2 g,2.56 mmol) in THF (5 mL) was added dropwise LAH (48.6 mg,1.28mmol,1.28mL of 1M solution). The resulting mixture was stirred at the same temperature for 1 hour. The reaction was then quenched by addition of rochelle salt solution (10 mL) and extracted with ethyl acetate (3 x 30 mL). The organic layers were combined, washed with water (30 mL) and brine (30 mL), and dried over Na ₂ SO ₄ Dried and concentrated in vacuo. The residual product was purified by flash chromatography using a mixture of ethyl acetate and hexane as eluent to give the title product. ES/MS:427.1 (M+H) ⁺ )。 ¹ H NMR(400MHz,CDCl3)δ8.42(s,1H),8.36(d,J＝1.1Hz,1H),7.40(s,1H),7.28(q,J＝1.2Hz,1H),4.91(s,2H),2.80(p,J＝6.9Hz,1H),2.70(s,3H),1.36(d,J＝1.2Hz,9H),1.33–1.23(m,6H)。

2-formyl-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester (I-30): tetrapropylammonium homoruthenate (TPAP) (49.4 mg,0.141mmol,5 mol%) was added at once to 2- (hydroxymethyl) -6-isopropyl-5- (8-room temperature under argonMethyl- [1,2,4 ]]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b ]Pyrrole-4-carboxylic acid tert-butyl ester (1.20 g,2.81 mmol), N-methylmorpholine-N-oxide (0.494 g,4.22 mmol) and powdered formMolecular sieve in CH ₃ In the CN, the mixture was stirred. The reaction mixture was stirred until LCMS showed completion of the reaction. The reaction mixture was filtered with the aid of celite, concentrated and purified by flash chromatography using a mixture of ethyl acetate and hexane as eluent to give the product. ES/MS:425.2 (M+H) ⁺ )。 ¹ H NMR(400MHz,CDCl3)δ9.96(d,J＝1.2Hz,1H),8.47(s,1H),8.41(d,J＝1.2Hz,1H),8.09(d,J＝1.2Hz,1H),7.29(q,J＝1.4Hz,1H),2.84(p,J＝6.8Hz,1H),2.73(s,3H),1.38(d,J＝1.3Hz,9H),1.30(d,J＝6.5Hz,6H)。

Preparation of intermediate I-31：

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carbaldehyde (I-31): 2-formyl-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester (I-30) (30 mg,0.07 mmol) was added to the vial along with potassium carbonate (10 mg,0.07 mmol) and methanol (1 mL). The reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc and water. The layers were separated and the organic layer was dried over MgSO ₄ Drying, filtration, and concentration under reduced pressure gave the product. ES/MS:325.2 (M+H) ⁺ )。

Preparation of intermediate I-32：

6-ethyl-2-formyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b ]Pyrrole-4-carboxylic acidsTert-butyl ester (I-32): prepared in a similar manner to I-30, but with 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid ethyl ester is replaced by 6-ethyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid ethyl ester (produced by the method described in the synthesis of I-8). ES/MS:411.2 (M+H) ⁺ )。

Preparation of intermediate I-33：

5- (7, 8-dimethyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2-formyl-6-isopropyl-4H-thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester (I-33): prepared in a similar manner to I-30, but with 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid ethyl ester is replaced by 5- (7, 8-dimethyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole-2-carboxylic acid ethyl ester (produced by the method described in the synthesis of I-17). ES/MS:439.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) δ9.96 (s, 1H), 8.70 (s, 1H), 8.43 (s, 1H), 8.26 (s, 1H), 2.72 (hept, j=7.0 hz, 1H), 2.66 (s, 3H), 2.20 (s, 3H), 1.35 (d, j=6.9 hz, 3H), 1.30 (s, 9H), 1.25 (d, j=6.9 hz, 3H).

Preparation of intermediate I-34：

4- (4-isopropyl-3-methyl-5- (8-methyl- [1,2, 4) ]Triazolo [1,5-a ]]Pyridin-6-yl) -6H-thieno [2,3-b]Pyrrol-2-yl) -3, 6-dihydropyridine-1 (2H) -carboxylic acid tert-butyl ester: 2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4) in acetonitrile (8.0 mL)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (I-20) (250 mg,0.67 mmol) was added to 2- (1, 4-dioxaspiro [ 4.5)]Dec-7-en-8-yl) -4, 5-tetramethyl-1, 3, 2-dioxaborolan (230 mg,0.87 mmol), bis (di-t-butyl (4-dimethylaminophenyl) phosphine) dichloridePalladium (II) (47.2 mg,0.067 mmol) and 1.0M potassium acetate/1.5M aqueous sodium carbonate (1.67 mL,1.67 mmol) and the reaction mixture was heated to 120℃in a microwave oven for 45 min. The reaction mixture was dried over sodium sulfate, filtered through celite, eluted with DCM and the filtrate concentrated under reduced pressure. The crude residue was purified by column chromatography (0% -100% EtOAc/hexanes) to give the title compound. ES/MS:435.2 (M+H) ⁺ )。

2- (1, 4-dioxaspiro [4.5 ]]Dec-8-yl) -6-isopropyl-5- (8-methyl- [1,2,4]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole: to 2- (1, 4-dioxaspiro [4.5 ]]Dec-7-en-8-yl) -6-isopropyl-5- (8-methyl- [1,2,4]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b ]Pyrrole (130 mg,0.30 mmol) was bubbled with nitrogen in a solution of ethanol (10 mL) and ethyl acetate (2 mL) for 4 min, then 10 wt% palladium on carbon (16.4 mg,0.15 mmol) was added and the reaction mixture was stirred for 48 h. The reaction mixture was degassed with argon, diluted with EtOAc, and filtered through celite, eluting with EtOAc and the filtrate concentrated under reduced pressure to give the crude product, which was used directly in the next step. ES/MS:437.2 (M+H) ⁺ )。

4- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]Cyclohexanone hydrochloride (I-34): to 2- (1, 4-dioxaspiro [4.5 ]]Dec-8-yl) -6-isopropyl-5- (8-methyl- [1,2,4]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]A solution of pyrrole (120 mg,0.27 mmol) in DCM (2.0 mL) was added 4.0NHCl in dioxane (1 mL) and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated in vacuo to give the title compound as HCl salt. ES/MS:393.2 (M+H) ⁺ )

Preparation of intermediate I-35：

(1R, 5S,6 s) -6- (methylamino) -3-azabicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester (I-35): prepared in a similar manner to I-13 but with (3R, 4S) -3-amino-4-fluoro-pyrrole Substitution of tert-butyl alkyl-1-carboxylate with (1R, 5S) -6-amino-3-azabicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester. ES/MS:213.2 (M+H) ⁺ )。

Preparation of intermediate I-36：

(3R, 4R) -3-fluoro-4- (methylamino) piperidine-1-carboxylic acid tert-butyl ester (I-36): prepared in a similar manner to I-13, but replacing (3 r,4 s) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester with (3 r,4 r) -4-amino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester. ES/MS:177.2 (M+H) ⁺ ) (mass minus t-butyl).

Preparation of intermediate I-37：

(3S, 4S) -3-fluoro-4- (methylamino) piperidine-1-carboxylic acid tert-butyl ester (I-37): prepared in a similar manner to I-13, but replacing (3 r,4 s) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester with (3 s,4 s) -4-amino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester.

Preparation of intermediate I-38：

(3S, 4R) -3-fluoro-4- (methylamino) piperidine-1-carboxylic acid tert-butyl ester (I-38): prepared in a similar manner to I-13 except that (3 r,4 s) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester is replaced with (3 s,4 r) -4-amino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester.

Preparation of intermediate I-39：

(3R, 4S) -3-fluoro-4- (methylamino) piperidine-1-carboxylic acid tert-butyl ester (I-39): prepared in a similar manner to I-13, but replacing (3 r,4 s) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester with (3 r,4 s) -4-amino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester.

Preparation of intermediate I-40：

/>

(S) -3, 3-difluoro-4- (methylamino) piperidine-1-carboxylic acid tert-butyl ester (I-40): prepared in a similar manner to I-13 except that (3 r, 4S) -3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester is replaced with (4S) -4-amino-3, 3-difluoro-piperidine-1-carboxylic acid tert-butyl ester.

Preparation of intermediate I-41：

5- (trifluoromethylsulfonyloxy) -3,3a,6 a-tetrahydro-1H-cyclopenta [ c ]]Pyrrole-2-carboxylic acid tert-butyl ester (I-41): 5-oxo-1, 3a,4,6 a-hexahydrocyclopenta [ c ] at-78deg.C under nitrogen]To a solution of tert-butyl pyrrole-2-carboxylate (700 mg,3.11 mmol) in anhydrous THF (26 mL) was added LiHMDS (1M solution in THF) (4.04 mL,4.04 mmol) dropwise. After 20 minutes, a solution of N-phenyltrifluoromethanesulfonyl imide (1464 mg,3.73 mmol) in THF (10 mL) was added, and the reaction system was gradually warmed to 0℃and stirred for 3 hours. With a minimum of saturated NaHCO ₃ The reaction system was quenched and the resulting mixture was concentrated under reduced pressure. Flash chromatography (eluent: etOAc/hexane) afforded the desired product. ¹ H NMR(400MHz,CDCl3)δ5.76–5.70(m,1H),3.65(q,J＝10.4Hz,1H),3.51(ddd,J＝17.4,11.0,7.4Hz,1H),3.21(dddd,J＝29.9,18.2,11.1,5.7Hz,2H),2.93(s,1H),2.46–2.33(m,3H),1.95–1.77(m,2H),1.48(s,9H)。

Preparation of intermediate I-42：

5- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -3,3a,6 a-tetrahydro-1H-cyclopenta [ c ]]Pyrrole-2-carboxylic acid tert-butyl ester (I-42): to a 100mL flask was added 5- (trifluoromethylsulfonyloxy) -3,3a,6 a-tetrahydro-1H-cyclopenta [ c ] ]Pyrrole-2-carboxylic acid tert-butyl ester (I-41) (800 mg,2.24 mmol), bis (pinacolato) diboron (682 mg,2.69 mmol), [1,1' -bis (diphenylphosphino) ferrocene]Palladium (II) dichloride (166 mg,0.224 mmol), potassium propionate (753 mg,6.72 mmol), and the mixture was dissolved in dioxane (20 mL). The solution was heated to 100 ℃ for 16 hours. The reaction mixture was concentrated under reduced pressure. The reaction mixture was cooled, filtered through celite (eluent: etOAc), and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: etOAc/hexane) to give the desired product. ¹ H NMR(400MHz,CDCl3)δ6.48(s,1H),4.14(qd,J＝7.1,1.5Hz,1H),3.69–3.43(m,2H),3.30–3.07(m,2H),2.73(s,1H),2.41(qd,J＝7.6,2.6Hz,1H),2.34–1.99(m,4H),1.48(d,J＝29.7Hz,9H),1.29(s,6H)。

Preparation of intermediate I-43：

5- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -1, 3a,4,7 a-hexahydro-2H-isoindole-2-carboxylic acid tert-butyl ester (I-43): prepared in a similar manner to I-42 and I-41, but replacing tert-butyl 5-oxo-1, 3a,4,6 a-hexahydrocyclopenta [ c ] pyrrole-2-carboxylate with tert-butyl 6-oxo-3, 3a,4,5,7 a-hexahydro-1H-isoindole-2-carboxylate.

Preparation of intermediate I-44：

6- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -2-azaspiro [3.5] non-6-ene-2-carboxylic acid tert-butyl ester (I-44): prepared in a similar manner to I-42 and I-41, except that tert-butyl 5-oxo-1, 3a,4,6 a-hexahydrocyclopenta [ c ] pyrrole-2-carboxylate was replaced with tert-butyl 6-oxo-2-azaspiro [3.5] nonane-2-carboxylate.

Preparation of intermediate I-45：

2-bromo-5- (7, 8-dimethyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole (I-45): prepared in a similar manner to I-20 and I-19, except that I-3 was replaced with I-17.ES/MS:389.1 (M) ⁺ )

Preparation of intermediate I-46：

2-bromo-6-isopropyl-5- (8-methoxy- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (I-46): prepared in a similar manner to I-20, I-19 and I-3, but with 8-methyl-6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) - [1,2,4]Triazolo [1,5-a ]]Pyridine is replaced with I-12.ES/MS:391.1 (M) ⁺ )。

Preparation of intermediate I-47：

2, 8-dimethyl-6- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) - [1,2,4 ]]Triazolo [1,5-a ]]Pyridine (I-47): prepared in a similar manner to I-10, but with 6-bromo-8-methyl-tetrazolo [1,5-a ]]Substitution of pyridine with 6-bromo-2, 8-dimethyl- [1,2,4]Triazolo [1,5-a ]]Pyridine. ES/MS:192.1 (M+H) ⁺ ) (mass of boric acid). ¹ H NMR(400MHz,CDCl3)δ8.72(s,1H),7.56(s,1H),2.63(d,J＝8.2Hz,6H),1.38(d,J＝1.0Hz,12H)。

Preparation of intermediate I-48：

2-bromo-5- (2, 8-dimethyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole (I-48): prepared in a similar manner to I-20, I-19 and I-3, but with 8-methyl-6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) - [1,2,4 ]Triazolo [1,5-a ]]Pyridine is replaced with I-47.ES/MS:389.1 (M) ⁺ )

Preparation of intermediate I-49：

6- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -8- (trifluoromethyl) - [1,2,4]]Triazolo [1,5-a ]]Pyridine (I-49): prepared in a similar manner to I-10, but with 6-bromo-8-methyl-tetrazolo [1,5-a ]]Substitution of pyridine for 6-bromo-8- (trifluoromethyl) - [1,2,4]]Triazolo [1,5-a ]]Pyridine. ES/MS:232.1 (M+H) ⁺ ) (mass of boric acid). ¹ H NMR(400MHz,CDCl3)δ9.11(s,1H),8.49(s,1H),8.18(t,J＝1.1Hz,1H),1.41(s,12H)。

Preparation of intermediate I-50：

6-isopropyl-5- (8- (trifluoromethyl) - [1,2,4] triazolo [1,5-a ] pyridin-6-yl) -4H-thieno [3,2-b ] pyrrole-2-carboxylic acid (I-50): prepared in a similar manner to I-3 except 8-methyl-6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) - [1,2,4] triazolo [1,5-a ] pyridine was replaced with I-49.

Preparation of intermediate I-51：

6-bromo-5-methyl-2H- [1,2,4]Triazolo [4,3-a ]]Pyridin-3-one: a suspension of (5-bromo-6-methyl-2-pyridinyl) hydrazine (1.15 g,5.69 mmol) and 1,1' -Carbonyldiimidazole (CDI) (1.02 g,6.26 mmol) in acetonitrile (10 mL) was heated at reflux for 2 hours. The reaction was then allowed to cool to room temperature overnight. The reaction was filtered to give the title product. ES/MS:228.0[ M ] ⁺ ]。 ¹ H NMR(400MHz,CDCl3)δ10.50(s,1H),7.09(d,J＝9.9Hz,1H),6.85(dd,J＝9.8,1.1Hz,1H),2.98(s,3H)。

6-bromo-2, 5-dimethyl- [1,2,4]Triazolo [4,3-a ] ]Pyridin-3-one (I-51): to 6-bromo-5-methyl-2H- [1,2,4 ] at room temperature]Triazolo [4,3-a ]]To a solution of pyridin-3-one (0.4813 g,2.12 mmol) in DMA (5 mL) was added K ₂ CO ₃ (0.439 g,3.18 mmol) and then methyl iodide (0.361 g,2.54 mmol) were added. The reaction mixture was heated at 110℃for 1 hour. The reaction mixture was then allowed to cool to room temperature, diluted with EtOAc (30 mL), and washed with water (2×20 mL) and brine (20 mL). The organic layer was dried over MgSO ₄ Drying, filtering and concentrating under reduced pressure to obtain I-51, which is used for subsequent reaction. ES/MS:242.1[ M ⁺ ]。

Preparation of intermediate I-52：

2, 5-dimethyl-6- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) - [1,2,4 ]]Triazolo [4,3-a ]]Pyridin-3 (2H) -one (I-52): prepared in a similar manner to I-10, but with 6-bromo-8-methyl-tetrazolo [1,5-a ]]Pyridine is replaced with I-51.ES/MS:290.2 (M+H) ⁺ )。

Preparation of intermediate I-53：

6- (2-bromo-6-isopropyl-4H-thieno [3, 2-b)]Pyrrol-5-yl) -2, 5-dimethyl- [1,2,4]Triazolo [4,3-a ]]Pyridin-3 (2H) -one (I-53): to be combined with I-20, I-19 andi-3 is prepared in a similar manner, but 8-methyl-6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) - [1,2,4 ]]Triazolo [1,5-a ]]Pyridine is replaced with I-52.ES/MS:405.1 (M) ⁺ )。

Preparation of intermediate I-54：

7- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -2-azaspiro [4.4] non-7-ene-2-carboxylic acid tert-butyl ester (I-54): prepared in a similar manner to I-42 and I-41, except that tert-butyl 5-oxo-1, 3a,4,6 a-hexahydrocyclopenta [ c ] pyrrole-2-carboxylate was replaced with tert-butyl 7-oxo-2-azaspiro [4.4] nonane-2-carboxylate.

Preparation of intermediate I-55：

6- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -3, 4a,5,8 a-hexahydroisoquinoline-2 (1H) -carboxylic acid tert-butyl ester (I-55): prepared in a similar manner to I-42 and I-41, except that tert-butyl 5-oxo-1, 3a,4,6 a-hexahydrocyclopenta [ c ] pyrrole-2-carboxylate was replaced with tert-butyl 6-oxo-octahydroisoquinoline-2 (1H) -carboxylate.

Preparation of intermediate I-56：

5- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -2-azabicyclo [2.2.2] oct-5-ene-2-carboxylic acid tert-butyl ester (I-56): prepared in a similar manner to I-42 and I-41, but replacing tert-butyl 5-oxo-1, 3a,4,6 a-hexahydrocyclopenta [ c ] pyrrole-2-carboxylate with tert-butyl 5-oxo-2-azabicyclo [2.2.2] octane-2-carboxylate.

Preparation of intermediate I-57：

8- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -5-azaspiro [3.5] non-7-ene-5-carboxylic acid tert-butyl ester (I-57): prepared in a similar manner to I-42 and I-41, except that tert-butyl 5-oxo-1, 3a,4,6 a-hexahydrocyclopenta [ c ] pyrrole-2-carboxylate was replaced with tert-butyl 8-oxo-5-azaspiro [3.5] nonane-5-carboxylate.

Preparation of intermediate I-58：

8-iodo-3-azabicyclo [3.2.1]Octane-3-carboxylic acid tert-butyl ester (I-58): to 8-hydroxy-3-azabicyclo [3.2.1]To a solution of tert-butyl octane-3-carboxylate (1 g,4.4 mmol) in toluene (50 mL) was added triphenylphosphine (1.3 g,5.28 mmol), molecular iodine (1.34 g,5.28 mmol) and imidazole (599 mg,8.8 mmol). The mixture was stirred at reflux overnight. The mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography (eluent: etOAc/hexane) to give the title product. ES/MS:282.1 (M+H) ⁺ ) (mass minus t-butyl)

Preparation of intermediate I-59：

3-iodo-8-azabicyclo [3.2.1]Octane-8-carboxylic acid tert-butyl ester (I-59): prepared in a similar manner to I-58 but with 8-hydroxy-3-azabicyclo [3.2.1]Substitution of tert-butyl octane-3-carboxylate with 3-hydroxy-8-azabicyclo [3.2.1]Octane-8-carboxylic acid tert-butyl ester. ES/MS:282.0 (M+H) ⁺ ) (mass minus t-butyl).

Preparation of intermediate I-60：

2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester (I-60): to 2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole (I-20) (0.23 g, 0.313 mmol) in THF (1 mL) was added N, N-dimethylpyridin-4-amine (DMAP) (0.097 g,797 mmol) and tert-butylbutoxycarbonyl carbonate (161 mg, 0.730 mmol). The mixture was stirred at room temperature for 60 minutes. The mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography (eluent: etOAc/hexane) to give the title product. ES/MS:475.1 (M) ⁺ )。

Preparation of intermediate I-61：

4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-yl) cyclohexane-1-carboxylic acid ethyl ester (I-61): prepared in a similar manner to procedure 11, but replacing tert-butyl 4- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -3, 6-dihydro-2H-pyridine-1-carboxylate with ethyl 4- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclohex-3-en-1-carboxylate. ES/MS:451.3 (M+H) ⁺ )。

Preparation of intermediate I-62：

4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) cyclohexane-1-carboxylic acid (I-62): to 4- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]To a solution of cyclohexane carboxylate I (0.12 g,0.27 mmol) in methanol (1 mL), THF (1 mL) and water (0.5 mL) was added LiOH H ₂ O(0.045g，106 mmol). The resulting reaction mixture was stirred at room temperature for 5 hours. Volatiles were removed under vacuum, and the reaction was diluted with water (5 mL) and neutralized with 1N HCl (2 mL). The aqueous layer was extracted with EtOAc (3X 10 mL). The combined organic layers were taken up over Na ₂ SO ₄ Drying, filtration and concentration gave the title product. ES/MS:423.2 (M+H) ⁺ )。

Preparation of intermediate I-63：

2- (2- (ethoxycarbonyl) cyclopropyl) -6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester: 2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4) in 3:1 toluene and water (13 mL)]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]To tert-butyl pyrrole-4-carboxylate (I-60) (200 mg,0.41 mmol) was added ethyl 2- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclopropanecarboxylate (141 mg,0.59 mmol), ruPhos Pd G3 (35.2 mg,0.041 mmol) and cesium carbonate (411 mg,1.26 mmol). The reaction mixture was heated to 100 ℃ for 2 hours. The reaction mixture was dried over sodium sulfate, filtered through celite, eluted with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (eluent: etOAc/hexane) to give the title compound. ES/MS:509.3 (M+H) ⁺ )。

2- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]Cyclopropanecarboxylic acid (I-63): to 2- (2- (ethoxycarbonyl) cyclopropyl) -6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-4-carboxylic acid tert-butyl ester in THF (1.00 mL) and water (1 mL) was added lithium hydroxide monohydrate (0.0152 g,0.362 mmol) and the reaction mixture was stirred at 80 ℃ for 4 hours. The reaction mixture was concentrated in vacuo, then diluted with hydrochloric acid (1.00 mol/L,1.18mL,1.18 mmol) and water, and the reaction system was filtered to give the title product. ES/MS:381.2 (M+H) ⁺ )。

Preparation of intermediate I-64：

9- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -3-azaspiro [5.5] undec-8-ene-3-carboxylic acid tert-butyl ester (I-64): prepared in a similar manner to I-42 and I-41, except that tert-butyl 5-oxo-1, 3a,4,6 a-hexahydrocyclopenta [ c ] pyrrole-2-carboxylate was replaced with tert-butyl 9-oxo-3-azaspiro [5.5] undecane-3-carboxylate.

Final program

Program 1: example 1：

[5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b ]]Pyrrol-2-yl]Piperazin-1-yl-methanone (example 1): to 5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (I-2) (50 mg, 0.1599 mmol) in DCM (0.4 mL) was added 1-Boc-piperazine (35.5 mg,0.191 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethyluronium Hexafluorophosphate (HATU) (44.9 mg,0.191 mmol) and N, N-diisopropylethylamine (0.0831 mL,0.23 mmol) and the reaction mixture was stirred for 1 hour. LCMS showed the starting material disappeared. TFA (0.1 mL) was added and the reaction mixture was heated at 45 ℃ for 1 hour. The crude mixture was concentrated under reduced pressure and dissolved in acetonitrile (0.75 mL). The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 1.ES/MS:383.2 (M+H) ⁺ )。 ¹ H NMR(400MHz,MeOD)δ7.71(s,2H),7.46(s,1H),4.07(t,J＝5.3Hz,4H),3.55(p,J＝6.8Hz,1H),3.40–3.34(m,4H),2.77(s,6H),1.45(d,J＝6.8Hz,6H)。

The following examples were prepared in a similar manner according to procedure 1 and are shown in table 1 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 1 were used, and these reagents/starting materials are noted in the last column of table 1- "procedure 1 variation: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 1 are replaced with different reagents/starting materials described below.

/>

Program 2: example 38：

[ 6-isopropyl-5- (8-methyl- [1,2,4 ]]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]Piperazin-1-yl-methanone (example 38): to a vial was added (I-4) (750 mg,2.37 mmol), 2, 6-dimethyl-4- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (750 mg,2.85 mmol), XPhos Pd G2 (178 mg,0.237 mmol), cesium carbonate (1932 mg,5.93 mmol) and a 10:1 mixture of 1, 4-dioxane: water (20.5 mL). The solution was degassed by bubbling argon for 30 seconds and then heated in a sealed tube at 110 ℃ for 3 hours. The reaction mixture was cooled, filtered through celite (eluent: etOAc), and concentrated. The resulting residue was purified by column chromatography on silica gel (eluent: etOAc/Hex). The isolated material was dissolved in 5:1 DCM/TFA (1 mL). The reaction mixture was heated at 45 ℃ for 1 hour. The crude mixture was concentrated under reduced pressure and dissolved in acetonitrile (0.75 mL). The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 38.ES/MS:409.3 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.74(dd，J＝1.7，0.8Hz，1H)，8.49(s，1H)，7.67(q，J＝1.2Hz，1H)，7.48(s，1H)，4.09(t，J＝5.3Hz，4H)，3.40-3.36(m，4H)，2.71(t，J＝0.9Hz，3H)，1.41(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 2 and are shown in table 2 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 2 were used, and these reagents/starting materials are noted in the last column of table 2- "procedure 2 variation: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 2 are replaced with different reagents/starting materials described below.

Program 3: example 40：

4- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carbonyl]Piperazin-2-one (example 40): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (I-3) (20 mg,0.059 mmol) in DCM (0.5 mL) was added piperazin-2-one (8.8 mg,0.088 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea Hexafluorophosphate (HATU) (26.8 mg,0.071 mmol) and N, N-diisopropylethylamine (0.031 mL,0.176 mmol), and the reaction mixture was stirred at room temperature for 1 hour. TFA (0.2 mL) was added and the mixture was concentrated under reduced pressure. The crude material was dissolved in acetonitrile (0.5 mL) and water (0.1 mL). The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 40.ES/MS:423.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.77 (s, 1H), 8.56 (s, 1H), 7.73 (s, 1H), 7.49 (s, 1H), 4.47 (s, 2H), 4.05 (t, j=5.4 hz, 2H), 3.51-3.45 (m, 2H), 3.31-3.20 (m, 1H), 2.72 (s, 3H), 1.41 (d, j=6.8 hz, 6H).

The following examples were prepared in a similar manner according to procedure 3 and are shown in table 3 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 3 were used, and these reagents/starting materials are noted in the last column of table 3- "procedure 3 variation: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 3 are replaced with different reagents/starting materials described below.

/>

Program 4: example 46：

5- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -3- (piperidin-4-yl) -1,2, 4-oxadiazole (example 46): to a 40mL vial was added 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid (I-3) (50 mg,0.147 mmol), 1-Carbonyldiimidazole (CDI) (83.4 mg,0.51 mmol) and 1, 4-dioxane (1 mL). The mixture was heated at 60℃for 2 hours. Adding 4- [ (Z) -N' -hydroxyformamidino to the mixture ]Tert-butyl piperidine-1-carboxylate (107 mg,0.441 mmol) and the mixture was heated at 130℃for 6 hours. The mixture was cooled and concentrated under reduced pressure. The crude residue was dissolved in acetonitrile (1.5 mL) and TFA (0.4 mL), and the mixture was heated at 50 ℃ for 1 hour. Water (0.2 mL) was added and the mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% TFA) to give product example 46.ES/MS:448.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) δ8.78 (dd, j=1.7, 0.8hz, 1H), 8.50 (s, 1H), 7.86 (s, 1H), 7.69 (t, j=1.4 hz, 1H), 3.53 (dt, j=13.0, 4.0hz, 2H), 3.32-3.16 (m, 4H), 2.72 (t, j=0.9 hz, 3H), 2.37 (dd, j=14.7, 4.0hz, 2H), 2.12 (dtd, j=14.8, 11.0,4.0hz, 2H), 1.43 (d, j=6.8 hz, 6H).

The following examples were prepared in a similar manner according to procedure 4 and are shown in table 4 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 4 were used, and these reagents/starting materials are noted in the last column of table 4— "change in procedure 4: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 4 are replaced with different reagents/starting materials described below.

Program 5: example 48：

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (5- (piperidin-4-yl) -1,3, 4-thiadiazol-2-yl) -4H-thieno [3,2-b]Pyrrole (example 48): to a 40mL vial was added 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid (I-3) (20 mg,0.059 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea Hexafluorophosphate (HATU) (15.2 mg,0.065 mmol), 1, 4-dioxane (1 mL), and N, N-diisopropylethylamine (0.021 mL,0.12 mmol) and the reaction mixture was stirred at room temperature for 15 min. To the mixture was added tert-butyl 4- (hydrazinocarbonyl) piperidine-1-carboxylate (17.2 mg,0.071 mmol), and the mixture was stirred at room temperature for 2 hours. Lawson reagent (95 mg,0.24 mmol) was added to the mixture, and the mixture was heated at 80℃for 2 hours. The mixture was cooled and purified directly by silica gel chromatography (eluent: etOAc/hexane). The isolated material was dissolved in acetonitrile (1 mL) and TFA (0.3 mL), and the mixture was heated at 50 ℃ for 1 hour. Water (0.2 mL) was added and the mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% TFA) to give product example 48.ES/MS:464.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.75 (s, 1H), 8.48 (s, 1H), 7.68 (s, 1H), 7.62 (s, 1H), 3.69-3.45 (m, 4H), 3.32-3.11 (m, 4H), 2.71 (s,3H)，2.51-2.35(m，2H)，2.16(dd，J＝13.1，9.2Hz，2H)，1.43(d，J＝6.8Hz，6H)。

the following examples were prepared in a similar manner according to procedure 5 and are shown in table 5 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 5 were used, and these reagents/starting materials are noted in the last column of table 5- "procedure 5 variation: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 5 are replaced with different reagents/starting materials described below.

Program 6: example 50：

4- (hydroxymethyl) -4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxamido) piperidine-1-carboxylic acid tert-butyl ester: to a 40mL vial was added 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid (I-3) (40 mg,0.12 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethyluronium Hexafluorophosphate (HATU) (54 mg,0.141 mmol), dichloromethane (0.5 mL) and N, N-diisopropylethylamine (0.062 mL,0.35 mmol) were added and the reaction mixture was stirred at room temperature for 15 min. To the mixture was added tert-butyl 4-amino-4- (hydroxymethyl) piperidine-1-carboxylate (41 mg,0.176 mmol), and the mixture was stirred at room temperature overnight. The mixture was then concentrated under reduced pressure and purified directly by silica gel chromatography (eluent: etOAc/hexane, then MeOH/EtOAc) to give the desired product. ES/MS:553.3 (M+H) ⁺ )。

2- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -3-oxa-1, 8-dioAzaspiro [4.5 ]]Dec-1-ene-8-carboxylic acid tert-butyl ester: to a mixture containing 4- (hydroxymethyl) -4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a vial of tert-butyl pyrrole-2-carboxamido) piperidine-1-carboxylate (21 mg,0.038 mmol) was added (methoxycarbonylsulfatidyl) triethylammonium hydroxide inner salt (Bogis reagent) (14 mg,0.057 mmol) and THF (1 mL). The vials were sealed and heated at 70 ℃ for 1 hour. The mixture was then concentrated under reduced pressure and purified directly by silica gel chromatography (eluent: etOAc/hexane, then MeOH/EtOAc) to give the desired product. ES/MS:535.3 (M+H) ⁺ )。

2- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -3-oxa-1, 8-diazaspiro [4.5]Dec-1-ene (example 6): to a catalyst containing 2- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -3-oxa-1, 8-diazaspiro [4.5]To a vial of tert-butyl dec-1-ene-8-carboxylate (9.1 mg,0.017 mmol) was added acetonitrile (0.7 mL) and TFA (0.15 mL), and the mixture was stirred at room temperature for 2 hours. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 50.ES/MS:435.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.74 (s, 1H), 8.48 (s, 1H), 7.67 (s, 1H), 7.62 (s, 1H), 4.38 (s, 2H), 3.63-3.47 (m, 3H), 3.31-3.26 (m, 2H), 2.71 (s, 3H), 2.06 (dd, j=6.8, 4.9hz, 4H), 1.41 (d, j=6.8 hz, 6H).

Program 7: example 51：

5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-2- (6-piperazin-1-yl-3-pyridinyl) -4H-thieno [3,2-b]Pyrrole (example 51): to the vial was added (I-6) (100 mg,0.232 mmol), 4- [5- (4, 5-tetramethyl-1, 3, 2-dioxapentaborane-2-yl) -2-pyridinyl]Tetrahydro-1 (2H) -pyrazinecarboxylic acid tert-butyl ester (109 mg,0.279 mmol), XPhos Pd G2 (18.3 mg,0.0232 mmol)l), cesium carbonate (227 mg,0.687 mmol), a 10:1 mixture of 1, 4-dioxane and water (3 mL). The solution was degassed by bubbling argon for 30 seconds and then heated in a sealed tube at 110 ℃ for 2 hours. The reaction mixture was cooled, the crude product was diluted with ethyl acetate, and the organic layer was washed with water. The organic layer was filtered through celite (eluent: etOAc) and concentrated. The crude residue was then purified by column chromatography on silica gel (eluent: etOAc/Hex). The resulting product was dissolved in 5:1 DCM/TFA (1 mL) and heated at 45℃for 1 hour. The reaction mixture was concentrated under reduced pressure, and acetonitrile (1 mL) was added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 51.ES/MS:432.3 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.53(d，J＝2.5Hz，1H)，7.96(dd，J＝9.0，2.6Hz，1H)，7.62(s，2H)，7.27(s，1H)，7.02(d，J＝9.0Hz，1H)，3.90(t，J＝5.2Hz，4H)，3.36(t，J＝5.2Hz，5H)，2.72(s，6H)，1.48(d，J＝6.8Hz，6H)。

Program 8: example 52：

4- [5- [5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b ]]Pyrrol-2-yl]-1,3, 4-oxadiazol-2-yl]Piperidine-1-carboxylic acid tert-butyl ester: to 5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (I-2) (34.6 mg,0.110 mmol) in THF (1.0 mL) was added tert-butyl 4- (hydrazinocarbonyl) piperidine-1-carboxylate (29.5 mg,0.121 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea Hexafluorophosphate (HATU) (31.1 mg,0.132 mmol) and N, N-diisopropylethylamine (0.0383 mL,0.220 mmol), and the reaction mixture was stirred for 1H. Subsequently, a Buerger reagent (136 mg, 0.578mmol) was added to the reaction mixture. The mixture was stirred at room temperature for 2 hours. The reaction mixture was adsorbed onto silica gel and purified by silica gel chromatography to give the product. ES/MS: (M+H) ⁺ )522.3。

2- [5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b ]]Pyrrol-2-yl]-5- (4-piperidinyl) -1,3, 4-oxadiazole (example 52): 4- [5- [5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b ]]Pyrrol-2-yl]-1,3, 4-oxadiazol-2-yl]Tert-butyl piperidine-1-carboxylate (57.5 mg,0.110 mmol) at 5: a solution in 1DCM/TFA (1 mL) was heated at 45℃for 1 hour. The reaction mixture was concentrated under reduced pressure, and acetonitrile was added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 52.ES/MS:422.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ7.76(d，J＝13.0Hz，3H)，3.62-3.47(m，4H)，2.78(s，6H)，2.45(dt，J＝12.9，3.9Hz，2H)，2.17(dtd，J＝14.7，10.9，4.0Hz，2H)，1.48(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 8 and are shown in table 6 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 8 were used, and these reagents/starting materials are noted in the last column of table 6— "change in procedure 8: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 5 are replaced with different reagents/starting materials described below.

Table 6.

Program 9: example 54：

4- (5- (5- (2, 6-dimethylpyridin-4-yl) -6-isopropyl-4H-thieno [3, 2-b)]Pyrrol-2-yl) -1,2, 4-oxadiazol-3-yl) piperazine-1-carboxylic acid tert-butyl ester: to 5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b]Pyrrole-2-carboxylic acidsTo a solution of (I-2) (50 mg, 0.1592 mmol) in 1, 4-dioxane (1 mL) was added 1,1' -carbonyldiimidazole (53.5 mg,0.330 mmol), and the reaction mixture was stirred at 80℃for 2 hours. Subsequently, 4- [ (E) -N' -hydroxyformamidino was added]Tert-butyl piperazine-1-carboxylate (59.1 mg,0.242 mmol) and the mixture was stirred at 100℃for 2 hours. The reaction mixture was cooled and then concentrated under reduced pressure. The crude residue was taken on directly to the next step. ES/MS: (M+H) ⁺ )523.3。

5- [5- (2, 6-dimethyl-4-pyridinyl) -6-isopropyl-4H-thieno [3,2-b ]]Pyrrol-2-yl]-3-piperazin-1-yl-1, 2, 4-oxadiazole (example 54): 4- (5- (5- (2, 6-dimethylpyridin-4-yl) -6-isopropyl-4H-thieno [3, 2-b)]A solution of pyrrole-2-yl) -1,2, 4-oxadiazol-3-yl-piperazine-1-carboxylic acid tert-butyl ester (57.5 mg,0.110 mmol) in 5:1 DCM/TFA (1 mL) was heated at 45℃for 1 h. The reaction mixture was concentrated under reduced pressure, and acetonitrile was added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 54.ES/MS:423.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ7.83(s，1H)，7.74(s，2H)，3.83-3.75(m，4H)，3.56(p，J＝6.8Hz，1H)，3.43-3.36(m，4H)，2.78(s，6H)，1.47(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 9 and are shown in table 7 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 9 were used, and these reagents/starting materials are noted in the last column of table 7— "change in procedure 9: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 9 are replaced with different reagents/starting materials described below.

Table 7.

Program 10: example 56：

6-isopropyl-N-methyl-5- (8-methyl- [1,2, 4) ]Triazolo [1,5-a ]]Pyridin-6-yl) -N- (4-piperidinyl) -4H-thieno [3,2-b]Pyrrole-2-carboxamide (example 56): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (I-3) (50 mg,0.147 mmol) in DCM (1 mL) was added tert-butyl 4- (methylamino) piperidine-1-carboxylate (40.9 mg,0.191 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea Hexafluorophosphate (HATU) (41.5 mg,0.176 mmol) and N, N-diisopropylethylamine (0.0768 mL,0.441 mmol) and the reaction mixture was stirred overnight. TFA (0.3 mL) was added and the reaction mixture was heated at 45 ℃ for 1 hour. The reaction mixture was concentrated under reduced pressure, and acetonitrile (1 mL) and water (0.2 mL) were added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 56.ES/MS:437.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.74(dd，J＝1.7，0.9Hz，1H)，8.51(s，1H)，7.69(t，J＝1.4Hz，1H)，7.47(s，1H)，4.65-4.57(m，1H)，3.60-3.52(m，2H)，3.31-3.27(m，1H)，3.26(s，3H)，3.18(td，J＝12.8，3.7Hz，2H)，2.71(d，J＝0.9Hz，3H)，2.13(dddd，J＝21.2，16.4，13.5，4.8Hz，4H)，1.41(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 10 and are shown in table 8 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 10 were used, and these reagents/starting materials are noted in the last column of table 8- "change in procedure 10: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 10 are replaced with different reagents/starting materials described below.

/>

Program 11: example 62

[ 6-ethyl-5- (8-methyl- [1,2,4 ]]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]Piperazin-1-yl-methanone (example 62): to a solution of I-8 (50 mg,0.147 mmol) in DCM (1 mL) was added piperazine-1-carboxylic acid tert-butyl ester (39.9 mg,0.214 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea Hexafluorophosphate (HATU) (43.3 mg,0.184 mmol) and N, N-diisopropylethylamine (0.0801 mL,0.460 mmol), and the reaction mixture was stirred for 1H. To this solution was added 5:1 DCM/TFA (1 mL) and the reaction mixture was heated at 45℃for 1 hour. The reaction mixture was concentrated under reduced pressure, and acetonitrile (1 mL) and water (0.2 mL) were added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 62.ES/MS:395.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.76(dd，J＝1.7，0.8Hz，1H)，8.51(s，1H)，7.74-7.69(m，1H)，7.46(s，1H)，4.09(t，J＝5.3Hz，4H)，3.39-3.35(m，4H)，2.86(q，J＝7.6Hz，2H)，2.70(t，J＝0.9Hz，3H)，1.38(t，J＝7.6Hz，3H)。

The following examples were prepared in a similar manner according to procedure 11 and are shown in table 9 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 11 were used, and these reagents/starting materials are noted in the last column of table 9- "procedure 11 variation: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 11 are replaced with different reagents/starting materials described below.

Table 9.

Program 12: example 64：

4- (6-isopropyl-5- (8-methoxy- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carbonyl) piperazine-1-carboxylic acid tert-butyl ester: addition of 4- (5-bromo-6-isopropyl-4H-thieno [3, 2-b) to the vial]Pyrrole-2-carbonyl) piperazine-1-carboxylic acid tert-butyl ester (I-4) (20.0 mg,0.044 mmol), 8-methoxy-6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) - [1,2,4]Triazolo [1,5-a ]]Pyridine (I-12) (14.5 mg,0.053 mmol) and Pd (AmPhos) ₂ Cl ₂ (3.1 mg,0.0044 mmol) then acetonitrile (2.0 mL) and 1.0M potassium acetate/1.5M aqueous sodium carbonate (0.11 mL,0.11mmol/0.17 mmol) were added. Nitrogen was bubbled into the reaction mixture for 3 minutes and the reaction was heated to 130 ℃ in a microwave oven for 30 minutes. The reaction mixture was filtered through celite, eluted with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (eluent: etOAc/hexane) to give the product. ES/MS:525.3 (M+H) ⁺ )

(6-isopropyl-5- (8-methoxy- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) (piperazin-1-yl) methanone (example 64): to 4- [ 6-isopropyl-5- (8-methoxy- [1,2, 4) ]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carbonyl]To a mixture of tert-butyl piperazine-1-carboxylate (22.9 mg,0.044 mmol) in DCM (0.75 mL) was added trifluoroacetic acid (0.25 mL), and the reaction mixture was stirred at room temperature for 10 min. The reaction mixture was concentrated under reduced pressureContracted, and acetonitrile (1 mL) and water (0.2 mL) were added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 64.ES/MS:425.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，DMSO-d6)δ11.67(s，1H)，8.92-8.79(m，2H)，8.60(s，1H)，8.52(s，1H)，7.47(s，1H)，7.16(s，1H)，4.08(s，3H)，3.94-3.87(m，4H)，3.33-3.14(m，5H)，1.33(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 12 and are shown in table 10 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 12 were used, and these reagents/starting materials are noted in the last column of table 10— "change in procedure 12: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 12 are replaced with different reagents/starting materials described below.

/>

The following examples were prepared in a similar manner according to the reference procedure and are shown in table 11a below. To prepare the following examples, reagents/starting materials different from some of those described in the reference procedure were used, and these reagents/starting materials are noted in the last column of table 11a— "change in reference procedure: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of the reference procedure are replaced with different reagents/starting materials described below. RT: LCMS retention time (C-3 column; eluent: water/MeCN 0.1% fa;10% to 100%;2 min gradient.)

/>

Program 13: example 154:

4- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]-3, 6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester: 2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4) in 10:1 dioxane and water (10 mL)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To pyrrole (I-20) (800 mg,2.13 mmol) was added 4- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -3, 6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (857G, 2.77 mmol), XPhos Pd G3 (271g, 0.150 mmol) and cesium carbonate (2.08G, 6.40 mmol). The reaction mixture was heated to 100 ℃ for 2 hours. The reaction mixture was dried over sodium sulfate, filtered through celite, eluted with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0% -100% etoac/hexanes) to give the title compound. ES/MS:478.3 (M+H) ⁺ )

4- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]Piperidine-1-carboxylic acid tert-butyl ester: to 4- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl ]Tert-butyl-3, 6-dihydro-2H-pyridine-1-carboxylate (900 mg,1.88 mmol) was bubbled with nitrogen in a solution of ethanol (10 mL) and ethyl acetate (2 mL) for 4 min, then palladium on carbon (10 wt%, 160.2mg,0.152 mmol) was added and the reaction mixture was taken up in H ₂ Stirring is carried out for 48 hours under an atmosphere. The reaction mixture was degassed with argon, diluted with EtOAc, and filtered through celite, eluting with EtOAc, and the filtrate concentrated under reduced pressure to give the crude product. ES/MS:480.3 (M+H) ⁺ )

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (4-piperidinyl) -4H-thieno [3,2-b]Pyrrole (example 154): to 4- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]To a solution of tert-butyl piperidine-1-carboxylate (457 mg,0.944 mmol) in DCM (20.0 mL) was added TFA (3 mL) and the reaction mixture was stirred at 60℃for 1 h. The reaction mixture was concentrated under reduced pressure, then dissolved in 1:1 ACN: water, and purified by RP-HPLC (0.1% TFA-ACN/0.1% TFA water, column: gemini 5. Mu.M, NX-C18. Ang. 110. With 250X 21.2 mm) to give the title compound. ES/MS:380.2 (M+H) ⁺ )。

The following examples were prepared in a similar manner according to procedure 13 and are shown in table 12 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 13 were used, and these reagents/starting materials are noted in the last column of table 12— "change in procedure 13: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 13 are replaced with different reagents/starting materials described below.

/>

Program 14: example 164

2- [4- [ 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl]-1-piperidinyl group]Acetamide (example 164): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (4-piperidinyl) -4H-thieno [3,2-b]To a solution of pyrrole (example 154) (60 mg,0.122 mmol) in 1, 2-dichloroethane (2 mL) was added 2-bromoacetamide (25.2 mg,0.182 mmol) and 1, 8-diazabicyclo [5.4.0]Undec-7-ene (0.0726 mL, 0.481 mmol). The mixture was stirred at RT overnight. To the mixture was added 0.5mL of water and 0.1mL of TFA, followed by removal of DCE under reduced pressure. Acetonitrile (0.2 mL) and water (0.6 mL) were added and the mixture was filtered through acrodisc before RP-HPLC (0.1% TFA-ACN/0.1% TFA water, column: gemini 5. Mu.M, NX-C18 110 Angstrom)250×21.2 mm) to give the title compound example 164.ES/MS:437.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.64(dd，J＝1.7，0.8Hz，1H)，8.46(s，1H)，7.66(q，J＝1.3Hz，1H)，6.88(s，1H)，4.00(s，2H)，3.76(d，J＝12.1Hz，2H)，3.26(dt，J＝13.7，7.3Hz，4H)，2.69(t，J＝0.9Hz，3H)，2.36(d，J＝14.5Hz，2H)，2.15(q，J＝12.9Hz，2H)，1.39(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 14 and are shown in table 13 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 14 were used, and these reagents/starting materials are noted in the last column of table 13— "change in procedure 14: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 14 are replaced with different reagents/starting materials described below.

/>

Program 15: example 180：

N- (4- (3, 3-difluoroazetidin-1-yl) cyclohexyl) -6-isopropyl-N-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxamide (example 180): to 6-isopropyl-N-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -N- (piperidin-4-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxamide (example 56) (20 mg,0.05 mmol) in DCE (1 mL) was added 2- (dimethylamino) acetyl chloride (5 mg,0.05 mmol) and triethylamine (0.02 mL,0.13 mmol) and the reaction mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure, and acetonitrile (1 mL) and water (0.2 mL) were added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 180.ES/MS:522.3 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.73 (dd, j=1.7, 0.9hz, 1H), 8.49 (s, 1H), 7.77-7.62 (m, 1H), 7.45 (s, 1H), 4.78-4.52 (m, 2H), 4.31 (q, j=16.0 hz, 2H), 3.81 (d, j=13.9 hz, 1H), 3.31-3.13 (m, 5H), 2.98 (d, j=9.6 hz, 6H), 2.89-2.76 (m, 1H), 2.71 (t, j=0.9 hz, 3H), 2.08-1.65 (m, 2H), 1.41 (d, j=6.8 hz, 6H).

The following examples were prepared in a similar manner according to procedure 15 and are shown in table 14 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 15 were used, and these reagents/starting materials are noted in the last column of table 14— "change in procedure 15: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 15 are replaced with different reagents/starting materials described below.

/>

Program 16: example 186

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (1- ((3-methyloxetan-3-yl) methyl) piperidin-4-yl) -4H-thieno [3,2-b]Pyrrole (example 186): to 6-isopropyl-5- (8-methyl- [1,2, 4) in 1, 2-dichloroethane (0.27 mL) and ethanol (0.2 mL)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (4-piperidinyl) -4H-thieno [3,2-b]To a vial of pyrrole (example 154) (15 mg,0.0314 mmol) was added 3-methyloxetane-3-carbaldehyde (6.3 mg,0.063 mmol), N-diisopropylethylamine (0.01 mL,0.056 mmol) and acetic acid (1 drop). The mixture was stirred at room temperature for 2 hours. Sodium Triacetoxyborohydride (STAB) (13 mg,0.063 mmol) was then added to the mixture, and the mixture was stirred at room temperature overnight. To the mixture was added 0.1mL TFA followed by removal of DCE under reduced pressure. Acetonitrile (0.5 mL) and water (0.1 mL) were added and the mixture was filtered through acrodisc and purified by RP-HPLC (0.1% TFA-ACN/0.1% TFA water, column: gemini 5. Mu.M, NX-C18A, 250X 21.2 mm) to give the title compound example 186.ES/MS:464.3 (M+H). ¹ H NMR (400 MHz, methanol-d 4) delta 8.67-8.62 (m, 1H), 8.47 (s, 1H), 7.68-7.63 (m, 1H), 6.87 (s, 1H), 4.65 (d, j=6.3 hz, 2H), 4.44 (d, j=6.3 hz, 2H), 3.50 (d, j=12.6 hz, 2H), 3.29-3.22 (m, 3H), 2.69 (s, 3H), 2.36 (d, j=14.1 hz, 2H), 2.16-2.02 (m, 2H), 1.62 (s, 3H), 1.38 (d, j=7.0 hz, 6H).

Program 17: example 187A

2- (4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) piperidin-1-yl) ethan-1-ol (example 187): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (4-piperidinyl) -4H-thieno [3,2-b]To a solution of pyrrole (example 154) (25 mg,0.06 mmol) in DCE (1 mL) was added 2- [ tert-butyl- (dimethyl)Radical) silyl groups]Oxyacetaldehyde (0.021 mL,0.10 mmol), sodium triacetoxyborohydride (20 mg,0.1 mmol) and acetic acid (0.01 mL), and the reaction mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure, and acetonitrile (0.5 mL) was added, followed by 0.2mL of tfa, and after 2 hours, water (0.5 mL) was added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 187.ES/MS:424.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.65-8.56 (m, 1H), 8.42 (s, 1H), 7.63 (t, j=1.4 hz, 1H), 6.78 (dd, j=3.9, 0.9hz, 1H), 3.74 (t, j=6.2 hz, 2H), 3.24 (dt, j=13.6, 6.8hz, 1H), 3.14-2.99 (m, 2H), 2.92-2.72 (m, 1H), 2.67 (s, 3H), 2.60 (t, j=6.2 hz, 2H), 2.24 (td, j=12.0, 2.4hz, 2H), 2.14-1.98 (m, 3H), 1.96-1.71 (m, 2H), 1.37 (d, j=6.8 hz, 6H).

The following examples were prepared in a similar manner according to procedure 17 and are shown in table 15 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 17 were used, and these reagents/starting materials are noted in the last column of table 15- "change in procedure 17: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 17 are replaced with different reagents/starting materials described below.

/>

Program 18: example 196

1- (4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) piperidin-1-yl) -2- (pyrrolidin-1-yl) ethan-1-one (example 196): to 6-isopropyl-5- (8-methyl- [1,2, 4) ]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (4-piperidinyl) -4H-thieno [3,2-b]To a solution of pyrrole (example 154) (20 mg,0.05 mmol) in DMF (1 mL) was added 2-pyrrolidin-1-ylacetic acid (10 mg,0.08 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea Hexafluorophosphate (HATU) (25 mg,0.1 mmol) and triethylamine (0.02 mL,0.1 mmol) and the reaction mixture was stirred overnight. TFA (0.2 mL) was added to the reaction mixture, and the reaction was stirred for 2 hours. Acetonitrile (0.5 mL) was added followed by water (0.5 mL). The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 196.ES/MS:491.3 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.63 (d, j=1.5 hz, 1H), 8.46 (s, 1H), 7.65 (t, j=1.4 hz, 1H), 6.82 (d, j=0.9 hz, 1H), 4.63 (d, j=13.4 hz, 1H), 4.40 (q, j=16.1 hz, 3H), 3.80 (d, j=13.8 hz, 5H), 3.32-3.05 (m, 3H), 2.92 (t, j=12.5 hz, 1H), 2.69 (t, j=0.9 hz, 4H), 2.32-1.94 (m, 1H), 1.76 (dqd, j=41.6, 12.6,4.2hz, 2H), 1.45-1.05 (m, 8H).

The following examples were prepared in a similar manner according to procedure 18 and are shown in table 16 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 18 were used, and these reagents/starting materials are noted in the last column of table 16— "change in procedure 18: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 18 are replaced with different reagents/starting materials described below.

/>

Program 19: EXAMPLE 209

2- (isoindolin-5-yl) -6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (example 209): 2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4) into acetonitrile (1.3 mL)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To pyrrole (I-20) (30 mg,0.0799 mmol) was added tert-butyl 5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) isoindoline-2-carboxylate (35.9 g,0.104 mmol) and 4-di-tert-butylphosphono-N, N-dimethyl-anilinopalladium dichloride (5.7 mg,0.008 mmol). 1M KOAc/1.5M Na ₂ CO ₃ (0.2 mL) and the reaction mixture was heated to 120 ℃ in a microwave oven for 1 hour. The reaction mixture was dried over sodium sulfate, filtered through celite, eluted with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% etoac/hexanes) to give the product. The product was dissolved in DCM (1 mL), TFA (1 mL) was added, and the reaction mixture was stirred at 60 ℃ for 1 hour and concentrated in vacuo. The crude reaction mixture was purified directly by RP-HPLC (0.1% TFA-ACN/0.1% TFA-water, column: gemini 5. Mu.M, NX-C18. Mu.110 Angstrom, 250X 21.2 mm) to give the product. ES/MS:414.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.71(s，1H)，8.48(s，1H)，7.70(d，J＝8.3Hz，2H)，7.50(d，J＝7.7Hz，1H)，7.39(d，J＝7.5Hz，1H)，7.22(s，1H)，4.92(s，2H)，4.71(s，2H)，2.72(s，3H)，1.44(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 19 and are shown in table 17 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 19 were used, and these reagents/starting materials are noted in the last column of table 17- "change in procedure 19: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 19 are replaced with different reagents/starting materials described below.

/>

Program 20: example 235

2- (1H-benzo [ d ]]Imidazol-2-yl) -6-isopropyl-5- (8-methyl- [1,2,4]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (example 235): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (I-3) (40 mg,0.118 mmol) in DCM (1 mL) was added benzene-1, 2-diamine (12.7 mg,0.118 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethyluronium Hexafluorophosphate (HATU) (53.6 mg,0.141 mmol) and N, N-diisopropylethylamine (0.0614 mL,0.353 mmol) and the reaction mixture was stirred for 1 hour. The reaction was concentrated in vacuo, dissolved in EtOAc, and washed with water (1×) and brine (1×). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The reaction mixture was dissolved in AcOH (1 mL) and the reaction mixture was heated to 100 ℃ for 2 hours. The reaction mixture was then concentrated under reduced pressure. The crude residue was dissolved in 5:1DCM/TFA (1 mL). The reaction mixture was heated at 45 ℃ for 1 hour, and then the reaction mixture was concentrated under reduced pressure. The crude residue was dissolved in acetonitrile and water and purified directly by RP-HPLC (0.1% TFA-ACN/0.1% TFA-water, column: gemini 5. Mu.M, NX-C18A, 250X 21.2 mm) to give product example 235.ES/MS:413.3 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.82(d，J＝1.6Hz，1H)，8.51(s，1H)，8.11(s，1H)，7.75(dt，J＝6.8，3.4Hz，2H)，7.71(t，J＝1.4Hz，1H)，7.63-7.54(m，2H)，2.73(s，3H)，1.47(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 20 and are shown in table 18 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 20 were used, and these reagents/starting materials are noted in the last column of table 18— "change in procedure 20: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 20 are replaced with different reagents/starting materials described below.

Program 21: example 240

(6-isopropyl-3-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) (piperazin-1-yl) methanone (example 240): to 6-isopropyl-3-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxylic acid (I-24) (30 mg,0.0846 mmol) in DCM (1 mL) was added tert-butyl 4- (methylamino) piperidine-1-carboxylate (18.9 mg,0.102 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea Hexafluorophosphate (HATU) (23.9 mg,0.102 mmol) and N, N-diisopropylethylamine (0.0442 mL,0.254 mmol) and the reaction mixture was stirred for 1H. The crude mixture was concentrated and dissolved in 5:1 DCM/TFA (1 mL). The reaction mixture was heated at 45 ℃ for 1 hour, and the reaction mixture was concentrated under reduced pressure. The crude residue was dissolved in acetonitrile and water and purified directly by RP-HPLC (0.1% TFA-ACN/0.1% TFA-water, column: gemini 5. Mu.M, NX-C18A, 250X 21.2 mm) to give the product. ES/MS:423.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.73(dd，J＝1.7，0.9Hz，1H)，8.52(s，1H)，7.73-7.68(m，1H)，3.97(t，J＝5.3Hz，4H)，3.26(p，J＝6.8Hz，1H)，2.71(t，J＝0.9Hz，3H)，2.45(s，3H)，1.38(d，J＝6.8Hz，6H)。

The following examples were prepared in a similar manner according to procedure 21 and are shown in table 19 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 21 were used, and these reagents/starting materials are noted in the last column of table 19— "change in procedure 21: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 21 are replaced with different reagents/starting materials described below.

Program 22: example 244：

6-ethyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (5- (piperazin-1-yl) -3H-imidazo [4,5-b]Pyridin-2-yl) -4H-thieno [3,2-b]Pyrrole (example 244): to 6-ethyl-2-formyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]To a solution of tert-butyl pyrrole-4-carboxylate (I-32) (90 mg,0.219 mmol) in 1:1 EtOH/water (2 mL) was added tert-butyl 4- (5, 6-diamino-2-pyridinyl) piperazine-1-carboxylate (I-26) (70.8 mg,0.241 mmol), sodium bisulphite (135 mg, 0.618 mmol) and the reaction mixture was stirred at 60℃for 16 h. Subsequently, the solvent was removed under reduced pressure, and the residue was separated by flash column (eluent: etOAc/hexane). The material was dissolved in 5:1 DCM/TFA (1 mL) and the reaction mixture was heated at 45℃for 1 hour. The reaction mixture was concentrated under reduced pressure and the crude residue was dissolved in acetonitrile and water and purified directly by RP-HPLC (0.1% TFA-ACN/0.1% TFA-water, column: gemini 5. Mu.M, NX-C18. Ang. 110. 250X 21.2 mm) to give the product. ES/MS:484.3[ M+H ] ⁺ ]。 ¹ H NMR(400MHz，MeOD)δ8.72(dd，J＝1.7，0.9Hz，1H)，8.45(s，1H)，7.91(s，1H)，7.87(d，J＝9.0Hz，1H)，7.67(t，J＝1.5Hz，1H)，7.05(d，J＝9.1Hz，1H)，4.00-3.86(m，4H)，3.42-3.36(m，4H)，2.89(q，J＝7.6Hz，2H)，2.68(t，J＝0.9Hz，3H)，1.44(t，J＝7.6Hz，3H)。

The following examples were prepared in a similar manner according to procedure 22 and are shown in table 20 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 22 were used, and these reagents/starting materials are noted in the last column of table 20— "change in procedure 22: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 22 are replaced with different reagents/starting materials described below.

Program 23: example 246

N- (4- (3, 3-difluoroazetidin-1-yl) cyclohexyl) -6-isopropyl-N-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxamide (example 246): to 6-isopropyl-N-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -N- (4-oxycyclohexyl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carboxamide (I-27) (20 mg,0.05 mmol) in DCE (1 mL) was added 3, 3-difluoroazetidine (12 mg,0.13 mmol), sodium triacetoxyborohydride (28 mg,0.13 mmol) and acetic acid (0.01 mL), and the reaction mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure, and acetonitrile (1 mL) and water (0.2 mL) were added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 246.ES/MS:527.3 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) δ11.14 (d, j=5.2 hz, 1H), 8.73 (d, j=1.5 hz, 1H), 8.48 (s, 1H), 7.78-7.58 (m, 1H), 7.43 (d, j=5.7 hz, 1H), 4.83 (t, j=11.0 hz, 4H), 4.67 (t, j=11.2 hz, 1H), 3.33 (q, j=1.7 hz, 3H), 3.31-3.25 (m, 1H), 3.22 (d, j=8.5 hz, 3H), 2.71 (s, 3H), 2.23 (d, j=12.1 hz, 1H), 2.12-1.70 (m, 4H), 1.47 (d, j=12.8 hz, 1H), 1.41 (d, j=6.8 hz, 6H).

The following examples were prepared in a similar manner according to procedure 23 and are shown in table 21 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 23 were used, and these reagents/starting materials are noted in the last column of table 21— "change in procedure 23: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 23 are replaced with different reagents/starting materials described below. RT: LCMS retention time (C-3 column; eluent: water/MeCN 0.1% fa;10% to 100%;2 min gradient.)

/>

Program 24: example 255

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (1- (2- (methylsulfonyl) ethyl) piperidin-4-yl) -4H-thieno [3,2-b ]Pyrrole (example 255): potassium carbonate (5 mg,0.03 mmol) and methyl vinyl sulfone (0.04 mL,0.05 mmol) were added to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (piperidin-4-yl) -4H-thieno [3,2-b]A solution of pyrrole (example 154) (10 mg,0.026 mmol) and triethylamine (0.06 mL,0.05 mmol) in methanol (1 mL) and dichloromethane (1 mL). After stirring for 2 hours, the reaction mixture was concentrated under reduced pressure, and acetonitrile (1 mL) and water (0.2 mL) were added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 255.ES/MS:486.6 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.68-8.62 (m, 1H), 8.45 (s, 1H), 7.70-7.58 (m, 1H), 6.89 (s, 1H), 3.73 (s, 2H), 3.26 (p, j=6.8 hz, 1H), 3.15 (s, 5H), 2.73-2.61 (m, 5H), 2.41 (d, j=13.9 hz, 3H), 2.07 (s, 3H), 1.38 (d, j=6.8 hz, 7H).

Procedure25: example 256

2- (4- (3-fluoropyrrolidin-1-yl) cyclohexyl) -6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (example 256): to 4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ] ]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrol-2-yl) cyclohexane-1-one (I-34) (10 mg,0.025 mmol) in DCE (1 mL) was added 3-fluoropyrrolidine (3.4 mg,0.04 mmol), sodium triacetoxyborohydride (11 mg,0.05 mmol) and acetic acid (0.01 mL), and the reaction mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure, and acetonitrile (1 mL) and water (0.2 mL) were added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 256.ES/MS:466.3 (M+H) ⁺ ). RT (C-3 column; eluent: water/MeCN 0.1% FA;10% to 100%;2 min gradient): 0.809,0.829; the cis-trans isomer ratio is arbitrarily assigned as 3:2.

the following examples were prepared in a similar manner according to procedure 25 and are shown in table 22 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 25 were used, and these reagents/starting materials are noted in the last column of table 22— "change in procedure 25: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 25 are replaced with different reagents/starting materials described below. RT: LCMS retention time (C-3 column; eluent: water/MeCN 0.1% fa;10% to 100%;2 min gradient.)

/>

Program 26: example 263

2-ethynyl-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole: to 2-formyl-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of tert-butyl pyrrole-4-carboxylate (I-30) (100 mg,0.25 mmol) in MeOH (5 mL) was added 1mL of dimethyl 1-diazo-2-oxopropyl phosphonate (0.226 mL,0.9 mmol) and potassium carbonate (130 mg,0.9 mmol) in MeOH. The reaction mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure and purified by silica gel chromatography (eluent: etOac/hexane) to give the product. ES/MS:321.1 (M+H) ⁺ )。

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (1- (piperidin-4-yl) -1H-1,2, 3-triazol-4-yl) -4H-thieno [3,2-b]Pyrrole (example 263): into ACN (1 mL) 2-ethynyl-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole (50 mg,0.15 mmol), cuprous iodide (3 mg,0.03 mmol) and triethylamine (0.42 mL,0.3 mmol) was added tert-butyl 4-azidopiperidine-1-carboxylate (68 mg,0.3 mmol) in 1mL MeOH. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and acetonitrile (1 mL) and TFA (0.25 mL) were added. After 30 min, the mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 263.ES/MS:447.2 (M+H) ⁺ ) The method comprises the steps of carrying out a first treatment on the surface of the RT: LCMS retention time (C-3 column; eluent: water/MeCN 0.1% fa;10% to 100%;2 min gradient.): 0.757.

program 27: example 264

2- (4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -1H-1,2, 3-triazol-1-yl-piperidin-1-yl) ethan-1-ol (example 264): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- (1- (piperidin-4-yl) -1H-1,2, 3-triazol-4-yl) -4H-thieno [3,2-b]To a solution of pyrrole (example 263) (25 mg,0.06 mmol) in DCE (1 mL) was added 2- [ tert-butyl- (dimethyl) silyl]Oxyacetaldehyde (0.021 mL,0.10 mmol), sodium triacetoxyborohydride (20 mg,0.1 mmol) and acetic acid (0.01 mL), and the reaction mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure, and acetonitrile (0.5 mL) was added, followed by 0.2mL of tfa, and after 2 hours, water (0.5 mL) was added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 264.ES/MS:491.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.75-8.63 (m, 1H), 8.45 (s, 1H), 8.36 (d, j=28.8 hz, 0H), 7.79-7.61 (m, 1H), 7.39 (s, 1H), 3.95 (t, j=5.2 hz, 2H), 3.38 (s, 3H), 3.28 (s, 3H), 2.70 (s, 3H), 2.57 (s, 8H), 1.43 (d, j=6.8 hz, 6H).

Program 28: example 265

6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -2- ((4-methylpiperazin-1-yl) methyl) -4H-thieno [3,2-b]Pyrrole (example 265): to 2-formyl-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-4-carboxylic acid tert-butyl ester (I-30) (15 mg,0.035 mmol) in DCE (1 mL) was added 1-methylpiperazine hydrochloride (9 mg,0.10 mmol), sodium triacetoxyborohydride (37 mg,0.17 mmol) and acetic acid (0.01 mL), and the reaction mixture was stirred overnight. The reaction mixture was concentrated, dissolved in 1mL of methanol, and stirred with 25mg of potassium carbonate for 1 hour. The reaction system was filtered, concentrated under reduced pressure, and acetonitrile (0) was added.5 mL) and then 0.2mL TFA was added followed by water (0.5 mL). The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 265.ES/MS:409.3 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) δ8.66 (dd, j=1.7, 0.8hz, 1H), 8.48 (s, 1H), 7.66 (t, j=1.4 hz, 1H), 7.01 (s, 1H), 4.04 (s, 2H), 3.45 (d, j=68.6 hz, 4H), 3.26 (H, j=6.8 hz, 1H), 2.91 (s, 7H), 2.70 (t, j=0.9 hz, 3H), 1.38 (d, j=6.8 hz, 6H).

The following examples were prepared in a similar manner according to procedure 28 and are shown in table 23 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 28 were used, and these reagents/starting materials are noted in the last column of table 23— "change in procedure 28: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 28 are replaced with different reagents/starting materials described below.

Program 29: example 269：

6-isopropyl-N-methyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -N- [1- (3, 3-trifluoropropyl) -4-piperidinyl]-4H-thieno [3,2-b ]]Pyrrole-2-carboxamide (example 269): to 6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carboxylic acid (I-3) (40 mg,0.118 mmol) in DCM (1 mL) was added tert-butyl 4- (methylamino) piperidine-1-carboxylate (37.7 mg,0.176 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethylurea Hexafluorophosphate (HATU) (53.6 mg,0.141 mmol) and N, N-diisopropylethylamine (0.0409 mL,0.235 mmol) and the reaction mixture stirred at 50℃ 30 minutes. TFA (0.3 mL) was added and the reaction mixture was kept at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure. To the crude residue dissolved in EtOH (2 mL) was added a solution of 3, 3-trifluoropropyl 4-methylbenzenesulfonate in EtOH (0.5 mL of 1M solution) and the resulting reaction mixture was stirred at reflux overnight. TFA (0.5 mL) was added and the reaction mixture was concentrated under reduced pressure. Acetonitrile (2 mL) and water (0.4 mL) were added. The mixture was filtered through acrodisc and purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give product example 269.ES/MS:533.2 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ11.16(s，1H)，8.72(s，1H)，8.48(s，1H)，7.66(t，J＝1.4Hz，1H)，7.47(s，1H)，4.62(td，J＝11.9，6.0Hz，1H)，3.77(d，J＝12.3Hz，2H)，3.49(t，J＝8.1Hz，2H)，3.36-3.09(m，6H)，2.95-2.80(m，2H)，2.71(s，3H)，2.27(q，J＝12.8，12.4Hz，2H)，2.15(d，J＝13.8Hz，2H)，1.40(d，J＝6.8Hz，6H)。

Program 30: example 270：

1- ((6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) methyl) -4-methylpiperidin-4-ol (example 270): 2-formyl-6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester (I-30) (24.3 mg,0.057 mmol) and K ₂ CO ₃ A mixture of (10 mg,0.07 mmol) in DCM (1 mL) was stirred at room temperature for 2 h. The solution was concentrated under reduced pressure. To the residual Boc-deprotected product in DCE (1 mL) was added 4-methylpiperidin-4-ol (19.8 mg,0.172 mmol) and acetic acid (1 drop), and the resulting reaction mixture was stirred at room temperature for 1 hour. After adding Na (OAc) ₃ After BH (36.4 mg,0.172 mmol), the reaction mixture was then stirred at room temperature overnight. After the reaction was complete, TFA (0.5 mL) was added and the resulting reaction mixture was concentrated under reduced pressure. The crude residue was dissolved in acetonitrile: in a water mixture (2 mL) byacrodisc was filtered and then purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to afford product example 270.ES/MS:446.2 (M+Na) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ11.16(s，1H)，8.69(s，1H)，8.47(s，1H)，7.65(t，J＝1.4Hz，1H)，7.30(s，1H)，4.61(s，2H)，3.61-3.15(m，5H)，2.70(s，3H)，1.86(dd，J＝8.5，3.4Hz，4H)，1.40(d，J＝6.8Hz，6H)，1.31(s，3H)。

The following examples were prepared in a similar manner according to procedure 30 and are shown in table 24 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 30 were used, and these reagents/starting materials are noted in the last column of table 24- "procedure 30 change: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 30 are replaced with different reagents/starting materials described below.

Table 24.

Program 31: example 272：

2- (3-fluoro-4- (4-methylpiperazin-1-yl) phenyl) -6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (example 272): addition of 2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4) to the vial ]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (I-20) (30 mg,0.080 mmol), 1- [ 2-fluoro-4- (4, 5-tetramethyl-1, 3, 2-dioxapenta-borane-2-yl) phenyl]-4-methyl-piperazine (33.3 mg,0.10 mmol), pd (amphos) ₂ Cl ₂ (5.66mg，0.008mmol)、1M KOAc/1.5M Na ₂ CO ₃ (0.2 mL) and a 10:1 mixture of acetonitrile: water (1.6 mL). The solution was bubbled with argon for 5 minutesDeaeration and then heating in a sealed tube in a microwave oven at 140 ℃ for 30 minutes. The reaction mixture was cooled, taken up in Na ₂ SO ₄ The bed (eluent: etOAc and DCM) was filtered and concentrated. The resulting residue was dissolved in acetonitrile: water: TFA mixture (2 mL), filtered through acrodisc, and purified by RP-HPLC (eluent: water/MeCN 0.1% TFA) to afford product example 272.ES/MS:489.3 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.65(s，1H)，8.45(d，J＝0.9Hz，1H)，7.65(d，J＝1.6Hz，1H)，7.49-7.35(m，2H)，7.27(s，1H)，7.09(t，J＝8.8Hz，1H)，3.64(d，J＝12.1Hz，4H)，3.43-3.34(m，1H)，3.26(q，J＝6.8Hz，1H)，3.16(t，J＝12.2Hz，2H)，3.03(d，J＝1.3Hz，1H)，3.00(s，3H)，2.78-2.64(s，3H)，1.41(d，J＝6.8Hz，6H)。

Program 32: examples 273 and 274：

5- (7, 8-dimethyl- [1,2,4] triazolo [1,5-a ] pyridin-6-yl) -6-isopropyl-N-methyl-N- ((3 s,5 r) -5- (trifluoromethyl) piperidin-3-yl) -4H-thieno [3,2-b ] pyrrole-2-carboxamide (example 273) and 5- (7, 8-dimethyl- [1,2,4] triazolo [1,5-a ] pyridin-6-yl) -N- ((3 s,5 r) -1-ethyl-5- (trifluoromethyl) piperidin-3-yl) -6-isopropyl-N-methyl-4H-thieno [3,2-b ] pyrrole-2-carboxamide (example 274): to a solution of 5- (7, 8-dimethyl- [1,2,4] triazolo [1,5-a ] pyridin-6-yl) -6-isopropyl-4H-thieno [3,2-b ] pyrrole-2-carboxylic acid (I-17) (25 mg,0.147 mmol) in DCM (1 mL) was added benzyl (3 s,5 r) -3- (methylamino) -5- (trifluoromethyl) piperidine-1-carboxylate; hydrochloride (I-29) (37.3 mg,0.106 mmol), 2- (7-aza-1H-benzotriazol-1-yl) -1, 3-tetramethyluronium Hexafluorophosphate (HATU) (32.2 mg,0.085 mmol) and N, N-diisopropylethylamine (0.049 ml,0.28 mmol) and the reaction mixture was stirred overnight. The mixture was then purified directly by silica gel chromatography (eluent: etOAc/hexane) to give the product. The product was dissolved in ethanol (5 mL) and degassed with argon for 30 seconds. Palladium on carbon (10 wt%, 30 mg) was added, and the mixture was degassed with hydrogen for 2 minutes. The mixture was stirred under an atmosphere of hydrogen overnight. The mixture was then degassed with argon and the solids removed by filtration and rinsed with ethanol. The filtrate was concentrated under reduced pressure and the crude residue was purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give the products.

Example 273 es/MS:519.3 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.63(s，1H)，8.42(s，1H)，7.53(s，1H)，4.81-4.67(m，1H)，3.63(d，J＝12.3Hz，1H)，3.58-3.45(m，1H)，3.32(s，3H)，3.19-3.06(m，2H)，3.05-2.89(m，1H)，2.84(p，J＝6.9Hz，1H)，2.66(s，3H)，2.38-2.07(m，5H)，1.33-1.21(m，6H)。

Example 274 ES/MS:547.3 (M+H) ⁺ )。 ¹ H NMR(400MHz，MeOD)δ8.63(s，1H)，8.43(s，1H)，7.54(s，1H)，4.83-4.73(m，1H)，3.75(dd，J＝34.9，11.9Hz，2H)，3.44-3.36(m，1H)，3.13(d，J＝15.9Hz，1H)，3.01(s，1H)，2.84(p，J＝6.9Hz，1H)，2.66(s，3H)，2.36(d，J＝12.5Hz，1H)，2.29(s，3H)，2.15(q，J＝12.4Hz，1H)，1.44(t，J＝7.3Hz，3H)，1.31(dd，J＝6.9，1.7Hz，6H)。

The following examples were prepared in a similar manner according to procedure 32 and are shown in table 25 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 32 were used, and these reagents/starting materials are noted in the last column of table 25— "change in procedure 32: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 32 are replaced with different reagents/starting materials described below.

Program 33: example 277：

6-isopropyl-5- (8-methyl- [1,2,4] triazolo [1,5-a ] pyridin-6-yl) -4H-thieno [3,2-b ] pyrrole-2-carbonyl chloride: to a solution of 6-isopropyl-5- (8-methyl- [1,2,4] triazolo [1,5-a ] pyridin-6-yl) -4H-thieno [3,2-b ] pyrrole-2-carboxylic acid (I-3) (200 mg,0.59 mmol) in toluene (5 mL) was added thionyl chloride (0.43 mL,5.9 mmol). The mixture was stirred under reflux and nitrogen atmosphere overnight. The reaction mixture was concentrated under reduced pressure and azeotroped once with toluene to give the product, which was used in the next step.

4- (6-isopropyl-5- (8-methyl- [1,2, 4) ]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carbonyl) -3, 6-dihydropyridine-1 (2H) -carboxylic acid tert-butyl ester: addition of 6-isopropyl-5- (8-methyl- [1,2, 4) to the vial]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carbonyl chloride (200 mg,0.56 mmol), 4-tributylstannyl-3, 6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (526 mg,1.1 mmol), trans-dichloro bis (triphenylphosphine) palladium (II) (59 mg,0.084 mmol) and toluene. The mixture was degassed with argon and the reaction mixture was heated to 100 ℃ overnight. The crude mixture was purified by column chromatography (eluent: etOAc/hexane) to give the title compound. ES/MS:506.2 (M+H) ⁺ )。

4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carbonyl) piperidine-1-carboxylic acid tert-butyl ester: 4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole-2-carbonyl) -3, 6-dihydropyridine-1 (2H) -carboxylic acid tert-butyl ester (50 mg,0.099 mmol) was dissolved in ethanol (4 mL) and degassed with argon for 30 seconds. Palladium hydroxide on carbon (20 wt%, 70 mg) was added, and the mixture was degassed with hydrogen for 2 minutes. The mixture was stirred under an atmosphere of hydrogen overnight. The mixture was then degassed with argon and the solids removed by filtration and rinsed with ethanol. The filtrate was concentrated under reduced pressure and the crude residue was continued to be worked up. ES/MS:508.3 (M+H) ⁺ )。

(6-isopropyl-5- (8-methyl- [1,2, 4)]The amino acid is a triazolo [1 ],5-a]pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) (piperidin-4-yl) methanone (example 277): to 4- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole-2-carbonyl) piperidine-1-carboxylic acid tert-butyl ester (10 mg,0.02 mmol) in acetonitrile (1.0 mL) was added TFA (0.2 mL). The reaction mixture was stirred at room temperature for 2 hours and then purified by RP-HPLC (eluent: water/MeCN 0.1% tfa) to give the product. ES/MS:408.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.77 (s, 1H), 8.49 (s, 1H), 7.93 (s, 1H), 7.67 (s, 1H), 3.80-3.63 (m, 1H), 3.59-3.47 (m, 2H), 3.31-3.10 (m, 3H), 2.72 (s, 3H), 2.16 (d, j=13.5 hz, 2H), 2.11-1.95 (m, 2H), 1.41 (d, j=6.8 hz, 6H).

The following examples were prepared in a similar manner according to the reference procedure and are shown in table 26 below. To prepare the following examples, reagents/starting materials different from some of those described in the reference procedure were used, and these reagents/starting materials are noted in the last column of table 26- "change in reference procedure: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of the reference procedure are replaced with different reagents/starting materials described below.

/>

Program 34: example 307：

(1R, 3s, 5S) -3- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -8-azabicyclo [3.2.1]Octane-8-carboxylic acid tert-butyl ester: 2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4) addition to the dry vial]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester (I-60) (120 mg,0.252 mmol), 3-iodo-8-azabicyclo [3.2.1 ]]Tert-butyl octane-8-carboxylate (I-59) (128 mg,0.379 mmol), tetrabutylammonium iodide (TBAI) (24 mg,0.063 mmol), ni (dtbbpy) (H) ₂ O) ₄ Cl ₂ (14 mg,0.03 mmol) and zinc powder (82 mg,1.26 mmol). Dry DMA (1.3 mL) was added and the mixture was degassed with argon for 1 min. The vial was sealed and the reaction was stirred at 70 ℃ for 16 hours. The reaction was then cooled and the crude mixture was purified directly by silica gel chromatography (eluent: etOAc/hexane). The purified material was dissolved in MeOH (1 mL) and potassium carbonate (saturated aqueous solution, 0.25 mL) was added. The mixture is heated to 40 DEG CStir overnight. The mixture was diluted with EtOAc (30 mL) and water (5 mL). The layers were separated and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO ₄ Dried, filtered, and concentrated under reduced pressure to give the title product. ES/MS:506.2 (M+H) ⁺ )。

2- ((1R, 3s, 5S) -8-azabicyclo [ 3.2.1)]Oct-3-yl) -6-isopropyl-5- (8-methyl- [1,2,4]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole (example 307): to (1R, 3s, 5S) -3- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -8-azabicyclo [3.2.1]To a vial of tert-butyl octane-8-carboxylate (55 mg,0.109 mmol) was added 1, 4-dioxane (0.25 mL) and methanol (0.5 mL). HCl (4 m in dioxane, 0.55ml,2.22 mmol) was added and the mixture was stirred at room temperature for 3 hours. The volatiles were evaporated under reduced pressure. To the mixture was added 0.2mL of TFA, acetonitrile (0.5 mL) and water (0.2 mL), and the mixture was filtered through acrodisc before purification by RP-HPLC (0.1% TFA-ACN/0.1% TFA water, column: gemini 5. Mu.M, NX-C18. Ang., 250X 21.2 mm) to give the title compound example 307.ES/MS:406.2 (M+H) ⁺ )。 ¹ H NMR(400MHz,MeOD)δ8.65–8.61(m,1H),8.45(s,1H),7.64(t,J＝1.4Hz,1H),6.88(d,J＝0.9Hz,1H),4.15(s,2H),3.57(dq,J＝11.9,5.7Hz,2H),3.26(p,J＝6.8Hz,2H),2.69(s,3H),2.24–2.08(m,8H),1.38(d,J＝6.8Hz,6H)。

The following examples were prepared in a similar manner according to procedure 34 and are shown in table 27 below. To prepare the following examples, reagents/starting materials different from some of those described in procedure 34 were used, and these reagents/starting materials are noted in the last column of table 27— "change in procedure 34: different reagents/starting materials). One of ordinary skill in the art will readily recognize which reagents/starting materials of procedure 34 are replaced with different reagents/starting materials described below.

Table 27.

Program 35: example 309：

8- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -3-azabicyclo [3.2.1]Octane-3-carboxylic acid tert-butyl ester: 2-bromo-6-isopropyl-5- (8-methyl- [1,2, 4) addition to the dry vial]Triazolo [1,5-a ]]Pyridin-6-yl) thieno [3,2-b]Pyrrole-4-carboxylic acid tert-butyl ester (I-60) (180 mg,0.379 mmol), 8-iodo-3-azabicyclo [3.2.1 ]]Tert-butyl octane-3-carboxylate (I-58) (192 mg, 0.618 mmol), tetrabutylammonium iodide (TBAI) (35 mg,0.095 mmol), ni (dtbbpy) (H) ₂ O) ₄ Cl ₂ (21 mg,0.0454 mmol) and zinc powder (123 mg,1.89 mmol). Dry DMA (1.5 mL) was added and the mixture was degassed with argon for 1 min. The vial was sealed and the reaction was stirred at 70 ℃ for 16 hours. The reaction was then cooled and the crude mixture was purified directly by silica gel chromatography (eluent: etOAc/hexane). The purified material was dissolved in MeOH (1 mL) and potassium carbonate (saturated aqueous solution, 0.25 mL) was added. The mixture was stirred at 40 ℃ overnight. The mixture was diluted with EtOAc (30 mL) and water (5 mL). The layers were separated and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO ₄ Dried, filtered, and concentrated under reduced pressure to give the title product. ES/MS:506.2 (M+H) ⁺ )。

2- (3-azabicyclo [ 3.2.1)]Oct-8-yl) -6-isopropyl-5- (8-methyl- [1,2,4]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrole: to a mixture containing 8- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -3-azabicyclo [3.2.1]To a vial of tert-butyl octane-3-carboxylate (56 mg,0.111 mmol) was added 1, 4-dioxane (0.25 mL) and methanol (0.5 mL). HCl (4 m in dioxane, 0.55ml,2.22 mmol) was added and the mixture was stirred at room temperature for 3 hours. The volatiles were evaporated under reduced pressure. The material was further treated as HCl salt. ES/MS:406.2 (M+H) ⁺ )。

2- (8- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -3-azabicyclo [3.2.1]Oct-3-yl) acetamide (example 309): to 2- (3-azabicyclo [ 3.2.1)]Oct-8-yl) -6-isopropyl-5- (8-methyl- [1,2,4]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]To a solution of pyrrole (HCl salt) (55 mg,0.124 mmol) in 1, 2-dichloroethane (1 mL) was added 2-bromoacetamide (20.6 mg,0.149 mmol) and 1, 8-diazabicyclo [5.4.0]Undec-7-ene (0.075 mL,0.5 mmol). The mixture was stirred at RT overnight. To the mixture was added 0.2mL TFA followed by removal of DCE under reduced pressure. Acetonitrile (0.5 mL) and water (0.2 mL) were added and the mixture was filtered through acrodisc and purified by RP-HPLC (0.1% TFA-ACN/0.1% TFA water, column: gemini 5. Mu.M, NX-C18A, 250X 21.2 mm) to give the title compound example 309.ES/MS:463.2 (M+H) ⁺ )。 ¹ H NMR (400 MHz, methanol-d 4) delta 8.64 (d, j=1.6 hz, 1H), 8.45 (s, 1H), 7.64 (t, j=1.4 hz, 1H), 6.86 (d, j=1.4 hz, 1H), 3.96 (s, 2H), 3.74 (dd, j=12.6, 3.2hz, 2H), 3.53 (s, 1H), 3.45 (d, j=12.0 hz, 2H), 3.27 (dt, j=13.6, 6.0hz, 1H), 2.90 (s, 2H), 2.69 (t, j=0.9 hz, 3H), 2.24-2.10 (m, 2H), 1.99-1.87 (m, 2H), 1.38 (d, j=6.9 hz, 6H).

Program 36: examples 310 and 311：

2- (6- (6-isopropyl-5- (8-methyl- [1,2,4] triazolo [1,5-a ] pyridin-6-yl) -4H-thieno [3,2-b ] pyrrol-2-yl) -2-azaspiro [3.4] oct-2-yl) acetamide (examples 310 and 311): 2- (6- (6-isopropyl-5- (8-methyl- [1,2,4] triazolo [1,5-a ] pyridin-6-yl) -4H-thieno [3,2-b ] pyrrol-2-yl) -2-azaspiro [3.4] oct-2-yl) acetamide (example 295) was isolated by chiral SFC (AD-H4.6X100 mm 5mic,35% MeOH-DEA co-solvent) as a mixture of 2 stereoisomers, which were arbitrarily assigned as isomer 1 (example 310) and isomer 2 (example 311).

Isomer 1:2- (6- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno[3,2-b]Pyrrol-2-yl) -2-azaspiro [3.4]Oct-2-yl) acetamide (example 310). ES/MS:463.3[ M+H ] ⁺ ]。 ¹ H NMR(400MHZ,MeOD)δ8.62(s,1H),8.44(s,1H),7.64(s,1H),6.80(d,J＝7.1Hz,1H),4.40–3.93(m,6H),3.55–3.41(m,1H),3.30–3.17(m,1H),2.69(t,J＝0.9Hz,3H),2.40–1.78(m,6H),1.38(d,J＝6.8Hz,6H)。

Isomer 2:2- (6- (6-isopropyl-5- (8-methyl- [1,2, 4)]Triazolo [1,5-a ]]Pyridin-6-yl) -4H-thieno [3,2-b]Pyrrol-2-yl) -2-azaspiro [3.4]Oct-2-yl) acetamide (example 311). ES/MS:463.3[ M+H ] ⁺ ]。 ¹ H NMR(400MHZ,MeOD)δ8.62(s,1H),8.44(s,1H),7.64(s,1H),6.80(d,J＝7.1Hz,1H),4.40–3.93(m,6H),3.55–3.41(m,1H),3.30–3.17(m,1H),2.69(t,J＝0.9Hz,3H),2.40–1.78(m,6H),1.38(d,J＝6.8Hz,6H)。

Biological examples

Example A

Cell-based assays for TLR7/9 human Peripheral Blood Mononuclear Cells (PBMCs)

Human Peripheral Blood Mononuclear Cells (PBMCs) consist of lymphocytes, monocytes and dendritic cells expressing TLR7, TLR8 and TLR 9. These cells respond to TLR7, TLR8 and TLR9 ligand stimulation and produce cytokines and chemokines in vitro and in vivo. Thus, human PBMCs are suitable for use in cell-based assays to assess the in vitro efficacy of TLR7, 8 and/or 9 antagonists. The results are expected to be more convertible into in vivo pharmacodynamic responses than cell line-based assays.

Frozen human PBMCs from healthy donors were thawed and resuspended in RPMI-1640 medium containing L-glutamine (Corning) and supplemented with 10% fetal bovine serum (Hyclone) and 1X penicillin-streptomycin (Corning). After counting, the cell density was adjusted to 2 million cells/ml and 5% CO at 37℃ ₂ Incubate for 1 hour to allow recovery. After recovery, cells were subjected to a 10-point dose response and in quadruplicates by adding 50 μl/well (100,000 cells) to 384-well cell culture plates (Greiner) (100% DMSO solution containing 250nl of test antagonist per well) And (5) paving. PBMCs were tested in the presence of test antagonists at 37 ℃ with 5% co ₂ Incubate for one hour and then stimulate with TLR7 or TLR9 agonists. GS-986 (Gilead Sciences) was used as a TLR7 agonist at a final concentration of 400 nM. ODN-2216 (InvivoGen) was used as a TLR9 agonist at a final concentration of 3. Mu.M. PBMCs were tested for antagonists and TLR7 (or TLR 9) agonists at 37 ℃ with 5% CO ₂ Incubate for another 6 hours. At the end of the incubation, the cell culture plates were centrifuged at 500g for 5 minutes and the cell culture supernatant was collected. The levels of cytokines (IL-6 and IFNα) in the supernatant were measured by electrochemiluminescence immunoassay (Mesoscale Discovery) according to the manufacturer's recommended protocol. The measured cytokine levels were plotted against the test antagonist concentration and fitted to a sigmoid function to determine EC ₅₀ The results are shown in table 11 below.

Cell-based assays for TLR8 human Peripheral Blood Mononuclear Cells (PBMCs)

Frozen human PBMCs from healthy donors were thawed and resuspended in RPMI-1640 medium containing L-glutamine (Corning) and supplemented with 10% fetal bovine serum (Hyclone) and 1X penicillin-streptomycin (Corning). After counting, the cell density was adjusted to 2 million cells/ml and at 37℃5% CO ₂ Incubate for 1 hour to allow recovery. After recovery, cells were plated by adding 50 μl/well (100,000 cells) to 384 well cell culture plates (Greiner) (100% dmso solution containing 250nl of test antagonist per well) in a 10-point dose response and quadruplicate manner. PBMC were exposed to 5% CO at 37deg.C in the presence of an antagonist ² Incubate for one hour and then stimulate with TLR8 agonist. Compound a (Gilead Sciences, U.S. patent No. 10,285,990) was used as a TLR8 agonist at a final concentration of 800 nM. PBMCs were incubated in the presence of antagonists and TLR8 agonists at 37 ℃, 5% CO ₂ Incubate for another 6 hours. At the end of the incubation, the cell culture plates were centrifuged at 500g for 5 minutes and the cell culture supernatant was collected. The levels of cytokines (TNFa and IL12p 40) in the supernatants were measured by electrochemiluminescence immunoassay (Mesoscale Discovery) according to the manufacturer's recommended protocol. The measured cellsFactor levels are plotted against antagonist concentration and fitted to sigmoid function to determine EC ₅₀ The results are shown in table 11 below. Compound a has the following structure:

TABLE 11.

/>

All references, including publications, patents, and patent documents, are incorporated by reference herein as if individually incorporated by reference. The present disclosure provides references to various embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the disclosure. It should be understood that this description is deemed to be an exemplification of the claimed subject matter and is not intended to limit the appended claims to the specific embodiments illustrated.

Claims

1. A compound of the formula I,

or a pharmaceutically acceptable salt thereof,

wherein the method comprises the steps of

wherein each of the 4-to 7-membered monocyclic heterocyclyl, the phenyl, the naphthyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, and the 8-to 10-membered fused bicyclic heteroaryl is independently optionally substituted with 1 to 4R ^a Group substitution;

R ² is H, -CN, C _1-6 Alkyl or C _3-7 Monocyclic cycloalkyl wherein said C _1-6 Alkyl and said C _3-7 Monocyclic cycloalkyl groups are each independently optionally substituted with 1 to 4 groups independently selected from halogen and C _1-6 Substitution of the alkoxy group;

x is N or CR ³ ；

R ³ Is H, halogen, -CN, C _1-6 Alkyl, C _3-6 Monocyclic cycloalkyl or-O (C) _1-4 Alkyl), wherein said C _1-4 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ⁴ R ⁴ And C _1-4 Substitution of the alkoxy group;

Wherein said C _1-10 Alkyl and said C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 4R ^b Group substitution;

wherein said C _3-7 Monocyclic cycloalkyl, the C _7-10 Fused bicyclic cycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, the 4-to 7-membered monocyclic heterocyclyl, the phenyl, the naphthyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiroheterocyclyl are each independently optionally substituted with 1 to 2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a Group substitution;

R ⁶ Is C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclylPhenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spiroheterocyclyl,

wherein said C _1-6 Alkyl is optionally substituted with 1 to 4R ^b The substitution of the groups is carried out,

wherein said C _3--7 Monocyclic cycloalkyl, the C _7-10 Fused bicyclic cycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, the 4-to 7-membered monocyclic heterocyclyl, the phenyl, the naphthyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiroheterocyclyl are each independently optionally substituted with 1 to 4R' s ^a Group substitution;

wherein said C _3-7 Monocyclic cycloalkyl, the C _7-10 Fused bicyclic cycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, the 4-to 7-membered monocyclic heterocyclyl, the phenyl, the naphthyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiroheterocyclyl are each independently optionally substituted with 1 to 4R' s ^a Group substitution;

each R ⁴ Independently H or C _1-3 An alkyl group;

R ⁷ is H, C _1-6 Alkyl, C _3-7 A monocyclic cycloalkyl group or a 4-to 6-membered monocyclic heterocyclic group, wherein the C _1-6 Alkyl, the C _3-7 Monocyclic cycloalkyl and said 4-to 6-membered monocyclic heterocyclyl are each independently optionally substituted with 1 to 4 groups independently selected from-OH, halogen, -CN and C _1-6 Substitution of the alkoxy group;

R ⁹ is C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 1-membered monocyclic heteroaryl0-membered fused bicyclic heterocyclic group, 6-to 10-membered bridged bicyclic heterocyclic group, 8-to 10-membered fused bicyclic heteroaryl group or 7-to 10-membered spiro heterocyclic group,

wherein said C _2-6 Alkenyl and said C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 4R ^b The substitution of the groups is carried out,

wherein said C _3-7 Monocyclic cycloalkyl, the C _7-10 Fused bicyclic cycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, the phenyl, the naphthyl, the 4-to 7-membered monocyclic heterocyclyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiroheterocyclyl are each independently optionally substituted with 1 to 4R ^a Group substitution;

wherein said C _1-6 Alkyl, the C _2-6 Alkenyl and said C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 4R ^b The substitution of the groups is carried out,

Wherein said C _1-6 Alkyl, the C _2-6 Alkenyl and said C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 3R ^c The substitution of the groups is carried out,

wherein said C _3-7 Monocyclic cycloalkyl, the C _7-10 Fused bicyclic cycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, the phenyl, the naphthyl, the 4-to 7-membered monocyclic heterocyclyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 3R ^d The substitution of the groups is carried out,

Wherein said C _3-7 Monocyclic cycloalkyl, the C _7-10 Fused bicyclic cycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, the phenyl, the naphthyl, the 4-to 7-membered monocyclic heterocyclyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiroheterocyclyl are each independently optionally substituted with 1 to 3R ^d Group substitution;

Each R ^d Independently oxo, halogen, -CN, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered monocyclic heterocyclylFused bicyclic heteroaryl, 7-to 10-membered spirocyclic heterocyclyl, -OR ¹² 、-C(O)R ¹² 、-C(O)OR ¹² 、-C(O)N(R ¹² )(R ¹² )、-NR ¹² R ¹² 、-N(R ¹² ) ₂ (R ¹² ) ⁺ 、-N(R ¹² )C(O)R ¹² 、-N(R ¹² )C(O)OR ¹² 、-N(R ¹² )C(O)N(R ¹² )(R ¹² )、-N(R ¹² )S(O) ₂ (R ^12a )、-NR ¹² S(O) ₂ N(R ¹² )(R ¹² )、-NR ¹² S(O) ₂ O(R ^12a )、-OC(O)R ¹² 、-OC(O)OR ¹² 、-OC(O)N(R ¹² )(R ¹² )、-SR ¹² 、-S(O)R ^12a 、-S(O)(NH)R ¹² 、-S(O) ₂ R ^12a 、-S(O) ₂ N(R ¹² )(R ¹² ) Or-n=s (R ^12a )(R ^12a )＝O；

wherein said C _1-6 Alkyl, the C _2-6 Alkenyl, the C _2-6 Alkynyl, the C _3-7 Monocyclic cycloalkyl, the C _7-10 Fused bicyclic cycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, the phenyl, the naphthyl, the 4-to 7-membered monocyclic heterocyclyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiroheterocyclyl are each independently optionally substituted with 1 to 3R ^c Group substitution;

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

x is N or CR ³ ；

Z is C _1-10 Alkyl, C _2-6 Alkynyl, -NR ⁶ R ⁷ 、-C(O)R ¹³ 、-C(O)NR ⁶ R ⁷ 、-S(O) ₂ R ⁶ 、C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkanesA group, 4 to 7 membered monocyclic heterocyclyl, phenyl, naphthyl, 5 to 6 membered monocyclic heteroaryl, 8 to 10 membered fused bicyclic heterocyclyl, 6 to 10 membered bridged bicyclic heterocyclyl, 8 to 10 membered fused bicyclic heteroaryl, 7 to 10 membered spiroheterocyclyl or L ¹ ，

Wherein said C _1-10 Alkyl and said C _2-6 Alkynyl groups are each independently optionally substituted with 1 to 4R ^b The substitution of the groups is carried out,

wherein said C _3-7 Monocyclic cycloalkyl, the C _7-10 Fused bicyclic cycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, the phenyl, the naphthyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a The substitution of the groups is carried out,

wherein the 4-to 7-membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with groups and optionally with 1 to 3R ^a Group substitution;

R ⁶ Is C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclic group, 6-to 10-membered bridged bicyclic heterocyclic group, 8-to 10-membered fused bicyclic heteroaryl group or 7-to 10-membered spiro heterocyclic group,

each R ⁴ Independently H or C _1-3 An alkyl group;

each R ⁸ Independent and independentEarth being halogen, -C (O) R ⁹ 、-NR ¹⁰ R ¹⁰ 、C _1-6 Alkyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, phenyl, naphthyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spiroheterocyclyl, -OR ⁵ 、-C(O)OR ⁵ 、-C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ ) ₂ (R ⁵ ) ⁺ 、-N(R ⁵ )C(O)R ⁵ 、-N(R ⁵ )C(O)OR ⁵ 、-N(R ⁵ )C(O)N(R ⁵ )(R ⁵ )、-N(R ⁵ )S(O) ₂ (R ^5a )、-NR ⁵ S(O) ₂ N(R ⁵ )(R ⁵ )、-NR ⁵ S(O) ₂ O(R ^5a )、-OC(O)R ⁵ 、-OC(O)OR ⁵ 、-OC(O)N(R ⁵ )(R ⁵ )、-SR ⁵ 、-S(O)R ^5a 、-S(O)(NH)R ⁵ 、-S(O) ₂ R ^5a 、-S(O) ₂ N(R ⁵ )(R ⁵ ) Or-n=s (R ^5a )(R ^5a )＝O，

R ⁹ is C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl8-to 10-membered fused bicyclic heteroaryl or 7-to 10-membered spirocyclic heterocyclyl,

each R ^b Independently oxo, imino, halogen, -NO ₂ 、-N ₃ 、-CN、C _3--7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridged bicyclic cycloalkyl, phenyl, naphthyl, 4-to 7-membered monocyclic heterocyclyl, 5-to 6-membered monocyclic heteroaryl, 8-to 10-membered fused bicyclic heterocyclyl, 8-to 10-membered bridged bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, 8-to 10-membered fused bicyclic heteroaryl, 7-to 10-membered spirocyclic heterocyclyl, -OR ¹¹ 、-C(O)R ¹¹ 、-C(O)OR ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-NR ¹¹ R ¹¹ 、-N(R ¹¹ ) ₂ (R ¹¹ ) ⁺ 、-N(R ¹¹ )C(O)R ¹¹ 、-N(R ¹¹ )C(O)OR ¹¹ 、-N(R ¹¹ )C(O)N(R ¹¹ )(R ¹¹ )、-N(R ¹¹ )S(O) ₂ (R ^11a )、-NR ¹¹ S(O) ₂ N(R ¹¹ )(R ¹¹ )、-NR ¹¹ S(O) ₂ O(R ^11a )、-OC(O)R ¹¹ 、-OC(O)OR ¹¹ 、-OC(O)N(R ¹¹ )(R ¹¹ )、-SR ¹¹ 、-S(O)R ^11a 、-S(O)(NH)R ¹¹ 、-S(O) ₂ R ^11a 、-S(O) ₂ N(R ¹¹ )(R ¹¹ ) or-N =S(R ^11a )(R ^11a )＝O，

each R ^11a Independently C _1-6 Alkyl, C _2-6 Alkenyl, C _2-6 Alkynyl, C _3-7 Monocyclic cycloalkyl, C _7-10 Condensed bicyclocycloalkyl, C _5-10 Bridging doubleA cycloalkyl group, a phenyl group, a naphthyl group, a 4-to 7-membered monocyclic heterocyclic group, a 5-to 6-membered monocyclic heteroaryl group, a 8-to 10-membered fused bicyclic heterocyclic group, a 6-to 10-membered bridged bicyclic heterocyclic group, a 8-to 10-membered fused bicyclic heteroaryl group or a 7-to 10-membered spiro heterocyclic group,

3. The compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein

Z is C _7-10 Fused bicyclic cycloalkyl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl or 8-to 10-membered fused bicyclic heteroaryl,

wherein said C _7-10 The fused bicyclic cycloalkyl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 8-to 10-membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a And (3) group substitution.

4. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein

wherein each of the 4-to 7-membered monocyclic heterocyclyl, the 5-to 6-membered monocyclic heteroaryl, and the 8-to 10-membered fused bicyclic heteroaryl is independently optionally substituted with 1 to 3R ^a Group substitution;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

wherein said C _1-10 Alkyl is optionally substituted with 1 to 3R ^b The substitution of the groups is carried out,

wherein said C _3-7 Monocyclic cycloalkyl, the phenyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a The substitution of the groups is carried out,

wherein said C _1-6 Alkyl is optionally substituted with 1 to 3R ^b The substitution of the groups is carried out,

wherein said C _3-7 Monocyclic cycloalkyl, the 4-to 7-membered monocyclic heterocyclyl and the 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3R ^a Group substitution;

wherein each of the 4-to 7-membered monocyclic heterocyclic group, the 8-to 10-membered fused bicyclic heterocyclic group, the 6-to 10-membered bridged bicyclic heterocyclic group, and the 7-to 10-membered spiro heterocyclic group is independently optionally substituted with 1 to 3R ^a Group substitution;

R ⁷ is H, C _1-3 Alkyl or C _3-7 A monocyclic cycloalkyl group,

wherein said C _1-3 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN and C _1-3 Alkoxy groupIs substituted by a group of (2);

wherein said C _3-7 Monocyclic cycloalkyl, the 4-to 7-membered monocyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 3R ^a Group substitution;

wherein each of the 4-to 7-membered monocyclic heterocyclyl and the 6-to 10-membered bridged bicyclic heterocyclyl is independently optionally substituted with 1 to 3R ^a Group substitution;

R ^5a is a 4 to 7 membered monocyclic heterocyclyl, wherein the 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a Group substitution;

5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein

wherein each of the 4-to 7-membered monocyclic heterocyclyl, the 5-to 6-membered monocyclic heteroaryl, and the 8-to 10-membered fused bicyclic heteroaryl are independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, and CN;

R ² is C _1-6 Alkyl, wherein the C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-3 Substitution of the alkoxy group;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

Wherein said C _1-10 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-4 The group of the alkoxy group is substituted,

wherein said C _3-7 Monocyclic cycloalkyl, the phenyl, the 5-to 6-membered monocyclic heteroaryl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, the 8-to 10-membered fused bicyclic heteroaryl, and the 7-to 10-membered spiroThe cyclic heterocyclic groups are each independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein the 4-to 7-membered monocyclic heterocyclyl is substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

wherein said C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and R ^e Is substituted by a group of (a) or (b),

wherein said C _3-7 Monocyclic cycloalkyl, the 4-to 7-membered monocyclic heterocyclyl and the 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -C (O) R ¹¹ 、-NR ¹¹ R ¹¹ 、C _1-4 Alkoxy, C _1-5 Alkyl and R ^f Is substituted by a group of (a) or (b),

wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹² R ¹² and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (a) or (b),

wherein each R is ^f Independently C _3-7 A monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl or 7-to 10-membered spiro heterocyclyl, wherein said C _3-7 Monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen;

wherein each of the 4-to 7-membered monocyclic heterocyclyl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 7-to 10-membered spiro heterocyclyl is independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ Phenyl, C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹² R ¹² 、-C(O)N(R ¹² )(R ¹² ) And R is ^g Is substituted by a group of (a) or (b),

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl;

R ⁷ is H, C _1-3 Alkyl or C _3-7 A monocyclic cycloalkyl group,

wherein said C _1-3 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen and C _1-3 Substitution of the alkoxy group;

Wherein said C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-S(O) ₂ R ^11a 、C _1-4 Alkoxy and R ^h Is substituted by a group of (a) or (b),

wherein said C _3-7 Monocyclic cycloalkyl, the 4-to 7-membered monocyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, oxo, and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (a) or (b),

wherein said C _1-4 Alkoxy groups optionally substituted with 1 to 3 halo groups,

Wherein the 4-to 7-membered monocyclic heterocyclyl and the 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, and-CN;

each R ¹⁰ Independently is H, a 4-to 7-membered monocyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, wherein the 4-to 7-membered monocyclic heterocyclyl and 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Alkyl substitution;

R ^5a is a 4 to 7 membered monocyclic heterocyclyl;

each R ^11a Independently H or C _1-4 An alkyl group;

each R ¹² Independently H or C _1-4 An alkyl group;

6. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein

R ² is C _1-6 An alkyl group, a hydroxyl group,

wherein said C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-6 Substitution of the alkoxy group;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

wherein each of the 5-to 6-membered monocyclic heteroaryl and the 7-to 10-membered spirocyclic heterocyclyl is independently optionally substituted with 1 to 2R ⁸ Substituted with groups and each independently optionally substituted with 1 to 3R ^a Group substitution;

R ⁶ is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

wherein the 4-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3R ^a Group substitution;

R ⁷ is H or C _1-3 An alkyl group;

each R ⁸ Independently a 4 to 7 membered monocyclic heterocyclyl,

7. A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein

wherein each of the 4-to 7-membered monocyclic heterocyclyl, the 5-to 6-membered monocyclic heteroaryl, and the 8-to 10-membered fused bicyclic heteroaryl are independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

x is CR ³ ；

R ³ Is H, halogen or C _1-4 An alkyl group;

wherein each of the 5-to 6-membered monocyclic heteroaryl and the 7-to 10-membered spirocyclic heterocyclyl is independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

R ⁶ is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

wherein said C _1-6 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ And C _1-4 The group of the alkoxy group is substituted,

Wherein the 4-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

wherein each of the 4-to 7-membered monocyclic heterocyclyl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 7-to 10-membered spiro heterocyclyl is independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein said C _1-5 Alkyl radicalOptionally from 1 to 3 independently selected from-OH, halogen, -CN, oxo and-NR ¹² R ¹² Is substituted by a group of (2);

R ⁷ is H or C _1-3 An alkyl group;

each R ⁸ Independently 4 to 7 membered monocyclic heterocyclyl, wherein said 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substitution of the alkyl group;

each R ¹¹ Independently H or C _1-4 An alkyl group;

each R ¹² Independently H or C _1-4 An alkyl group;

8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R ¹ Is a 6-membered monocyclic heterocyclyl, a 6-membered monocyclic heteroaryl, or an 8-to 10-membered fused bicyclic heteroaryl, wherein each of said 6-membered monocyclic heterocyclyl, said 6-membered monocyclic heteroaryl, and said 8-to 10-membered fused bicyclic heteroaryl is independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R ¹ Is a pyridyl group,

Each of them is independently optionally selected from-OH, halogen, -CN, oxo, -NR, independently from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of an alkyl radical, wherein said C _1-5 The alkyl group is optionally substituted with 1 to 3 halogen groups.

10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R ¹ Is independently selected from oxo, C1 to 3 _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R ¹ Substituted with 1 to 3 groups independently selected from oxo, methoxy and methyl.

12. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R ¹ Is pyridyl or

13. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R ¹ Is that

14. The compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R ¹ Is that

15. The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R ² Is C _1-4 Alkyl, wherein the C _1-4 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and C _1-3 The groups of the alkoxy groups are substituted.

16. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R ² Is C _1-3 An alkyl group.

17. The compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R ² Is ethyl or isopropyl.

18. The compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein R ² Is isopropyl and R ¹ Is that

19. The compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein X is N or CH.

20. The compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein X is CH.

21. The compound of any one of claim 1 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is a 5 to 6 membered monocyclic heteroaryl or a 7 to 10 membered spirocyclic heterocyclyl,

wherein each of the 5-to 6-membered monocyclic heteroaryl and the 7-to 10-membered spirocyclic heterocyclyl is independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

22. The compound of any one of claim 1 to 21, or a pharmaceutically acceptable salt thereof, wherein Z is a 5 to 6 membered monocyclic heteroaryl or a 7 to 10 membered spirocyclic heterocyclyl,

Wherein each of the 5-to 6-membered monocyclic heteroaryl and the 7-to 10-membered spirocyclic heterocyclyl is independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

wherein the 5-to 6-membered monocyclic heteroaryl and the 7-to 10-membered spiro heterocyclyl each independently have one or two ring heteroatoms which are N.

23. The compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein Z is 5 to 6 membered monocyclic heteroaryl, wherein the 5 to 6 membered monocyclic heteroaryl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

24. The compound of any one of claim 1 to 23, or a pharmaceutically acceptable salt thereof, wherein Z is a 5 to 6 membered monocyclic heteroaryl,

wherein the 5-to 6-membered monocyclic heteroaryl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

25. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein Z is pyridinyl or

26. The compound according to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein Z is oxadiazolyl or thiadiazolyl, each of which is independently optionally substituted with one R ⁸ And (3) group substitution.

27. The compound of any one of claims 1 to 24 and 26, or a pharmaceutically acceptable salt thereof, wherein Z is

28. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein Z is

29. The compound of any one of claim 1 to 22, or a pharmaceutically acceptable salt thereof, wherein Z is a 7-to 10-membered spirocyclic heterocyclyl,

30. The compound of any one of claims 1 to 22 and 29, or a pharmaceutically acceptable salt thereof, wherein Z is

31. According to claim 1 to 3The compound of any one of claims, or a pharmaceutically acceptable salt thereof, wherein Z is C _7-10 Fused bicyclic cycloalkyl, 8-to 10-membered fused bicyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl or 8-to 10-membered fused bicyclic heteroaryl,

wherein said C _7-10 The fused bicyclic cycloalkyl, the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 8-to 10-membered fused bicyclic heteroaryl are each independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

32. The compound of any one of claims 1 to 5, 8 to 20 and 31, or a pharmaceutically acceptable salt thereof, wherein Z is 8 to 10 membered fused bicyclic heterocyclyl, 6 to 10 membered bridged bicyclic heterocyclyl or 8 to 10 membered fused bicyclic heteroaryl,

wherein each of the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 8-to 10-membered fused bicyclic heteroaryl is independently optionally substituted with 1 to 2R ⁸ Groups are substituted and each independently is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The alkyl group, and wherein the 8-to 10-membered fused bicyclic heterocyclyl, the 6-to 10-membered bridged bicyclic heterocyclyl, and the 8-to 10-membered fused bicyclic heteroaryl each independently have one or two ring heteroatoms that are N.

33. The compound according to any one of claims 1 to 5, 8 to 20 and 31 to 32, or a pharmaceutically acceptable salt thereof, wherein Z is

Each of them is independently optionally substituted with one R ⁸ Radicals (C)Substituted and independently optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

34. The compound of any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is phenyl, wherein the phenyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

35. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is azepanyl, wherein the azepanyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

36. The compound according to any one of claims 1 to 5, 8 to 20 and 35, or a pharmaceutically acceptable salt thereof, wherein Z is azepanyl.

37. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein is substituted with 1 to 2R ⁸ Z substituted by radicals is

38. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein is substituted with 1 to 2R ⁸ Z substituted by radicals is

39. The compound according to any one of claims 1 to 5, 8 to 20 and 38, or a pharmaceutically acceptable salt thereof, wherein is substituted with 1 to 2R ⁸ Z substituted by radicals is

40. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is cyclopropyl, wherein the cyclopropyl is optionally substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

41. The compound according to any one of claims 1 to 5, 8 to 20 and 39, or a pharmaceutically acceptable salt thereof, wherein Z is cyclopropyl, wherein said cyclopropyl is substituted with one R ⁸ And (3) group substitution.

42. A compound according to any one of claims 1 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is a 4 to 7 membered monocyclic heterocyclyl.

43. The compound according to any one of claims 1 to 6 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 4-to 7-membered monocyclic heterocyclic group substituted with a group of an alkyl group,

wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, oxo, and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (C) and

wherein said C _1-4 The alkoxy groups are optionally substituted with 1 to 3 halogen groups.

44. The compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is a 6-membered monocyclic heterocyclic group.

45. The compound according to any one of claims 1 to 42 and 44, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is piperidinyl or piperazinyl.

46. The compound of any one of claims 1 to 42 and 44 to 45, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is that

47. The compound according to any one of claims 1 to 6, 8 to 41 and 43, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is piperidinyl or piperazinyl, each of which is independently selected from-OH, halogen, C, independently from 1 to 3 _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein said C _1-5 The alkyl group is optionally substituted with one member selected from the group consisting of-OH and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (C) and

48. A compound according to any one of claims 1 to 6, 8 to 41, 43 and 47Or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is piperidinyl or piperazinyl, each of which is independently selected from-OH, fluoro, -OCF, by 1 to 3 ₃ 、-CH ₂ CH ₂ OH and-CH ₂ C(O)NH ₂ Is substituted with a group of (a).

49. The compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is pyrrolidinyl.

50. The compound according to any one of claims 1 to 6, 8 to 41 and 43, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is independently selected from-OH, halogen, C by 1 to 3 _1-4 Alkoxy and C _1-5 Pyrrolidinyl substituted with a group of an alkyl group,

51. The compound according to any one of claims 1 to 6, 8 to 41, 43 and 50, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is independently selected from the group consisting of-OH, halogen and C by 1 to 3 _l-3 Pyrrolidinyl substituted with a group of an alkoxy group, and wherein the C _l-3 The alkoxy groups are optionally substituted with 1 to 3 fluoro groups.

52. The compound according to any one of claims 1 to 6, 8 to 41, 43 and 50 to 51, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is independently selected from-OH, fluorine, -OCF by 1 to 3 ₃ 、-CH ₂ CH ₂ OH and-CH ₂ C(O)NH ₂ Pyrrolidinyl substituted with a group of (a).

53. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is quilt1 to 3 are independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 C substituted by groups of alkyl groups _3-7 A monocyclic cycloalkyl group,

54. The compound according to any one of claims 1 to 5, 8 to 38 and 53, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is quilt-NR ¹¹ R ¹¹ Substituted cyclohexyl wherein R ¹¹ Is H or C _1-4 An alkyl group.

55. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is optionally selected from-OH, halogen, -CN, oxo, -NR, optionally from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 6-to 10-membered bridged bicyclic heterocyclic group substituted with a group of an alkyl group,

56. The compound according to any one of claims 1 to 5, 8 to 41 and 55, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is optionally C _1-5 Alkyl substituted 6-to 10-membered bridged bicyclic heterocyclyl wherein the C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, oxo, and-C (O) N (R) ¹² )(R ¹² ) Wherein R is a group substituted with ¹² Is H or C _1-4 An alkyl group.

57. The compound according to any one of claims 1 to 5, 8 to 41 and 55 to 56, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is that

Which is optionally covered by-CH ₂ C(O)NH ₂ And (3) substitution.

58. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is optionally selected from-OH, halogen, -CN, oxo, -NR, optionally from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 7-to 10-membered spirocyclic heterocyclic group substituted with a group of an alkyl group,

59. The compound according to any one of claims 1 to 5, 8 to 41 and 58, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is a 7-to 10-membered spirocyclic heterocyclyl optionally substituted with one or two oxo groups.

60. The compound according to any one of claims 1 to 5, 8 to 41 and 58, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is that

61. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、-C(O)N(R ¹¹ )(R ¹¹ )、-S(O) ₂ R ^11a And C _1-4 C substituted by groups of alkoxy groups _1-6 An alkyl group.

62. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is C _1-6 Alkyl, wherein the C _1-6 Alkyl:

i) Is substituted with one oxo group and is substituted with one oxo group,

63. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is C _1-6 Alkyl, wherein the C _1-6 The alkyl group is substituted with an oxetanyl group.

64. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is C _1-6 Alkyl, wherein the C _1-6 Alkyl is substituted by-C (O) N (R) ¹¹ )(R ¹¹ ) And (3) substitution.

65. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is that

66. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ Is that

67. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ is-C (O) R ⁹ 。

68. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁹ Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group has one ring heteroatom which is N.

69. The compound according to any one of claims 1 to 5, 8 to 38 and 67, or a pharmaceutically acceptable salt thereof, wherein R ⁹ Is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 4-to 7-membered monocyclic heterocyclic group substituted with a group of an alkyl group.

70. The compound according to any one of claims 1 to 5, 8 to 38, 67 and 69, or a pharmaceutically acceptable salt thereof, wherein R ⁹ Is azetidinyl, pyrrolidinyl or piperidinyl, each of which is C _1-3 Alkyl substitution.

71. The compound according to any one of claims 1 to 5, 8 to 41 and 67, or a pharmaceutically acceptable salt thereof, wherein R ⁹ Is morpholinyl or piperazinyl, each of which is optionally substituted C (C) _1-3 Alkyl substitution wherein said C _1-3 The alkyl group is optionally substituted with one group independently selected from-OH, halogen, and-CN.

72. The compound according to any one of claims 1 to 5, 8 to 41 and 67, or a pharmaceutically acceptable salt thereof, wherein R ⁹ Is optionally selected from-OH, halogen, -CN, oxo, -NR, optionally from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted with a 6-to 10-membered bridged bicyclic heterocyclic group.

73. The compound of any one of claims 1 to 5, 8 to 41 and 72, or a pharmaceutically acceptable salt thereof, wherein R ⁹ Is that

74. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ is-NR ¹⁰ R ¹⁰ 。

75. The compound according to any one of claims 1 to 5, 8 to 41 and 74, or a pharmaceutically acceptable salt thereof, wherein one R ¹⁰ Is optionally selected from-OH, halogen, -CN, oxo, -NR, optionally from 1 to 3 ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 A 4 to 7 membered monocyclic heterocyclyl or a 6 to 10 membered bridged bicyclic heterocyclyl substituted with a group of an alkyl group.

76. The compound according to any one of claims 1 to 5, 8 to 41 and 74 to 75, or a pharmaceutically acceptable salt thereof, One of R ¹⁰ Is a 4-to 7-membered monocyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group.

77. The compound according to any one of claims 1 to 5, 8 to 41 and 74 to 76, or a pharmaceutically acceptable salt thereof, wherein one R ¹⁰ Is oxetanyl or

78. The compound according to any one of claims 1 to 5 and 8 to 41, or a pharmaceutically acceptable salt thereof, wherein R ⁸ is-S (O) ₂ R ^5a 。

79. The compound of any one of claims 1 to 5, 8 to 41 and 78, or a pharmaceutically acceptable salt thereof, wherein R ^5a Is a 4-to 7-membered monocyclic heterocyclic group, wherein the 4-to 7-membered monocyclic heterocyclic group has one or two ring heteroatoms which are N.

80. The compound according to any one of claims 1 to 5, 8 to 41 and 79, or a pharmaceutically acceptable salt thereof, wherein R ^5a Is piperidinyl.

81. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ A cyclohexyl group substituted with a group such as a hydroxyl group,

wherein R is ⁸ is-NR ¹⁰ R ¹⁰ Or a 5 to 7 membered monocyclic heterocyclyl, wherein the 5 to 7 membered monocyclic heterocyclyl is selected from the group consisting of-OH, halogen, -CN, -NR, by 1 to 3 groups independently ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein said C _1-4 Alkoxy groups are optionally substituted with 1 to 3 halogen groups, and

82. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is pyrrolidinyl.

83. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ is-C (O) R ⁹ And R is ⁹ Is azetidinyl, pyrrolidinyl, or piperidinyl, wherein each of said azetidinyl, said pyrrolidinyl, and said piperidinyl is optionally substituted with one methyl group.

84. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ is-C (O) R ⁹ And R is ⁹ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The groups of the alkyl groups are substituted.

85. The compound of any one of claims 1 to 5, 8 to 20 and 84, or a pharmaceutically acceptable salt thereof, wherein R ⁹ Is that

86. The compound of any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is piperidinyl, wherein the piperidinyl is substituted with 1 to 2R ⁸ Substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of alkyl, wherein R ⁸ Is C _1-6 An alkyl group.

87. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is piperidinyl substituted with one cyclobutyl group.

88. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ Is C _1-6 Alkyl, wherein the C _1-6 Alkyl is independently selected from-OH, halogen, -CN, oxo, -NR by 1 to 3 ¹¹ R ¹¹ 、-S(O) ₂ R ^11a And C _1-4 The groups of the alkoxy groups are substituted.

89. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ Is C _1-6 Alkyl, wherein the C _1-6 Alkyl:

i) Is substituted with one oxo group and is substituted with one oxo group,

90. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ Is C _1-6 Alkyl, wherein the C _1-6 The alkyl group is substituted with an oxetanyl group.

91. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ A group-substituted piperidinyl group wherein R ⁸ is-S (O) ₂ R ^5a 。

92. The compound of any one of claims 1 to 5, 8 to 20 and 86, or a pharmaceutically acceptable salt thereof, wherein Z is piperidinyl, wherein the piperidinyl is substituted with 1 to 4 methyl groups.

93. The compound according to any one of claims 1 to 5 and 8 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ Group-substituted C _1-6 Alkyl, wherein R is ⁸ Is a 7-to 10-membered spiro heterocyclic group,

94. The compound according to any one of claims 1 to 5, 8 to 20 and 93, or a pharmaceutically acceptable salt thereof, wherein Z is substituted with one R ⁸ Group-substituted C _1-3 Alkyl, wherein R is ⁸ Is that

95. The compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is-C (O) NR ⁶ R ⁷ 。

96. The compound of any one of claims 1 to 20 and 95, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is C _1-6 Alkyl or 4 to 7 membered monocyclic heterocyclyl,

wherein said C _1-6 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -NR ¹¹ R ¹¹ And C _1-3 Substituted by groups of alkoxy groups, and

wherein the 4-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

97. The compound according to any one of claims 1 to 20 and 95 to 96, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is optionally covered with a-NR ¹¹ R ¹¹ Substituted C _1-4 An alkyl group.

98. The compound according to any one of claims 1 to 20 and 95 to 97, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is independently selected from-NH ₂ 、NH(CH ₃ ) And N (CH) ₃ ) ₂ C substituted by a group of (C) _1-4 An alkyl group.

99. The compound according to any one of claims 1 to 5, 8 to 20 and 95 to 97, or a pharmaceutically acceptable salt thereof, wherein one R ¹¹ Is C _3-7 A monocyclic cycloalkyl group.

100. The compound according to any one of claims 1 to 5, 8 to 20, 95 to 97 and 99, or a pharmaceutically acceptable salt thereof, wherein one R ¹¹ Is cyclopropyl.

101. The compound according to any one of claims 1 to 6, 8 to 20 and 95 to 96, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is C substituted with 1 to 2 groups independently selected from 4 to 7 membered monocyclic heterocyclyl and 5 to 6 membered monocyclic heteroaryl _1-6 An alkyl group.

102. The compound according to any one of claims 1 to 6, 8 to 20, 95 to 96 and 101, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is C substituted with one group selected from pyrrolidinyl, piperidinyl, morpholinyl and pyridinyl _1-4 An alkyl group.

103. The compound according to any one of claims 1 to 5, 8 to 20 and 95, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is C optionally substituted with a 4-to 7-membered monocyclic heterocyclic group or a 7-to 10-membered spirocyclic heterocyclic group _3-7 A monocyclic cycloalkyl group, wherein the 4-to 7-membered monocyclic heterocyclyl group and the 7-to 10-membered spiro heterocyclyl group are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

104. The compound according to any one of claims 1 to 5, 8 to 20 and 95, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is C optionally substituted by a 6-to 10-membered bridged bicyclic heterocyclic group _3-7 A monocyclic cycloalkyl wherein the 6 to 10 membered bridged bicyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

105. The compound according to any one of claims 1 to 5, 8 to 20, 95 and 103 to 104, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is cyclobutyl.

106. The compound according to any one of claims 1 to 5, 8 to 20, 95 and 103, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is a cyclohexyl substituted with: azetidinyl, pyrrolidinyl, and,

107. The compound according to any one of claims 1 to 5, 8 to 20, 95 and 104, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is a cyclohexyl substituted with one 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

108. The compound according to any one of claims 1 to 5, 8 to 20, 95, 104, and 107, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is a cyclohexyl substituted with:

109. the compound according to any one of claims 1 to 20 and 95 to 96, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is optionally selected from-OH, halogen, -CN, -NR, optionally by 1 to 3 ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 A 4-to 7-membered monocyclic heterocyclic group substituted with a group of an alkyl group.

110. The compound according to any one of claims 1 to 20, 95 to 96 and 109, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is azetidinyl.

111. The compound according to any one of claims 1 to 20, 95 to 96 and 109, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is optionally selected from-O by 1 to 3H. Halogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 A 5-to 6-membered monocyclic heterocyclic group substituted with a group of an alkyl group.

112. The compound according to any one of claims 1 to 5, 8 to 20 and 95, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -C (O) R ¹¹ 、-NR ¹¹ R ¹¹ 、C _1-4 Alkoxy, C _1-5 Alkyl and R ^f A 5-to 6-membered monocyclic heterocyclic group substituted with a group of (C),

Wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹² R ¹² and-C (O) N (R) ¹² )(R ¹² ) Is substituted by a group of (C) and

wherein R is ^f Is C _3-7 Monocyclic cycloalkyl or 4-to 7-membered monocyclic heterocyclyl.

113. The compound according to any one of claims 1 to 5, 8 to 20, 95 and 112, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is pyrrolidinyl or piperidinyl, each of which is 1 to 3 independently selected from fluoro, methyl, -CH ₂ OH、-CH ₂ CN、-CF ₃ Ethyl group,

-CH ₂ CH ₂ OH、-CH ₂ CH ₂ CN、-CH ₂ CF ₃ 、-CH ₂ CHF ₂ 、-CH ₂ CH ₂ CF ₃ Cyclobutyl, oxetanyl, -CH ₂ C(O)NH ₂ 、-CH ₂ C(O)N(CH ₃ ) ₂ 、-C(O)CH ₂ NH ₂ and-C (O) CH ₂ N(CH ₃ ) ₂ Is substituted with a group of (a).

114. The compound according to any one of claims 1 to 20, 95 to 96, 109 and 111, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is pyrrolidinyl or piperidinyl, each of which is optionally selected from-OH by 1 to 3 independentlyHalogen, -CN, -NR ¹¹ R ¹¹ 、C _1-3 Alkoxy and C _1-3 The groups of the alkyl groups are substituted.

115. The compound according to any one of claims 1 to 20, 95 to 96, 109, 111 and 114, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Optionally from 1 to 3 independently selected from halogen and C _1-3 The groups of the alkyl groups are substituted.

116. The compound of any one of claims 1 to 20, 95 to 96, 109, 111, and 114 to 115, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Optionally substituted with 1 to 3 groups independently selected from fluoro and methyl.

117. The compound according to any one of claims 1 to 5, 8 to 20 and 95, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group, wherein the 6-to 10-membered bridged bicyclic heterocyclic group is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -C (O) R ¹¹ 、-NR ¹¹ R ¹¹ 、C _1-4 Alkoxy, C _1-5 Alkyl and R ^f Is substituted by a group of (a) or (b),

wherein each R is ^f Independently C _3-7 A monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl or 7-to 10-membered spiro heterocyclyl, wherein said C _3-7 The monocyclic cycloalkyl, 4-to 7-membered monocyclic heterocyclyl, 6-to 10-membered bridged bicyclic heterocyclyl, and 7-to 10-membered spiro heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

118. The compound of any one of claims 1 to 5, 8 to 20, 95 and 117, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is a 6-to 10-membered bridged bicyclic heterocyclic group.

119. The compound of any one of claims 1 to 5, 8 to 20, 95 and 117 to 118, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is that

120. The compound according to any one of claims 1 to 20 and 95 to 96, or a pharmaceutically acceptable salt thereof, wherein R ⁶ Is that

121. The compound according to any one of claims 1 to 20 and 95 to 120, or a pharmaceutically acceptable salt thereof, wherein R ⁷ Is H or methyl.

122. The compound according to any one of claims 1 to 5, 8 to 20 and 95 to 120, or a pharmaceutically acceptable salt thereof, wherein R ⁷ Is C _2-3 Alkyl or C _3-7 Monocyclic cycloalkyl wherein said C _2-3 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen and C _1-3 The groups of the alkoxy groups are substituted.

123. The compound according to any one of claims 1 to 5, 8 to 20, 95 to 120 and 122, or a pharmaceutically acceptable salt thereof, wherein R ⁷ Is ethyl, -CH ₂ CH ₂ OCH ₃ Cyclopropyl, cyclobutyl, or cyclopentyl.

124. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein Z is-COR ¹³ 。

125. The compound of any one of claims 1 to 20 and 124, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is a 4-to 7-membered monocyclic heterocyclic group, a 8-to 10-membered fused bicyclic heterocyclic group, a 6-to 10-membered bridged bicyclic heterocyclic group or a 7-to 10-membered spiro heterocyclic group,

wherein said C _1-5 Alkyl is optionally substituted with 1 to 2 groups independently selected from-OH, halogen, -CN and-NR ¹² R ¹² Is substituted by a group of (C) and

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

126. The compound according to any one of claims 1 to 6, 8 to 20 and 124, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is a 4-to 7-membered monocyclic heterocyclic group,

wherein the 4-to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -NR ¹¹ R ¹¹ Phenyl and C _1-5 The group of the alkyl group is substituted,

wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, NR ¹² R ¹² 、-C(O)N(R ¹² )(R ¹² ) Phenyl and R ^g Is substituted by a group of (a) or (b),

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl.

127. The compound according to any one of claims 1 to 6, 8 to 20 and 124, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclic group or a 6-to 10-membered bridged bicyclic heterocyclic group,

wherein the 8 to 10 memberedThe fused bicyclic heterocyclyl and the 6-to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ Phenyl, C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl.

128. The compound according to any one of claims 1 to 6, 8 to 20, 124 and 126 to 127, or a pharmaceutically acceptable salt thereof, wherein R ^g Is pyrrolidinyl.

129. The compound of any one of claims 1 to 20, 124 to 125 and 127, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is pyrrolidinyl, piperidinyl, piperazinyl, diazepanyl,

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

130. The compound of any one of claims 1 to 6, 8 to 20, 124 and 127 to 128, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is 8 to10 membered fused bicyclic heterocyclyl or 6-to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and-C (O) N (R) ¹² )(R ¹² ) Is substituted with a group of (a).

131. The compound of any one of claims 1 to 6, 8 to 20, 124, 127 to 128, and 130, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with one member selected from-NH ₂ 、-CF ₃ or-CH ₂ C(O)NH ₂ Is substituted with a group of (a).

132. The compound of any one of claims 1 to 6, 8 to 20, 124, 127 to 128, and 130, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is that

Each of them is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Radical substitution of an alkyl radical, wherein said C _1-5 Alkyl is optionally substituted with 1 to 3 groups independently selected from halogen and-C (O) N (R) ¹² )(R ¹² ) And wherein each R is substituted with a group ¹² Independently H or C _1-3 An alkyl group.

133. The compound according to any one of claims 1 to 6, 8 to 20 and 124, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is optionally covered with a C _1-5 Alkyl-substituted 7-to 10-membered spirocyclic heterocyclyl, wherein said C _1-5 Alkyl groups optionallyGround cover-C (O) N (R) ¹² )(R ¹² ) And (3) substitution.

134. The compound according to any one of claims 1 to 6, 8 to 20, 124 and 133, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is that

Each of them is optionally substituted with one C _1-5 Alkyl substitution wherein said C _1-5 Alkyl is optionally substituted by-C (O) N (R) ¹² )(R ¹² ) Substituted, and wherein each R ¹² Independently H or C _1-3 An alkyl group.

135. The compound of any one of claims 1 to 20 and 124 to 125, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is piperidinyl or piperazinyl, each of which is independently optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 The group of the alkyl group is substituted,

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

136. The compound according to any one of claims 1 to 6, 8 to 20, 124 and 126, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is azetidinyl, pyrrolidinyl, piperidinyl or piperazinyl, each of which is independently selected from 1 to 3 methyl groups

CH ₂ OH、-CHF ₂ 、-CF ₃ 、-CH ₂ NH ₂ 、-CH ₂ N(CH ₃ ) ₂ 、-CH ₂ (pyrrolidinyl) -CH ₂ CH ₂ OH、-NH ₂ 、-NHCH ₃ 、-N(Me) ₂ And phenyl groups.

137. The compound of any one of claims 1 to 6, 8 to 20 and 124, wherein the compound is a compound of formula II:

Or a pharmaceutically acceptable salt thereof, wherein

wherein each R is ^g Independently 4 to 7 membered monocyclic heterocyclyl.

138. The compound of any one of claims 1 to 6, 8 to 20, 124 and 137, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with 1 to 3 groups independently selected from-OH, halogen, -CN, oxo, -NR ¹¹ R ¹¹ 、C _1-4 Alkoxy and C _1-5 Substituted by alkyl radicals, and

139. The compound according to any one of claims 1 to 6, 8 to 20, 124 and 137 to 138, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is an 8-to 10-membered fused bicyclic heterocyclyl or a 6-to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with one member selected from-NH ₂ 、-CF ₃ or-CH ₂ C(O)NH ₂ Is substituted with a group of (a).

140. The compound of any one of claims 1 to 6, 8 to 20, 124 and 137, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is optionally covered with a C _1-5 Alkyl-substituted 7-to 10-membered spirocyclic heterocyclyl, wherein said C _1-5 Alkyl is optionally substituted by-C (O) N (R) ¹² )(R ¹² ) And (3) substitution.

141. The compound of any one of claims 1 to 6, 8 to 20, 124 and 137, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Is azetidinyl, pyrrolidinyl, piperidinyl or piperazinyl, each of which is independently selected from 1 to 3 methyl, -CH ₂ OH、-CHF ₂ 、-CF ₃ 、-CH ₂ NH ₂ 、-CH ₂ N(CH ₃ ) ₂ 、-CH ₂ (pyrrolidinyl) -CH ₂ CH ₂ OH、-NH ₂ 、-NHCH ₃ 、-N(Me) ₂ And phenyl groups.

142. The compound of any one of claims 1 to 20 and 124, wherein the compound is a compound of formula II:

/>

or a pharmaceutically acceptable salt thereof, wherein

R ¹³ Is a 4-to 7-membered monocyclic heterocyclic group, an 8-to 10-membered fused bicyclic heterocyclic ringA group, a 6-to 10-membered bridged bicyclic heterocyclic group or a 7-to 10-membered spiro heterocyclic group,

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

143. A compound according to claim 142, or a pharmaceutically acceptable salt thereof, wherein

Is that

wherein each R is ¹² Independently H or C _1-3 An alkyl group.

144. The compound or pharmaceutically acceptable salt thereof according to claim 137, wherein

Is that

145. The compound or pharmaceutically acceptable salt thereof according to claim 137, wherein

Is that

146. The compound according to any one of claims 1 to 20 and 142 to 143, or a pharmaceutically acceptable salt thereof, wherein

Is that

147. The compound according to any one of claims 1 to 20 and 124 to 146, or a pharmaceutically acceptable salt thereof, wherein R ¹³ Optionally substituted with 1 to 3 groups independently selected from: halogen, -NH ₂ 、-OH、-OCH ₃ Oxo, -CN, -CF ₃ Methyl and

148. the compound of any one of claims 1 to 54, 56, 58 to 60, 62, 65 to 67, 70 to 73, 76, 79 to 81, 84 to 86, 88 to 89, 91, 93, 95 to 97, 109, 111 to 112, 114, 117, 124 to 127, 129 to 130, 132, 135, 137 to 138, and 142 to 144, or a pharmaceutically acceptable salt thereof, wherein each R ¹¹ Independently H or methyl.

149. A compound selected from the group consisting of:

/>

Or a pharmaceutically acceptable salt thereof.

150. A compound selected from the group consisting of:

/>

or a pharmaceutically acceptable salt thereof.

151. A compound selected from the group consisting of:

/>

or a pharmaceutically acceptable salt thereof.

152. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

153. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

154. A compound selected from the group consisting of:

/>

or a pharmaceutically acceptable salt thereof.

155. A compound selected from the group consisting of:

/>

or a pharmaceutically acceptable salt thereof.

156. A compound selected from the group consisting of:

/>

or a pharmaceutically acceptable salt thereof.

157. A pharmaceutical composition comprising a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

158. The pharmaceutical composition of claim 157, further comprising one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

159. The pharmaceutical composition of claim 158, wherein the one or more additional therapeutic agents comprise an antimalarial agent.

160. The pharmaceutical composition of claim 159, wherein the antimalarial agent is selected from chloroquine and hydroxychloroquine or their respective pharmaceutically acceptable salts.

161. A method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition of any one of claims 157-160.

162. A method of inhibiting toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition of any one of claims 157-160.

163. A method of inhibiting toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition of any one of claims 157-160.

164. A method of treating a disease or disorder associated with increased toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition according to any one of claims 157 to 160.

165. A method of treating a disease or disorder associated with increased toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition according to any one of claims 157 to 160.

166. A method of treating a disease or disorder associated with increased toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition according to any one of claims 157 to 160.

167. A method of treating an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition of any one of claims 157 to 160.

168. The method of claim 167, wherein the inflammatory disorder is selected from the group consisting of inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, glomerulonephritis, mixed Connective Tissue Disease (MCTD), dermatomyositis, polymyositis, systemic sclerosis, anti-neutrophil cytoplasmic antibody associated vasculitis, anti-phospholipid syndrome, autoimmune hemolytic anemia, macrophage activation syndrome driven inflammatory anemia, igA nephropathy, type I diabetes, non-alcoholic steatohepatitis, and sjogren's syndrome.

169. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition of any one of claims 157-160.

170. A method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition of any one of claims 157-160.

171. A method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-156, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition of any one of claims 157-160.

172. The method of any one of claims 161-171, further comprising administering a therapeutically effective amount of one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

173. The method of claim 172, wherein the one or more additional therapeutic agents are selected from the group consisting of: wituzumab, PF-06835375, ekuizumab, mi Latuo, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, cilazalizumab, damadyl Li Shan, TAK-079, fezeitumumab, illimumab, anilurab, iskarituximab, pegylated dapirox Bead mab, ranavilamide, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obelimumab, tatuzumab, wo Bali bead mab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, lobifuα, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, asenapine, tiazepine, BMS-986256, M-5049, KZR-616, KPG-818, vandicable, ALPN-303, valoxepin, LA-1, cinamomod, prednisone, corticotropin, deuterostatinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, juliemic acid, I Bei Du amine, TAM-01, BML-258, bupacitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, datazapeptide, GSK-2646264, SKI-O-703, lanprinib (GS-9876), GNS-1653, HMPL-523; RSLV-132, interleukin-2 subsequent biological preparation, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-X (SLE), AC-0058, non-Nibutinib, XNW-1011, tiralutinib hydrochloride, brinbutinib, albutinib, obutinib, DWP-213388, INV-103, R-salbutamol sulfate, ankyrin, NIK-SMI1, X-6, INV-17, O Sha Di D, barittinib, wu Pati, non-golitinib, itatinib, INCB-54707, dighatinib, DWP-212525, CKD-971, as mometasone, betamethasone, furitol, arachidonylethanolamine, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (Qu Tai), allogenic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, TPX-6001, TPX-7001, dihydroartemisinin and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

174. The method of any one of claims 161-173, wherein the subject is a human.

175. A compound according to any one of claims 1 to 156 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to any one of claims 157 to 160 for use in therapy.

176. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

177. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

178. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

179. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of treating a disease or disorder associated with increased toll-like receptor 7 and/or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

180. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of treating a disease or disorder associated with increased toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

181. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of treating a disease or disorder associated with increased toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

182. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of treating an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

183. The use of claim 182, wherein the inflammatory disorder is selected from inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, glomerulonephritis, mixed Connective Tissue Disease (MCTD), dermatomyositis, polymyositis, systemic sclerosis, anti-neutrophil cytoplasmic antibody-associated vasculitis, anti-phospholipid syndrome, autoimmune hemolytic anemia, macrophage activation syndrome-driven inflammatory anemia, igA nephropathy, type I diabetes, non-alcoholic steatohepatitis, and sjogren syndrome.

184. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

185. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

186. Use of a compound according to any one of claims 1 to 156, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 157 to 160, in a method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

187. The use of any one of claims 175-186, further comprising administering one or more additional therapeutic agents.

188. The use of claim 187, wherein the one or more additional therapeutic agents are selected from the group consisting of: veltuzumab, PF-06835375, exkutuzumab, mi Latuo, SM-06, SM-03,BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, siradilizumab, damascen Li Shan, TAK-079, feizumab, illici group mab, anilumab, islamic mab, pegylated dapiromab, ranali mab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obelimab, tatuzumab, wo Bali bead mab, TE-2324, PRV-3279, chloroquin, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, lobifuα, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, asenapine, tiazepine, BMS-986256, M-5049, KZR-616, KPG-818, vandicable, ALPN-303, valoxepin, LA-1, cinamomod, prednisone, corticotropin, deuterostatinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, juliemic acid, I Bei Du amine, TAM-01, BML-258, bupacitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, datazapeptide, GSK-2646264, SKI-O-703, lanprinib (GS-9876), GNS-1653, HMPL-523; RSLV-132, interleukin-2 subsequent biological preparation, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-X (SLE), AC-0058, non-Nibutinib, XNW-1011, tiralutinib hydrochloride, brinbutinib, albutinib, obutinib, DWP-213388, INV-103, R-salbutamol sulfate, ankyrin, NIK-SMI1, X-6, INV-17, O Sha Di D, barittinib, wu Pati, non-golitinib, itatinib, INCB-54707, dighatinib, DWP-212525, CKD-971, as mometasone, betamethasone, furitol, arachidonylethanolamine, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (Qu Tai), allogenic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, TPX-6001, TPX-7001, dihydroartemisinin and AMG-592, or pharmaceutically acceptable salts thereof.

189. The use of any one of claims 175-188, wherein the subject is a human.